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INTRODUCTION
Fast disintegrating tablets (FDT) dissolve rap-
idly in the saliva. It is useful for those who has 
difficulty in swallowing, pediatrics, geriatrics, 
and also if there is little or no access to wa-
ter.  Superdisintegrant is the most important 
excipient in FDT. By the mechanism of wick-
ing and swelling, water is pulled then particles 
swell and break up the matrix form within the 
tablet. Mefenamic acid is one of Non Steroidal 
Anti Inflammatory Drugs (NSAIDs) which most-
ly used for its analgesic effect. The formulation 
of mefenamic acid  FDT is expected to give 
more rapid onset of action of the analgesic 
effect. Two swelling mechanism superdisinte-
grants were chosen to be analyzed. They were 
sodium starch glycolate (SSG) and croscarmel-
lose sodium (CCS). The objective of this study 
is to compare those two superdisintegrants 
and find the optimal concentration. 
MATERIAL & METHODS
Materials
Mefenamic acid, crosscarmellose sodium, mi-
crocrystalline cellulose, sodium starch glyco-
late, and magnesium stearate were obtained 
from Kimia Farma. Mannitol and Talc were ob-
tained from Bratachem.
Methods
THE RESEARCH WAS IN TRUS EXPERIMENTAL 
DESIGN. WE DESIGNED SIX FORMULAS AS 
FOLLOWS: 
Mixing of Bulk
Each of material was weighed and homog-
enized. Mefenamic acid, superdisintegrants 
(CCS or SSG) and microcystalline cellulose 
were mixed  for 7 minutes until homogen. 
Mannitol, talc and magnesium stearate were 
added and mixed for 2 minutes
Flow Properties
As many as 100 grams of bulk was flowed 
through the funnel. Angle of Repose were 
between 46-55 which means poor flow prop-
erty. It must be agitated or vibrated.The flow 
property was stated good or excellent if the 
angle of repose more than 30. Also, the flow 
rate was not good because the value was be-
low 10 grams/second.
Ingredient (%) Formulation
Table 1. Formulation of Mefenamic Acid Tablets 
(Total Weight of tablet = 500 mg)
2Table 2. Flow PropertiesTable 2. Flow Properties
Manufacturing of Mefenamic Acid Tablets
The tablets were made by direct compression 
method.
Evaluation of Mefenamic Acid Tablets
They were evaluated for characteristics of pre-
pared tablets such as organoleptic, size and 
weigh uniformity, hardness, friability, wetting 
time, disintegration time, dissolution test and 
drug content. 
 
RESULT
All of the tablets were white, smooth, round 
and flat. Those six formulas have diameter and 
thickness of tablet as 1.1 cm and 0.4 cm re-
spectively. The weigh uniformity of the tablets 
was also fullfilled the requirement from Far-
makope Indonesia. Meanwhile, the result of 
hardness, friability, disintegration time, swell-
ing time, dissolution and drug content can re-
fer to Table 3. 
ANOVA One Way and HSD Tukey were per-
formed to analyze the data and obtain the 
most optimum concentration of superdisin-
tegrant. From the statistical analysis, the op-
timum concentration was denoted in F6 (SSG 
8%).
 
DISCUSSION
All of the formulas have completed the re-
quirements for weight variation and hardness. 
The friability value was more than 1%. It indi-
cated that the tablets were friable. It might be 
due to manual direct compression had been 
used. 
The result also pointed out the higher swell-
ing and disintegration time for sodium starch 
glycolate as superdisintegrant.  Crosscarmel-
lose sodium is one of crosslinked cellulose. Its 
mechanism as superdisintegrant is swelling 
and wicking. It swells 4-8 times in less than 10 
seconds. It swells in two dimensions. Mean-
while, sodium starch glycolate is one of cross-
linked starch which has swelling mechanism. 
It swells 7-12 times in three dimensions less 
than 30 seconds. Based on their characteris-
tics, it can be seen that sodium starch glyco-
late has higher swelling ability than crosscarm-
ellose sodium. That is the reason why sodium 
starch glycolate gave faster swelling and disin-
tegration time. 
From the dissolution data, we can see that 
the result is below the requirements (<10%). 
Based on USP-NF25, the dissolution test of 
mefenamic acid can be approved if Q value 
was 75% or more in 45 minutes. The low Q 
value can be due to the medium. Aquadest 
was chosen as the medium based on Albreiki 
et al. 2013. Mefenamic acid soluble in alkali 
Table 3.  Characteristics of prepared Mefenamic Acid Tablets
3solution. Before measurement of the concen-
tration, as 1 ml of dissolution samples were 
diluted in NaOH 0.1 M untuil 10 ml. According 
to Patil et al. 2010, mefenamic acid in aquad-
est dissolution medium was only soluble about 
5,4%. Although, we had diluted in alkali solu-
tion, the result was similar when using aquad-
est only. We suggest phosphate buffer pH 7.4 
or Tris buffer as alternative in dissolution me-
dia for mefenamic acid tablet.
CONCLUSION
Sodium starch glycolate is more rapid in wet-
ting time and disintegration time than cross-
carmellose sodium. It might be due to the 
three dimensional swelling mechanism of SSG. 
The optimal concentration is the formula with 
SSG 8%.  
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ABSTRACT
Recombinant human erythropoietin (EPO) is a glycoprotein with three complex type N-glycans 
and one O-glycan.  EPO is the principle growth factor produced as a therapeutic agent for the 
treatment of anemia associated with severe kidney damage. EPO is composed of 165 amino acids 
in its mature form with an average molecular weight of 30 kDa. Sixty percent (by weight) of the 
molecule is the weight of the polypeptide, while the rest 40% of the weigh is the carbohydrate 
molecules. 
Earlier study has proved that EPO with two additional N-link sugar chains showed better biological 
activity and longer half-life than EPO with native pattern (containing only 3 N-link sugar chains). In 
this study, EPO containing two additional N-link sugar chains (total 5 N-link sugar chains) was con-
structed. The recombinant plasmid, pcDNA3-EPO, was transfected to CHO-K1 cells. Besides study 
the expression of hEPO in CHO-K1 cells, we are also interested in determining the growth curve 
of the cells in relation to when the protein exactly expressed. How the CHO-K1 cell grow without 
being transfected was also studied and compared.  
Keywords: erythropoietin, CHO-K1, protein expression. 
INTRODUCTION
Erythropoietin (EPO) is a glycoprotein that 
stimulates the differentiation of late eryth-
roid progenitor cells to mature red blood cells 
and as a consequence increases haemoglobin 
levels. EPO is approximately 30-37 kDa glyco-
protein (exact molecular weight depends on 
degree of glycosylation) in which sixty percent 
of the molecule is an invariant 165 amino acid 
single polypeptide chain containing two disul-
phide bonds. The remaining 40% of the EPO 
mass consists of carbohydrate covalently at-
tached at three N-linked and one O-linked sug-
ar chain at Ser126 (Skibeli et al., 2001)
Recombinant human EPO (rHuEPO) has been 
known to be a stimulating agent in the treat-
ment of anemia associated with various pa-
thologies (i.e. cancer, HIV, chemotherapy, 
chronic renal insufficiency) (Egrie et al., 2001). 
With the patents of rhEPO and other therapeu-
tic proteins expired, the market has opened 
for biosimilar recombinant products from the 
same cell line with identical or improved phar-
macokinetic properties and less immunogenic 
response.   The production of recombinant 
human proteins has enabled great progress in 
healthcare and drug technology. With this, the 
availability of approved biopharmaceuticals 
has increased tremendously in the last several 
years. 
Recently, the use of alternative expression sys-
tems was often mentioned. Two of well-known 
alternative systems for protein expression are 
yeast (e.g. Pichia pastoris) (Cereghino GPL and 
Cregg, 1999) and Escherichia coli (Fischer et 
al., 1999). However, for the therapeutic gly-
coprotein to be functional the glycosylation 
pattern has to be properly expressed. Thus, al-
most 70% of therapeutic proteins available in 
the market are expressed in mammalian cells. 
5This has enabled mammalian cells to provide 
the potential for stable and correctly folded 
recombinant proteins that have undergone 
all the post-translational modifications re-
quired for functionality (Mataschi et al., 2008). 
For this reason the demand of rhEPO protein 
currently met by recombinant expression in 
mammalian cells, especially CHO cells. In this 
study the growth curve and density of cells in 
relation to when the protein exactly expressed 
was examined.   
MATERIALS AND METHODS
Cell Culture and Reagents
The CHO-K1 cells were obtained from Prof. 
Masashi Kawaichi, Nara Institute of Science 
and Technology (NAIST), Japan. The cells were 
grown in Nutrient Mixture F-12 Ham (F12) me-
dia (Sigma N6658) in the presence of 10% of 
fetal bovine serum (FBS, Sigma), 100U of ben-
zylpenicillin and 100μg of streptomycin (Gibco, 
Invitrogen). The cell culture was grown in an 
incubator with the condition of 5% CO2 and 
37oC temperature.  
 
Expression of rhEPO CHO-K1 Cells
The pcDNA 3 recombinant plasmid contain-
ing human epo gene with five N-linked carbo-
hydrate chains was transfected into CHO-K1 
cells by using Lipofectamin 2000 (Invitrogen) 
according to manufacturer’s protocol. Stable 
expressing transformants were screened by 
using 1,000ng of G418. For single cell clon-
ing, the cell was cultured in 96 well plate with 
the density of 1 cell per well. The cells were 
cultured untouch for 10 days. After 10 days, 
the cell colonies that grown from a single cell 
were transferred to 24 well plates. After con-
fluencies have been reached the cell was then 
transferred to a bigger plate (6 well plates) and 
finally to 10 cm dish. 
SDS-PAGE and Western Blotting
The purity of the protein analyzed by SDS/
PAGE performed as previously described19 in 
a 12% separating gel with a 5% stacking gel us-
ing the Mini-PROTEAN-3 apparatus (Bio-
Rad, Hercules, CA, USA). Following elec-
troporation, proteins were transferred to 
Amersham Hybond ECL (GE Healthcare) 
by electroblotting. Western blots were 
performed using  polyclonal anti human 
EPO antibody (Sigma, St. Louis, MO, USA) 
as the primary antibody and anti rabbit 
IgG alkaline phosphatase linked whole 
antibody (Promega, Madison, WI, USA) 
as the secondary antibody. The bands 
were detected by BCIP/NBT color devel-
opment substrate (5-bromo-4-chloro-3-
-indolyl-phosphate/nitro blue tetrazo-
lium) (Promega, Madison WI, USA).
RESULTS AND DISCUSSION
Recombinant plasmid pcDNA 3 contain-
ing human epo gene with five N-linked 
oligosaccharide chains was constructed. 
The coding sequence was fused with 
polyhistidine tag to enable easy and rap-
id purification and was placed under the 
control of CMV promoter. The plasmid 
was transfected into CHO-K1 cells using 
Lipofectamine 2000, and G418 resistance 
colonies were selected. Having pool of 
cells resistent to G418, the cells were 
then screened individually in 96 well 
plates. A cell clone that originated from 
a single cell was then transferred and 
continued to be screened successively in 
24 and 6 well plates. Finally, the cell was 
cultured in 10 cm dish using the media 
mentioned above. 
Untransfected cells 
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Figure 1. The growth curve of transfected and 
untransfected cells 
One clone expressing hEPO and the CHO-K1 
cell with no plasmid as negative growth curve 
control were used for subsequent study. The 
media were                      collected by centrifuga-
tion at 6000rpm for 5 min and the supernatant 
containing rHuEPO was collected while the 
cells were removed. Following purification, 
the sample was run on SDS/PAGE and detect-
ed with Western blot analysis using polyclonal 
anti human EPO antibody. 
To find the optimum condition of rhEPO ex-
pression in CHO-K1 cells, 5 x 104 cells/ml media 
were cultured in 10cm in diameter dish con-
taining 10 ml media. Before the experiment, 
the cell culture was passaged three times to 
make sure that the cells were ready for the ex-
pression study.  The cells were cultured for five 
days and the samples were taken for protein 
rhEPO analysis using Western blot technique. 
For comparison of the growth curve between 
CHO-K1 with and without being transfected 
with plasmid, the CHO-K1 cell without trans-
fection was cultured.   The result (Fig. 1 A) 
show that, for transfected cells, the growth of 
the cell increased tremendously on day one. 
Right after day one, the cell density reached 
plateau. The density remained high until day 
4 with the peak at day 2 which is about 1.16 
x 106 cells/ml media. When we compared the 
growth curve of the transfected cells (Fig. 1 
A) with Figure 2 interesting result was found. 
Analysis using Western blot shown that the 
highest rhEPO protein expressed was at day 5. 
On the contrary, the highest density of the cell 
occurred at day 2 (Fig. 1A). Thus, the peak of 
cell density was not followed by the peak of 
protein expression. This data might show that 
it takes time for the cell to synthesize the pro-
tein of interest, in this case rhEPO. 
Figure 1. The growth curve of transfected and 
untransfected cells 
One clone expressing hEPO and the CHO-K1 
cell with no plasmid as negative growth curve 
control were used for subsequent study. The 
media were collected by centrifugation at 
6000rpm for 5 min and the supernatant con-
taining rHuEPO was collected while the cells 
were removed. Following purification, the 
sample was run on SDS/PAGE and detected 
with Western blot analysis using polyclonal 
anti human EPO antibody. 
To find the optimum condition of rhEPO ex-
pression in CHO-K1 cells, 5 x 104 cells/ml media 
were cultured in 10cm in diameter dish con-
taining 10 ml media. Before the experiment, 
the cell culture was passaged three times to 
make sure that the cells were ready for the ex-
pression study.  The cells were cultured for five 
days and the samples were taken for protein 
rhEPO analysis using Western blot technique. 
For comparison of the growth curve between 
CHO-K1 with and without being transfected 
with plasmid, the CHO-K1 cell without trans-
fection was cultured.   The result (Fig. 1 A) 
show that, for transfected cells, the growth of 
the cell increased tremendously on day one. 
Right after day one, the cell density reached 
plateau. The density remained high until day 
4 with the peak at day 2 which is about 1.16 
x 106 cells/ml media. When we compared the 
growth curve of the transfected cells (Fig. 1 
A) with Figure 2 interesting result was found. 
Analysis using Western blot shown that the 
highest rhEPO protein expressed was at day 5. 
On the contrary, the highest density of the cell 
occurred at day 2 (Fig. 1A). Thus, the peak of 
cell density was not followed by the peak of 
7protein expression. This data might show that 
it takes time for the cell to synthesize the pro-
tein of interest, in this case rhEPO. 
To study and compare on how transfection af-
fect cell growth in CHO-K1, CHO-K1 cells were 
cultured on the same media and time. The data 
showed that, on day 5, the density of untrans-
fected cells was still high (9.4 x 105 cells/ml 
media), while the transfected one was about 
3.6 x 105 cells/ml media). On day 1, 2, 3, and 
4 the density of the cells was comparable. It 
is very possible that overproduction of specific 
protein like heterologous recombinant protein 
production affect the growth of the cell itself.    
CONCLUSION
The data of this research showed that the 
connection between cell growth, cell density 
and peak of the interested protein being ex-
pressed was complex and not linear. As differ-
Table 1. Cell density of cultured cells
Day Transfected cells /ml media 
Untransfected 
/ml media 
0 50.000 50.000 
1 827.500 1.100.000 
2 1.010.000 1.162.500 
3 1.130.000 1.130.000 
4 1.030.000 1.050.000 
5 942.500 360.000 
 
1 2 3 4 5 M C
ent cell line and protein may have their own 
complexity, the best way of finding the right 
timing, cell density and cell growth to obtain 
the highest protein production was to per-
form cell growth and protein expression ex-
periment of that specific protein.  
ACKNOWLEDGEMENT
This study was supported by the National 
Innovation Program (SiNas), Ministry of Re-
search and Technology (Menristek) (grant 
No. RD 2013-096). The authors are grateful to 
Prof. Masashi Kawaichi for providing CHO-K1 
cells.
REFERENCES
1. Cereghino GPL and Cregg JM. (1999). Ap 
 plications of yeast in biotechnology: pro 
 tein production and genetic analysis, Curr  
 Opin Biotech, 10(5): 422–427.
2. Egrie JC, Browne JK. (2001). Development  
 and characterization of novel erythropoi 
 esis stimulating protein (NESP), Neophrol  
 Dial Transplant, 16(7): 3-13. 
3. Fischer R, Drossard J, Emans N, Comman 
 deur U and Hellwig S. (1999).  Towards  
 molecular farming in the future: 
 mov ing from diagnostic protein and 
 anti body production in microbes to   
 plants, Biotechnol. Appl. Biochem. 30:  
 117-120. 
4. Matasci M, Hacker DL, Baldi L and Wurm  
 FM. (2008). Protein therapeutics recom 
 binant therapeutic protein production in  
 cultivated mammalian cells: current sta 
 tus and future prospects. In: Drug Discov 
 ery Today: Technologies, 5: 37-42.  
5. Skibeli V, Nissen-Lie G, and Torjesen P.  
 (2001). Sugar profiling proves that human  
 serum erythropoietin differs from re  
 combinant human erythropoietin, Blood,  
 98:  3626-3634.
Figure 2. Western blot analysis of rhEPO pro
   tein expression. 1-5: day 1 to day 5  
   (molecular weight: approximately 47  
   kDa), M: protein marker, C:  Positive  
   control (molecular weight: approxi 
   mately 30 kDa).
8ANTIOXIDANT STABILITY ASSAY OF ALPHA TOCOPHERYL ACETATE 
IN SOLID LIPID NANOPARTICLE SYSTEM (LIPID BASE BEESWAX AND 
MONOSTEARIC GLISERYL 50:50)
Anggie Widhi, Pharmaceutics Department Faculty of Pharmacy Universitas Airlangga, anggiewip@gmail.com, 
Noorma Rosita, Pharmaceutics Department Faculty of Pharmacy Universitas Airlangga, Widji Soeratri, Pharma-
ceutics Department Faculty of Pharmacy Universitas Airlangga
ABSTRACT
Introduction : As an antioxidant, alpha tocopheryl acetate is easily degraded by light and free 
radical in air. Solid Lipid Nanoparticle (SLN) is a system that can provide protection of active in-
gredient because of its drug entrapment ability and physical protective from UV light due to its 
nano-sized. The aim of this study is for investigated the ability of SLN that could increase stability 
of antioxidant potency from alpha tocopheryl acetate. SLN is expected to have higher stability of 
antioxidant potency compared with simple cream.
Methods : SLN and simple cream was made SLN was made using lipid beeswax (BW) and monos-
tearic glyceryl (GMS) as base and Tween 80 as stabilizer. SLN was produced using high shear ho-
mogenization method and simple cream was produced using hot plate magnetic stirrer. Antioxi-
dant potency was measured by DPPH method. Sample was radiated by UV C light as free radical 
initiator.
Result and Discussion : Alpha tocopheryl acetate loaded in SLN system has higher stability of anti-
oxidant potency compared with simple cream that shown with k value as constanta of antioxidant 
potency degradation between time. This could be due to its physical blocker of UV light and drug 
entrapment properties.
Conclusion :  SLN was selected as antioxidant carrier due to its ability to increase antioxidant sta-
bility of alpha tocopheryl acetate.
Keywords : antioxidant, alpha tocopheryl acetate, DPPH, stability, SLN
INTRODUCTION
Solid Lipid Nanoparticle (SLN) is a dispersion 
system  with nano-sized particles  in range 
40-1000 with spherical shape (Muller, 2009). 
SLN has widely used in cosmetic formulation 
because of its advantages due to its nano-
sized particle such as UV protective effect and 
enhance emmolient (Souto, 2008; Wissing, 
2002). 
Alpha tocopheryl acetate is derivate from to-
copherol that commonly used as an antioxi-
dant in cosmetic due to its properties of photo 
protective for skin and could decrease skin’s 
damage of free radical (Nam, 2012; Tsai, 2012). 
As an antioxidant, alpha tocopheryl acetate is 
easily degraded by light and free radical in air. 
SLN is one of the system that could prevent 
the antioxidant degradation of alpha tocoph-
eryl acetate especially because the  presence 
of light. It is result from SLN ability to scat-
tering light with its nano-sized particles and 
produce physical UV protective effect (Golmo-
hammadzadeh, 2012). The lipid matriks that 
contained in SLN also has the protective effect 
for active ingredient (Souto, 2008).
The aim for this study was for investigated the 
impact of SLN system with binary lipid bees-
wax and monostearic glyceryl (50:50) on an-
tioxidant stability of alpha tocopheryl acetate 
compared with simple cream. Antioxidant 
activity is measured by DPPH method. Com-
bination 50:50 of lipid component beeswax 
and monostearic glyceryl was selected due to 
the combination has higher physical stability 
and drug entrapment (Jenning, 2000; Rosita, 
2013).
9MATERIALS AND METHOD
Materials:
Tocopheryl acetate, DPPH (Sigma Aldrich), 
beeswax,  monostearic glyceryl, tween 80, (PT. 
Bratako). Dapar component: acetic acid and 
sodium citrate (E. Merck) , aquadest (PT. Jawis-
esa). 
Instrument: 
Double beam UV Spectrophotometer UV-1800 
Shimadzu, One Fourier Transform Infrared 
(FTIR) Spectrophotometer, pH meter Eutech 
Instruments pH 700 , Differential Thermal Ana-
lyzer (DTA), DelsaTMNano C Particle Analyzer, 
JEOL JEM-1400 Electron Microscope, Ultra Tur-
rax IKA® T25 Digital  High Shear Homogenizer, 
Sentrifuge Hettich Rotofix 32, Ultrasonic LC 
60h Elma, , Hot plate, UV C lamp 
Preparation method of SLN
SLN formed by beeswax and monostearic glyc-
eryl (GMS) as lipid core 50: were prepared 
by high shear homogenization method . 10% 
of tween 80 was used as surfactant and 20% 
of propylene glycol was used as co-surfac-
tant. Acetic buffer pH 4.2, µ=0,5 was used as 
aqueous phase (table 1). They were stirred at 
24,000 rpm for 8 minutes, with 30 seconds in-
tervals every two minutes, using an Ultra Tur-
rax homogenizer T-25. The hot dispersion were 
cooled keep in stirring decreased speed gradu-
ally.
Characterization of SLN
Measurement of Particle Size
Each sample was diluted with water before 
measurement. The particle sizes were ana-
lyzed by Delsa Nano Particle Size Analyzer at 
25°C. Each measurement was performed in 
triplicates and the particle average diameter 
and polydispersity index (PI) was determined.
Observation of SLN morphology  
The morphology of SLNs was observed by 
Transmission Electron Microscope (TEM). Ei-
ther SLN blanks or SLN-PMCA were stained 
with phosphotungstic acid 2% w/v and placed 
on copper grids with former film for viewing 
at 120 kV (JEOL JEM-1400) and operated us-
ing software. The shape of SLN observed with 
Thermal Electron Microscope (TEM) and Drug 
entrapment of PMCA was measured by cen-
trifugation method.
Measurement IC 50 Value of Alpha Tocopheryl 
Acetate 
IC 50 value of alpha tocopheryl acetate was 
measured by DPPH method. The series of con-
centration of alpha tocopheryl acetate was 
prepared. 2 ml of sample in ethanol solution 
was centrifuged  with 2 ml of DPPH solution. 
After 30 minutes absorbance of sample was 
measured by spectrophotometer in 517 nm.
Measurement of Antioxidant stability of Alpha 
tocopheryl acetate in SLN and simple cream 
Each sample of SLN and simple cream alpha 
tocopheryl acetate was radiated by UV C light 
as free radical initiator. 1 gram of each sample 
was taken and diluted in ethanol and then cen-
trifuged at 2500 rpm for 20 minutes. Superna-
tant was taken 2 ml and then mixed with 2 ml 
of DPPH. The reduction in DPPH radical was 
measured by spectrophotometer at 517 nm.
Table 1. Formula of SLN and simple cream
 tocopheryl acetate
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The existence of the particle size of SLN alpha 
tocopheryl acetate that are outside the range 
because the weakness of the manufacturing 
method of SLN with high shear homogenizer 
/ high speed homogenizer which can result in 
the size of the microparticles in the SLN (La-
son, 2011). 
From table 3 it shown the IC 50 value of alpha 
tocopheryl acetate. The mean value of IC 50 
alpha tocopheryl acetate is 2,56% ± 0,0850.
Table 3. IC 50 value of alpha tocopheryl 
acetate
The antioxidant stability of SLN and sim-
ple cream alpha tocopheryl acetate was 
shown in table 4 and fig.2. Fig 1. Morfology of SLN-alpha tocopheryl acetate
           measured by TEM
Fig 1. Morfology of SLN-alpha tocopheryl acetate
           measured by TEM
Table 2. Range of particle size,  average of particle size and their Polydispersity Index (PI)
RESULT AND DISCUSSION
SLN-alpha tocopheryl acetate had most spher-
ical shape (fig 1,). Range of particle size, aver-
age of particle size and their Polydispersity In-
dex (PI) can be seen in table 2.
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From graphic in fig.2 it can be determined 
that SLN alpha tocopheryl acetate shown less 
sloping than simple cream alpha tocopheryl 
acetate. It means that decrease of antioxidant 
stability of alpha tocopheryl acetate loaded in 
SLN  over the time is smaller than loaded in 
simple cream. This result was confirmed with 
constanta value of antioxidant potency degra-
dation between time among SLN and simple 
cream loaded alpha tocopheryl acetate. SLN 
alpha tocopheryl acetate has smaller value 
of constanta of antioxidant potency degrada-
tion between time than simple cream alpha 
tocopheryl acetate. This phenomenon may oc-
cur as a result of UV blocker by SLN and drug 
entrapment effect of SLN that  could protect-
ing active ingredient.
Fig. 2. Graphic % reduction alpha tocopheryl acetate loaded in SLN and simple cream against DPPH absorbance between time
CONCLUSION
SLN was selected as antioxidant carrier due to 
its ability to increase antioxidant stability of 
alpha tocopheryl acetate.
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INTRODUCTION
The utilizing of drug delivery system (DDS) for 
releasing of drug locally is very important in 
aspect of therapy and orthopedic surgical, due 
to there is no guarantee it is free from microor-
ganism infection during surgical perfectly. One 
of serious complications in case of open frac-
ture and bone defect reconstruction is infec-
tion which are usually delivered by contamina-
tion of Gram positive Staphylococci (S aureus, 
S epidermidis) and Gram negative such as Es-
cherichia coli and Pseudomonas aeruginosa. 
In osteomyelitis case, if serious complications 
happen such as decrease of function and sep-
sis should be avoid by implant as a must be 
choiced.1
Penetration of drug locally is a difficult prob-
lem in the therapy of bone infection. Utilizing 
of antibiotic by intravena or oral way caused 
drug reached its target in low concentration. 
This is meant, dose of antibiotic used should 
be in high concentration to fulfill therapheu-
tic dose in the target, but this way could 
cause side effect. Based on the condition, it is 
needed to develop biomaterial which biode-
gradable and osteoconductive that could take 
the function as drug delivery system (DDS). 
The beneficial of using DDS which biodegrad-
able, bioresorption are: there is no need of 
re-surgical operation for taking the material 
off, decrease toxicity of foreign things, and the 
speed of drug releasing could be controlled 
through degradation modification.2 Recently 
biomaterial is developed, those materials such 
as polimer natural collagen, gelatin, chitosan, 
and calcium compound (calcium phosphate, 
hydroxyapatite) as antibiotic delivery agent for 
bone infection therapy, to build protein-like 
composition and bone mineral.3 
A BIOACTIVE BOVINE HYDROXYAPATITE–GELATIN IMPLANT FOR IN 
VITRO GENTAMICIN RELEASE
Aniek Setiya Budiatin, Faculty of Pharmacy Universitas Airlangga, anieksb@yahoo.co.id; M. Zainuddin, Faculty 
of Pharmacy Universitas Airlangga; Junaidi Khotib Faculty of Pharmacy Universitas Airlangga;  Diah Himawati, 
Faculty of Science and Technology Universitas Airlangga
This study used bovine hydroxyapatite (BHA) 
–gelatin (GEL) as bioactive, biodegradable, 
and biocompatible material which take role 
as DDS and gentamicin as antibiotic. The ben-
eficial of BHA-GEL are: there is no need of re-
surgical operation to take it off because the 
biomaterial is one of bone mineral compo-
nents and protein. The osteoconductivity of 
BHA is higher than HA synthesis. BHA-GEL pel-
let could deliver gentamicin (GEN) in higher 
concentration than MIC (minimum inhibitory 
concentration) that could eradicate pathogen 
microorganism, avoid over-dose and toxic-
ity. Gentamicin widely used in bone infection 
therapy, having narrow therapy index, broad 
spectrum, resistant of high temperature, 
cause side effect of using systemic-ototoxi-
cally, and nephrotoxic that cause GEN by its 
characters which well used for local applica-
tion to less the side effects. To control GEN 
releasing from DDS, it is used cross-link agent 
glutaraldehyde (GA). In vitro characteristic of 
crosslinking BHA-GEL-GEN processed to GA 
could be performed; the changing of function 
cluster with FITR; morphology of compound 
surface with SEM; the changing of porosity 
and density and releasing of GEN from DDS.
METHODS
Material 
Bovine hydroxyapatite (BHA) was accepted 
from RSUD Dr Soetomo Surabaya. Gelatin 
was purchased from Rousselot (Guangdong 
Chines). Acetone; glutaraldehyde, ethanol, 
K2HPO4, KH2PO4, NaCl, were purchased from 
Aldrich Chemical Co.,USA Gentamicin sulfate 
was purchased from Arshine Technology CO, 
Limited, Wanchai Chines; Gentamicin ELISA 
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Kit Catalog No CSB-E 12088f, Nutrient agar was 
purchased from E. Merck.
Implant preparation modified method2
BHA powder (20g) were mixed with 10 ml 
gelatin 20 % and added with gentamicin 10%. 
It was then mixed until looked such paste and 
then passed through a 1 mm mesh screen to 
granulate it and finally dried at 400C over-
night. It was then immersed with 0.5%; 1.0% 
and 2.5% glutaraldehyde for 24 hr, subse-
quently washed  with distilled water and then 
repeated with phosphate buffer saline and fi-
nally dried at  400C  overnight.
Implants were molded into cylinder shape by 
compressing 100 mg of the resulting granulate 
in cycle dying (4 mm diameter) with force of 3 
ton for 1 min, using Carver hydraulic press at 
room temperature. The pellet resulted was 4 
mm in diameters and 3.2 mm in thickness. 
Characterization
Measurement of Porosity and Density
A liquid displacement method  was used to 
measure the porosity and density of  compos-
ite of BHA-GEL-GA and BHA-GEL-GA-GEN. The 
density measurements provided information 
about pore size and distribution, permeabil-
ity and composite structure. A composite of 
weight W was immersed in a graded cylinder 
containing a known of  volume (V1) of water. 
The total volume of the water and composite 
was then recorded as V2. The volume differ-
ence (V2-V1) was the volume of the ceramic. 
The composite was removed from the water 
and the residual water volume was measured 
as V3. 
Fourier Transform Infra Red (FT-IR)
In the present study, FT-IR spectroscopy (Par-
kin-Elmer) was used to estimate the confor-
mational change of the structure in BHA-GEL 
and BHA-GEL-GEN composites cross-linked by 
GA.2
Scanning Electron Microscopy (SEM) 
The morphology and microstructure of the 
ceramic were examined using SEM (FEI type 
Inspect S 50 at 10 kV). The composite were cut 
by a razor and polished and then were gold-
sputtered.4
In Vitro Release Study
Determination of Release Kinetics and Bioac-
tivity5
The composite BHA–GEL-GA-GEN pellet  was 
immersed in 2,0 ml of phosphate buffer sa-
line (PBS), pH 7,4 at 370C. To determine the 
concentration of gentamicin release: 0,5 ml 
of PBS were withdrawn and replaced by fresh 
PBS after 3, 6, 12, 24 h and everyday until 21st 
and 28th. The eluted of PBS samples were fro-
zen at -200C for microbiological assay. Control 
experiment using gentamicin-free composite 
sample was performed under the same ex-
periment conditions and negative control, all 
sample were performed in triplicate.  The con-
centration and bioactivity of the GEN release 
was determined using the diffusion method. 
Nutrient Agar plate inoculated with Staphylo-
coccus aureus (ATCC 25923) was used to cre-
ate a 106 colony- forming units/ml (CFU/ml) 
in 0,45% NaCl. One milliliter of S. aureus sus-
pension was incorporated into 15 mL of Nu-
trient Agar medium heated at 450C. The agar 
was poured into a sterile glass plate and left to 
reach room temperature. Sixty microliters of 
samples were deposited in triplicate into 10- 
mm hole was made in the agar. Sample were 
located in different areas in the plates and left 
at room temperature for 30 min before incu-
bation at 370C. After 24 hr of incubation, the 
diameters of inhibition zone were measured 
in triplicate and expressed as mean ± SD as a 
function of time. The corresponding negative 
control samples (PBS) were measured using 
the same methodology. In addition, standard 
solutions of known gentamicin concentra-
tions were prepared and tested with the same 
method to calculate the unknown gentamicin 
concentration in the samples.
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RESULTS AND DISCUSSION
Implant Preparation 
Result of cross-link process on BHA-GEL gran-
ule and BHA-GEL-GEN in concentration of GA 
0.5%; 1.0% and 2.5%, shown that concentra-
tion of GA 0.5 % was more appropriate to be 
used than concentration 1.0% and 2.5%, this 
is shown at Figure 1. The utilizing of GA > 0.5% 
was just too much, it was detected by the ap-
pearance of turbidity or deposit which it came 
from result of reaction between GEL that re-
leased from the granule and shown excessive 
of GA would be reacted with GEL released 
from BHA-GEL granule  and BHA-GEL-GEN 
which caused GA solution turned from clear to 
turbid, misty one.
Porosity  and  Density Analysis. Density of the 
pellet influenced mechanical power, perme-
ability and the cure form of defect. Density 
measurement result of composite of BHA-
GEL and BHA-GEL-GEN which cross-link with 
GA in the following way: chronologically were 
0.3460 ± 0.1584 g/cm3 ;0.9120 ± 1.698 g/cm3 
and porosity 11.6667 ± 3.2146%  and   2.6633 
± 1.3395%; while for trabecular bone density, 
generally its number were between 0.14 to 
1.10 g/cm3, it was meant that both sample 
were fulfilled density number.6
Observation result by SEM as seen in Figure 
1A and Figure 1B shown that with addition of 
GEN and cross-linking with GA, caused change 
of surface morphology of BHA-GEL-GEN pellet 
turned to got more solid which this condition 
would affect porosity. SEM result figured out 
that the surface of pellet showing asymetric 
surface and roughness, these would make cell 
got easier to attach and enter into it to pro-
liferate and differentiate as also make antibi-
otic got easier to elute. In micrograph was also 
shown that GEL turned BHA to be more solid 
and trapped GEN particle inside and part of it 
attached outside (adsorbed). Adsorbed GEN 
would be first dissolved when got in touch with 
liquid that cause drug level released directly in 
much amount as load dose.7
Figure 1: SEM of  BHA-GA-GEL (A) and BHA-GEL-GA-
GEN (B)
Infrared Analysis    
Figure 2 shows FITR spectra (Absorption vs 
wave-number) of composite material of BHA-
GEL-GEN and  BHA-GEL-GEN-GA. Specific 
wave-number of glutaraldehyde (GA) is 1715 
cm-1  which shown C=O cluster of aldehyde, 
and after cross-linking process the wave-num-
ber was no longer seen. Because C=O cluster 
would turn to C=N which given wave-number 
range 1670-1650 cm-1. This fact shown that GA 
was united with BHA-GEL and BHA-GEL-GEN 
formed covalent bond and turned to BHA-GEL-
GA and BHA-GEL-GEN-GA. The wave-number 
1400-1260 show specific characteristic of C=O 
cluster of prolin GEL which it is 1337 cm-1, 
which this is specific wave-number of collagen 
type 1 (Narbat et al., 2006). Wave-number of 
PO4-  range 1090-1030-957 cm-1  and 600-500 
cm-1 , –NH2- cluster ; -N=C  from amida 1650-
1628 cm-1 ; 1540 and 1240 cm
4000.0 3000 2000 1500 1000 450.0
cm-1
%T 
Glutaraldehid
BHA-gel-Ga
BHA-Gel-Gen-Ga
Figure 2: FTIR spectra of the materials: GA; BHA-
GEL-GEN  and BHA-GEL-GEN-GA
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Release Profile and Biological Activity
The making of calibration curve of inhibition 
zone diameter and GEN consentration of some 
consentrations of GEN (1.25 to 40.00 ppm) 
was obtained  equation Y = 0.1515X + 10.313; 
R= 0.9869, and the method taken was some 
standard concentrations of gentamicin flow-
ing into a hole on media agar which contained 
Staphylococcus aureus, resulted correlation 
between standard concentration of gentami-
cin (GEN) and diameter of zone inhibition and 
resulted there was a linear correlation in R2-
value = 0.9740. From the equation obtained it 
could be used to count sampling samples of in 
vitro release test during 28 days.
 Figure 3 shows incubation result of re-
leasing test sampling of GEN pellet by in-vitro, 
observed that inhibition zone diameters were 
bigger than MIC value during long periode,  28 
days. It  is mean that BHA-GEL-GEN-GA able to 
control GEN release during long periode and 
total releasing  about 99,43%.
Result shows (Figure 4)  that gentamicin (GEN) 
released from pellet BHA-GEL-GEN-GA in in-
Figure 3: Solution from dissolution test were 
determined with diffusion test with Staphylo-
coccus aureus in Nutrient Agar
Figure 4: Concentration (ppm) vs Release time of GEN from BHA-GEL-GEN-GA implant
vitro releasing test during 28 days and than 
microbiologically tested gave antibacterial ac-
tivity with inhibition zone diameter that bigger 
than MIC value of Staphylococcus aureus. It is 
expected that BHA-GEL-GEN-GA pellet could 
be in-vivo tested in rabbit as testing animal by 
making a defect/hole in the middle of its femur 
and than pellet is put into the hole as what 
performed by Meseguar- Olmo et al.,  (2006).
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CONCLUSION
The characteristic of composite BHA-GEL-GEN-
GA is similar bone mineral-protein phase and 
GEN can be released higher than MIC from 
GEN to inhibit Staphylococcus aureus  for 28 
days.  
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INTRODUCTION
Topically administering vaccines are currently 
being developed because of many bacterial 
and viral pathogens are able to enter the body 
through the skin1). Topical administration has 
the advantage, among others, to avoid the 
first-pass effect in the liver metabolism, pre-
vent degradation in the gastrointestinal tract, 
as well as easier to use and comfortable for the 
patient2). Therefore we need a system that is 
capable of delivering the vaccine to be able to 
penetrate the skin.Microemulsion is a stable 
colloidal dispersion system is thermodynami-
cally and consists of phases of oil, water, sur-
factant, and cosurfactant which forms a clear 
solution with a droplet size of < 200 nm3). 
This system is an ideal system for use as a drug 
delivery has advantages because it is ther-
modynamically stable, ease of manufacturing 
process, has a low viscosity, and droplet sizes 
are very small so that it has a greater surface 
area which facilitates penetration of the active 
compound molecules into the membrane2). 
As a prototype vaccine protein, ovalbumin 
used as an active ingredient. Therefore oval-
bumin dissolved in water, it will be made the 
microemulsion with the type w/o (Water in oil) 
where ovalbumin will be in the water phase 
which trapped by the oil phase. With the mi-
croemulsion type w/o active ingredient will 
be stable. Comparison between the surfactant 
and cosurfactant composition will affect the 
characteristics of the microemulsion system4). 
The characteristics of this system to be a fac-
tor of the release of the active ingredient.The 
aim of this study was to investigate the effects 
of comparison surfactant (Span 80-Tween 80): 
cosurfactant (ethanol) = 5:1, 6:1, and 7:1 in re-
leased of ovalbumin from microemulsion wa-
ter/oil (w/o) system.
METHODS
Material
Ovalbumin (Sigma-Aldrich), soybean oil  food 
grade (PT Pan Pacific Indonesia), Tween 80 
(Croda), Span 80 (Croda), ethanol (Merck), re-
agen Coomassie Brilian Blue (Sigma-Aldrich), 
aquabidest (PT Widatra Bhakti). 
Preparation
Span 80, Tween 80, soybean oil, surfactan 
and cosurfaktan were mixed in different ratio 
(Table 1). In every ratio total concentration 
Surfactant and cosurfactan were 60% . Added 
aquabidest as water phase slowly to form a 
stable water in oil system. Then, mixed Oval-
bumin into the system at high speed.
Table 1. Formula of ovalbumin in W/O microemulsion
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Evaluation
Organoleptic Evaluation
Organoleptic evaluation carried out visually 
includes examining the color, odor, and con-
sistency. The evaluations performed on micro-
emulsion before and after added ovalbumin.
Evaluation Size Distribution of Droplet 
Examination of the size and distribution of the 
microemulsion droplet size was performed 
with a submicron Delsa ™ Nano Particle Size 
and Zeta Potential Dynamic Light Scattering. 
The evaluations performed on microemulsion 
before and after added ovalbumin.
In vitro release studies
The in vitro release of the diclofenac was per-
formed using Franz diffusion Cell with selofan 
as a membran. All in vitro released study were 
performed at 100 rpm, with each medium of 
dissolution (aquabidestilata) was ± 21.5 mL. 
In every 50 µl samples added 2.5 mL reagen 
Coomassie Briliant Blue  at different time in-
tervals were analyzed for drug content using 
spectrophotometer Double Beam UV-VIS Re-
cording UV 18000 (Shimadzu) at a maximum 
wavelength. All of the results were analyzed 
by statistic one way analysis of variance with 
degree of believed 95%. 
RESULT AND DISCUSSION
Organoleptic evaluation of the microemulsion 
before and after added ovalbumin ovalbu-
min in each ratio have the same organoleptic 
which has a distinctive odor, clear yellow color 
and viscous consistency like oil.
In Figure 1 shown the result of the size and 
distribution of the microemulsion droplet 
size showed that the value ± SD from 3 rep-
lications before added ovalbumin in formula 
5:1 was 30.7± 4.01nm; formula 6:1 was 27.6 
± 2.97 nm; and formula 7:1 was 27.1 ± 1.70 
nm. Meanwhile, at the formula that has been 
added ovalbumin has a droplet size in formula 
5:1 was 26.4 ± 0.94nm; formula 6:1 was 23.8 
± 0.26 nm; and formula 7:1 was 25.0 ± 1.14 
nm. The statistical analysis using Independent 
T-Test showed that the value of Tcalculation 
(1,781) < Ttable (2.776) in formula 5:1, Tcalcu-
lation (2.190) < Ttable (2.776) in formula 6:1, 
and  Tcalculation (1.804) < Ttable (2.776) in 
formula 7:1. It means that there was no sig-
nificant difference in each formula before and 
after added ovalbumin.
Figure 1 Histogram of the droplet size in mi-
croemulsion before and after added ovalbu-
min. Each column represents the mean ± SD 
(n=3) 
Figure 2 showed the released process of oval-
bumin  in system microemulsion W/O. Oval-
bumin release was calculated by calculating the 
AUC (Area Under Curve) value of the cumu-
lative amount of ovalbumin released per unit 
area per time. Figure 3 showed the AUC (Area 
Under Curve) of  in vitro ovalbumin released 
study  in system microemulsion W/O each for-
mula. AUC results obtained in the formula 5: 
1 was  4693.46 g /cm2 ± 1764.77,formula 6:1 
was  6590.04 g /cm2 ± 1084.94, and formula 
7: 1 was 5288.90 g /cm2 ± 412.30. The result 
of statistic using ANOVA one way showed that 
Fcalculated (1.898) <  Ftable (5.14). It means 
that there was no significant difference mini-
mum one pair data. Based on these results as 
a whole, with an increase in surfactant-cosur-
factant ratio on formula ratio 5: 1, 6: 1 and 7: 
1 have not been able to provide a statistically 
significant difference from the results of drop-
let size. Therefore, the release of the results 
obtained did not give a significant difference.
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Figure 2. Profile between the amount of oval-
bumin released per unit area (g /cm2) in a va-
riety of formulas versus time
 
Figure 3. Histogram of  AUC the cumulative 
amount of ovalbumin released in each for-
mula. Each column represents the mean ± SD 
(n=3).
CONCLUSION
The released of ovalbumin from microemul-
sion with the comparison of surfactant (Span 
80-Tween 80):  cosurfactant  (ethanol) =5:1, 
6:1, and 7:1) was no significant difference.
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INTRODUCTION
Mycolic acids (MAs) are specific lipid fractions 
of the outer cell wall of Mycobacterium spe-
cies. The characteristic structure of MA is not 
affected by culture conditions. MAs are recog-
nized as a stable phenotypic property of Myco-
bacterium species (1). MAs are high-molecular 
weight of β-hydroxyl fatty acids with long alkyl 
chains at α position. Each MA molecule con-
tains 60-90 carbon atoms with some cyclopro-
pane ring at meromycolate chain (Figure 1). M. 
tuberculosis (MTB) produces alpha MA (70%), 
methoxy MA and keto MA (10-15) %. Different 
strains of MTB contained significantly different 
MAs components (5). 
Identification of anomaly structure (or compo-
sition) of MAs can be based on MAs chromato-
gram profile using gas chromatography (GC). 
MAs can be identified as MAs methyl ester (6) 
or as MAs cleavage products (3, 4). 
Since producing MAs methyl ester using Meth-
anol-toluene-H2SO4 is time consuming (3-16 
hours at 80oC) (4, 6), this study used BF3-
methanol reagent, in order to shorten produc-
tion time of MAs methyl ester. Although, meth-
anolic-BF3 had been reported could cleave 
the cyclopropane ring, oxidize unsaturated of 
fatty acid and produce methoxy artifacts when 
be used in a high concentration, it has same 
disadvantages as other acidic reagents in low 
concentration (2). 
The aim of this study was to obtain a specific 
cleavage product or MAs cleavage product 
profile that can be used as a marker for identi-
fication of MAs MTB strain. 
MATERIALS AND METHODES
Sample
H37Rv strain MTB, INH sensitive MTB isolate 
and INH resistant MTB isolate. All strains were 
supplied from Clinical Microbiology depart-
ment of Dr. Soetomo Hospital.
Reagents 
Middlebrook 7H10 with OADC supplement, 
Trehalose dimycolate (TDM) of M. Bovis ex 
Sigma, Tricosanoic methyl ester (TME) ex 
Sigma. KOH, NaOH, HCl, Na2SO4 exciccatus, 
NaCl, BF314% in methanol, methanol, hep-
tane chloroform, (all of the reagents were pro 
analyze grade) except for heptane was pro 
GC.
Instrument
GC Agilent 6890 series, HP5 capillary column 
(30 m x 0,32 mm x 0,25 µm), with  Flame Ion-
ization Detector (FID)
Sample preparation
Samples were grown on middlebrook media 
for 21-30 days.  Biomass (+50 mg) placed in 
pyrex tube containing 2 ml of 25% KOH in a 
Figure 1.  Mycolic acids structure (6)
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mixture of methanol: water (1:1), and auto-
claved for 1 hour at 121oC.
Isolation of mycolic acids of M. tuberculosis
1.5 ml of hydrochloric acid (1:1) was added to 
the pyrex tube and MAs were extracted with 
3x 2 ml of CHCl3. The collected chloroform ex-
tracts was dried in a gentle stream of N2 gas. 
Esterification of mycolic acids
1.0 ml of 0.5N methanolic-NaOH was added to 
the dried MAs extract in a pyrex cupped tube, 
and heated on the water bath for 5 minute at 
95oC. The sample have been cooled to room 
temperature before addition of 1.0 ml 14% 
BF3 in methanol and heating in water bath 
at 95oC for 1 hour. The obtained methyl es-
ter MAs fragment was extracted using 3x1 ml 
heptane by agitation on vortex for 2 minutes. 
Heptane extract was separated by centrifuga-
tion at 2000 rpm for 2 minute and then trans-
ferred to another clean tube. Heptane extract 
was added with 2 ml saturated NaCl and agi-
tated for 2 minute before separated to anoth-
er tube. 1 g of Na2SO4 exsiccatus was added 
to heptan phase before the extract was dried 
by a stream of N2 gas. The dried extract was 
re-dissolved in 0.30 ml heptane prior to injec-
tion in GC-FID.
RESULT AND DISCUSSION
The optimum operational conditions of GC-FID 
were as follow. Inlet and detector tempera-
tures were set at 285oC, carrier gas (He) flow 
rate was 1 ml/minute, 2μL sample was inject-
ed by splitless technique. Column tempera-
ture was programmed as follow. It was started 
at 180 oC and hold for 6 minute, ram 2  oC/
minute to 200 oC, maintained at 275oC for 1 
minute, increased 5 oC/minute to 300 oC, and 
finally maintained at 300oC for 14 minute.
Esterification of MAs using methanolic-BF3 
fragmented TDM (ex. M. bovis) into 3 specific 
fragments which have tR of 26.89, 28.51 and 
30.09 minute respectively. Those specific frag-
ments were also obtained in chromatogram of 
H37Rv strain, INH resistant MTB isolate and 
INH sensitive MTB isolate (figure 2). Those 
fragments were identified (by GC-MS) as tet-
racosane methyl ester (C24), pentacosane 
methyl ester (C25) and hexacosane methyl 
ester (C26) (figure 2). MAs fragment of H37Rv 
has a different profile compared to two MAs 
fragment profiles of MTB isolates when using 
MAs fragments which have tR of (6.22, 10.62, 
11.32, 12.44 minute) and tR of (8.45, 11.30, 
12.44, 17.77, 26.82, 28.43, 28.85, 32.23 min-
ute) (Table 1). Those MAs profiles are charac-
teristic. MAs fragment profile of INH resistant 
MTB isolate distinguished from MAs fragment 
profile of INH sensitive MTB isolate with match 
factor (MF) of 8926. 
* Average of three sample   ** average of 6 sample
Table 2. Area normalization of MAs cleavage signal
CONCLUSION
This study concluded that the profile of MAs 
fragment of MTB strain was characteristic and 
can be distinguished each other. But, the pro-
file of MAs fragment couldn’t show which one 
of the MAs structure that had been changed .
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INTRODUCTION
Many growth factors and their receptors play 
important roles in modulating cell division, 
proliferation and differentiation. Overexpres-
sion of growth factor receptors has been im-
plicated as an important factor in the prolif-
eration of malignancies and has also been 
identified as a marker of poor prognosis (Kuan 
et al., 2001).
Epidermal growth factor receptor variant III 
(EGFRvIII) is a mutant variant of EGFR that 
commonly overexpressed in human malignant 
cells. EGFRvIII has in frame deletion of exons 
2-7 that encodes extracellular domain, result-
ing in the formation of new Glycine residue. 
Although EGFRvIII is unable to bind EGF or 
other EGFR-binding ligands, it is constitutively 
phosphorylated and able to activate down-
stream signaling cascades, which end up with 
cell differentiation (Pedersen et al., 2001). The 
possibility of disrupting this process has led to 
the development of novel therapeutic agents 
for cancer treatment (Kuan et al., 2001).
EGFRvIII is commonly found in glioblastoma 
multiforme and has been reported also in 
breast, ovarian, prostate, lung, head and neck 
carcinomas, but did not found in normal cells 
(Huang et al., 1997; Batra et al., 1995; Sok et 
al., 2006). Lacks of 267 amino acids from ex-
tracellular domain of EGFRvIII has resulted in 
the formation of a new immunogenic epitope 
near the amino terminus. Therefore this recep-
tor might be used as an ideal molecular target 
in immunology based cancer therapy (Gupta 
et al., 2010). In such kind of targeted cancer 
therapy, antibody fragments were frequently 
used as targeting moiety.
Fv fragment is the smallest unit of antibody 
molecule that preserves its antigen-binding 
properties. Thus, it can facilitate a targeted 
drug delivery for a treatment that requires 
high specificity. Single-chain variable fragment 
(scFv) is an antibody fragment that consists of 
variable regions of heavy (VH) and light chains 
(VL), joined together by a flexible peptide 
linker. Thus, it can be easily expressed in Es-
cherichia coli (Ahmad et al., 2012). However, 
an scFv molecule has at least two disulfide 
bonds in its structure which are required to be 
correctly formed in order to preserve its anti-
gen-binding affinity. In E. coli expression sys-
tem, periplasmic compartment is preferably 
used for recombinant protein production that 
needs a correct protein folding and disulfide 
bond formation (Kipriyanov et al., 1997). 
Periplasmic production of recombinant pro-
teins provides several advantages compared 
to cytosolic production. For example, the 
authentic N-terminal amino acid sequence 
without the Methionine extension can be ob-
tained after cleavage by the signal peptidase. 
Also, there appears to be much less protease 
activity in the periplasmic space than in the 
cytoplasm. In addition, recombinant protein 
purification is simpler due to fewer contami-
nating proteins in the periplasm (Makrides, 
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1996; Choi et al., 2000)
In this study, we reported the periplasmic 
expression of an anti-EGFRvIII scFv in E. coli 
BL21(DE3) periplasm. Prior to periplasmic 
expression, the DNA fragment encoding anti-
EGFRvIII scFv was subcloned into pJ414 expres-
sion vector containing pelB leader sequence, 
which is derived from Erwinia carotovora (Lei 
et al., 1987). This leader sequence consists of 
22 amino acids residues, which directs the re-
combinant protein production fused with this 
leader sequence into periplasmic compart-
ment in gram-negative bacteria, such as E. coli 
(Choi and Lee, 2004).
MATERIALS AND METHODS
Plasmid containing DNA fragment of anti-
EGFRvIII scFv  (pJ201_scFv) was obtained from 
previous research. Expression vector contain-
ing pelB leader sequence (pJ414_pelB), E. coli 
TOP10 and BL21(DE3) are available in our labo-
ratory. Primers used in this study were: scFv1-
forward primer containing NcoI site (5’-GGC-
CATGGC TCAAGTTCAATTGGTTGAGTCAGG-3’), 
scFv1-reverse primer containing XhoI site (5’-
CGCCATGGCTCGAGT GATTAACAATGATGATG-
GTGG-3’), and T7-promoter primer. All primers 
were purchased from IDT. 
Construction of plasmid pJ414_pelB¬_scFv
DNA fragment encoding anti-EGFRvIII scFv was 
amplified from pJ201_scFv by PCR method. 
PCR was conducted as follows: initial denatur-
ation at 95 °C for 1 m; 25 to 30 cycles of dena-
turation at 95 °C for 1 m, annealing at 60 °C 
for 30 s, and extension at 72 °C for 1 m, then 
final extension at 72 °C for 5 m. PCR products 
were analyzed with 1 % agarose gel electro-
phoresis. 
Purified PCR product and pJ414_pelB expres-
sion vector were double digested using NcoI 
and XhoI enzymes (3 IU /1 µg product), then 
incubated at 37 °C for 18 h. Digested products 
were examined with 1% agarose gel electro-
pho-resis, subsequently isolated from an aga-
rose gel using Gel/PCR DNA Fragments Extrac-
tion Kit (Geneaid). 
Purified scFv gene and plasmid were ligated 
using T4-DNA ligase (1 IU/50 ng plasmid), then 
transformed into E. coli TOP10 using transfor-
mation and stock solution (TSS) (Chung et al., 
1989). Recombinant plasmids were isolated 
from E. coli transformants, then characterized 
by migration, restriction, and PCR analyses. 
It was subsequently sequenced to ensure no 
mutation presents within the gene sequence. 
Confirmed recombinant plasmid was then 
transformed into E. coli BL21(DE3).
Growth conditions for scFv expression
E. coli BL21(DE3) carrying pJ414_pelB_scFv 
were grown overnight in Luria Bertani me-
dium with 100 µg/mL ampicilin (LBamp) at 
37°C. This culture was diluted 1:50 with 20 
mL LBamp medium, grown at 37°C in 100 mL 
shaking flask. When cultures reached OD600 
= 0.8, IPTG was added and growth was con-
tinued at room temperature (20-23°C) for 
18-20 h. Optimization of IPTG concentration 
was carried out by varying IPTG concentration 
from 0.1 to 1 mM.
Isolation of soluble periplasmic proteins
Cells were harvested by centrifugation at 5000 
x g and 4°C for 15 m. Pelleted cells were resus-
pended with hypertonic solution consisting of 
20% sucrose, 30 mM Tris-Cl, and             1 mM 
EDTA pH 8. After 1 h incubation on ice with oc-
casional stirring, the spheroplasts were cen-
trifuged at 11600 x g and 4 °C for 30 m, leaving 
the soluble periplasmic extract as the super-
natant and spheroplasts plus the insoluble 
periplasmic material as the pellet (Kipriyanov 
et al., 1997). Supernatant containing periplas-
mic proteins were separated, and then ana-
lyzed by 10% SDS-PAGE. 
Comparation of total proteins, soluble 
periplasmic and cytoplasmic proteins
As much as 100 mL culture was prepared by 
method previously described, induced by op-
timized IPTG concentration. Analysis of total 
proteins was done by adding 100 µL sample 
buffer into pellet cells from 1 mL culture. The 
remaining culture was pelleted, and then 
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soluble periplasmic and cytoplasmic proteins 
were isolated. 
Isolation of cytoplasmic proteins was per-
formed by freeze thaw method. Spheroplasts 
from periplasmic extraction were resuspend-
ed with lysis buffer consisting of 50 mM Tris-
Cl, 3 mM EDTA, and 1 mM PMSF. Spheroplast 
suspension was subjected to five freeze-thaw 
cycles by freezing at -20 °C for 15 m and thaw-
ing for 15 m in room temperature. After that, 
thawed spheroplasts suspension was centri-
fuged at 11600 x g and 4 °C for 30 m, leaving 
the soluble cytoplasmic extract as the super-
natant (Johnson and Hecht, 1994; Shrestha et 
al., 2012). Total proteins, soluble cytoplasmic 
and periplasmic proteins were then analyzed 
by 10% SDS-PAGE.
RESULT AND DISCUSSION
The pJ201_scFv plasmid was used as tem-
plate for the scFv gene amplification, result-
ing in 802 bp of PCR product. The amplifica-
tion product contains poly-histidine tag at the 
downstream of scFv sequence, and also NcoI 
and XhoI restriction sites to facilitate the clon-
ing step. This DNA fragment was subcloned 
into NcoI and XhoI sites of pJ414_pelB vector. 
The recombinant plasmid obtained was named 
pJ414_pelB_scFv. To confirm correct recombi-
nant plasmids, some analyses were carried out 
including migration, restriction, PCR and DNA 
sequencing.
Recombinant plasmid (4852 bp) and control 
plasmid (5452 bp) were run on agarose gel 
electrophoresis. Migration rate of recombi-
nant plasmid would be faster than the control 
plasmid due to their sizes. Figure 1A showed 
the band of recombinant plasmid compared 
to control plasmid. To determine the actual 
size of the plasmid and insert DNA, restriction 
analysis was carried out. Figure 1B showed 
restriction of recombinant plasmid using NcoI 
or XhoI, which showed a single DNA band of 
4852 bp. Double restriction analysis using both 
(NcoI and XhoI) resulting DNA bands with size 
of 802 and 4050 bp which corresponded to the 
A B
theoretical size of insert DNA and pJ414_pelB, 
respectively. 
The PCR analysis was performed using T7-pro-
moter and scFv1-reverse primers. These prim-
ers were used to determine the full-length 
construct of the gene within the pJ414_pelB 
plasmid. Thus, the PCR product would con-
sist of T7 promoter, pelB leader sequence, 
scFv gene, and poly-histidine tag. Figure 1C 
showed a DNA band of approximately 900 bp, 
which corresponds to the theoretical size of 
desirable fragment. Based on DNA sequenc-
ing analysis (data not shown), there were no 
mutation in DNA encoding anti-EGFRvIII scFv 
gene. After all of analyses conducted, it could 
be concluded that the recombinant plasmid 
was successfully constructed.
E. coli is currently used as the host for produc-
ing antibody fragments. For disulfide-bonded 
proteins, good expression levels have been 
achieved via soluble production, secreting the 
proteins into the oxidizing environment of the 
bacterial periplasm where assembly and dis-
ulfide bond formation can occur. Periplasmic 
secretion is achieved by genetically fusing the 
leader sequence onto the N-terminus of the 
antibody sequence (Popplewell et al., 2005)
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Figure 1. (A) Migration analysis of pJ414_pelB_scFv. 
Lane 1, comparator plasmid (5452 bp); lane 2, pJ414_
pelB_scFv recombinant plasmid (4582 bp). (B) Re-
striction analysis of pJ414_pelB_scFv. Lane 1, pJ414_
pelB_scFv uncut; lane 2, digested with NcoI restriction 
enzyme; lane 3, digested with XhoI restriction en-
zyme; lane 4, digested with NcoI and XhoI restriction 
enzyme. (C) PCR analysis of pJ414_pelB_scFv.   Lane 1, 
using T7 promoter and reverse primers; lane 2, using 
forward and reverse primers; lane 3, negative control.
Figure 2. SDS-PAGE analysis of total proteins induced 
with various IPTG concentration.The scFv band is 
marked with an arrow (28.76kDa). Lane 1, non trans-
forman induced with  0.5 mM IPTG; lane 2, non in-
duced transforman; lane 3, transforman induced with 
0.1 mM IPTG; lane 4, transforman induced with 0.25 
mM IPTG; lane 5, transforman induced with 0.5 mM 
IPTG; lane 6, transforman induced with 1 mM IPTG.
The oxidizing environment of periplasmic 
space, rich in proteins which are important 
for folding and catalyzing disulfide bond for-
mation (PDI, DsbA and DsbC) or chaperones 
such as SKp (Fernandez, 2004; Bothmann and 
Pluckthun, 2000), is most suitable for proper 
folding of scFv fragment. Antibody fragments 
expressed in the periplasmic space have been 
shown to be correctly folded with excellent 
yield. Additionally, extraction of periplasmic-
expressed proteins can easily be performed 
by a simple osmotic shock procedure (Tiwari 
et al., 2010)
The early stage in overproduction of scFv 
proteins was to optimize the optimal concen-
tration of IPTG as inducer. Figure 2 lanes 3-6 
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showed total protein bands of induced E. coli 
culture using various IPTG concentrations. The 
scFv band is deduced to have approximate 
size of 28.76 kDa as it is shown on the SDS-
PAGE analysis (Figure 2). The band size corre-
sponds to the theoretical size of scFv proteins. 
Furthermore, total scFv proteins induced with 
0.1 and  0.25 mM IPTG has a thicker band com-
pared to those from 0.5 and 1 mM IPTG. How-
ever, such information was not enough to be 
used as a reference to determine the optimal 
concentration of IPTG in producing scFv pro-
teins in periplasmic space. Therefore, analy-
sis was continued to determine the effect of 
various IPTG concentration in the periplasmic 
protein expression. 
Figure 3 gives an overview of protein profiles 
extracted from the E. coli periplasm. Analysis 
was carried out to compare periplasmic pro-
tein profiles from induced and uninduced E. 
coli cultures. Based on the electrophoregram, 
it was observed that the bands of scFv pro-
tein clearly detected in periplasmic extract of 
transformant E. coli cultures induced with 0.1 
and 0.25 mM IPTG. Considering these results, 
low concentration of IPTG was apparently op-
timum for periplasmic-proteins expression of 
this scFv.
28
Figure 3. SDS-PAGE analysis of periplasmic proteins 
induced with various IPTG concentrations. The scFv 
bands are marked with arrows. Lane 1, non induced 
transforman; lane 2, transforman induced with 0.1 
mM IPTG; lane 3, transforman induced with 0.25 mM 
IPTG; lane 4, transforman induced with 0.5 mM IPTG; 
lane 5, transforman induced with 1 mM IPTG
To find out the protein profiles produced using 
this expression system, a comparative analysis 
of total proteins, periplasmic proteins, and cy-
toplasmic proteins was carried out. Cytoplasm 
has a much larger space than periplasm. How-
ever, Figure 4 lanes 5 and 6 showed that the 
soluble scFv protein in cytoplasmic space was 
much less than in periplasmic space. This re-
sult indicates that the majority of scFv proteins 
in the cytoplasm were in the form of inclusion 
bodies.
ScFv protein has a disulfide bond in each VH 
and VL domains, but the cytoplasmic space 
has a reductive environment (Snyder and 
Champness, 2003). Therefore, disulfide bonds 
are unlikely be formed within the cytoplasm. 
Theoretically, it could be the cause of inclusion 
bodies formation within the cytoplasm.  
Figure 4. SDS-PAGE analysis of total proteins, 
soluble periplasmic and cytoplasmic proteins. 
The scFv band is marked with an arrow. Lane 
1, total proteins of non induced non transfor-
mant; lane 2, total proteins of non transfor-
mant induced with 0.5 mM IPTG; lane 3, total 
proteins of non induced transformant; lane 
4-6, total proteins, periplasmic and cytoplas-
mic proteins (respectively) of transformant 
cultures induced with 0.1 mM IPTG,.
 All of those analyses indicates a protein band 
of 28.76 kDa  observed in protein profiles of 
periplasmic and cytoplasmic of induced cul-
ture extracts which is not present in uninduced 
culture extracts. These results suggest that the 
scFv protein has been successfully expressed 
and found in samples of total proteins, peri-
plasmic and cytoplasmic fractions. Thus, it can 
be concluded that pJ414_pelB_scFv plasmid 
has successfully express scFv protein in the 
periplasmic space using PelB leader sequence.
CONCLUSION
The pJ414_pelB_scFv plasmid has been suc-
cessfully constructed and its sequence has 
been confirmed. Protein expression analyses 
have confirmed that the scFv protein has suc-
cessfully been expressed in periplasmic space 
using pelB leader sequence and showed mo-
lecular size of approximately 28.76 kDa. 
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INTRODUCTION
Malaria was a major global public health con-
cern due to the development of resistance by 
the most lethal causative species, Plasmodium 
falciparum. Natural products were potential 
sources of new antimalarial drugs (Bero, 2011; 
Nogueira, 2011). In vitro antimalarial activity 
screening of several Indonesian plants using 
HRP2 method showed that ethanol extract 
and ethyl acetate (EA) fraction of Alectryon 
serratus were active as an antimalarial  (Widy-
awaruyanti, 2014). The aim of this study is to 
identify Thin Layer Chromatography (TLC) pro-
file and investigate in vivo antimalarial activity 
of extract and fraction of Alectryon serratus 
leaves.  
MATERIALS AND METHOD 
Plant material and extraction
Leaves of Alectryon serratus was collected 
from Alas Purwo National Park, Banyuwangi, 
East Java, Indonesia, Authentication and iden-
tification of plant was carried out at the Pur-
wodadi Botanical Garden, East Java. 1 kg of 
powdered material was extracted using 80% 
ethanol by ultrasonic assisted extraction (UaE) 
for two minutes, three times replication. The 
ethanol extract were filtered, pooled, and 
dried at 40oC using rotary evaporator and 
weighed afterwards. 100 grams of crude ex-
tract was suspended in distilled water and 
partitioned with dichloromethane and ethyl 
acetate successively, which were in turn con-
centrated to dryness in rotary evaporator. The 
crude extract and fractions were kept in air 
tight containers and were stored at 4oC for use 
in phytochemical screening and antimalarial 
bioassay.
Phytochemical screening
Dried crude extract and ethyl acetate fraction 
(10 mg) was dilute in methanol. The phyto-
chemical screening was performed by Thin 
Layer Chromatography (TLC) method to de-
termine the content of chemical compound 
of extract and fraction using certain optimized 
mobile phase and sprayed by 10% sulphuric 
acid reagent.
Animals 
Male mice BALB/C strain were obtained  from 
LPPT-Universitas Gajah Mada, Yogyakarta. 
They were weighting between 20-30 g and 
maintained on standard animal pellets and wa-
ter ad libitum at Animal Laboratory of Institute 
of Tropical Disease, Universitas Airlangga. Per-
mission and approval for animal studies were 
obtained from Faculty of Veterinary Medicine, 
Universitas Airlangga. 
Rodent malaria parasite
Rodent parasites used were Plasmodium ber-
ghei ANKA strain. The parasite has been main-
tained at Institute of Tropical Disease, Universi-
tas Airlangga by passage in male BALB/C mice.
In vivo antimalarial activity test 
In vivo antimalarial activity was performed 
based on Peter’s test (The 4-days suppressive 
test) (Phillipson, 1991). 
Ethanol extract and ethyl acetat (EA) fraction 
were tested using 28 mice which divided to 7 
groups. 3 groups were treated using extract at 
a dose of 100 mg/kgBW, 10 mg/kgBW, and 1 
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 Picture 1. TLC Profile of extract Alectryon serratus
Picture 2.   Percentage parasitemia of ethanol extracts 
(a) and EA fraction (b) of A. serratus leaves against P. 
berghei.
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 a   b 
 
 a   b 
mg/kgBW, respectively. Meanwhile, 3 other 
groups were treated using EA fraction at a 
dose of 100 mg/kgBW, 10 mg/kgBW, and 
1 mg/kgBW, respectively.     One group was 
treated using CMC-Na 0.5% (as negative con-
trol). Each mice received 0,2 ml of diluted 
blood containing 5% P. berghei infected eryth-
rocytes by intraperitonial route. Treatment of 
extract, EA fraction and negative control was 
given at one day after inoculation of parasite 
by orally at day-0 until day-3 (four consecutive 
days).  Thin blood smears were made every 
day for 7 days (day-0 until day-6) and stained 
using 10% giemsa dye. Percentage of parasit-
emia and percentage of inhibition growth of 
P. berghei were calculated using the formula 
in below.
Percentage of parasitemia:  
Xe/Xk x 100%
Percentage of inhibition: 
100%-(Xe/Xk x 100%)
Xe: % parasitaemia growth of experimental 
group
Xk: % parasitaemia growth of negative control
Data analysis 
The ED50 (Effective dose) were analyzed using 
probit analysis (SPSS software).
RESULTS DAN DISCUSSION 
TLC profile showed that EA fraction of A. ser-
ratus (Picture 1, spot number 3) contained 
flavonoid compounds. 
In vivo antimalarial assay of ethanol extract 
and EA fraction of A. serratus was done on P. 
berghei infected mice at a concentration of 
100 mg/kgBW, 10 mg/kgBW and 1 mg/kgBW, 
respectively. The result showed that ethanol 
extract and EA fraction of A. serratus active as 
antimalarial agent with ED50 value of 13.82 
mg/kg BW and 5.92 mg/kg BW. Flavonoid 
compound is considered to take effect in an-
timalarial activity of EA fraction from Alec-
tryon serratus leaves. Further study to deter-
mine the active antimalarial compounds from 
A.Serratus leaves was needed. 
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CONCLUSION
Ethanol extract and EA fraction of A.serratus 
were very active as antimalarial agent (very 
active if ED50<100 mg/kgBW based on Mu-
noz, 2000). EA fraction had higher antimalarial 
activity with ED50 value of 5.92 mg/kgBW and 
potential to be develop as a new antimalarial 
drug. 
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INTRODUCTION
Influenza is one of the most common minor ill-
ness experienced and self-medicated by com-
munity (Sulistyarini, et al., 2010; Yuda, et al., 
2011). Influenza comprises a mixture of upper 
respiratory tract viral infections. Although it is 
self limiting many people choose to buy OTC 
medicines for symptomatic relief. Some of the 
ingredients of OTC cold remedies may inter-
act with prescribed drugs, occasionally with 
serious consequences. Therefore, these con-
sequences can be avoided  by carefully taking 
medicine history and selecting an appropriate 
product (Blekinsopp et al., 2009). The use of 
OTC medicines in the treatment of influenza is 
widespread and such products are heavily ad-
vertised to the public. There is little doubt that 
appropriate symptomatic treatment can make 
the patient feel better; the placebo effect also 
plays an important part here. The pharmacist’s 
role is to select appropriate treatment based 
on the patient’s symptoms (Blekinsopp et al., 
2009). Through patient assessment, commu-
nity pharmacist can guarantee the accuracy, 
safety, and rational self medication (WHO, 
1998; Blekinsopp et al., 2009).
This study aims to determine the knowledge 
of community pharmacists in patient assess-
ment with influenza and its products.
METHODS
Data collection
This research was conducted by cross sectional 
study. Questionnaire distributed to 100 com-
munity pharmacists in Surabaya. Respondents 
were taken by random sampling technique. 
PROFILE OF COMMUNITY PHARMACISTS KNOWLEDGE
IN PATIENT ASSESSMENT WITH INFLUENZA SYMPTOMS AND ITS 
PRODUCTS
Azza Faturrohmah, Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University Dharmawangsa 
Dalam Surabaya 60286, +62-31-5033710, azzaseza04@yahoo.com, Arie Sulistyarini, Department of Pharmacy 
Practice, Faculty of Pharmacy, Airlangga University
Dharmawangsa Dalam Surabaya 60286, Ana Yuda, Department of Pharmacy Practice, Faculty of Pharmacy, Air-
langga University Dharmawangsa Dalam Surabaya 60286. 
The study was conducted during the months 
of August to November 2010. 
Instrument
The questionnaire was consisted of closed 
and open questions. Closed questions related 
to respondent demographics. Open questions 
ask about patient assessment (extracting in-
formation) with influenza symptoms that 
were asked by pharmacist and drug product 
for self-medication. Open questions about 
patient assessments were provided four col-
umns of answers and about frequently ad-
ministered drug product of influenza were 
provided six columns.
Data analysis
Community pharmacists as respondents were 
classified into two categories. Respondents 
who could answer correctly more than half 
from four columns (3 & 4 answers) about 
patient assessment and six columns (4,5,& 
6 answers) about drug product of influenza 
were categorized as having good knowledge. 
On the other hand, respondents who could 
answer correctly less and half from those col-
umns were classified as having lack of knowl-
edge. 
RESULTS AND DISCUSSIONS
A total of 47 community pharmacists willing 
to fill out the questionnaire (response rate = 
47%). Demographics of respondents are pro-
vided in table 1, shows that the majority of re-
spondents were women, aged up to 50 years, 
and the working hour per week between 31 
to 50 hours.
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The total of respondents’ answers can be seen 
from Table 2, shows that majority of communi-
ty pharmacists had good knowledge (59.57%) 
in patient assessment with influenza symp-
toms. The mean of answer of respondents in 
this study was 2.66 with maximum point of 
four.  It shows that respondents willing to an-
swer of the four columns and also indicated 
that respondents were confidence with their 
knowledge.
As Table 3 shown, most of components of 
patient assessments that asked by commu-
nity pharmacists to patient were the duration 
of symptoms (18.60%), present medication 
(17.05%), high temperature (13.95%) and pre-
vious history (13.95%). Pharmacists should 
develop a method of information seeking 
that suitable for them. There is no right and 
wrong here. WWHAM is one of a mnemonic 
frequently used, although care needs to be 
taken not to recite questions in rote fashion 
The majority of pharmacists had good knowl-
edge which answered four until six products 
(89.36%) in providing examples of influenza 
medicine products that were often adminis-
tered at the their pharmacy (Table 4). In aver-
age, respondents gave 5.19 number of prod-
uct, from six of products. Interestingly, there 
were 6.38% (3) respondents who did not com-
plete the six columns at all. This result could 
be caused these respondents did this in pur-
pose for certain reason or did not know at all 
influenza medicines products. If the last cause 
happened, it indicates that respondents who 
were community pharmacists did not prac-
tice at all in their pharmacies so they had lack 
knowledge about those products. 
Table 2. Number of answers of respondents about 
patient assessment with influenza symptoms 
Number of answers Respondents, n(%) 
4 16 (34.04) 
3 12 (25.53) 
2 13 (27.66) 
1 3 (6.38) 
0 3 (6.38) 
Total 47 (100) 
Mean  2.66 
 
without considering their relevance to the in-
dividual case. Good listening will glean much 
of the information required. The mnemonic 
can help to ensure all relevant information 
has been obtained. Developing rapport is es-
sential to obtain good information, WHAM 
is abbreviation from: W – Who is the patient 
and what are the symptoms?, H – How long 
have the symptoms been present?, A – Action 
taken?, and M – Medication being taken? (Ble-
kinshopp, 2009)
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According to the respondents’ answers, the 
most often medicine products dispensed to 
patients with influenza symptoms in the phar-
macy for self-medication was Decolgen® (Ta-
ble 5). 
Table 4. Number of answers of influenza 
medicines products 
Number of answers Respondents, n(%) 
6 35 (74.47) 
5 3 (6.38) 
4 4 (8.51) 
3 0 (0.00) 
2 1 (2.13) 
1 1 (2.13) 
0 3 (6.38) 
Total 47 (100) 
Mean  5.19 
 
The results of this study show that medicine 
product of influenza that frequently adminis-
tered for self-medication contains more than 
one active ingredient. Products containing 
drug combination combinations should be se-
lected carefully in order to ensure that they 
are suitable for the symptoms and rational 
(Nathan, 2010). Pharmacists in particular can 
play a key role in giving advice to consumers 
on the proper and safe use of medicinal prod-
ucts intended for self-medication. Therefore, 
it is important to take this role into account 
both in their training and in practice (WHO, 
2000).
CONCLUSIONS
The majority of community pharmacists had 
good knowledge in influenza medicine prod-
uct than in patient assessment with influenza 
symptoms. This knowledge should be fol-
lowed up by interacting directly with patients 
as a form of professional responsibility of the 
community pharmacists to ensure the accu-
racy, security, and rational of self-medication. 
Improving directly interaction with patients 
can increase the role of the community phar-
macists and the quality of the self-medication 
service in the pharmacy.
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INTRODUCTION 
Ketoprofen is a NSAID (non-steroid anti inflam-
matory) that decreases inflammation, pain 
and fever, probably through non-selective in-
hibition of cyclooxygenase activity and pros-
taglandin synthesis (Sweetman, 2009). Use of 
ketoprofen is associated with two major limi-
tations; first, rare, but serious and sometimes 
fatal, gastrointestinal (GI) side-effects, and 
second, poor water solubility due to which its 
dissolution in GI fluid is very low, which in turn 
adversely affects the bioavailability (50–60% 
only) (Kaur et al., 2013). Based on BCS, keto-
profen is in class II that have poor solubility 
but high permeability (Shohin et al., 2011).
Dissolution rate is a function from solubility 
in a dissolution media, then it influences in 
absorption of insoluble drugs (Wadke et al., 
1989. Improvement of drug solubility will be 
increase on it absorption and bioavailibity 
(Jayshree et al., 2012).
Complexation is one of several ways to en-
hance the physicochemical properties of phar-
maceutical compounds. These complexes are 
formed when a ‘‘guest’’ molecule is partially 
or fully included inside a ‘‘host’’ molecule 
e.g., CD with no covalent bonding. When in-
clusion complexes formed, physicochemical 
parameters of guest molecule are altered and 
improvements in the molecule’s solubility, 
stability, taste, safety, bioavailability, etc., are 
commonly seen (Mosher & Thompson, 2007).
CDs are cyclic oligosaccharides derived from 
starch (Brewster & Loftsson, 2007). CDs are 
able to form water-soluble inclusion com-
plexes with many poorly soluble lipophilic 
drugs (Kurkov & Loftsson, 2013). Cyclodex-
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HIDROXYPROPYL-β-CYCLODEXTRIN INCLUSION COMPLEX
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Department of Pharmaceutics – Faculty of Pharmacy Airlangga University, Arafah Zulhana, Department of Pharma-
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trin have hydrophobic cavity and hydrophilic 
on surface. That makes be able to interac-
tion with the most molecules then form non-
covalent inclusion complexes (Brewster & 
Loftsson, 2007). Based on these dimensions, 
β-cyclodextrin will complex aromatics and 
heterocycles (Del Valle, 2004). β-cyclodextrin 
is the most commonly use. Because its rela-
tively poor solubility, so that derivated into 
hydroxypropyl-β-cyclodextrin (HPβCD) with 
high solubility and safe (Gould & Scott, 2005).
On this study, we made ketoprofen - 
hydroxypropyl-β-cyclodextrin (HPβCD) inclu-
sion complexes with kneading method. The 
advantage of kneading method is simple and 
only use small solvent (Patil, 2010). Then we 
did solubility and dissolution test of ketopro-
fen - hydroxypropyl-β-cyclodextrin (HPβCD) 
inclusion complexes.
MATERIALS, EQUIPMENTS AND METHODS
Materials
Ketoprofen;hydroxypropyl-β-cyclodextrinp.g.; 
ethanol p.a.; and aquadest
Equipments
- Spectrophotometer UV-Vis (Cary 50   
 Conc),
- Spectrophotometer IR (Jasco FT - IR   
 5300), 
- DTA (Mettler Toledo FP9 TA Cell), 
- Diffractometer X-ray Philips X’pert, 
- Sieve with mesh no. 60 (Retsch Type   
 ASTM), 
- Shaker, 
- Dissolution machine (Erweka DT 700),
- Glasses
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Methods
Inclusion Complex Preparation
In equimolar of ketoprofen and hydroxypropyl-
β-cyclodextrin (1:1) is prepared. Mix them 
until homogen. Little amount of ethanol are 
added into mixture until form kneaded mass 
(paste). Dried at 45oC oven in vacuum condi-
tion. Sieve mass with mesh 60.
Determination of Ketoprofen, Physical Mixture 
and Inclusion Complex Solubility
Prepare 50.0 mg or equivalent 50.0 mg keto-
profen then dissolved in buffer pH 1.2 on shak-
er at 37 ± 0.5oC 50 rpm until 5 hours (satu-
rated solubility). Observe the absorbances use 
spectrophotometer UV-Vis.
Dissolution test of Ketoprofen, Physical Mix-
ture and Inclusion Complex
Dissolution test was performed using appara-
tus II at 37 ± 0.5oC 75 rpm in phosphate buffer 
medium pH 7.4. Observe the absorbances of 
3, 5, 10, 20 and 30 minutes sample use spec-
trophotometer UV-Vis.
RESULTS
On this study, solubility and dissolution test 
of ketoprofen - hydroxypropyl-β-cyclodextrin 
(HPβCD) inclusion complexes.have done.
Table 1.  Ketoprofen,ketoprofen -   
 hydroxypropyl-β-cyclodextrin   
 physical mixture and inclusion   
 complex solubility at 37 ± 0,5oC
Table 2.  ED 30 of ketoprofen, ketoprofen  
 -hydroxypropyl-β-cyclodextrin   
 physical mixture and inclusion   
 complex
Table 3. Slope of ketoprofen, ketoprofen -  
 hydroxypropyl-β-cyclodextrin physi 
 cal mixture and inclusion complex
Table 4. Angle of ketoprofen, ketoprofen -  
 hydroxypropyl-β-cyclodextrin phys 
 ical mixture and inclusion complex
Based on dissolution test we can determine 
values of ED 30, slope and angle.
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CONCLUSSION
The study can be concluded that the solubil-
ity and dissolution rate of ketoprofen was in-
creased with ketoprofen – hydroxypropyl-β-
cyclodextrin inclusion complex prepared by 
kneading method.
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INTRODUCTION 
Non- Steroid Anti-Inflammatory Drugs (NSAIDs) 
are a class of drugs most often used in the 
treatment given by health personnel. Meloxi-
cam is one of NSAID drug that can be used in 
the treatment of arthritis, rheumatic, osteo-
arthritis, and other joint diseases. Meloxicam 
can cause GI disorders,dyspepsia,diarrhea, 
upper gastrointestinal tract infections, and 
nausea, in oral use. These side effects are 
reported to occur in 15-20 % of patients and 
mild when compared to piroxicam, diclofenac, 
and naproxen on long-term oral use (Aronson, 
2005). Topical gel was preffered as selected 
dosage form to prevent unwanted effects of 
Meloxicam. Gel preparation can provide a 
good drug release, has the ability to spread 
good, easily removed in case of irritation of 
the skin, and gives a cool effect when used 
(Voight, 1994). The poor solubility and wetta-
bility of meloxicam leads to poor dissolution of 
meloxicam in topical gel (Kumar and Mishra, 
2006). Pharmaceutical strategies that can be 
used to overcome the low solubility in Meloxi-
cam is the development in the form of solid 
dispersion (Anshu and Jain, 2011).
OBJECTIVES
The objectives of this research were to gener-
ates a stable NSAID drug product using solid 
dispersion technique  to prevent the occur-
rence of undesirable side effects of meloxi-
cam, but can provide an optimal bioavailability 
and therapeutic effect. 
METHODS
Meloxicam Solid Dispersion Preparation
Meloxicam solid dispersion systems were pre-
pared using PVP (1:1; 1:5; 1:7) and PEG 6000 
(1:1; 1:5; 1:8) and evaluated for its FTIR and 
DTA profile
Meloxicam Gel Preparation
Meloxicam-PVP solid dispersion gel
Table 3. Meloxicam-PVP gel formulation
Table 2. Meloxicam-PEG 6000 gel formulation
Meloxicam-PEG 6000 solid dispersion gel
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Meloxicam solid dispersion gels were stored 
in temperature 25°C and 50°C for 1 month in 
order to observed its stability. Meloxicam solid 
dispersion in topical gel were evaluated for 
color, viscosity, pH, drug content, rheological 
properties, spreadability and in vitro drug re-
lease.
RESULTS
Meloxicam Solid Dispersion FTIR Profile
Meloxicam-PVP solid dispersion was prepared 
using solvent method, on the other hand 
meloxicam-PEG 6000 solid dispersion was pre-
pared using fusion method. Solid dispersions 
were evaluated for its FTIR and DTA profile 
(see Figure 1, Figure 2, Figure 3 and Figure 4)
Meloxicam Solid Dispersion Gel Evaluation
Meloxicam gel were characterized for physi-
co-chemical properties such as color, viscos-
ity, pH, drug content, rheological properties, 
spreadability and in vitro drug release. The 
results shows that meloxicam-PVP gel have 
a significant when PVP composition was in-
creased. While meloxicam-PEG 6000 show no 
significant respon. Meloxicam solid dispersion 
gel release profile show no significant respon 
on stability testing (see Fig. 5 and Fig. 6)Figure 1. Meloxicam-PVP FTIR Profile
Figure 4. Meloxicam-PEG 6000 DTA Profile
Figure 5. Meloxicam-PVP DTA Profile
Figure 6. Meloxicam-PEG 6000 DTA Profile
Figure 2. Meloxicam-PEG 6000 FTIR Profile
Figure 3. Meloxicam-PVP DTA Profile
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CONCLUSION
The result shown that improving composi-
tion of meloxicam-PVP solid dispersion have 
a significant influence on the physico-chem-
ical characteristics of the gel formulation. In-
creased meloxicam-PEG 6000 solid dispersion 
composition did not have a significant influ-
ence on the physico-chemical characteristics 
of the gel, but significantly increase the rate 
of meloxicam in vitro release. Neither physico-
chemical characteristics nor meloxicam in vi-
tro release of gel show significant changes on 
stability testing at a temperature of 50˚C and 
25˚C for 30 days.
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INTRODUCTION
Inflammation is a non-specific immune re-
sponse that occurs in reaction to any type of 
bodily injury. The cardinal signs of inflamma-
tion can be explained by increased blood flow, 
elevated cellular metabolism, vasodilatation, 
release of soluble mediators, extravasation of 
fluids and cellular influx1. 
Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) are drug class which commonly used 
to treat inflammation. Diclofenac sodium is 
one of the drug class of non steroidal anti-in-
flammatory drugs (NSAIDs) are widely used to 
relieve pain and inflammation. Absorption of 
sodium diclofenac in oral delivery is very fast 
but only about 60% of which reaches the sys-
temic circulation, this is because first-pass me-
tabolism that occurs in the liver2. Half-life of 
diclofenac sodium was also very brief about 2 
hours and a few other side effects such as gas-
trointestinal disorders (ulcers in the stomach) 
and the reaction idionsynchratic. One way to 
overcome this problem, given by way of diclof-
enac sodium transdermal. Diclofenac sodium 
is not absorbed through the skin as perfect 
hydrophilic can be seen from log P of sodium 
diclofenac of 4.42, 
Absorption of sodium diclofenac into the skin 
can be improved by the addition of enhancers 
such as menthol. Adding one or more excipi-
ents could change dosage form characteris-
tics. This study was aimed to determine effect 
of menthol to patch characteristics when it 
added to diclofenac sodium membrane-typed 
patch.
METHODS
Material
Diclofenac sodium (Aarti Drugs Limited), al-
ginate sodium (Sigma-Aldrich), hydroxypro-
pil methylcellulose E-15 (ILE Pharmaceuti-
cal), propylenglycol (Bratachem), L-menthol 
(Bratachem), ethanol 96% (Bratachem), and 
aquades
Preparation of patch
Patches were made using formula in Table 1. 
Dose of diclofenac sodium in dosage is 100 
mg/50 cm2 patch. Sodium alginate were dis-
solve in water:ethanol (80:20) and stirred 
constantly to make alginate sodium 9%. Di-
clofenac sodium previously dissolved in same 
solvent and were added with alginate sodium 
9%, and stirred homogenously. The mixture 
were poured into mold and it dried on 45°C 
for an hour. HPMC E-15 were dissloved in wa-
ter to made 20% concentration. Propylengly-
col were added and stirred constantly. Men-
thol were dissolved in ethanol, previously, 
and were added to HPMC E-15 and propylen-
glycol, and stirred. This mixture were poured 
on to alginate sodium and dried on 40°C for 
an hour
Table 1 Formulation of diclofenac sodium membrane-
typed patch
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Organoleptic evaluation
Organoleptic evaluation were observed on 
patch characteristic, odor, and consistency.
Moisture content evaluation
The films were weighed and kept in a desic-
cator contain- ing calcium chloride at room 
temperature for 24 hours. Values for the per-
centage of moisture content, calculated as the 
percentage of difference between the con-
stant final and initial weight with respect to 
the initial weight.
Surface homogeneity
Surface homogeneity were observed using 
Scanning Electron Microscope (SEM) FEI IN-
SPECT S50 om magnification x1000.
Stabilty evaluation
Stability evaluation were performed 12 weeks 
(1,3,6,12 weeks), regarding to change of or-
ganoleptic, moisture content, and concentra-
tion of active ingredient (diclofenac sodium). 
Statistical analysis
The results were expressed as arithmetic 
mean ± SD. The statistical analysis was per-
formed using Anova one-way. The data was 
considered significant at p>0.05.
RESULTS
Organoleptic evaluation
As menthol added, there were only odor dif-
ference on patches. Their color and elasticity 
remain same.
The results of evaluation of diclofenac sodi-
um membrane-typed patch were summarize 
on Table 2.
The results of evaluation of diclofenac sodium 
membrane-typed patch were summarize on 
Table 2.
Figure 1.  Diclofenac sodium membran-typed patch  
 with and without menthol (left and right, re 
 spectively)
Figure 2. Scanning electrone microscope photograph  
 of diclofenac sodium membrane-typed trans 
 dermal patch with (left) and without (right)  
 menthol on magnification x 1000.
Table 2. Evaluation of diclofenac sodium membrane-
typed patch
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CONCLUSION
Menthol as penetration enhancer did not gave 
difference on diclofenac sodium membran-
typed transdermal patch characterization.
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ABSTRACT
Microsphere formulations have been widely 
used for oral applications. The aim of this re-
search was to study physical characteristics 
and release study of ovalbumin from alginate 
microspheres prepared by different concen-
tration of alginate polymer and BaCl2. This re-
search used concentrations of BaCl2 of 0,5M 
and 0,75M and concentrations of alginate of 
2,5% w/v and 3,5% w/v. Ionotropic gelation 
using aerosolisation technique was applied 
in this study. All ovalbumin – loaded alginate 
microspheres were characterized in terms of 
size, morphology, protein loading, encapsu-
lation efficiency, yield, and release profile of 
ovalbumin. In vitro release study was con-
ducted in the simulated gastric fluid (HCl pH 
1.2) and simulated intestinal fluid (PBS pH 7,4) 
at temperature 370C. Results showed spheri-
cal and smooth microspheres were produced. 
In addition, smaller particle size of less than 8 
µm was produced by increasing alginate and 
BaCl2 concentration. A factorial design ANOVA 
and one way ANOVA were used for statistical 
analysis at a 95% confidence interval. No sig-
nificant effect was shown by increasing algi-
nate and BaCl2 concentration on the protein 
loading, encapsulation efficiency, and yield. 
No significant differences of ovalbumin re-
lease were found when increasing concentra-
tion of BaCl2 from 0,5M to 0,75M, however 
ovalbumin release decreased by increasing al-
ginate concentration and slower release in HCl 
PHYSICAL CHARACTERISTICS AND RELEASE STUDY OF OVALBUMIN 
FROM ALGINATE MICROSPHERES PREPARED BY DIFFERENT CONCEN-
TRATION OF ALGINATE AND BACL2 USING AEROSOLIZATION TECH-
NIQUE
Dewi Melani Hariyadi, Faculty of Pharmacy Airlangga University, Dharmawangsa Dalam Surabaya, dewi-m-h@
ff.unair.ac.id,dewiffua96@yahoo.com ; Tristiana Erawati, Faculty of Pharmacy Airlangga University, Dharmawa-
ngsa Dalam Surabaya, era_ffua@yahoo.co.id ; 
Sisilia Ermawahyuningtyas, Faculty of Pharmacy Airlangga University, Dharmawangsa Dalam Surabaya
pH 1,2 during 2 hours followed by complete 
release in PBS pH 7,4 after 17 hours. 
Keywords: Microspheres, Ovalbumin, Sodium 
alginate, Aerosolisation, Release.
INTRODUCTION
Alginate microspheres have been investigated 
to protect antigen from acid pH and enzymatic 
degradation in gastrointestinal tract. The aim 
of this research was to investigate physical 
characteristics of ovalbumin-loaded alginate 
microspheres. Ovalbumin is egg white glyco-
protein that comprises 385 aminoacids (mo-
lecular weight 43 kDa) that easily denatured 
at high temperature and acid pH (O’neil et al., 
2001). Ovalbumin as a model antigen, could 
stimulate the formation of antibodies and im-
prove immunity. Administering oral antigen 
is the most effective way to induce immuno-
logical tolerance to protein antigens (Mowat, 
1985).
Current study applies ionotropic gelation 
method based on polyelectrolyte capability 
to form hydrogel using polymer and crosslink-
ing agent. Aerosolization technique was used 
because it is a cost effective, fast, simple tech-
nique. Moreover, it does not involve organic 
solvent which can contribute to protein in-
tegrity (Yeo et. al., 2001). Polymer is required 
to coat drug or the core of  active substance 
(Dubey et al., 2009). Sodium alginate is a bio-
degradable and biocompatible natural poly-
mer, non toxic to the body, cheap and most 
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F1: Alginate 2.5% and BaCl2 0.5 M; F2: Algi-
nate 2.5% and BaCl2 0.75 M 
F3: Alginate 3.5% and BaCl2 0.5 M ; F4: Algi-
nate 3.5% and BaCl2 0.75M
Morphology analysis
The morphology of microspheres were char-
acterized by optical microscope with camera 
and scanning electron microscopy (SEM). 
Protein Loading
Loading of ovalbumin into microspheres was 
analyzed following breakdown of 400 mg of 
microspheres suspensions in 50 mL sodium 
citrate solution over 12 hours at 1000 rpm 
at room temperature. The drug content was 
determined using protein quantification as-
say using UV spectrophotometry.
RESULTS AND DISCUSSION
The Aerosolization technique produced ho-
mogenous, small, smooth and spherical mi-
crospheres. Small particle size of less than 8 
µm was produced by increasing alginate and 
BaCl2 concentration (Table 2). 
This smaller ovalbumin-loaded alginate mi-
crospheres were suitable for oral admin-
istrtaion. Mishra et al (2008) that immune 
response after oral administration could be 
achieved from microspheres with 1-30 m 
in size. Manjanna et al (2010) reported that 
by increasing concentration of Ba2+ formed 
commonly used as polymer in the micropar-
ticles (Maria et al., 2012). Crosslinking agents 
are usually cations such as Pb2+, Cd2+, Zn2+, 
Cu2+, Co2+, Ca2+, Ba2+, dan Sr2+ (Gombotz et 
al., 1998). Barium ions have been extensively 
used as crosslinking agents because its ability 
to produce strong gel and high potential (Cio-
fani et al., 2007). In addition, Ba2+ resulted 
high biocompatibility with alginate and able to 
protect human cell from xenorejection follow-
ing transplantion (Lanza et al., 2007).
Several factors affect the microparticles prepa-
ration such as concentration of polymer and 
crosslinking agents (Jin et al., 2009). Higher 
polymer concentration produced bigger micro-
spheres, but more spherical in shape (Joshi et 
al, 2012). Crosslinking agents also influenced 
particle size. Lower crosslinking agents, pro-
duced fragile and amorphous microspheres, 
even it could not form the microspheres 
(Suksamra et al., 2009). Higher concentration 
of crosslinker produced smaller microspheres 
size as a result of stronger binding between 
them, but often resulted rough surface (Jin et 
al., 2009). Therefore, this research were con-
ducted to study the potential of ovalbumin-
alginate microspheres 
MATERIAL AND METHODS
Alginate microsphere preparation using  Iono-
tropic Gelation – Aerosolization Method
Preparation of alginate microsphere using 
using different concentration of alginate polymer and 
BaCl2 crosslinker. 
ionotropic gelation method by aerosolization 
techniques could be explained as follows: 
Alginate solution (concentration of 2.5 and 
3.5%) containing 2.5% ovalbumin was sprayed 
into crosslinking agent BaCl2 solution (con-
centration of 0.5 and 0.75M) at 40 psi and was 
stirred continously for 2 hours at 1000 rpm. 
The microspheres were collected by centrifu-
gation at 2500 rpm for 6 minutes, washed two 
times with aquadest and finally freeze dried 
20 hours at -80°C. Alginate microspheres for-
mulation were summarized in Table 1. 
Table 1. Ovalbumin-alginate microspheres 
formulation
Table 2. Particle size of formula F1,F2.F3 and F4.
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spherical and smaller microsphere’s size. This 
report was in agreement with Joshi et al (2012) 
and Singh dan Kumar (2012).
Figure 1 shows  that almost spherical morpho-
logical microspheres were produced by scan-
ning electron microscope. Some rough surface 
was maybe caused by no cryoprotectant agent 
to protect microspheres during freeze drying 
was added to stabilize microspheres. 
Figure 1. Scanning electron microscope of ov-
albumin-loaded alginate microspheres  
Encapsulation efficiency, protein loading and 
yield of microspheres can be seen in Table 3. 
Table 3. Encapsulation efficiency, protein load-
ing and yield of microspheres
It was observed that larger amounts of BaCl2 
(from 0.5Mto 0.75M), increased encapsulation 
efficiency ovalbumin in alginate microspheres 
(from 80% to 82% in formula F1 and F2; from 
90% to 92% in formula F3 to F4). An increase of 
encapsulation efficiency is most likely caused 
by larger amounts of availability of Ba2+ that 
crosslinked with carboxylates from guluronic 
acid in alginate indicates more ovalbumin was 
entrapped within alginate microspheres (Gu-
F2 F4
lati, et. al., 2011). This trend was also similar 
to an increase of alginate concentration.  The 
more number of alginate amounts, the more 
number of crosslinked alginate-BaCl2, re-
sulted the more ovalbumin was encapsulated 
(Manjanna et al, 2010). Similar studies were 
also confirmed that encapsulation efficiency 
increased by increasing concentration of poly-
mer and crosslinking agents (Joshi et al, 2012 ; 
Singh dan Kumar, 2012). 
In terms of yield, similar results were shown. 
Alginate microspheres produced using both 
alginate concentration (2.5 and 3.5%) using 
highest concentration of CaCl2 (0.75M) indi-
cated the highest yield of about 72% compare 
to formulas produced using lower concen-
tration of BaCl2. In the case of microspheres 
crosslinked using higher alginate concentra-
tion, the yield was also increased. This behav-
iour indicates that the more number of Ba2+ 
contact with alginate provide a gel network 
that able to increase yield of microspheres (Jin 
et.al., 2009). 
There was no significant differences of all 
loading’s formula. This may be explained by 
similar strength and network between carbox-
ylates and Ba2+ ions produce similar amount 
of space for ovalbumin inside microspheres.
In terms of release study, formula F2 and F4 
were incubated in HCl medium for 2 hours fol-
lowed by PBS buffer pH 7.4 for 1020 minutes. 
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Figure 2. Profile of ovalbumin release from al-
ginate microspheres
Results of release profile showed that ovalbu-
min-loaded alginate microspheres was able 
to protect protein from acid degradation, in-
dicated by very small amount of ovalbumin 
was released during 2 hours incubation in 
acid pH (less than 25%) in both formulas (Fig-
ure 2). Moreover, 100% ovalbumin released 
from F2 microspheres in 900 minutes, where-
as complete released of ovalbumin from F4 
microspheres was occurred after 1020 min-
utes. However, the differences of ovalbumin 
release were not significant. It may be due 
to the similar swelling behaviour of alginate 
microspheres in pH 7.4 followed by diffusion 
of ovalbumin from the matrix. By increasing 
alginate concentration, the viscosity of algi-
nate increased therefore avoid ovalbumin re-
lease from the matrix and slower the rate of 
release. From the results, this delivery system 
may be potential as protein or vaccine delivery 
system.
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INTRODUCTION
Diabetes mellitus (DM) is a metabolic disease 
with chronic hyperglycemia that occurs due to 
abnormal insulin secretion, insulin damage, 
or a combination of both (Dipiro et al., 2009). 
Based on data from the Ministry of Health, 
diabetes prevalence rate in Indonesia, 2008, 
reached 5.7% of Indonesia’s population or 
about 12 million people. In Central Java, the 
prevalence of type 2 diabetes has increased 
from 2006 to 2008, 0.83% in 2006, 0.96% in 
2007, and 1.25% in 2008 (Anonymous, 2008). 
The increasing prevalence of diabetes same 
with increasing risk factors, like obesity (over-
weight), lack of physical activity, lack of fiber 
consumption, smoking, hypercholesterolemia, 
hyperglycemia, and others.
Treatment of diabetes mellitus use traditional 
medicine is mostly done by developing coun-
tries such as Indonesia. Traditional medicine 
has no side effects compared to synthetic 
drugs. Traditional drug therapy for diabet-
ics can be obtained from various medicinal 
plants, which one is sambiloto (Andrographis 
paniculata).
Antidiabetic effects of sambiloto have been 
shown in rabbits and diabetics. In testing us-
ing the glucose tolerance test, the non-polar 
components of sambiloto has no activity to 
decrease blood sugar. Decreases blood sugar’s 
activity found in the polar components, name-
ly ethanol extract (Soetarno et al., 1999).
The use of sambiloto liquid extract’s for the 
treatment of diabetes mellitus less attractive 
to consumers / patients because sambiloto 
has a bitter taste and is used repeatedly in a 
day. One way to make effective preparation 
of sambiloto in diabetes mellitus treatment 
is make it become Mucoadhesive dosage in 
tablet form so it is not too bitter and can used 
once a day. Mucoadhesive drug delivery sys-
tems purpose to extend the residence time of 
the preparation at the site of application or 
extend the time of absorption and facilitate 
contacts between preparations with strong 
absorption surface so that it can fix and / or 
improve the performance of drug therapy 
(Agoes, 2008). Preparation of Mucoadhesive 
tablets requires a polymer bioadhesive. One 
type of polymer is chitosan bioadhesive (Ber-
nkop-Schnurch, 2002).
Chitosan is obtained from chitin deacetylation 
leaving a free amino group that can make 
polycationic nature (Khan et al., 2002). Chi-
tosan has been shown to have Mucoadhesive 
properties due to the electrostatic interaction 
between the positively charged chitosan and 
negatively charged mucosal surfaces. Chito-
san has one primary amino group and two 
free hydroxyl groups for each monomer. Free 
amino groups in chitosan carries a positive 
charge then reacts with the surface/negative-
ly charged mucus (Bernkop-Schnurch et al., 
2004).
Based on that description, it is necessary to 
make a research on the formulation of the 
ethanol extract of sambiloto in Mucoadhesive 
tablet form so it can prolong the contact time 
of the drug with the intestinal mucosa, and 
improving the absorption of the drug. Drug 
absorption has important influence on the 
therapeutic effects of the drug in the body.
51
METHODS
Materials and Equipments
The materials of this study include: simplicia 
of sambiloto (Andrographis paniculata) pur-
chased in the Wage Market Purwokerto, chi-
tosan, 70% ethanol, lactose, magnesium stea-
rate, talc, potassium dihydrogen phosphate 
(KH2PO4), disodium hydrogen phosphate 
(Na2HPO4), hydrochloride acid (HCl), sodium 
hydroxide (NaOH), aquadest, NaCl, fresh cow 
intestines.
The equipments of this study include: analyti-
cal balance, blender, water bath, stirrer, filter, 
spatulas, bowls vaporizer, stopwatch, calipers, 
evaporators, oven, sieve mesh (5, 14, and 16), 
single punch tablet machine, mucoadhesive 
tester (rotating cylinder), friabilator, dissolu-
tion tester from Erweka DT600, filter paper, 
glass apparatus.
Experimental Procedure
Preparation of ethanol extract of sambiloto
1. Preparation of simplisia
 To make simplisia of sambiloto’s pow 
 der, we used a blender and sieved with  
 a 5 mesh sieve until we get granules to  
 be easy for the extraction of sambiloto  
 leaf.
2. Preparation of Ethanol Extract Sambi 
 lo to The simplisia are macerated using  
 70% ethanol with ratio 1:4 in a closed  
 container, then stirred and allowed to  
 stand for 24 hours.
a) Every day after 24 hours, squeezed and  
 filtered with filter paper and a Buchner  
 funnel. Then squeezed again with 70%  
 ethanol for 3 days.
b) Liquid maceration and pulp results   
 mixed together.
c) The results of the extraction solvent was  
 evaporated to help separate and extract  
 condensed
d) The evaporated allowed for one   
 day and concentrated on a water bath  
 until a constant volume.
3.   Preparation of Tablets
 a. Tablet formulation
 Preparation of ethanol extract   
 of sambiloto granules made using   
 wet granulation method by varying   
 the amount of chitosan. The number of  
 active substances used in the formula 
 tion is determined based on the dose  
 that has been studied by Nugroho et al.  
 (2012), which is 150 mg.
 Table 1. Formula of tablets Ethanol Ex 
 tract of sambiloto leaf
 b. Preparation of granules (granulation) 
  The phases of making granules were: 
 1) Ethanol extract of sambiloto, chi  
  tosan, lactose, talc, and Mg-stearate  
  was weighed.
 2) The ethanol extract was mixed with  
  partially lactose, and then added   
  to the chitosan. The materials are  
  mixed  and stir until homogeneous,  
  then added residual lactose. 
 3) The result sieved using a 14 mesh  
  sieve. 
 4) After become granules, spread out  
  on a sheet of aluminum foil on a flat  
  tray and dried in an oven at a tem 
  perature of 40 - 60⁰C. 
 5) The dried granules were sieved with  
  a 16 mesh sieve. 
 6) Then magnesium stearate and talc  
  as the outer phase is added to the  
  granules, mixed until homogeneous. 
 7) Granules were prepared felted mass.
 c.  Examination of Flowing Properties  
  of granules Examinations of the
  flowing proer     
 
Formula 
Materials  
1 2 3 4 
Ethanol extract of 
sambiloto (mg) 
150 150 150 150 
Chitosan (%) 20 40 60 80 
Laktose (%) 77 77 77 77 
Talk (%) 1 1 1 1 
Mg-stearat (%) 2 2 2 2 
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 ty  of granules were observed by station 
 ary angle and flowing time methods.
 1) Angle of repose Method
  Angle of repose measurement is   
    carried out by weighing 100 g of gran 
  ules, the granules inserted into the  
  funnel flow time test standing at a  
  height H above the graph paper in  
  the horizontal plane. Cover is opened  
  so that the granules out and placed  
  on a flat surface (Carstensen, 1977).  
  Measurements replicated three   
  times. Angle of repose can be calcul 
  ated by the formula:
 2) Flowing time
  The flow time measurement method  
  is done by weighing 100 g of gran
  ules, the granules then inserted into
   the funnel that closed. Cover is   
  opened and the granules allowed to  
  flow until the end. Calculated flow  
  time granule. The granules have good  
  flow properties when it has a flow  
  time of no more than 10 seconds   
  (Fudholi, 1983). Measurement of   
  flow time was replicated three times.
 d. Tablet compression
  Compression tablets using a single  
  punch tablet machine to adjust the  
  size and weight of the tablet mass.  
  When the tool has finished setting,  
  granules were prepared and then in 
  serted through the hopper and the  
  machine starts (Voigt, 1994).
 e. Evaluation of Tablets
 1) Physical Characteristic
  Tests of physical characteristic de  
Description:   = stationary angle
H = height 
R = radius or ½ d
  scriptively include testing for uni
  formity  of color, presence or ab  
  sence of odor, surface shape, consis 
  tency, and presence or absence of 
  physical defects  (damage).
 2) Uniformity of size
  Each formula is taken 20 tablets,   
  then the tablet’s diameter and tab
  let’s thickness was measured using  
  calipers and analyzed with the stan 
  dard of uniformity in the size of the  
  tablet edition of Indonesian Pharma 
  copoeia III (Anonymous, 1979).
 3) Weight uniformity
  Each formula is taken 20 tablets,
   and tablets that free from dust,   
  weighed and the average weight was  
  calculated, and then matched with a  
  table percentage weight deviation al 
  lowed in the third edition of the Indo
  nesian Pharmacopoeia (Anonymous,  
  1979).
 4) Hardness test
  Each formula is taken 10 tablets,   
  then one by one tablet is placed in  
  the middle to the hardness tester,
   first scale on the zero position, and  
  then the tool rotated slowly until the  
  tablet breaks. Read scale achieved  
  when broken or crushed tablets (Voi 
  ght, 1994). Hardness is expressed in  
  kilograms. The tablet has a hardness
   between 4 kg to 10 kg (Parrott,   
  1971).
 5) Friability (fragility)
  According Agoes (2006), 20 tab
  lets of each formula that free from  
  dust, placed in friabilator. Friabila tor
   run 4 minutes or 100 times a round.  
  Tablets were taken and cleaned of  
  particles attached, by weight, calcu 
  lated the percentage in weight. The  
  total weight of the tested tablets   
  should not be reduced by more than  
  1 % of the initial weight of the test.  
  Testing was replicated three times.
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  Friability test results can be calculat 
  ed using the following equation:
 
   
  Description: 
  W0 = initial weight of the tablet be 
  fore intervened friabilator
  Wt = weight of tablet after inter  
  vened friabilator
 f. In vitro evaluation of mucoadhesive  
  properties by the rotating cylinder  
  method 
  Tablet attached to the pressure of  
  500 Pa in the intestinal mucosa of
   cow, which was attached to a stain
  less steel cylinder (diameter 4.4 cm,  
  height 5.1 cm, the 4-cylinder, USP  
  XXVI) using cyanoacrylate adhesive.  
  The cylinder is placed in the dissolu 
  tion apparatus according to USP, en
  tirely immersed in the dissolution  
  medium of 100 mM phosphate buf 
  fer pH 6.8, at a temperature of 37ºC  
  and stirred at 100 rpm. Testing tools  
  can be seen in picture 1. Tablet test  
  apart, disintegrated and/or eroded
   observed for a period of 10 hours  
  (Bernkop-Schnurch, 2002).
 
  Picture 1. Testing system scheme   
  which is used to evaluate the propert
  ies of mucoadhesive tablets based  
  on various polymers. c: cylinder, if: in 
  testinal fluid, m: bovine intestinal mu
  cosa, t: tablets (Bernkop-Schnurch,  
  2002).
 g. Data analysis
  Data results of testing the physical  
  properties of granules and tablets  
  compared to physical evaluation re 
  quirements of tablets according to  
  the third edition of the Pharmaco  
  poeia of Indonesia (1979), Indonesia  
  Pharmacopeia IV edition (1995), and  
  related literature .
RESULTS AND DISCUSSION
Results of determination of plant stated that 
the plant is sambiloto with the scientific name 
of Andrographis paniculata (Burm f .) Nees. 
Dry powder of sambiloto was 1788 mg, ob-
tained after the extraction process as much as 
153 mg of extract thick, mean yield of extract 
of dried powder is 8.56%. Viscous extract ob-
tained was then conducted organoleptic test. 
The results of the ethanol extract of sambiloto 
organoleptic test are shown in Table 2.
Table 2. The results of organoleptic test etha-
nol extract of sambiloto
Ethanol extract of sambiloto granules that 
made by wet granulation subsequent physical 
characteristic test, including flowing proper-
ties of granules and granule moisture content. 
Data of flowing properties of granules are pre-
sented in Table 3 .
Table 3. Test results of flowing properties of 
ethanol extract of sambiloto
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* replicated 3 times.
Based on Table 3 , known that all formulas 
have the flowing time and repose angle quali-
fied because 100 grams of ethanol extract of 
sambiloto granules flowing less than 10 sec-
onds and repose angle less than or equal to 
30⁰. Repose angle measurement shown that 
the higher amount of chitosan added, the 
smaller repose angle got. It means that the 
addition of chitosan effect on repose angle of 
granules.
Test of flowing time and repose angle describe 
the flowing properties of granules. Good flow-
ing properties of the granules is essential 
to ensure efficient mixing and uniformity of 
weight (Siregar and Wikarsa, 2005).
Flowing properties are affected by particle 
size, particle shape, moisture granules, gravity 
and friction forces 
Based on Table 3 , known that all formulas 
have the flowing time and repose angle quali-
fied because 100 grams of ethanol extract of 
sambiloto granules flowing less than 10 sec-
onds and repose angle less than or equal to 
30⁰. Repose angle measurement shown that 
the higher amount of chitosan added, the 
smaller repose angle got. It means that the 
addition of chitosan effect on repose angle of 
granules.
Test of flowing time and repose angle describe 
the flowing properties of granules. Good flow-
ing properties of the granules is essential 
to ensure efficient mixing and uniformity of 
weight (Siregar and Wikarsa, 2005).
Flowing properties are affected by particle 
size, particle shape, moisture granules, gravity 
and friction forces 
between particles. If a large particle size and 
spherical shape as well as gravity and friction 
forces small, it will be faster and easier flow-
ing. The more flat cone generated, then the 
smaller the tilt angle and the better of the 
flowing properties. Based on the results of the 
study, increased of chitosan will accelerate the 
flowing time. This is due to the formula with 
the higher chitosan concentration resulted 
in large granules, granules that are large will 
have little friction so the flowing time is small 
(Lachman et al., 1994; Voigt, 1995).
The results of the determination of moisture 
content of the ethanol extract of sambiloto 
granules can be seen in Table 4 .
Table 4. The results of the determination of 
moisture content of ethanol extract of sambi-
loto granules.
* replicated 3 times
Based on the data in Table 4, shows that the 
granules of all formulas qualify moisture con-
tents, because the content is in the range 2-4% 
moisture. According to Lachman et al., (1994) 
that the good moisture content of the gran-
ules is 2-4%.
The test results of physical characteristic etha-
nol extract of sambiloto tablet can be seen in 
Table 5. Physical characteristic showed that 
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tablets produced relatively good. Greenish 
black color tablet, the younger of the formula 
1 to formula 4, it is caused by increasing of chi-
tosan. The more chitosan used in this study re-
sulted in younger creamy white colored tablet 
produced.
Uniformity test results measure the ethanol 
extract of sambiloto tablets are presented in 
Table 6 .
Tabel 5. The results of testing the physical 
characteristic of tablets
Table 6. Test results of tablet size uniformity 
ethanol extract of sambiloto
Based on the data in Table 6, it is seen that 
all the tablets eligible with requirements of 
uniformity of size . Thus, the ethanol extract 
of sambiloto tablet can be declared to have 
good size uniformity. One good indicator is ex-
pressed tablet is a tablet that has a good size 
uniformity.
Tablet weight uniformity test results of ethanol 
extract of sambiloto can be seen in Table 7.
Table 7. The results of uniformity test of etha-
nol extract of sambiloto tablet
Based on the data in Table 7, it is seen that all 
formula eligible weight uniformity, because 
none of the tablets deviated 5% and 10% of 
the average weight of the tablet and has a CV 
less than 5%. Tablets with a good weight uni-
formity can be assumed that the levels of ac-
tive ingredient in the tablet as well uniform so 
that the therapeutic effect produced identical 
(Anonymous, 1979; Voigt, 1995).
The results of hardness test of the ethanol 
extract of sambiloto tablets are presented in 
Table 8.
Table 8. The results of hardness test of etha-
nol extract of sambiloto tablets
Based on the data in Table 8, it is seen that 
all formulas eligible with tablet hardness 
scale between 4-10 kg (Anonymous, 1979). 
Hardness of formula 1 to formula 4 is getting 
smaller. Formula 1 with the highest levels of 
chitosan has the greatest hardness is 4.15 kg. 
Supposedly greater levels of chitosan will in-
crease the bond between chitosan with other 
ingredients to produce a stronger bond and 
tablets are formed more compact and hard. 
But the results showed different results, this 
was caused by the size of the chitosan used 
larger than it should be. The size of chitosan 
amorphous powder/powder causes compact-
ibility less than the maximum.
The results of ethanol extract of sambiloto 
tablet friability test can be seen in Table 9.
Table 9. The results of friability test of ethanol 
extract of sambiloto tablets
*replicated 3 times
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Based on the data in Table 9, shows that the 
friability test of formula 1 to formula 3 were 
eligible, because of losses weight were not 
more than 1% ( Banker and Anderson , 1994). 
Friability formula 4 wasn’t eligible, because 
the amount of chitosan used was more than 
it should, where the size of chitosan was large, 
so tablet compactibility and hardness wasn’t 
good. Compactibility and hardness of tablets 
are good enough to make the tablets brittle. 
Tablet which has a high hardness means have 
strong bond between particles, so it is not eas-
ily damaged by shocks.
Friability is a parameter to assess the resil-
ience of the tablet to a variety of things that 
can cause damage to the surface of the tablet 
(Ansel, 1989). According to Voigt (1995) fri-
ability is expressed as the mass of the entire 
particle released from the tablet due to me-
chanical load testers . Friability expressed as a 
percent of friability which refers to the mass of 
the initial tablet before testing.
Friability test is very important because tablet 
that easily crushed into powder, flakey, and 
cracked in handling will loses its aesthetic val-
ue so the consumer won’t accept it, it also can 
caused contamination at the site of the trans-
port and packaging, and also caused variations 
in tablet weight and content uniformity (Bank-
er and Anderson, 1994).
At the time of the tablet contacted with a solu-
tion of phosphate buffer pH 6.8, all formulas 
tablet looked swell and form a hydrogel, and 
stick/attached firmly to the intestinal mucosa. 
Adhesion of tablets on the intestinal mucosa 
can be seen in Picture 2 .
Picture 2. Adhesion to the intestinal mucosa 
tablet
Hydrophilic chitosan can undergo hydration 
contact with water and form a hydrogel that 
expands into a tablet formula (Varshosaz et al., 
2006). Hydrogels are three- dimensional cross 
linked polymer chains that have the ability to 
hold water in the porous structure. This hydro-
gel is formed by the presence of hydrophilic 
functional groups, such as hydroxyl, amino, 
and carboxyl. In the chitosan structure, there 
is a hydroxyl group that can form a chitosan 
hydrogel (Mythri et al., 2011).
Tablet expands slowly because chitosan has 
the ability controlled hydration (Jain et al., 
2008). Hydration is controlled to prevent the 
occurrence of excessive hydration. Excessive 
hydration would reduce the flexibility of the 
polymer chains due to the formation of cross 
linked polymer chains thereby limiting exces-
sive interpenetration of polymer chains into 
the mucus and eventually will reduce muco-
adhesive strength (Mythri et al., 2011).
In theory, this mucoadhesive phenomenon 
takes place in two steps. The first step is a con-
tact between the polymer bioadhesive (chi-
tosan) and mucus due to wetting and devel-
opment of bioadhesive materials (chitosan). 
The second phase is consolidation, a process 
where bioadhesive polymer penetrate into 
crevices and surface mucus occurring chemi-
cal bonds between the polymer and mucin 
bioadhesive (Carvalho et al., 2010). Mucoad-
hesive properties test results in vitro are pre-
sented in Table 10 .
Table 10. The results of in vitro testing muco-
adhesive properties tablets ethanol extract of 
sambiloto
*replicated 3 times
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on Table 10, it is seen that of formula 1 to for-
mula 4 with the increasing of chitosan result-
ed in an increase in mucoadhesive properties. 
Formula 4 with the highest levels of chitosan 
having the greatest mucoadhesive properties 
that can be attached for 23 minutes 16.33 
seconds, while the lowest adhesion owned by 
Formula 1 with the lowest levels of chitosan 
which can be attached for 4.33 minutes 25,67 
seconds. This is due to the higher levels of chi-
tosan used; the ability of bonding with mucin 
is stronger. Chitosan has hydroxyl groups that 
are responsible for adhesion. Mucoadhesive 
properties possibbly caused by the forma-
tion of hydrogen bonds between the hydroxyl 
groups of the chitosan with mucus compo-
nents and ionic bonds between atoms N in chi-
tosan with the S atom of cysteine contained in 
the mucus layer (Majithiya et al., 2008; Sreeni-
vas and Pai, 2008). Hydrogen bonds are the 
bound between the H atoms in the molecule 
which attracted by the highly electronega-
tive atom, in example F, O, or N from adjacent 
molecules. While the ionic bond is a bound 
that is formed due to the difference in charge 
between the two components, between chi-
tosan and mucin (Petrucci, 1985). The higher 
levels of chitosan used, the stronger bond pro-
duced, so the mucoadhesive properties will be 
stronger (Majithiya et al., 2008). 
CONCLUSION
Ethanol extract formula of sambiloto tablets 
made by using chitosan as a carrier qualify 
physical characteristic of tablets (physical ap-
pearance, uniformity of size, weight uniformi-
ty, hardness, and friability). Increased levels of 
chitosan on the ethanol extract of sambiloto 
tablets can improve mucoadhesive properties. 
Formula 4 with the highest levels of chitosan 
have the strongest mucoadhesive properties 
which can be attached for 23 minutes 16.33 
seconds, while the lowest power possessed 
by the formula 1 with the lowest levels of chi-
tosan which can be attached for 4.33 minutes 
25.67 seconds.
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INTRODUCTION
Ibuprofen is a non steroid anti-inflammatory 
drug (NSAID) derived from propionic acid [3]. 
It has low aqueous solubility but high perme-
ability so it is classified into BCS (Biopharma-
ceutical Classification System) Class II [6]. High 
cohesivity and adhesivity cause ibuprofen has 
bad powder flow and also contributes to its 
high tendency for sticking to the punch. Gran-
ulation step is necessary in ibuprofen tableted 
dosage form manufacturing due bad compac-
tion behaviour [9]. Thus, addition of appro-
priate excipients is hardly avoidable in order 
to improve powder properties in ibuprofen 
tableted dosage form formulation.
Pharmaceutical dosage form manufacturing 
always involves heat and mechanical energy 
during the process [10]. This energy could in-
duce interaction between drug and excipient 
molecules [10] as well as eutectic formation. 
Eutectics are intimate crystalline mixture of 
one compound in another and it has unique 
property in its lower melting temperature 
than that pure compound. Generally, eutectic 
interaction does not impact the pharmacologi-
cal activity, but may contribute in alteration of 
the pharmaceutical properties. Unintentional 
eutectic formation in tableted dosage form de-
velopment have been reported to lead to un-
wanted changes in the physical and/or chemi-
cal characteristics of the tablets [2].
Ibuprofen is a kind of drug that forms eutec-
tic with some kind of excipients as reported in 
many studies [7, 11, 1]. It has been identified 
by DSC analysis that ibuprofen forms eutectic 
with stearic acid [7], one of most frequently 
used lubricant [4]. Therefore, further physical 
characterization was conducted in this study 
for better understanding of eutectic formation 
in ibuprofen-stearic acid binary system.
MATERIALS AND METHODS
Materials
Ibuprofen was purchased from Shasun Chemi-
cals and Drugs Ltd., India. Stearic acid was ob-
tained from Hense Chemicals Manufacture 
Ltd., China.
Binary mixture was prepared by weighing 
each compound separately and mixing them 
gently in a mortar at ambient temperature. 
Weight ratio of 4:6 of ibuprofen and stearic 
respectively was used for each binary system. 
Eutectic formation of binary mixture was in-
duced by heating the prepared binary mixture 
upon water-bath at temperature about 70C.
Methods
Hot Stage Microscopy
Hot stage microscopy was performed under 
polarizing microscope observation equipped 
with heating apparatus. The higher melting 
compound, which is ibuprofen, was melted 
first on a microscope slide to occupy about 
half the area under cover slip. After the first 
compound had cooled and solidified, the sec-
ond compound, stearic acid with lower melt-
ing temperature, was placed at very edge of 
cover slip, near the first compound. The sam-
ple was heated until stearic acid completely 
melted to contact with solidified ibuprofen. 
Then, the sample was allowed to cool. After 
the sample had solidified, the contact area of 
two compounds was observed whilst the tem-
perature was gradually raised.
X-ray Powder Diffraction
X-ray powder diffraction data were obtained 
using a Phillips Xpert X-ray diffractometer, 
Netherland, with CuK radiation (1,54Å), at 
40 kV and 30 mA, and passing through a nick-
el filter with divergence slit (0,25). Samples 
were scanned over 2 range of 5-50 with 
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step size of 0,017.
Scanning Electron Microscopy
Scanning electron-micrographs of crystal of 
pure compounds and binary mixture were col-
lected by a Hitachi TM3000, Japan. Observa-
tion was conducted by magnification of 1000. 
Samples were fixed on aluminium stub with 
conductive double-sided adhesive tape and 
coated with gold in a low vacuum atmosphere.
Fourier Transform Infrared Spectroscopy
Fourier transform infrared spectra were ob-
tained using a Shimadzu 8400s FTIR spectrom-
eter, Japan. Samples of ~2 mg were mixed with 
300 mg potassium bromide and then com-
pressed in a hydraulic press to form transpar-
ent disc. Each sample was analysed from 4000 
to 400 cm-1.
RESULTS AND DISCUSSION
Hot stage microscopy was performed to iden-
tify the type of physical interaction between 
two compounds. It is a simple technique to 
understand phase behaviour in binary sys-
tem upon heating. Under polarizing micro-
scope, only crystalline phases will be visible 
because they direct the polarized light and, in 
other hand, liquid phases allow the light to pass 
through unchanged so no light reaches micro-
scope [5]. Crystalline phases will be seen full of 
colours with different intensity which is affected 
by fragment orientation, thickness, and polar-
ized light absorbed or pass through crystalline 
fragment [13]. When crystalline phases melt to 
form liquid phases, it will be quickly seen and 
recognized as a black line or region [5].
Figure 1 shows the behaviour of ibuprofen and 
stearic acid under hot stage microscopy ob-
servation. Area of A.1 and B.1 is re-crystallized 
phase of ibuprofen, A.2 and B.2 is re-crystallized 
phase of stearic acid, A.3 and B.3 is contact area 
of two compounds. It’s clearly seen that contact 
area of two compounds is melted first than the 
pure compound when temperature increases 
(Figure 1 B), leaving single blank line between 
crystalline phases. This single eutectic forma-
tion indicates conglomerate crystallization [5].
Figure 1 The mixed fusion behavior of ibuprofen 
and stearic acid, A. Contact area is formed, and B.  
Contact area is melted first.
Eutectic formation between two compounds 
also shown thermal analysis study we con-
ducted (result not shown). Diagram phase 
obtained from DTA analysis of various weight 
ratio binary mixture in our study shows simi-
larity pattern compared to previous study by 
Lerdkanchanaporn et al. (2001).
Figure 2 X-ray diffractograms of A. Ibuprofen, B. 
Stearic acid, C. Binary mixture in 4:6 weight ratio, and 
D. Eutectic-formed binary mixture in 4:6 weight ratio.
The crystalline nature of binary mixture of 
ibuprofen and stearic acid was examined by X-
ray powder diffraction of binary mixture and 
eutectic-formed binary mixture as well as each 
pure compound.
Ibuprofen showed numerous strong diffraction 
peaks in 2 of 6.07, 12.18, 16.71, 17.71, 
18.83, 19.59, 20.32, 22.45. Stearic acid 
showed few strong diffraction peaks in 2 of 
6.94, 11.62, 21.49, and 23.91. These pure 
compound peaks superimpose each other as it 
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shown in X-ray diffractogram of binary mixture 
in 4:6 weight ratio (Figure 2 C). Eutectic-formed 
binary mixture showed similar X-ray diffraction 
pattern with binary mixture and it also shown 
superimposition diffraction peaks of the pure 
compound. This phenomenon indicates eutec-
tic formation between ibuprofen and stearic 
acid do not result new crystalline phase but 
conglomeration two crystalline in solid state. 
Difference of peak intensity showed shifting 
on degree of crystallinity [13].
CONCLUSION
Identification of physical interaction with hot 
stage microscopy showed eutectic formation 
of ibuprofen and stearic acid leads to con-
glomerate crystallization. It is supported by X-
ray powder diffraction that is diffraction peak 
superimposition characterizes conglomeration 
phenomena. Eutectic formation also leads to 
disappearance of ibuprofen crystal amongst 
stearic acid existence. Moreover, hydrogen 
bonding interaction is present in eutectic for-
mation of two compounds. The study pre-
sented here allows a better understanding of 
the drug/excipient phase behavior in binary 
system.
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INTRODUCTION
Cancer is a top killer of human beings. There 
is an urgency to develop highly efficacious and 
minimally toxic treatments for cancer. Most of 
the current cancer drugs usually exhibit high 
toxicity and are severely resisted by tumor 
cells in the clinic. This dilemma is particularly 
true for DNA-damaging agents, the mainstay 
of cancer treatment (Tao et al, 2007). Follow-
ing DNA damage, normal cells arrest and at-
tempt to repair at the cell cycle checkpoints G1 
and S phases through tumor suppressor p53, 
and at G2 and S phases through checkpoint 1 
kinase (Chk1) (Zhao et al, 2010). Checkpoint 
Kinase-1 (Chk1, CHK1, CHEK1) is a Ser/Thr 
protein kinase that mediates the cellular re-
sponse to DNA-damage. Upon DNA-damage, 
Chk1 is activated by ATM and ATR kinases, 
which phosphorylate residues Ser-317 and/or 
Ser-345. Chk1 mediated signaling ultimately 
leads to S-phase or G2/M cell cycle arrest pri-
marily driven by Cdk inhibition. Consequently 
Chk1 inhibition would abrogate this arrest, 
and therefore permit a cell with damaged DNA 
to continue through the cell cycle, ultimately 
resulting in mitotic catastrophe and/or apop-
tosis (Oza et al, 2006). Thus, selective inhibi-
tors of Chk1 may be of great therapeutic value 
in cancer treatment (Li et al, 2006).
Several studies have been developed on 
urea derivatives as Chk1 inhibitors. As a 
part of our research for novel antican-
cer agents, we designed and synthesized 
1-(3,4-dichlorobenzoyl)-1,3-dimethylurea. 
Docking simulation was performed using Mo-
legro Virtual Docker of the Chk1 in complex 
with an inhibitor to explore the binding modes 
of this compound at the active site.
MOLECULAR MODELING AND SYNTHESIS OF
1-(3,4-DICHLOROBENZOYL)-1,3-DIMETHYLUREA
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MATERIAL AND METHODS
Materials and Measurements 
All chemicals and reagents used in current 
study were analytical grade. The IR spectra 
was recorded on FT-IR Perkin Elmer Spectrum 
One. The 1H-NMR and 13C-NMR spectra were 
recorded on BRUKER BioSpin Avance III NMR 
Spectrometer in Chloroform-d6 and chemical 
shift was reported in ppm (δ). 
General Procedure for Synthesis of 
1-(3,4-Dichlorobenzoyl)-1,3-Dimethylurea
To a stirred solution of 1,3-dimethylurea 
(0,08 mol) and triethylamine (0,08 mol) in 
THF (30 mL) was added 3,4-dichlorobenzoyl 
chloride (0,04 mol) in THF (15 mL) and the 
reaction mixture was reflux for 4 hour. The 
product was washed carefully with water 
and extracted with ethyl acetate; the result-
ing 1-(3,4-dichlorobenzoyl)-1,3-dimethylurea 
was purified by crystallization from EtOH (Fig-
ure 1).
Molecular Modeling
To assess the anti-cancer behavior of 
1-(3,4-dichlorobenzoyl)-1,3-dimethylurea on 
structural basis, automated docking stud-
ies were carried out using Molegro Virtual 
Docker program, the scoring functions and 
hydrogen bonds formed with the surrounding 
amino acids are used to predict their binding 
modes, their binding affinities and orientation 
of this compound at the active site of the Chk-
1 enzyme. The protein-ligand complex was 
constructed based on the X-ray structure of 
Chk-1 (2YWP.pdb downloaded from the pdb). 
RESULT AND DISCUSSION
Chemistry
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In our study, 1,3-dimethylurea and 3,4-di-
chlorobenzoyl chloride were dissolved in a 
mixture of TEA and THF, then refluxed for 
4 h at 80ºC, and white needle crystal of 
1-(3,4-dichlorobenzoyl)-1,3-dimethylurea was 
obtained with yields of 75% and melting point 
110°C. The synthetic compound gave satisfac-
tory analytical and spectroscopic data, which 
was in full accordance with their depicted 
structures.
The IR spectrum of the synthesized urea was 
recorded (Figure 2) and it gives an  absorption 
band 3316 cm-1 representing the  presence of 
-NH group. The absorption band at 1696 and 
1652 cm-1 confirms the imide group, and the 
absorption band at 1534 cm-1 confirms the 
aromatic -C=C- group
Molecular Modeling
In order to gain more understanding of the ac-
tivity observed at the Chk1, molecular docking 
of 1-(3,4-dichlorobenzoyl)-1,3-dimethylurea 
into ATP binding site of Chk1 was performed 
on the binding model based on the Chk1 com-
plex structure (2YWP.pdb). The binding model 
of this compound and Chk1 is depicted in Fig-
ure 5. 1-(3,4-dichlorobenzoyl)-1,3-dimethyl-
urea shows Rerank Score of -68,1456 and form 
one hydrogen bond between carbonyl moiety 
and Cys 87.
The 1H-NMR spectra (Figure 3) of synthesized 
urea give 1H-NMR (400 MHz, Chloroform-d6, 
δ ppm): 2.89 (d, 3H), 3.15 (s, 3H), 7.21-7.52 
(m,3H), 8.83 (s,1H). The 13C-NMR spectra (Fig-
ure 4) of synthesized urea give 13C-NMR (400 
MHz, Chloroform-d6, δ ppm): 27.22 (-CH3), 
35.75 (-CH3), 125.93-135.74 (-Ph), 155.79 
(-C=O), 173.53 (-C=O).
Figure 1. Synthetic scheme for                    
                1-(3,4-dichlorobenzoyl)-1,3-dimethylurea                 
Figure 3. 1H-NMR spectra of 
1-(3,4-dichlorobenzoyl)-1,3-dimethylurea in Chloro-
form-d6
Figure 4. 13C-NMR spectra of 
1-(3,4-dichlorobenzoyl)-1,3-dimethylurea in Chloro-
form-d6
Figure 2. IR spectra of 1-(3,4-dichlorobenzoyl)-1,3-
dimethylurea in KBr
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CONCLUSION
A novel 1-benzoyl-1,3-dimethylurea has been 
designed and synthesized. The white needle 
crystal of 1-(3,4-dichlorobenzoyl)-1,3-dimeth-
ylurea was obtained with yields of 75% and 
melting point 110°C. The synthetic compound 
gave satisfactory analytical and spectroscopic 
data, which was in full accordance with their 
depicted structures. Docking simulation was 
performed to position the compound into the 
Chk1 active site to determine the probable 
binding model. 1-(3,4-dichlorobenzoyl)-1,3-
dimethylurea shows Rerank Score of -68,1456 
and form one hydrogen bond between car-
bonyl moiety and Cys 87.
Figure 5. Docking of 1-(3,4-dichlorobenzoyl)-1,3-
dimethylurea with Chk 1 shows intramolecular hydro-
gen bonds with Cys 87  
REFERENCES
*. Li, G., Hasvold, L.A., Tao, Z., Wang, G.T.,  
 et al. (2006). Synthesis and biological 
 evaluation of     
 1-(2,4,5-trisubstitutedphenyl)-3-(5-cy 
 anopyrazin-2-yl)ureas as potent Chk1 
 kinase inhibitors. Bioorg Med Chem  
 Lett. 16: 2293–229
*. Oza, V., Ashwell, S., Brassil, P., Breed, J., 
 et al. (2010). Discovery of a novel   
             class of triazolones as Checkpoint Kinase 
 inhibitors—Hit to lead exploration.   
 Bioorg Med Chem Lett. 20: 5133–5138
*. Tao, Z., Li, G., Tong, Y., Stewart, K.,   
 et al. (2007). Discovery of 4’-(1,4-di  
 hydro-indeno[1,2-c]pyrazol-3-yl) ben
 zonitriles and 4’-(1,4-dihydro-  
 indeno[1,2-c]pyrazol-3-yl) pyridine-2’- 
  carbonitriles as potent checkpoint  
 kinase 1 (Chk1) inhibitors. Bioorg Med  
 Chem Lett. 17: 5944–5951
*. Zhao, L., Zhang, Y., Dai, C., Guzi, T., et al. 
 (2010). Design, synthesis and SAR of thi 
 enopyridines as potent CHK1 inhibitors. 
 Bioorg Med Chem Lett. 20: 7216–7221
66
INTRODUCTION
G-CSF is a single polypeptide chain that consist 
of 174 amino acids, five cysteines that form 
two intra-molecular disulfide bridges (Cys36-
Cys42 and Cys64-Cys74) and one free cysteine 
at residue 17 (Nagata et. al., 1986 and Lu et 
al, 1989). Overexpression of G-CSF generally 
results in partitioning of the expressed pro-
tein as insoluble material into inclusion bod-
ies (IBs) (Vans et al., 2008). Protein in IBs form 
requires solubilization and renaturation steps 
to be biologically active. Disulfide bond forma-
tion in recombinant protein is important for 
their folding, stability, and function (Jalalirad, 
2013). Incorrect disulfide bond formation can 
be solved by directing the recombinant pro-
teins into the periplasm of E. coli (Yoon et al., 
2010). Fusion of PelB leader peptide to mature 
protein sequences, had been well known to 
assist and facilitate the protein translocation 
into periplasmic compartment (Jin et al, 2011, 
Yoon et al, 2010).
However, some studies have also reported 
that the use of signal sequences such as pelB 
and ompA did not assist the secretion of ma-
ture proteins in E. coli (Sooryanarayana and 
Visweswadah, 1996; Chung et al, 1998). It ap-
pears that the secretion of heterologous pro-
teins in E. coli is greatly influenced by the prop-
erties of the proteins themselves (Chung et al, 
1998). In this study, a gene encoding hG-CSF 
was constructed by fusing with S-tag as well 
as poly-His tag at its N-terminal region in or-
der to increase protein solubility. The S-tag se-
quence corresponds to the first 15 amino acid 
residues of the ribonuclease A. It is believed 
that the peptide with its abundance of charges 
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and polar residues could improve solubility of 
proteins that attached to (Raines et al, 2000).
MATERIAL AND METHODS
Bacterial strains, vectors and growth media
Two E. coli strains were used in the experi-
ments, DH5α for subcloning and plasmid am-
plification, and BL21(DE3) for protein expres-
sion. The pJ414 vector (DNA2.0) was linearized 
with XhoI and NcoI enzymes (Fermentas). The 
CSF3syn synthetic gene encoding hG-CSF has 
been previously constructed by PCR method 
(Fuad et al, 2013). Luria-Bertani broth (LB) and 
agar (LBA) media containing 50 µg/ml of ampi-
cillin (LBamp) were used for growing recombi-
nant E. coli and protein p roduction.
Protein expression 
Induction. A single colony of E. coli BL21(DE3) 
harboring pJ414-GCSF plasmid was inoculated 
into LB amp and incubated with 150 rpm at 
37°C overnight (18-20 h). Five percent (v/v) of 
this overnight culture was inoculated into fresh 
LBamp broth and incubated with 150 rpm at 
37°C until OD600 0.6-0.8 was reached. Protein 
expression was induced by addition of 0.4 mM 
IPTG (Isopropil-β-D-1-Thiogalactopyranoside). 
Cells were harvested 3 hours after induction 
by cold centrifugation at 4500 × g for 15 min.
Autoinduction. Protein expression was also 
carried out using autoinduction media, which 
contains ZY (1% N-Z amine AS,  0.5% Yeast Ex-
tract), 1 M MgSO4, 1000x metals mix (50 uM 
Fe, 20 uM Ca, 10 uM Mn, 10 uM Zn, 2 uM Co, 
2 uM Cu, 2 uM Ni, 2 uM Mo, 2 uM Se, 2 uM 
H3BO3, 50x 5052 (0.5 % glycerol, 0.05% glu-
cose, 0.2% α-lactose), 20x NPS (100 mM PO4, 
25 mM SO4, 50 mM NH4, 100 mM Na, 50 mM 
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K). One percent (v/v) of overnight culture was 
inoculated into fresh autoinduction media, 
then incubation was continued overnight at 
22°C with agitation at 150 rpm.
Cell Fractionation
Osmotic shock. Cell pellets harvested from 
fermentation culture were resuspended in 
five percent of osmotic shock solution com-
prising 20 mMTris-HCl buffer pH 8.0, supple-
mented with 2.5 mM EDTA and 20% sucrose. 
After a static incubation on ice for 30 min, 
the cells were harvested by centrifugation 
(15800 x g, 10 min) and the supernatants 
were immediately frozen at -20ºC.
Freeze Thaw. Wet cell pellets were washed 
by phosphate buffer pH 7.4 (20 mM sodium 
phosphate and 0.5 M NaCl) and recovered 
by cold centrifugation at 4500 x g for 10 min. 
The cells were resuspended in lysis buffer (50 
mM Tris HCl pH 7.4, 3 mM etilen diamin tetra 
acetate (EDTA), 1 mM phenil metil sulfonil 
florida (PMSF)) with ratio of 8 ml lysis buf-
fer per gram pellet. The cell suspension was 
frozen at -20°C for 15 min, and then thawed 
at room temperature for 30 min, this freeze-
thaw process was repeated 10 times. The 
crude cell lysate was recovered by cold cen-
trifugation at 9600 x g for 10 min at 4°C.
RESULT AND DISCUSSION
With the aim of secretion of hG-CSF in E. coli, 
a PCR product containing S-tag and a gene 
encoding G-CSF (CSF3syn) was inserted into 
pJ414 at NcoI and XhoI sites, and fused in-
frame with pelB signal sequence. The G-CSF 
fragment was cloned into linearized pJ414 
previously digested with XhoI and NcoI. The 
recombinant pJ414-GCSF plasmid was trans-
formed into E. coli BL21(DE3) strain. PCR 
amplification of transformed colonies using 
CSF-NcoF (forward) and CSF-XhoR (reverse) 
primers, showed a DNA band at 750 bp (Fig-
ure 1). The positive clone was named pJ414-
GCSF. Eleven colonies out of 22 gave positive 
results. Confirmation of DNA integration into 
plasmid was conducted by restriction analy-
sis using XhoI and NcoI (Figure 2). Correct 
G-CSF protein expression was conducted 
with induction and autoinduction methods. 
Culture samples were centrifuged at 4500×g 
and 4°C for 3 min. After removal of the super-
natant, cell pellets were stored until further 
analysis. Preparation of cell extracts and de-
termination of soluble and insoluble product 
fractions were performed by osmotic shock 
DNA integration into plasmid was verified by 
DNA sequencing using T7 primer.
Figure 1.Electrophoregram of colonies PCR. Upper gel 
: 1. DNA ladder, 2. Negative control, 3. Positive con-
trol, 4–13 transformant colonies #1–#10. Lowergel : 
1. DNA ladder, 2–13 transformant colonies #11–#22
Fig 2.Electrophoregram of recombinant plasmids 
restriction. 1. DNA ladder, 2. pJ 414-GCSF-01 uncut, 3. 
pJ414-GCSF-01cut w/ XhoI, 4. pJ414-GCSF-01 cut w/ 
NcoI, 5. pJ 414-GCSF 01 cut w/ XhoI+NcoI, 6. pJ414-
GCSF-02 cut w/XhoI+NcoI, 7. pJ414-GCSF-06 cut w/ 
XhoI+NcoI
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and freeze thaw method. Sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-
PAGE) analysis of total cell protein and soluble 
and insoluble protein fractions was performed 
(Figure 4).
Figure 4.Protein extraction profiles from two 
different expression methods: autoinduction 
(lanes 1-3) and IPTG-induction (lanes 4-5)1. 
Periplasmic fraction, 2. Cytoplasmic fraction 
(after periplasmic extraction), 3.Cytoplasmic 
fraction (without periplasmic extraction), M: 
protein marker, 4.Periplasmic fraction (in-
duced w/ IPTG), 5. Cytoplasmic fraction (in-
duced w/ IPTG).
Protein expression profiles analyzed by SDS-
PAGE showed several protein bands, includ-
ing protein bands in around 25 kDa, which is 
the suggested size of the recombinant G-CSF 
fusion protein. The band size corresponds to 
theoretical size of fusion protein of G-CSF with 
S-tag and 6xHis-tag. This periplasmic-derived 
Figure 3. Plasmid construction                
recombinant G-CSF has not been isolated or 
purified yet. However, western blot analysis 
that has been carried out confirmed this find-
ing. Figure 5 shows the result of western blot 
analyses of both periplasmic and cytosolic 
protein extracts using either anti-His (Fig 5A) 
or anti-GCSF primary antibodies (Fig 5B). From 
Both western method, the periplasmic and 
cytosolic-derived recombinant G-CSF were 
detected. The periplasmic-derived G-CSF has 
a smaller molecular size compared to the cy-
tosolic-derived one, which is accordance to 
the assumption that the PelB leader peptide 
was processed and cleaved. The cytoplasmic-
derived G-CSF was higher than that from 
periplasmic space, indicating that the signal 
peptide was not processed and remained at-
tached with target protein.
Protein expression using T7 lac promoter re-
quires induction of T7-RNA polymerase fol-
lowed by the release of lac repressor from 
its binding site at the T7 lac promoter. In 
BL21(DE3), protein expression is triggered by 
the release of lac repressor, which is generally 
induced by IPTG or auto-induced by the pres-
ence of lactose in the medium. The combina-
tion of expressing T7-RNA polymerase in the 
BL21(DE3) chromosome and the target gene 
from the T7 lac promoter in a multi-copy plas-
mid provides enough control that auto-induc-
tion of target protein production is feasible 
(Studier, 2005). Carbon substrate mixtures of 
glucose, glycerol, and lactose were used, where 
glucose as the preferred carbon substrate was 
utilized first, followed by glycerol then lactose 
which also acts as the inducer of lac operon-
controlled protein production (Blommel et 
al, 2007). Auto-induction expression depends 
on bacteria mechanism to regulate the use of 
carbon and energy sources which present in 
the medium. If glucose is present, catabolite 
repression and inducer exclusion prevent the 
uptake of lactose by lactose permease, the 
product of lacY, thought to be the only means 
of lactose uptake in wild-type cells (Saieret al, 
1996 and Kimata et al, 1997)
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Figure 5. Western blot analyses of periplasmic 
and cytosolic-derived protein extracts using 
anti-His (A) and anti-GCSF (B) primary antibod-
ies. 1. periplasmic extract from autoinduction, 
2. G-CSF in cytoplasm, 3.G-CSF in periplasm, 4. 
G-CSF in cytoplasm
Generally, proteins found in the outer mem-
brane or periplasmic spaces are synthesized in 
the cytoplasm as premature proteins. These 
premature proteins contain a short (15–30) 
specific amino acid sequence (called as signal 
sequence) that allows proteins to be exported 
outside the cytoplasm. A number of signal se-
quences have been used for efficient secretory 
production of recombinant proteins in E. coli, 
including PelB, OmpA, PhoA, endoxylanase-SP, 
and StII (Choi and Lee, 2004). In general, signal 
sequences are rich in hydrophobic amino ac-
ids, such as alanine, valine, and leucine, a fea-
ture essential for secretion of the proteins into 
the periplasm of E. coli (Pugsley 1993).
Some studies have shown that the use of 
pelB signal sequence did not result immature 
protein secretion. Expression of recombi-
nant hG-CSF in E.coli periplasm has been re-
ported using pYHM plasmid and expressed in 
BL21(DE3). There was no secretion of hG-CSF 
and no processing of signal peptide from the 
fusion protein have been detected (Chung et 
al., 1998). Although the same signal peptide 
(PelB) has been used to direct secretion of hG-
CSF in E. coli, Chung et al (1998) has not suc-
ceed to express the recombinant hG-CSF into 
periplasm. However, the recombinant hG-CSF 
was highly expressed as IBs or insoluble pro-
tein within the cytosol of E. coli. The main dif-
ference of this study with our work is the ad-
dition of S-tag and 6xHis-tag sequences at the 
N-terminus of G-CSF. S-tag fusion is expected 
to convey the protein target more hydrophilic. 
Therefore, addition of S-tag as fusion partner 
in N-terminal of G-CSF would help the protein 
expression and translocation into periplasmic 
compartement of E. coli. S-tag peptide is com-
posed of 7 charged polar, 3 uncharged polar 
and 5 non polar residues. This composition 
makes the S-tag peptide very soluble (Ter-
pe, 2013). It provides an excessively soluble 
peptide with small structure and net charge 
in neutral pH. Fusion with S-tag as the car-
rier would not interfere the proper folding or 
function of a fused target protein (Kim and 
Raines, 1993).
CONCLUSION
Expression of G-CSF into periplasmic com-
partment of  E. coli using pelB leader peptide 
was successfully performed. Addition of S-tag 
fusion protein in N-terminal of G-CSF as well 
as fusion with PelB were suggested to assists 
the delivery of the recombinant hG-CSF into 
periplasmic space of E. coli.
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INTRODUCTION
Bawang tiwai (Eleutherine palmifolia (L.) 
Merr.) is a bulbous plant that numerously 
grows in Kalimantan. People in Kalimantan 
consume use the bulbs as an alternative medi-
cine to treat constipation, also as diuretic and 
vomiting agent. The leaves are also consumed 
to stimulate breast-milk production from a 
breastfeeding mother. Bawang tiwai shows 
differences from red onion (Allium cepa L.) 
and garlic (Allium sativum L.). It has less odor 
and distinct flavour compared to the other 
bulbous plants. Moreover, it shows a stronger 
red pigment than the red onion.
Bawang tiwai contains flavonoid, alkaloid, gly-
coside, polyfenol, tanin, and steroid. It also 
contains eleutherin, eleutherol, and isoeleu-
therin which have been reported to show 
antifungal activity and improve the coronary 
bloodstream. At least 25 different flavonols 
have been characterized from onion cultivars. 
Quercetin derivatives are the most important 
showing a strong inhibition to activity  of xan-
thine-oxidase (IC50 = 7.23 µM)(Chang et al. 
1993), IC50 to bovine milk xanthin oxidase = 
0,12 ppm (Hanaee et al. 2004). 
Xanthine oxidase is an enzyme that catalyzes 
the oxydation of xanthine to uric acid in hu-
man body. The excess of uric acid (hyperuri-
cemia) gives rise to arthritis gout, an inflam-
matory joints caused by deposition of the 
crystals. Although its risk of mortality is rela-
tively low, the disease affects the productivity 
of the patients. Allopurinol, a drug used pri-
marily to treat hyperuricemia and gout, inhib-
its the activity of xanthin oxidase to produce 
uric acid. Until now, Indonesia still imports 
this substance from foreign countries. The de-
pendency of imported drugs tends to rise the 
medication price in Indonesia. We performed 
this study to observe our local resources with 
potential anti-hyperuricemia activity. Thus, it 
would become the alternatives of allopurinol 
to treat the disease.  
This study consisted of in vitro and in vivo 
studies. We performed the in vitro assay to 
investigate the inhibition of xanthine oxidase 
acitivty from ethanol extracts of bawang tiwai. 
Then, we performed the in vivo assay to study 
the antihyperuricemic effect on mice.
MATERIALS AND METHODS
Materials
Fresh bulbs of bawang tiwai were obtained 
directly from Kalimantan. The bulbs were de-
termined by Herbarium Bogoriense-LIPI Bogor 
as Eleutherine palmifolia (L) Merr. Chemical 
solvent used to extract the bulbs was ethanol 
70%. Allopurinol tablets 100 mg were used as 
control positive. Other chemical substances 
were xanthine oxidase (SIGMA 4376), xan-
thine (SIGMA 4002), and phosphate buffer 
(pH 7.5).   
For the in vivo assay, thirty six of two-month old 
male ddY mice with body weight 20-30 gram 
were given daily standard-lab diet. We used fer-
mipan yeast 15 mg/kg body weight to induce 
the level of uric acid in the blood serum, and 
potassium oxonate (SIGMA 156124), to inhibit 
the uricase in mice. The levels of uric acid were 
measured using spectrophotometer with dichlo-
rohydroxybenzen sulfonate (DHBS) (BIOLABO) as 
reagent.
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Methods
Preparation of Extract
Four hundred grams of dried bulbs of Eleu-
therina palmifolia (L.) Merr. were extracted 
with ethanol 70% by maceration process for 
24 hours. The suspension was filtrated, and 
the precipitate was re-macerated twice sub-
sequently.  The resultant extract was concen-
trated using rotary evaporator at 50-60oC to 
obtain the dense ethanol-extract of E. palmifo-
lia. (Extract of Bawang Tiwai /EBT)
In Vitro Assay of Xanthine Oxidase Inhibitory 
Activity
The in vitro assay to investigate the inhibitory 
activity of EBT was done by indirect methods 
measuring absorbans of remain xanthine at 
265 nm. A half mililitre of extract solution with 
concentrations of 1, 5, 10, 20, 50, and 100 ppm 
were added with 1.45 mL of phosphate buffer 
50 mM, pH 7.5. Then, 1 mL of 0.2 mM xanthine 
(Sigma X4002) in phosphate buffer was added 
to the previous mixture. The tubes were incu-
bated at 25oC for 15 minutes.  
incubation, 0.05 mL of 0.3 U/mL xanthine oxi-
dase (Sigma X4376) was added to the tube and 
incubated for 45 minutes. The reaction was 
stopped by adding 0.5 mL HCl 1N. The absor-
bance of xanthine residue was measured using 
spectrophotometer at 265 nm. Allopurinol, as 
control positive, was measured with the same 
procedure. The standard curve was made using 
the absorbance of xanthine with known con-
centrations. The absorbance of the mixture of 
substrate and enzyme was used as blank, and 
the absorbance of substrate was used as nega-
tive control. The percentages of inhibitions 
were calculated using this equation:
In Vivo Assay of Antihyperuricemic Activity 
Thirty six of male ddY mice were divided into 
six groups: a normal, negative control, posi-
tive control (allopurinol), experimental groups 
given low dose (84 mg/kg) of ethanol extracts 
tubes were incubated at 25oC for 15 minutes. 
from bulbs of bawang tiwai (EBTL), experi-
mental groups given middle doe (126 mg/
kg) of the extract (EBTM), and experimental 
groups given high dose (186 mg/kg) of the 
extract (EBTH).  Normal group was given stan-
dard lab diet, while other five groups were 
each given high-purine diet from 50% yeast, 
15 mg/kg body weight for 7 days. Then one 
hour after feeding the yeast, mice from EBTL, 
EBTM, and EBTH were given the extract with 
referred dose.  On day 7, one hour after feed-
ing the yeast and extracts, the mice were giv-
en potassium oxonate 250 mg/kg body weight 
intraperitoneally. Three hours after the induc-
tion, all mice (except normal) were anesthe-
tized with ether and the blood was collected 
intracardially. Plasma was separated from 
blood cells by centrifugation at 3000 rpm for 
10 minutes. Uric acid levels were measured 
by DCHBS (dichloro-hydroxybenzene sulfo-
nate) method using Biolabo kit and spectro-
photometer (RD-60 Semi Auto Biochemistry) 
at 520 nm.
RESULTS
The extract yield obtained from the masera-
tion process with ethanol 70% was 17.2 %. The 
result of the assay of the xanthine oxidase in-
hibitory activity was presented in Table 1. The 
ethanol extract of bawang tiwai at 600 ppm 
showed 73.52% inhibition to the enzyme’s ac-
tivity. While allopurinol showed 73.74% inhi-
bition only at 2 ppm concentration. 
The result of the in vivo assay of antihyperuri-
cemic activity was shown Figure 1. EBTM gave 
a significant lower uric acid level compared to 
negative control. Even mice from EBTH had 
similar uric acid level (2.52 mg/dL) to the nor-
mal group (2.16 mg/dL).
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Table 4. Percent inhibition of xanthine oxidase from 
the ethanol extract of bawang tiwai and allopurinol.
Figure 1. Effect of the ethanol extracts of bawang tiwai 
on uric acid level in mice serum (mean ± SD, n = 6).
DISCUSSION
We studied the ethanol extract of bawang ti-
wai (Eleutherine palmifolia (L.) Merr) in order 
to screen potential plants which are able to re-
duce the uric acid level; while each year gout 
and hyperuricemia increased rapidly. 
In previous report, flavonoid showed inhibi-
tion to xanthine oxidase activity. Cos et al, in 
his in vitro study, approved that flavonoid in-
cluding isorhamnetin, baicalein, kaempferol, 
and morin had inhibition to the enzyme’s ac-
tivity with IC50 2.51, 2.79, 1.06, dan 10.1 µM 
respectively (Cos et al. 1998). While Mo et al 
performed in vivo assays of flavonoid includ-
ing quercetin, morin, myricetin, kaempferol 
and puerarin which significantly reduced 
the uric acid level in mice in the amount of 
26.94%, 28.99 %, 30.59%, 35.39%, 31.28%, re-
spectively (Mo et al. 2007).   
Bulbous plants are cultivars that contain fla-
vonoid especially kaempferol and quercetin. 
We suspected bawang tiwai to possess these 
flavonoids as the other bulbous plants. Still, 
we could not find reports about flavonoid in 
bawang tiwai. 
The amount of quercetine in bawang tiwai still 
have not been reported, thus we suggest a 
further research investigating the qualitative 
and quantitave study of flavonoids contained 
in bawang tiwai.
Different from the in vitro test, the in vivo as-
say gave an expected result. Least significant 
different, a statistical test, showed that EBTM 
(126 mg/kg body weight) had a significant 
lower uric acid level than negative control. 
EBTH also had lower uric acid, even the uric 
acid levels were similar to normal. The reduc-
tion effectiveness of EBTL (84 mg/kg body 
weigh)t, EBTM (126 mg/kg body weight), and 
EBTH (187 mg/kg body weight) were 18,74 % , 
45,09 %, 79,96 % respectively.
SUMMARY
In summary, the ethanol extracts of bawang 
tiwai (Eleutherine palmifolia (L.) Merr) were 
potential to reduce uric acid level at 186 mg/
kg body weight, but possibly without inhibi-
tion of xanthine oxidase.  
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INTRODUCTION
The growth in industrial sector  causes pollu-
tion enhancement. That can change life style 
including food consumption alteration. Ac-
cording to National Social Economic Survey 
in 2012, the percentage of Indonesian popu-
lation’s expense for instant food and drink 
products was 24,90% which was the highest. 
Consumption of instant food and drink prod-
ucts continuously, such as instant noodle and 
canned products.
Pollution enhancement and life style altera-
tion induce free radical production in the 
body. It induces oxidative stress that make cell 
damage and perceive as harm for the health 
(atherosclerosis, coronary heart, stroke, can-
cer)
Antioxidant is a compound to reduce free 
ABSTRACT
Strawberry and star fruit are fruit that have an antioxidant activity. Strawberry contains flavonoids, fenolic acid, 
and tannins while starfruit contains vitamin C, alkaloid, and tannins. This study aimed to determine the antioxidant 
activity of the extract using ABTS free radical Scavenging method (2,2’-azinobis[3-etilbenzatiazolin-6-sulfonat]) us-
ing visible light spectrophotometer. The tested samples were single and combination extracts of strawberry and 
star fruit using the ratio : 1: 1; 1: 3; 3: 1 in which vitamin C serves as a positive control. Strawberry and star fruit 
were extracted by maceration using 96% ethanol as a solvent. Phytochemical screening was carried out on both 
fruits and the extracts. The results of phytochemical screening showed the presence of flavonoids compound. 
Antioxidant activity of  the strawberry extract is stronger than the starfruit extract in which  IC50 value of  the 
strawberry and starfruit extract are 20.76 and 131.99 ppm, respectively. In contrast, both activities are lower than 
vitamin C with IC50 value of 1.22 ppm, whereas the  IC50 value of the combination extract with ratio of  1:1; 1:3; 
and 3:1 are 48.83; 79.88; 44.15 ppm, respectively. The highest antioxidant activity was found in the combination 
extract with ratio of 3:1 with IC50 value of 44.15 ppm.  The analysis of statistical tests using one way ANOVA 
showed significant differences in antioxidant activity of combination extracts in all ratio.
Keywords: antioxidant, ABTS, strawberry, starfruit
radical. Fruits are the examples of antioxidant 
sources, especially strawberry and starfruit
In this research, antioxidant activity of combi-
nation of 96% ethanol  extract of starfruit and 
strawberry was tested with free radical scav-
enging method ABTS. Sample absorption was 
measured by a visible light spectrophotom-
eter and vitamin C serves as positive control .
INSTRUMENTS
The instruments in this research area UV-VIS 
spectrophotometer Shimadzu UV-1800, mix-
ers, an analytic balance , glass beakers, Erlen-
meyer, a vacuum rotavapor, a stir bar, filter 
papers, waterbath, vaporizer cups,dark bot-
tles, Pasteur pipettes, aluminium foil, micropi-
pettes, measuring glasses, andMoisturemeter 
Karl Fischer.
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MATERIALS
1. Fresh strawberry and starfruit.
2.  Chemical reagents: ABTS, 96% ethanol, 
aquadest, Magnesium plates, concentrated 
HCl, amilalcohol, ethanol pro analysis, and vi-
tamin C.
RESEARCH PRINCIPAL
Strawberry and starfruit plants were deter-
mination, fruit drying exsiccate, extract water 
content, and phytochemical screening for both 
was obtained fresh fruit and extracts. Thick ex-
tract was using 96% ethanol by color changes. 
Macerate from each extract was concentrated 
until thick extract. Thick extract was combi-
nated = 1:0, 0:1, 1:1, 1:3, and 3:1. Then, all 
combination were tested by ABTS free radical 
method with visible light spectrophotometer 
at 412 nm
RESULT AND DISCUSSION
Figure 1. Result of antioxidant activity test (IC50) 
with ABTS method
According to antioxidant activity assay with 
ABTS method, we knew that strawberry thick 
extract had 20,76 ppm antioxidant activity. 
This result showed that IC50 value of straw-
berry was less than 50 ppm and it categorized 
as very strong antioxidant because strawberry 
had high vitamin C (about 58,8 mg in 100 gram 
fresh fruit) and flavonoid (4). Thick extract 
starfruit had 131,99 ppm antioxidant activity. 
It showed that IC50 value of which was about 
100-150 ppm and categorized as medium an-
tioxidant. It due to the strongest antioxidant 
was flavonoid, eventhough starfruit content 
of had high vitamin C, but contributed in small 
part as antioxidant (5).
This result was compared to combination 
extracts. The extract combination (1:1) IC50 
value of 48,83 ppm and was categorized as 
very strong antioxidant because strawberry 
was categorized as very strong antioxidant 
and could improve antioxidant activity of star-
fruit which was categorized as medium anti-
oxidant.
The extract combination 1:3 showed 79,88 
ppm and was categorized as strong antioxi-
dant because IC50 in the range of value was 
50-100 ppm. It due to amount of starfruit-
was more that of strawberry. Hence starfruit 
antioxidant activity shares more effect. The 
extract combination 3:1 test got result 44,15 
ppm. This result was as not far as 1:1 compo-
sition which had very strong antioxidant activ-
ity. We assumed it because amount of straw-
berry was more than amount of starfruit. 
Hence, the antioxidant activity could raise. 
IC50 value of the combination in the ratio of 
was lower than that of 3:1 composition. It be-
cause the amount of strawberry used. 
CONCLUSION
Antioxidant activity of strawberry extract was 
stronger than starfuit extract with IC50 value 
of 20,76 ppm and 131,99 ppm, but was lower 
than vitamin C as positive control with IC50 of 
1,22 ppm. Antioxidant activity of combination 
extract with composition of strawberry and 
starfruit in the ratio 1:1, 1:3, and 3:1 had IC50 
for each composition were 48,83 ppm, 79,88 
ppm, 44,15 ppm and showed that the highest 
antioxidant activity was 1:3 composition. 
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INTRODUCTION
Low drug solubility in water is an important 
factor affecting the bioavailability of the drug. 
The solubility of drugs is one factor that de-
termines the speed of absorption of the drug 
(Varshosaz J., et al, 2008). Atorvastatin includ-
ing a group of drugs called statins are used to 
treat dyslipidemia and prevent coronary heart 
disease. Atorvastatin has a bioavailability of 
12% (Parke-Davis, 1997). Small bioavailabil-
ity can be used as an indication that the drug 
has a low dissolution rate. A drug that has a 
low dissolution rate can lead to a decrease in 
absorption power. Increased bioavailability of 
drugs that have low solubility, is one of the 
challenges in drug formulation development 
aspects. One way to improve the dissolution 
rate is to reduce the particle size, which will 
increase the total surface area, so it will easily 
dissolve drugs (Varshosaz J., et al, 2008). 
One technique that can be used to reduce the 
particle size is mikrokristalisasi (Varshosaz J., et 
al, 2008). Mikrokristalisasi is a suitable method 
to produce micron-sized particles. The result-
ing particle size more uniform than the meth-
od of grinding (milling) (Soewandhi, 2006). 
Micronization using milling (milling) is very in-
efficient because it requires great energy. On 
the other hand, disorder in the crystal lattice 
can cause instability of physics and chemistry, 
because the irregularity in shape will result in 
products that are thermodynamically unsta-
ble. Changes in surface energy may also affect 
processing such as powder flow properties. 
Micronization powder with high surface ener-
gy indicates poor flow properties (Varshosaz 
J., et al, 2008). 
In this study, the technique mikrokristalisasi 
performed using a ultra-high speed homog-
enizer (13,500 rpm and 24000 rpm) to obtain 
small crystals. After stabilization of the par-
ticles was carried out using a polymer mate-
rial. Generally stabilization of the particles is 
not easy because of the tendency of the par-
ticles to grow, to see the ability of the poly-
mer material as the stabilizing agent is then 
conducted two treatments with the addition 
of stabilizing agents and without the addition 
of stabilizing agent. 
Crystals will be characterized using X-ray Dif-
fraction (XRD), Infrared Spectroscopy and 
Scanning Electron Microscopy (SEM) to evalu-
ate the crystal habit and size of the particles 
formed. Then the characterization results 
compared with before treatment. The dis-
solution test is then performed using UV-Vis 
spectrophotometer with a wavelength of 242 
nm and a visible absorbance maximum of 
each treatment. 
METHODOLOGY 
The tools used in this study is the Ultra-ho-
mogenizer (IKA T25, Germany), freeze dryer 
(Vacuubrand, Germany), UV-Vis spectropho-
tometer (SPECORD 200, UK), means of X-Ray 
Diffractometer (Philips PW 1710 Diffractom-
eter, Japan ), Scanning Electron Microscopy 
(JEOL JSM-5310LV), analytical balance (Ac-
culab VI, UK), stopwatch, oven glassware and 
tools commonly used in the laboratory. 
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The materials used in this study consisted of 
atorvastatin (DSM Anti-Infectives India), car-
boxymetylcellulose (Daichi, Japan), distilled 
water, methanol (Brataco), ethanol (Brataco), 
sodium hidoksida (Merck), potassium dihydro-
gen phosphate (Merck) ¬¬ ¬, sodium acetate 
(Merck), glacial acetic acid (Merck), kloida acid 
(Merck), and potassium chloride (Merck). 
Examination of Raw Materials 
The examination was conducted to identify 
atorvastatin. Inspection procedures in accor-
dance with the fourth edition of the Phar-
macopoeia Indonesia and other literature or 
by attaching a certificate of analysis of these 
substances. Examination includes: defining a, 
solubility, and chemical identification of the 
organoleptic and qualitative. 
Preparation of microcrystals 
Preparation of microcrystals with a stabilizing 
agent atorvastatin 5% using a ultra-homoge-
nizer and freeze dryer 
 Make a solution of atorvastatin with atorvas-
tatin by dissolving 0.5 grams in 30ml of metha-
nol. In a separate container made the develop-
ment of CMC CMC by dissolving 0.05 g in 70 ml 
of distilled water. Mixed with CMC rapidly to 
a solution of atorvastatin were accompanied 
stirring using ultra-homogenizer at a certain 
speed (13500 rpm and 24000 rpm) for ± 15 
minutes. After it was put into ice bath with 
stirring tool ultra-homogenizer at a speed of 
3200 rpm for ± 15 minutes, microcrystals will 
form spontaneously. Furthermore, the solu-
tion was put into an oven at 50 ° C for 3 hours 
to draw an organic solvent to obtain a solution 
of atorvastatin in water. Transfer the solution 
into a special container for frozen freeze dry. 
Once frozen, the samples are ready to freeze 
dry. 
Preparation of microcrystals atorvastatin with-
out stabilizing agents using a ultra-homogeniz-
er and freeze dryer 
Make a solution of atorvastatin with atorvas-
tatin by dissolving 0.5 grams in 30ml of metha-
nol. Then added to 70 mL of distilled water to 
a solution of atorvastatin were accompanied 
stirring using a ultra-homogenizer at a certain 
speed (13500 rpm and 24000 rpm) for ± 15 
minutes. After it was put into ice bath with 
stirring tool ultra-homogenizer at a speed of 
3200 rpm for ± 15 minutes, microcrystals will 
form spontaneously. Furthermore, the solu-
tion was put into an oven at 50 ° C for 3 hours 
to draw an organic solvent to obtain a solution 
of atorvastatin in water. Transfer the solution 
into a special container for frozen freeze dry. 
Once frozen, the samples are ready to freeze 
dry. 
Preparation of calibration curve of atorvas-
tatin 
Weighed 20 mg of atorvastatin standard, then 
diluted with phosphate buffer pH 6.8 in a 100 
mL volumetric flask. Whisk until dissolved. 
Further dilution to obtain concentrations of 
8, 10, 12, 15, and 20 ppm. Uptake of each 
solution was measured using UV-Vis spectro-
photometer at a wavelength of 240nm. Then 
made a calibration curve in the equation y = 
ax + b. 
Characterization of microcrystals 
crystal morphology 
To microscopic examination by means of scan-
ning electron microscopy (SEM) (JSM-5310LV 
EOL) to see the shape and size of the particles. 
A number of samples (standards and micro-
crystals atorvastatin) is placed on the holder 
which has been coated conductors. Subse-
quently incorporated into the vacuum device 
and wait until the coating is complete. Then 
examined the morphology of crystals. 
 X-ray diffraction 
The samples were characterized using X-ray 
diffractometer (Philips PW 1710 Diffractom-
eter, Japan). At first, the sample is placed in a 
holder made of aluminum. Then flattened par-
allel to the surface of the sample holder sur-
face. Holder containing the sample is inserted 
in the goniometer then measured by means of 
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X-ray diffractometer. 
Infrared Spectroscopy 
Analysis of crystals was also performed using 
infrared spectroscopy. For infrared spectros-
copy, 1 mg of sample was mixed with 200 mg 
KBr, and then made pellets. Measurement us-
ing infrared spectroscopy, and performed with 
the wave number range 4000 - 400cm-1. 
Solubility test 
Solubility test conducted in accordance with 
the method of Higuchi and Connor. Solubility 
testing is done by adding an excess amount 
of a substance into the medium ethanol until 
the solution is saturated. Then do the shuffle 
using a shaker for 48 hours at a temperature 
of 25 ° C and constant speed. Further filtering 
performed using filter paper. The filtrate was 
measured using a UV-Vis spectrophotometer 
(SPECORD 200, UK). Each sample triplo. 
 Dissolution  Test
Weighed amount of standard ± 20 mg atorvas-
tatin, ± 20 mg atorvastatin with ultra-homog-
enizer processes and ± 20 mg of atorvastatin 
containing 5% CMC with ultra-homogenizer 
processes. Then put in 900 mL dissolution me-
dium HCl buffer pH 1.2, acetate buffer pH 4.5, 
and phosphate buffer pH 6.8 and dissolution 
testing using dissolution apparatus type II at a 
speed of 50 rpm and a temperature of ± 37 ° 
C. The Decision samples were taken at 5, 10, 
15, 30, and 45 minutes as much as 5 ml. Every 
time sampling, the addition of 5 ml of dissolu-
tion medium to maintain the volume remains. 
The absorbance of samples was measured 
using a UV-Vis spectrophotometer (SPECORD 
200, UK) at a wavelength of 240 nm. 
RESULTS 
Preparation of microcrystals 
Making microcrystals aims to improve the dis-
solution rate of atorvastatin which is based 
on the BCS (Biopharmaceutical Classification 
System) has a low solubility. One way to in-
crease the solubility of the particle size shrink. 
This method was chosen because it has sev-
eral advantages, one of which is the active 
substance contained greater than with other 
methods, such as the method of solid disper-
sions using excipients that are usually larger 
than the active substance (Varshosaz J., et al, 
2008). Therefore, by increasing the solubility 
of atorvastatin, is expected to increase the 
bioavailability of atorvastatin. In this study, 
a method for particle size reduction using a 
ultra-homogenizer. 
In the ultra-homogenizer tool, mikrokristal-
isasi made using methanol solvent with ro-
tary speed optimization ultra-homogenizer. 
Optimization is done on a rotational speed 
of 13,500 rpm and 24,000 rpm for 15 min ±, 
after it was put into the glass beaker ice bath 
with stirring at a speed of 3200 rpm. After 
optimization of rotational speed, turns micro-
crystals produced at speeds of 24,000 rpm has 
a greater solubility than the speed of 13,500 
rpm. Then do the process of withdrawal of an 
organic solvent, ie methanol were carried out 
using an oven at 50 ° C for 3 h. Temperature 
used in the oven is under the boiling point of 
methanol is 63.5 ° C. 
The addition of the stabilizing agent CMC (car-
boxymethylcelulose) aims to inhibit the rate 
of crystal growth and crystal form that can lat-
er affect the solubility. CMC addition of 5% of 
the amount of solution is expected to produce 
crystals with micro size and have a stable form 
(uniformity of crystal form). 
The results from the manufacture of micro-
crystals are as follows: 
Table 1: Results of the manufacture of ultra-
crystals using a homogenizer
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Calibration Curve
Here is a calibration curve was made (Figure 
1) with 0.9991 linearity and line equation y = 
0.002 + 0,0339x 
X-Ray Diffraction (XRD
In testing using XRD, it appears that the char-
acteristics of a particular polymorph of the 
peaks seen in the diffractogram (Figure 3). In 
raw diffractogram atorvastatin and equally 
atrovastatin microcrystals showed the same 
peaks. This shows that there is a change in 
polymorph of microcrystals formed. 
The difference of each diffractogram is high 
(intensity) of the peak generated. This shows 
that there has been a change in the crystal 
habit. May also indicate a change in the size 
of the crystals formed. According to the Bragg 
equation, if the X-ray beam was dropped on 
the sample crystal, then the crystal field will re-
fract X-rays which have a wavelength equal to 
the distance between the lattice in the crystal. 
Refracted rays will be captured by the detector 
is then translated as the diffraction peaks. The 
decrease in the intensity of this sample is the 
result of a reduction in the field of crystal lat-
tice or atorvastatin after experiencing microni-
zation. Each peak that appears in the XRD pat-
tern representing a lattice or fields that have 
specific orientation in three-dimensional axis, 
so that more and more areas of the crystal lat-
tice or contained in a sample, the more power-
ful the resulting intenstitas. 
Figure 3. Diffratoghram of a) Pure atorvastatin b) Ator-
vastatin microcrystal with stabilizing agent 5%
Figure 2. Micrograph of SEM  a) Pure atorvastatin b) 
Atorvastatin microcrystal with stabilizing agent 
A
B
 Characterization of microcrystals 
Microcrystal Characterization
The morphology of microcrystals 
Microcrystals on morphological observation 
using Scanning Electron Microscopy (SEM) is 
to look at the shape of the resulting microcrys-
tals and crystals of raw itself. In these obser-
vations it appears that the form of raw blocks 
and atorvastatin have not distributed perfect-
ly. While the microcrystals formed and distrib-
uted beam has the shape better. It is also seen 
that there is a stabilizing agent that coats the 
lining microcrystals formed. 
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Infrared Spectroscopy 
In infrared spectroscopy results (Figure 4), 
visible infrared spectrum of the substance 
and the microcrystals formed atorvastatin 
showed identical characteristics to the peak of 
3403 cm-1 (NH stretching), 3059 cm-1 (C-HO 
stretching alcohol group), 2966 , 15 cm-1 (CH-
stretching), 1656 cm-1 (C = C bending), 1564 
cm-1 (C = O stretching amide groups) 1313.56 
cm-1 (CN -stretching), 1104 cm-1 (OH bend-
ing), 751 cm-1 and 695.08 cm-1 (CF stretch-
ing). This indicates the absence of a functional 
group changes microcrystals made and the 
lack of interaction between the stabilizing 
agent with microcrystals. The intensity of the 
microcrystals formed visible atorvastatin de-
creased compared with standard atorvastatin. 
This shows that there has been a change in the 
crystal habit and particle size reduction occurs 
in microcrystals (Varshosaz J., et al, 2008). 
Solubility test 
Testing the solubility of atorvastatin and mi-
crocrystals conducted by Higuchi and Con-
nor. Testing is done by adding the number of 
Figure 4. Infrared spectrum of (a) pure Atorvastatin (b) 
microcrystals with a stabilizing agent atorvastatin 5%
samples in ethanol and stirring until saturated 
with a shaker for 48 hours. And obtained the 
results as in Table 2. 
Table 2: Results of solubility test in ethanol
From Table 2 it can be concluded that the F4 
has the greatest solubility. It also shows that 
the solubility of the microcrystals are formed 
due to the increased cross-sectional area of 
the enlarged substances. 
Dissolution Test comparative 
In this research, dissolution testing compa 
atorvastatin crystalline powder. Basically dis-
solution rate was measured from the amount 
of active substance dissolved in a liquid me-
dium tertebtu in a known volume and a rela-
tively constant temperature. The purpose of 
microcrystalline powder dissolution profile 
testing is to determine how much powder 
crystals dissolved at a given time. 
Dissolution test conducted in the medium of 
900 mL HCl buffer pH 1.2, Acetate buffer pH 
4.5 and phosphate buffer pH 6.8 and stirring 
with type II dissolution apparatus at 50 rpm at 
a temperature of 37 ° C ±. Sampling interval 
was performed at 5, 10, 15, 30 and 45 minutes 
by taking a sample of 5mL and with the addi-
tion of medium with the same volume so that 
the volume of dissolution medium remains.
84
A
B
C
Figure 5: Dissolution profile of each treatment on (a) 
Media HCl pH 1.2 (b) Media Acetate buffer pH 4.5 (c) 
Media phosphate buffer pH 6.8
The results of dissolution testing in Figure 5 
shows that the microcrystals are generated 
from mikrokristalisasi process can increase 
the solubility of atorvastatin. The number of 
pure atorvastatin (%) who terdisolusi after 45 
minutes on medium HCl buffer, acetate buffer, 
and phosphate buffer was 44.12%, 74.42% and 
98.17%. While microcrystals atorvastatin-CMC 
5% through the homogenizer speed 24,000 
rpm ultra results showed 90.16%, 97.07% and 
123%. The difference in dissolution rate is of-
ten related to the crystal surface area, particle 
distribution and purity of the crystal. 
CONCLUSION 
Based on the research that has been conduct-
ed, an increase of dissolution of the active 
compound can be done with the process and 
the results of testing mikrokristalisasi showed 
that at pH 1.2 HCl solution increased about 2 
times, in acetate buffer pH 4.5 an increase of 
1.3 times and in phosphate buffer pH 6.8 an 
increase of 1.25 times. 
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INTRODUCTION
Malaria is a serious infectious disease caused 
by protozoan parasites in tropical and subtrop-
ical regions. In 2010, malaria was endemic in 
about 104 countries worldwide and approxi-
mately 219  million cases of malaria caused 
660.000 deaths. Approximately 90 % of malar-
ia deaths occur in Africa (WHO, 2012). Global 
spread of multiple drug-resistant malaria has 
become a major health problem and efforts to 
search for new antimalarial are needed.
Eucalyptus globulus  is a plant of the Myrtace-
ae family that in Indonesia commonly known 
as kayu putih and empirically used as an an-
tipyretic (Backer, 1968). In Brazil, E.  globulus 
is used as an antimalarial plants (Nagpal et 
al., 2010). In Cameroon, E. globulus, Carica 
papaya and Psidium guajava leaves are mixed 
and boiled as a decoction that is drunk for the 
treatment of malaria (Titanji et al., 2008). In 
Venezuela, E. globulus leaves is boiled as de-
coction for the treatment of malaria (Carballo 
et al., 2004). 
Our preliminary study showed that the 80% 
ethanol extract and dichloromethane fraction 
were very active as an antimalarial with IC50 
of 0.090 µg/mL and 0.022 µg/mL, respectively. 
This study aims to separate the dichlorometh-
ane fraction and to test antimalarial activity of 
its subfractions.
MATERIAL AND METHODS
Plant Material
Eucalyptus globulus stem was obtained from 
Cangar Forest at Malang, East Java on April 
2010. Sample was authenticated by the au-
thority of Purwodadi Botanical Garden, Pa-
suruan, East Java.
Separation Method
Vacuum liquid chromatography (VLC) of di-
chloromethane fraction of E. globulus stem 
was performed using hexane-CHCl3 (25% 
gradient) to CHCl3-MeOH (98:2, 96:4, 94:6, 
90:10, 85:15 and 80:20). 
Thin Layer Chromatography (TLC) Method
Sub-fractions obtained from Vacuum liquid 
chromatography (VLC) of dichloromethane 
fraction were monitored by TLC using  silica 
gel F254 as stationary phase and chloroform-
methanol (98:2) as mobile phase. The sepa-
rated spots were visualized under ultra-violet 
light of two different wavelengths (UV254 nm 
and UV365 nm) and visible light before and 
after sprayed with 10% H2SO4 and heated at 
105oC for 5 minutes.
In Vitro Antimalarial Activity Test 
Antimalarial activity of sub-fractions was as-
sessed against Plasmodium falciparum strain 
3D7 which is sensitive to chloroquine. This 
strain was maintained in continuous culture in 
flask according to the methodology described 
by Tragger and Jensen (1976).
Percentage inhibition was calculated using for-
mula:   
[(% parasitaemia in control wells – % parasi-
taemia of test wells)/(% parasitaemia of the 
87
control)] x 100 (Ngemenya et al., 2006).  
IC50 values refers to the concentration re-
quired to  inhibit 50% of parasite’s growth 
(Mustofa et al., 2007).
RESULTS AND DISCUSSION
Vacuum liquid chromatography of dichloro-
methane fraction produced 8 sub-fractions 
(D.1 - D.8 sub-fractions). TLC chromatogram of 
dichloromethane sub-fractions was shown in 
figure 1.
Antimalarial activity test showed that IC50 val-
ue of each dichloromethane sub-fractions was 
10.284 µg/mL, 16.387 µg/mL, 0.053 µg/mL, 
1.059 µg/mL, 0.318 µg/ml, 0.387 µg/mL, 0.150 
µg/mL and 0.040 µg/mL. D.8 sub-fraction has 
the lowest IC50 value of 0.040 µg/L. This activ-
ity was analysed in accordance with the norm 
of plants antimalarial activity of Rasoanaivo et 
al. (1992). According to this norm, an extract is 
very active if IC50 < 5 µg/mL, active 5 µg/mL 
< IC50 < 50 µg/mL, weakly active 50 µg/mL < 
IC50 < 100 µg/mL and inactive IC50 > 100 µg/
mL.  Based on this classification, result from 
this study of D.8 sub-fraction of E. globulus 
stem with IC50 of 0.040 µg/mL is said to have 
very active antimalarial activity. The result of 
antimalarial activity test of dichloromethane 
sub-fractions (D.1 - D.8 sub-fractions) can be 
seen in Table 1.
TLC test of sub-fractions indicated the pres-
ence of the most dominant spot (spot D) on 
D.8 sub-fraction with Rf values of 0.40 which 
gave a red purple colour after sprayed with 
10% H2SO4 and heated at 105 oC for 5 min-
utes. Spot D began to appear on D.6 sub-frac-
tion which has the IC50 value of 0.387 µg/L. 
Colour intensity of spot D increased on D.7 
and D.8 sub-fractions which have the IC50 val-
ues lower than  that of D.6 sub-fraction (0.387 
µg/mL). From these data can be seen that the 
higher concentration of spot D, the lower IC50 
value of sub-fractions. Therefore, it can be 
presumed that spot D on D.8 sub-fraction is a 
substance that is responsible for activity of D.8 
sub-fraction.
Figure 1. TLC chromatogram of dichlorometh-
ane sub-fraction using  silica gel F254 as sta-
tionary phase and chloroform-methanol (98:2) 
as mobile phase, viewed under UV light : (a) 
254 nm; (b) 366 nm; (c) after sprayed with 10% 
H2SO4 and heated at 105oC for 5 minutes. (d) 
366 nm after sprayed with 10% H2SO4  and 
heated at 105oC for 5 minutes; D = dichloro-
methane fraction, D.1-D.8 = sub-fraction. 
Table 1. IC50 values of  dichloromethane sub-
fractions of  E. globulus L. stem against P. fal-
ciparum
CONCLUSION
D.8 sub-fraction of E. globulus possesses a 
very active antimalarial activity and might be a 
good candidate for antimalarial. Further work 
Sam
ple 
Percent of average inhibitions at various 
doses  (µg/mL) IC50 
(µg/mL) 
100 10 1 0.1 0.01 
D.1  73.46 40.42 31.63 21.42 16.32 10.284 
D.2  63.27 46.95 29.77 10.38 1.63 16.387 
D.3  89.83 79.10 69.52 51.22 41.12 0.053 
D.4  87.40 54.41 44.55 39.60 21.58 1.059 
D.5  92.41 75.86 52.80 43.27 24.13 0.318 
D.6  90.20 70.94 55.43 36.34 27.30 0.387 
D.7  89.50 73.96 58.95 45.41 36.15 0.150 
D.8  92.24 80.80 72.99 53.92 41.85 0.040 
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is suggested to isolate, identify and character-
ize the active principles from this substance.  
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INTRODUCTION
As a country rich of natural resources, espe-
cially in medicinal plant, Indonesia has many 
opportunities to develop medicinal sources 
originated from plants. One of the potential 
medicinal plant used for cancer chemopre-
vention agent is Arcangelisia flava. This plant 
was shown to have antioxidant and cytotoxic 
activity against breast cancer cell line, MCF-
7. These ability were considered to be corre-
sponding to the alkaloid content, especially 
berberine (Keawpradub et al., 2005). As this 
plant is easily to be found in Meru Betiri Na-
tional Park situated in Jember (Koran Jakarta, 
2012), we are eager to explore further about 
this plant.
To be developed as medicine, we have to 
know its safety. The sub-chronic toxicity assay 
was choosen to study the safety of ethanolic 
extract of A. flava leaves (EEAfL) use. This re-
search was done to determine the EEAfL effect 
on leukocytes and lymphocytes cell count of 
rats receiving sub chronic EEAfL. 
OBJECTIVES
This research was done to determine the EE-
AfL effect on immune response, especially on 
leukocytes and lymphocytes cell count of rats 
receiving sub chronic EEAfL.
MATERIAL AND METHODS
Plant materials and extraction
The A. flava leaves were collected from Meru 
Betiri National Park, Jember, Indonesia. They 
were selected for their freshness, old age, 
and healthy ones. The leaves were washed 
Arcangelisia flava INCREASES RATS’ LEUKOCYTES 
BUT HAS BIPHASIC EFFECT ON RATS’ LYMPHOCYTE
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thoroughly with water, then, were air dried 
followed by oven drying at 50 0C. The dried 
leaves were grounded and sieved. The etha-
nolic extract were prepared using 500 g of 
leaves powder according to the previous 
study with a slight modification (Keawpradub 
et al., 2005).  The ground-dried leaves was 
sequentially extracted with n-hexane, chloro-
form, and ethanol. The extraction was repeat-
ed three times for each solvent. The ethanol 
extract was evaporated under reduced pres-
sure (Heidolph, Laborota) resulting EEAfL. EE-
AfL was then suspensed in CMC Na 1% before 
being administered to the animal.
Animals
Male Wistar rats (weighing 100-150 g) were 
housed at a constant temperature and light-
dark cycle. Rats were fed with standard feed 
and water as libitum. The rats were acclima-
tized and quarantined for at least 10 days 
prior to the experiment. The animal handling 
protocols of this study were in accordance 
with the guidelines of the animal care of Uni-
versity of Jember.
Experimental design
Fifteen rats were devided into three groups. 
Group I as control, received CMC Na 1 %. 
Group II received EEAfL 500 mg/kg BW. Group 
III received EEAfL 1,500 mg/kg BW. The treat-
ment was done orally for 11 days. At the 12th 
day, the blood sample was collected and ana-
lyzed further for leukocytes and lymphocytes 
cell count.
Statistical analysis
All data were presented as mean + the stan-
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dard error of the mean (SEM). Kruskal Wallis 
assay followed by Mann Whitney test were 
used to know the significance difference be-
tween groups, since the data could not meet 
the requirement for Anova analysis (p < 0,05).
RESULTS AND DISCUSSION
Leukocytes cell count
The leukocytes cell count (Figure 1) of rats re-
ceiving EEAfL were increased significantly than 
that of the control group, either at the dose of 
500 or 1,500 mg/kg BW.
Lymphocytes cell count
The lymphocytes cell count of rats receiving 
500 mg/kg BW EEAfL was increasing signifi-
cantly, but the rats treated with EEAfL at the 
dose of 1,500 mg/kg BW had decreased lym-
phocytes (Figure 2).
Figure 1. Leukocytes cell count of rats. Data 
represented as mean + SEM (n = 5). Different 
letter notation expressed significant difference 
according to Mann Whitney test (p < 0,05).
Figure 2. Lymphocytes cell count of rats. Data 
represented as mean + SEM (n = 5). Different 
letter notation expressed significant difference 
according to Mann Whitney test (p < 0,05).
Discussion
EEAfL seems to increase the immune system 
of normal rats, as it was expressed by leyko-
cytes cell count. But it had biphasic effect on 
lymphocytes, as the higher the dose  lowered 
the lymphocytes cell count. We could say that 
high dose of EEAfL decreased spesific immune 
system as it decreased the lymphocytes cell 
count. 
EEAfL contained berberine (Puspitasari and 
Ulfa, 2013). The higher the dose, the higher 
the berberine content. Berberine itself is an 
immunosuprressive agent. It inhibits the ac-
tivation and proliferation of T cells, but no 
cytotoxic effect known (Xu et al., 2005). EE-
AfL might increase the non-spesific immune 
system. Leukocytes consist of neutrophyls, 
lymphocytes, monocytes, eosinophyls, and 
basophyls. Lymphocytes plays role in specific 
immune response, while others play in non-
specific immune response. 
Leukocytes cells count that was increasing 
while the lymphocytes cell count that was de-
creasing after treated with high dose of EEAfL 
suggested that the other kinds of leykocytes 
involving in non-specific immune response 
were higher. Water extract of A. flava increases 
macrophage activity (Florentina, 2013). Thus, 
EEAfL might also increase the macrophage ac-
tivity. Still, we need to examined further for 
these hypothesis. 
CONCLUSION
Based on the results, we can conclude that 
EEAfL increased the immune response on 
rats, but it had biphasic effect on lymphocytes 
suggesting that high dose of EEAfL might in-
creased non-specific immune response in-
stead of the specific one.
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INTRODUCTION
Malaria is still an endemic disease in more than 
90 countries, mainly in developing countries 
(Sanchez et al., 2004). Patients infected with 
malaria have doubled in the last two decades. 
This occurred mainly due to the emergence 
of resistant strains of Plasmodium falciparum 
malaria to the chloroquine and its derivatives 
(Trape et al., 2002). Perez et al. (1997) stated 
that the global spread of malaria parasites 
that are resistant to current antimalarial drug 
is a major health problem. Therefore, it is need 
to find new antimalarial substances to replace 
current drugs that are not sensitive anymore. 
One attempt to discover new antimalarial sub-
stances is through active exploration of the 
natural sources.
It is known that some species of the family 
Myrtaceae has an antimalarial activity. Previ-
ous studies shown that ethanol extract and 
chloroform fraction of A. acuminatissima 
leaves (Myrtaceae) were exhibited antimalar-
ial activity with IC50 value of 0.040 µg/ml and 
0.006 µg/ml, respectively. Therefore, the sep-
aration of the chloroform fraction was done to 
determine the antimalarial activity substances 
of A.acuminatissima.
MATERIALS AND METHODS
Plant materials
 A.acuminatissia leaves was obtained from 
Purwodadi Botanical Garden on December 
2012. Sample was authenticated by the au-
thority of  Purwodadi Botanical Garden, Pa-
suruan, East Java. 
Fractionation
Chloroform fractions which obtained from 
the fractionation  of  ethanol extract of 
A.acuminatissima leaves was separated by 
vacum liquid chromatography (VLC) using 
hexane, chloroform, and ethanol at gradient 
condition. This separation was produced six 
subfractions, then evaporated using a vacum 
evaporator and dried. These six subfractions 
was then analyzed by TLC and tested for anti-
malarial activity.
In vitro antimalarial activity test
Antimalarial in vitro test was performed based 
on Budimulya et al. (1997). Sample prepared 
in serial dilution at concentration of 0.01; 0.1; 
1; 10 and 100 g/ml in microwells. Each mi-
crowell was added with 500 l parasite culture 
(1% parasitemia, 5% haematocrit) and incu-
bated for 48 hours in 37oC. After incubation, 
thin blood smears were made and stained 
using 20% giemsa dye. Percentage of para-
sitemia was determined by counting infected 
erythrocytes per 1000 total erythrocytes un-
der microscope. 
RESULTS AND DISCUSSION
The separation results of A.acuminatissima 
leaves chloroform fraction was produced 
six subfractions (A-F).  Each subfraction was 
tested for in vitro antimalarial activity against 
P. falciparum (3D7). According to Rasoanaivo 
et al. (2004), an extract is very active if IC50 < 
5 µg/mL, active 5 µg/mL < IC50 < 50 µg/mL, 
weakly active 50 µg/mL < IC50 < 100 µg/mL 
and inactive IC50 > 100 µg/mL. The test re-
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sults showed that all chloroform subfractions 
classified as very active and subfraction E was 
the most active with IC50 value of 0.007 µg/
mL. The result of antimalarial activity test of 
chloroform subfractions (A-F) can be seen in 
Table 1.
Identification of chloroform subfraction was 
performed by TLC method using silica gel 
GF254 as stationary phase and chloroform: 
methanol (98:2) as a mobile phase. Then ob-
served under UV light in wavelength of 254 
nm, 366 nm and sprayed with H2SO4 10%. TLC 
chromatogram profile showed that all subfrac-
tions contain purple spot (Fig.1). According to 
Sharifa et al. (2012), terpenoid compounds 
will form a pink to purple or violet after being 
sprayed with 10% H2SO4. It can be considered 
that all subfractions were containing terpe-
noids. 
Table 1. IC50 values of Chloroform subfrac-
tions against P. falciparum 3D7
Figure 1. TLC chromatogram of chloroform 
subfraction using  silica gel F254 as station-
ary phase and chloroform-methanol (98:2) as 
mobile phase, viewed under UV light : (a) 254 
nm; (b) 366 nm; (c) after sprayed with 10% 
H2SO4 and heated at 105oC for 5 minutes. (d) 
366 nm after sprayed with 10% H2SO4  and 
heated at 105oC for 5 minutes; K = chloroform 
fraction, A-F = subfraction.
Subfraction A-F were exhibited antimalarial 
activity (IC50 value of 0.007-1.469 µg/ml) and 
containing terpenoids substances. Based on 
that result, it is possible to conclude that an-
timalarial activity of subfractions was derived 
from terpenoids substances.
CONCLUSION
Subfraction E of  A.acuminatissima leaves was 
the most active as antimalarial with IC50 value 
of  0.007 µg/ml. The antimalarial activity was 
possible derived from terpenoids substances. 
Further study needed to isolate and identify 
the active compounds from A.acuminatissima
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INTRODUCTION
Diclofenac is NSAID that has activated as an-
tiinflammation, analgesic and antipyretics 
(Schuelert, 2011).  Diclofenac sodium has par-
tition coefficient of 13.4 (Hasan et.al.2005) 
which means diclofenac sodium has a parti-
tion in oil a higher amount than in the water. 
By usage two phases to diclofenac sodium  like 
emulsion, diclofenac sodium can dispersed in 
the initial phase oil and water. But emulsion 
has thermodynamically unstable (Allen, 1997).
So that, needed a system more stable for dis-
persion  of diclofenac sodium to produce a 
more effective preparation, namely micro-
emulsion system.
The characteristics of microemulsion are sta-
ble in thermodynamics, transparent, low vis-
cosity, and have high solubilisasion so that it 
can increase bioavailability drugs in the body 
(Santos et al., 2008). To overcome the low vis-
cosity of microemulsion by adding hydroxi pro-
phyl methyl cellulose (HPMC).  The aim of this 
study was to observe characterization dosage 
form and penetration of diclofenac sodium in 
microemulsion system which contained ratio 
surfactant Span 80-Tween 80 an cosurfactant 
ethanol= 6:1.
METHODS
Material
Diclofenac sodium (PT. KIMIA FARMA), soy-
bean oil (Sime Draby Edible Product Limited), 
Span 80 and Tween 80 (Croda), ethanol 96% 
(Merck), HPMC 4000 (Cosmetic Grade) (Dow 
Chemical Pacific), aquadem (PT Widatra Bhak-
CHARACTERIZATION OF DOSAGE FORM AND PENETRATION DICLOFE-
NAC SODIUM WITH MICROEMULSION SYSTEM IN HPMC 4000 GEL BASE 
(Microemulsion W/O with rasio use of surfactant Span 80 – Tween 80 : Cosurfactan 
Ethanol 96% = 6:1)
Esti Hendradi, Pharmaceutics Department of Faculty of Pharmacy Universitas Airlangga, Surabaya, Indonesia
esti_hendradi@yahoo.com; Tutiek Purwanti, Pharmaceutics Department of Faculty of Pharmacy Universitas Air-
langga, Surabaya, Indonesia; Karina Wahyu Irawati, Pharmaceutics Department of Faculty of Pharmacy Universitas 
Airlangga, Surabaya, Indonesia
ti), propyleneglycol (BASF SE, Germany).
Preparation of Microemulsion and emulsion
The composition of microemulsion and emul-
sion system in table 1. 
Preparation of Emulsion 
Emulsion was made by mixing Span 80 and 
soybean oil as oil phase. As water phase was 
aquadem and Tween 80. Diclofenac sodium 
was added in the water phase and oil phase 
was 2% and 3%, respectively. Mixed the sys-
tem using magnetic stirer 500 rpm for 30 min-
utes.
Preparation of Microemulsion 
Span 80, Tween 80, soybean oil, surfactant 
and cosurfaktant were mixed using magnetic 
stirrer 100 rpm for 15 minutes. Added aqua-
dem and mixed 100 rpm, 15 minutes.Then, 
added diclofenac sodium into the system 
mixed at 150 rpm for 60 minutes.
Table 1. Formula of microemulsion and emul-
sion W/O type of diclofenac sodium
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Table 2. Componen HPMC 4000 gel
Preparation of Microemulsion and emulsion 
diclofenac sodium in HPMC gel  
The concentration of diclofenac sodium of Mi-
croemulsion and emulsion in HPMC gel was 
made 1%. Weigh the microemusion or emul-
sion that contained 1% diclofenac and added 
in to HPMC gel and mixed.
Evaluation
Organoleptic Evaluation
Organoleptic evaluation carried out visually 
includes examining the color, odor, and con-
sistency. The evaluations performed on micro-
emulsion and emulsion of diclefenac sodium.
Determination of  Droplet Size Distribution   
Examination of the size and distribution of the 
microemulsion droplet size was performed 
with a submicron Delsa™ Nano Particle Size 
and Zeta Potential Dynamic Light Scattering. 
The droplet of emulsion of diclofenac sodium 
was determined using microscope.
Determination of conductivity 
Determination of conductivity was measured 
using conductometer to microemulsion and 
emulsion preparation.
Penetration of diclofenac sodium from the 
preparation
The penetration of dicofenac sodium from mi-
croemulsion gel through Wistar rat skin mem-
brane was determined by dissolution test for 8 
h. The gel microemulsions of diclofenac sodi-
um (in cell diffusion) were placed respective in 
the dissolution chamber (Figure 1).  All in vitro 
penetration were performed at 100 rpm, with 
each medium of dissolution (phosphate buffer 
saline pH 7.4 ± 0.05 at temperature 37 ± 0.5°C) 
was 500 mL. The samples withdrawn at differ-
ent time intervals were analyzed for drug con-
tent using Spectrophotometer Double Beam 
UV-VIS Recording UV 160 A (Shimadzu). The 
result was analyzed by statistic programmed 
of using Independent sample t-Test with de-
gree of confident 95% (α = 0.05).
Figure 1. Apparatus 5-paddle Over Disk 
(TheUnited States Pharmacopeia Convention, 
2002)
Penetration of diclofenac sodium was 
calculated using equation 1
Where
J   : flux
M : mass of compound (gram)
S  : surface area of barier/membrane (cm2)
t   : time  (minute/hour)
(1)
Place for 
sampling
 A :Diffusion chamber 
contain PBS pH 7.4 
C: Distance from paddle to 
diffusion membrane 
D:  Diffusion cell 
E:  Thermometer 
F:  Sample holder 
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RESULTS AND DISCUSSION
The appearance system of microemulsion and 
emulsion shown in Figure 2 and Table 3. In this 
figure showed that microemulsion was clear 
and the emulsion was not clear. 
  
                        A                               B
Figure 2. The appearence of microemulsion (A) 
and emulsion (B) 
Table 3. The organoleptics, droplet size and 
conductivity microemulsion and emulsion of 
diclofenac. 
The droplet size of microemulsion smaller 
compared with the droplet of emulsion of 
diclofenac. The results of conductivity test 
showed both of microemulsion and emulsion 
of diclofenac  0,40 ± 0,01 µS and 0,92 ± 0,01 
µS, respectively. It means both the emulsion 
type were W/O.
The data of spread diameter of microemul-
sion of diclofenac was lower than emulsion 
of diclofenac but the pH of two preparations 
were same. In this research the penetration 
of diclofenac from emulsion preparation was 
not done because the stability of emulsion of 
diclofenac only 2 hours. The flux of diclofenac 
from microemulsion preparation shown in ta-
ble 5.
Table 5.Flux of diclofenac from microemulsion 
preparation
The permeability of rat skin to diclofenac 
shown in table 6.
Table 6. The permeability of rat skin to diclof-
enac sodium
Table 4. The spread diameter and pH of micro-
emulsion and emulsion of diclofenac.
Each data represents the mean ± S.D. of 3 de-
terminations
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CONCLUSION
1. Characteristics of microemulsion system  
 in gel base HPMC 4000 showed thicker  
 consistency than emulsion system in gel  
 base HPMC 4000. Different system gave  
 no effect on pH but gave effect on spread 
 diameter of zero load. 
2. Penetration flux in microemulsion system 
 in gel base HPMC 4000 was 0.22 ± 0.03 
 µg/cm2/minute and permeability of   
 membrane was 2.01 x 10-5 ± 3.27 x 10-6  
 cm/minute. 
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ABSTRACT
Recently, a need to develop more potent COX-2 inhibitors is very important and one of the method that has been 
proven the effectivity and eficiency for new drugs research is in silico. Structure-based virtual  screening (SBVS) 
protocols  were  developed  to  find  cyclooxygenase-2  (COX-2)  inhibitors  using  the  Protein-Ligand  ANT  System 
(PLANTS) docking software, SPORES, BKChem and Open Babel. The directory of useful decoys (DUD) dataset for 
COX-2 was used to validate the protocols retrospectively; the DUD consist of 426 known COX-2 inhibitors and 
13289 decoys. Based on the criteria value of EF20% and EFmax, the default validated protocol  EE_COX2_v.1.0 
showed very good results, with enrichment factor 20% (EF20%) value of  4,0 and maximum enrichment factor 
(EFmax) value of  ~  
Keywords: protocols, virtual screening, inhibitor, COX-2  
INTRODUCTION
Non-steroidal anti inflamatory drugs (NSAID) 
as COX-2 inhibitor have been written by more 
than 70 milion prescriptions everyday and 
reach 30 bilion USD income each year (Roman 
B, 2011). The structure-based virtual screen-
ing protocols research can reduce costs and 
make the research of new drugs become more 
efficient.
Structure-based  virtual  screening  (SBVS) 
protocols  were  developed  to  find  cyclooxy-
genase-2  (COX-2)  inhibitors  using  the  new 
crystals structure COX-2 had been founded 
with agreat revolution with code PDB 3LN1. 
Based on the criteria value of EF20% and  EF-
max used in the article Huang et al (2006) and 
Yuniarti et al (2011).
METHOD
Instruments: Hardware: A set of computer 
with Intel (R) Core™ i3-2350 CPU M @ 2.30Ghz, 
4 GB of RAM, 64bit operating system.
Software: Linux Ubuntu 10.04 LTS Operating 
System, SPORES, PLANTS, PyMOL, Open Babel 
and statistics R i386 3.0.1
RESULT AND DISCUSSION
Validated SBVS
The default validated protocol EE_COX2_v.1.0 
showed very good results, with enrichment 
factor 20% (EF20%) value of  4,0 and maxi-
mum enrichment factor (EFmax) value of  ~  
3LN1
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#!/bin/sh
rm -rf penapisan
mkdir penapisan
cd penapisan
cp ../conﬁ g.txt .
cp ../protein.mol2 .
cp ../ZINC03814547.mol2 .
export PLANTS=’/home/esti/PLANTS’
bkchem uji.mol
babel --gen3d -p 7.4 --title uji 
-imol uji.mol -omol2 uji.mol2
obconformer 10 1000 uji.mol2 > min_
uji.mol2
$PLANTS/SPORES --mode settypes min_
uji.mol2 uji.mol2
cat ZINC03814604.mol2 uji.mol2 > li-
gand_input.mol2
$PLANTS/PLANTS1.2 --mode screen con-
ﬁ g.txt
rm conﬁ g.txt protein.mol2 
ZINC03814547.mol2
grep -Ev TOTAL results/bestranking.
csv | awk -F, ‘{print $1” “$2}’ > 
hasil.tmp
sed “s/_entry_00001_conf_01//g” ha-
sil.tmp > hasil.tmp2
sed “s/_entry_00002_conf_01//g” ha-
sil.tmp2 > hasil.txt
more hasil.txt
rm hasil.tm*
cd ..
echo “ “
echo “bagaimana prediksi senyawa uji 
anda?”
Figure 1. Protocol SBVS EE_COX2_v1.0; Enrich-
ment factor 20% (EF20%) = 4,0; maximum En-
richment factor (EFmax)  -  ~
Figure 3. Reference ligand ZINC03814547 
(IUPAC: 1-(4-fl uorophenyl)-2-methyl-5-(4-
methylsulfonylphenyl)-3-(trifl uoromethylsul-
fonyl) pyrrole)  as basic to build soft ware
Table 1. Based on score ChemPLP from simu-
lati on docking with EE_COX2_V.1.0, the com-
pound that have potenti al as anti -infamati on 
and anti -cancer with the mechanism of acti on 
as inhibitor COX-2 is Demetoxicurcumin with 3 
acti ve amino acid residue
Figure 2. Ligand co-cristal protocol SBVS 
EE_COX2_V.1.0; IUPAC:4-[5-(4-Methylphenyl)-3-
(Trifl uoromethyl)-1H-Pyrazol-1-YL]Benzenesul-
fonamide
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CONCLUSION
Based on criteria value of EF20% and EFmax 
used in the article Huang et al (2006) and Yu-
niarti et al (2011), the default validated proto-
col EE_COX2_v.1.0 showed very good results, 
with enrichment factor 20% (EF20%) value of 
4,0 and maximum enrichment factor (EFmax) 
value of  ~  
The SBVS protocol with PDB code of 3LN1 
(SOFTWARE EE_COX2_v1.0) to discover cyclo-
oxigenase-2 inhibitors  was succesfully applied 
to identify COX-2 inhibitor in Curcuminoid. 
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VALIDATED UV SPECTROPHOTOMETRIC METHOD FOR THE DETERMI-
NATION OF ASPIRIN IN  RABBIT PLASMA : APLICATION TO BIOAVAIL-
ABILITY STUDY OF ASPIRIN MICROCAPSULE IN RABBIT
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INTRODUCTION
Aspirin is non-steroidal anti-inflammatory 
(NSAID), acidic and has a greater cohesiveness 
than the adhesive properties making it hard 
contact with water. Aspirin has a rapid absorp-
tion and practically complete, especially in the 
first part of the duodenum. Lower bioavailabil-
ity due to hydrolysis during absorption. At low 
doses of aspirin can inhibit platelet aggrega-
tion and used in the treatment of infarct mio-
cardiac and stroke. Aspirin acetilated cyclo-
oxygenase enzyme and inhibits the formation 
of cyclic endoperoxides. Aspirin also inhibits 
the synthesis of thromboxane A 2 (TXA-2) in 
platelets, so that ultimately inhibits platelet 
aggregation. Onset of effect after 30 minutes 
and lasts 3-6 hours, t½ 2-3 hours. Aspirin usu-
ally given orally but there are problems associ-
ated with side effects that can cause bleeding 
in the gastrointestinal tract.
Aspirin 80 mg is still the main choice as anti-
thrombotic. Here is needed to bioavailability 
test of 80 mg aspirin as quality control efforts 
to protect consumers from 80 mg aspirin dos-
age that does not meet the standards, so that 
consumers get the precision of the dose of as-
pirin 80 mg dosage.
For the determination of plasma levels of aspi-
rin are needed method of selective and sensi-
tive analysis. Visible light spectrophotometry 
provide benefits fast, simple and selective. As-
pirin was hydrolyzed to salicylic acid and acetic 
acid under alkaline conditions, then neutral-
ized with acid, salicylic acid formed complexed 
with iron (III) nitrate will react with the phenol 
group of salicylic acid and produces a purple 
complex. Once validated analytical method, 
then this method will be applied to test the 
bioavailability of microencapsulated aspirin 80 
mg in rabbits.
MATERIALS AND METHODS
MATERIALS. Asetosal BPFI (POM), aspirin raw 
materials (Yixing city, China), rabbit, heparin, 
ethanol, nitric acid, sodium hydroxide, iron 
(III) nitrate, distilled water.
INSTRUMENTATION. UV-Vis spectrophotome-
try (Shimadzu-1800), Microsentrifuge, vortex, 
micropipette.
METHODS. Fresh  blood (from rabbit) was add-
ed anticoagulant (heparin) and centrifuged 
3500 rpm for 10 minutes, the blood plasma 
of rabbits used for analytical method valida-
tion process aspirin in plasma. Visible light 
spectrophotometer optimization done by set-
ting the maximum wave and a steady uptake 
of aspirin. Rabbit blood plasma was added a 
solution of a certain concentration asetosal 
then ethanol, and centrifuged divorteks back 
at 3500 rpm for 10 min, the supernatant ob-
tained was added nitric acid, sodium hydrox-
ide and iron (III) nitrate, was measured with 
a spectrophotometer absorbance of visible 
light at a wavelength of 525 nm maximum 
. Validation parameters tested were linear-
ity, LLOQ determination, precision, accuracy, 
and recovery. The solution was prepared at a 
concentration asetosal low, medium and high 
absorbance measured at the maximum wave-
length, using the solvent as a blank. Accuracy 
was calculated as the percent error, precision 
as coefficient of variation and recovery as the 
recovery value. For testing LLOQ can be ob-
tained by dilution of the concentration LOQ 
obtained from calibration curves to one-half 
103
or one-quarter and absorbance was measured 
5 times with each concentration of visible light 
spectrophotometry. Data obtained calculated 
value percent error and relative standard devi-
ation. LLOQ shows the accuracy shown by the 
percent error average value does not deviate 
from the ± 15% and -15% except LLOQ levels 
of ± 20% and -20%, and the precision indicated 
by the coefficient of variation of less than 15% 
except LLOQ levels of less than 20%.
RESULT
Linearity show that the relationship between 
the absorbance with concentration has linear-
ity in accordance with the equation of the line 
and the price coefficient of variation is close to 
1, as shown in Figure 1.
Figure 1. Calibration curve of aspirin in plasma 
at λ 525 nm
LLOQ
LLOQ measured by conducting experiments on 
concentration ½ fold and ¼ fold of the LOQ, 
LOQ obtained from the linearity test is at a 
concentration of 1 ppm. Based on these ex-
periments, it can be concluded that the level 
of LLOQ was 0.5 ppm, due to the accuracy of 
0.5 ppm still meet the requirements of the FDA 
LLOQ ie% error ≤ + 20% and -20%, while the 
accuracy at 0, 25 ppm does not meet the re-
quirements of the LLOQ, and the recovery at 
0.5 ppm is still said to be good because it is in 
the range of 80-120%.
Precision
Precision describes the closeness between the 
test results to one another, carried out using 
a minimum of 5 replicates for each concentra-
tion. The average value does not deviate from 
the 15% except LLOQ levels of less than 20%. 
Precision test results can be seen in Table V.4. 
precision of the test results at LLOQ level (0.5 
ppm); 2 ppm and 40 ppm, it is known that all 
levels of precision to meet the requirements 
of the FDA.
Table 1. Precision results show repeatability
Table 2. Acuracy readings of aspirin
ACURACY
Accuracy describes the closeness of the test 
results with the actual levels in order to ob-
tain the deviation of the actual values used 
to calculate the percent error. Performed by 
using a minimum of 5 replicates for each con-
centration. The average value does not stray 
from the + 15% and -15% except LLOQ levels 
+ 20% and -20%. Accuracy of the test results 
can be seen in Table V.5. precision of the test 
results at LLOQ level (0.5 ppm); 2 ppm and 40 
ppm, it is known that all the levels of accuracy 
to meet the requirements of the FDA.
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Recovery
Recovery of the detector response ratio of 
analyte extracted from a biological sample 
detector response versus actual levels of pure 
standards. Extraction efficiency of the analyti-
cal method and measured at three different 
levels (high, medium, low), the recovery does 
not need a 100% recovery is important to be 
consistent, and reproducible pesisi. Recovery 
test results can be seen in Table V.6. the ac-
quisition of the test results back to the LLOQ 
level (0.5 ppm); 2 ppm and 40 ppm, it is known 
that all levels to meet the requirements of the 
FDA’s recovery.
CONCLUSION
Methods of analysis of aspirin by spectropho-
tometric methods are valid and can be used 
for the determination of bioavailability test of 
aspirin microcapsul in rabbits
Table 3. % recovery
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INTRODUCTION
Microemulsions are macroscopically isotropic 
mixtures of at least a hydrophilic, a hydro-
phobic and an amphiphilic component. Their 
thermodynamic stability and their nanostruc-
ture are two important characteristics that 
distinguish them from ordinary emulsions 
which are thermodynamically unstable1). Mi-
croemulsions can protect drug from degrada-
tion2). Ovalbumin is protein carrier that used 
as adjuvant for vaccine. Mean while, many 
topical vaccines developed to induced imunne 
function response3). Microemulsion expected 
to protect ovalbumin from degradation. In 
this study, microemulsions made from oval-
bumin, aquabidestillata Span 80, Tween 80 as 
surfactant and ethanol as cosurfactant (sur-
factant : cosurfactant = 5:1; 6:1 and 7:1). The 
aim of this study was to know the influence 
of curfactant and cosurfactant comparison to 
microemulsion characteristics. Evaluation of 
this study included organoleptic, pH, surface 
tention, particle size distribution and drug en-
trapment.
MATERIALS AND METHODS
Material used in this study are ovalbumin 
pharmaceutical grade (Sigma-Aldrich), soy 
bean oil food grade (Moi Foods), Span 80 cos-
metical grade (Croda), Tween 80 cosmetical 
grade (Croda), ethanol pro analysis (MERCK) 
dan aquabidestilata (PT. Widatra Bakti), Coo-
massie Billiant Blue (Sigma-Aldrich).
Microemulsion Preparation
EFFECT OF COMPARISON OF SURFACTANT AND COSURFACTANT  W/O 
MICROEMULSION OVALBUMIN WITH SOYBEAN OIL TO PHYSICOCHEMI-
CAL CHARACTERIZATION 
(w/o Microemulsion with Surfactant Span 80- Tween 80 : Cosurfactant Ethanol 96% 
=  5:1; 6:1 and 7:1)
Farida Mutiara Sari,  Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia; Riesta Primaharinastiti, 
Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia; Esti Hendradi, Faculty of Pharmacy, Universitas 
Airlangga, Surabaya, Indonesia, esti_hendradi@yahoo.com
Soy bean oil, Span 80, Tween 80 and ethanol 
96% mixed in beaker glass with magnetic stir-
rer at 1000 rpm for 15 minutes then aqua-
bidestilata added and stired at 1500 rpm for 
15 minutes. Ovalbumin dissolved in micro-
emulsion and stired at 1500 rpm for 60 min-
utes.
Evaluation of Microemulsion
Organoleptic
Organoleptic evaluation determined visually 
including color, odor, and consistension.
pH
pH evaluation determined by Eutech In-
stument pH700 pH/ mV/ ºC/ ºF meter. All 
measurements were carried out in triplicate
Table 5. Formula of the microemulsion.
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Surface Tension
Surface tension evaluation determined by Du 
Noüy tensiometer.
Droplet Size Distribution
Droplet size distribution evaluation deter-
mined by  Delsa™ Nano Submicron Particle 
size and Zeta Potentialt Dynemic Light Scatter-
ing. Sample observed in 165º angle and tem-
perature 25ºC.
Drug Entrapment
The loaded microemulsion centifuged in 2500 
rpm for 15 minutes. 50 µl fltrate added with 
aquabidestillata up to 50,0 ml in volumettic 
flask. 50 µl aliquotes added with 2,5 ml Coo-
massie Brilliant Blue. Absorbance checked in 
wave length 620 nm. Ovalbumin absorbance 
was absrbance difference between loaded mi-
croemulsion and unloaded microemulsion.
Statistics
All of the results were analyzed by statistic us-
ing one way analysis of variance with degree of 
believed 95% (α = 0,05) and followed by HSD 
(Honestly Significant Difference). Independent 
sample t-test used to know the difference be-
tween loaded and unloaded microemulsion.
RESULTS AND DISCUSSION
The results of organoleptics evaluation showed 
that microemulsions have transparent yellow 
colour and high fluidity for all formulas.
The data showed the mean of pH for unloaded 
and loaded of formula I were 6.89±5.77x10-3 
and 6.95±0.036, formula II were 6.87±0.010 
and 6.90±5.77x10-3 and formula III were 
6.76±0.026 and 6,89±5.77x10-3. This showed 
there was no significant difference between 
formulas but there is difference between load-
ed and unloaded microemulsions.
The results of surface tension studies showed 
that the mean for unloaded and loaded of for-
mula I were 0.3705±0.0000 and 0.3297±0.0051 
Nm-2, formula II were 0.3562±0.0045 and 
0.3397±0.0015 Nm-2 and formula III were 
0,3900±0,0000 and 0.3377±0.00351 Nm-2. 
This result sowed there is difference between 
formulas  for loaded and unloaded micro-
emulsion. Surface tension value decresed af-
ter microemulsion loaded with ovalbumin this 
can be caused ovalbumin had a function as 
emulsifying agent at the interface of the mi-
croemulsion4).
The droplet size distributon for unloaded 
and loaded of formula I were 30.7±4.01 and 
0.26±0.10 mn, formula II were 27.6±2.97 and 
23.8±0,26 nm and formula III were27.1±1.70 
and 25.0±1.14 nm. This result showed that 
there was no significant difference between 
unloaded microemulsion and there was dif-
ference bertween loaded microemulsion. The 
loaded and unloaded microemulsion had no 
significant difference result.
Figure 1. Histogram of microemulsions pH 
Figure 2. Histogram of microemulsion surface 
tension
Figure 3. Histogram of microemulsion droplet 
size
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Drug entrapment study showed the mean val-
ue of formula I was 25.77±10.12 %, formula II 
was 46.01±10.12 % and formula III was 29.14± 
5.84 %. This result showed there was no sig-
nificant difference between formulas made.
Figure 4 Histogram of microemulsion drug en-
trapment
CONCLUSION
The best formula can not define because in 
comparison of surfactant and cosurfactant in 
microemulsion showed no significant differ-
ence in physicochemical characteristic of mi-
croemulsion.
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pH INFLUENCE IN DESALTING PROCESS OF CRUDE PERTUSSIS TOXIN 
(PT) AND FILAMENTOUS HEMAGGLUTININ (FHA) PURIFICATION FROM 
Bordetella pertussis BY SEPHADEX G-25 COLUMN CHROMATOGRAPHY
Faris Adrianto, Airlangga University Department of Pharmaceutical chemistry, farisadrianto@gmail.com; Esti 
Hendradi, Airlangga University Department of Pharmaceutical sciences; Neni Nurainy, Biofarma; Isnaeni, Air-
langga University Department of Pharmaceutical chemistry
INTRODUCTION
Preventing human infection by vaccination had 
been done by more than two centuries.  Per-
tussis, commonly called whooping cough—is a 
highly contagious bacterial disease caused by 
Bordetella pertussis. In some countries, this 
disease is called the 100 days’ cough or cough 
of 100 days. Symptoms are initially mild, and 
then develop into severe coughing fits, which 
produce the namesake high-pitched “whoop” 
sound in infected babies and children when 
they inhale air after coughing. The coughing 
stage lasts approximately six weeks before 
subsiding (Mahon et al.,  2001).
The best way to prevent pertussis is to get vac-
cinated. Two different types of pertussis vac-
cine have been used in infant immunization 
programs. The whole-cell pertussis vaccine 
(Pw) consists of heat- and formalin-inactivated 
virulent whole bacteria, whereas the acellular 
pertussis vaccine (Pa) is composed of purified 
components of the bacteria, typically includ-
ing inactivated pertussis toxin (PT) and Fila-
mentous Hemagglutinin. Immunization with 
Pw has a high degree of efficacy and is associ-
ated with the induction of antigen-specific Th1 
cells (Noble et al., 1987). 
Purification of Acellular pertussis components 
has been done by many researchers before. 
This research was means to study the effect 
of pH in desalting, a step of purification of per-
tussis toxin (PT) and Filamentous Hemaggluti-
nin (FHA) from Bordetella pertussis
MATERIALS AND METHODS 
Equipments:
GE ÄKTApurifier UPC 900, Column GE XK 16, 
Resin Hydroxy Apatite (HA) Ultrogel®, Column 
GE HiTrap® Desalting 5 mL, Sample Collector 
Frac-950, Column Sepharose, Vertical elektro-
phoresis Mini-Protean®3 Cell BIO-RAD, Water-
bath 95 oC, Varimix, Polystirene microtitres 
plate, ELISA reader, Nanodrop 2000 spectro-
photometer
Materials: 
Bordetella pertussis Tahoma strain isolate 
(isolated by PT. BioFarma), NaOH 0.5 M ,WFI, 
Phosphate Buffer (PB) 50 mM pH 6, 7, and 8. 
Ethanol 20%, SDS PAGE kits, B. pertussis PT 
anti serum (sheep), antibody FHA anti serum 
(sheep), standard antigen FHA (JNIH-4), anti 
FHA monoclonal (JNIH-11), washing buffer 
(0.05% Tween 80 in aquadest), dilution buffer 
(0.1% protifar and 0.05% Tween 80 in PBS pH 
7.2), blocking buffer (Protifar 0.05 gram in 50 
mL PBS), standard Purified PT JNIH-5, anti-PT 
S1 subunit monoclonal antibody 10D6, Anti 
PT JNIH-12, anti mouse peroxidase conjugate, 
substrat TMB (Sodium acetate buffer pH 5.5 
+in ethanol 96% + H2O2 7.5 mL buffer asetat 
+ 125 uL TMB/Etanol 96% + 1.5 uL H2O2, 2M 
H2SO4
Methods:
1. Capturing PT dan FHA
 Capturing was done for PT and FHA in the 
 previous research. The sample obtained  
 were used for this research.
2. Desalting PT and FHA
 XK 16 Column packed with Sephadex  
 G-25 medium 25 ml was attached to ÄK 
 TApurifier UPC 900 system. WFI 4 CV was 
 flows through the column with flowrate  
 0.5 mL/min. For the column stabilization, 
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 phosphate Buffer (PB) 50 mM with suit 
 able pH (6, 7, or 8) was flows with flow 
 rate 1 mL/min. Sampel crude PT-FHA were 
 injected and eluated with phosphate  
 Buffer (PB) 50 mM pH 6.0 flowrate 1 mL/ 
 min. Fraction which produces peak were  
 collected, and protein concentration were 
 calculated for each fraction. 
3. Protein quantitation 
 Protein quantitation was done using   
 Nanodrop 2000 spectrophotometer with  
 280 nm wavelenght.
4. SDS PAGE 
 SDS PAGE fpr the protein fraction was  
 done using Vertical elektrophoresis Mini- 
 Protean®3 Cell BIO-RAD with standard  
 SDS PAGE kit 
5. ELISA 
 ELISA was done using suitable ELISA kits  
 for PT and FHA
RESULT AND DISCUSSION
1. Capturing PT dan FHA 
 Capturing was done in the previously re 
 search and the protein concentration re 
 sulted was shown in the next table.
Table 1. Protein concentration for the desalt-
ing process
After the protein concentration was obtained, 
ELISA was done to specify the PT and FHA in 
the sample. The ELISA resulted for  PT titre in 
crude PT-FHA was 5,5 µg/mL and the FHA titre 
was  32,8 µg/mL. SDS PAGE was done to con-
firm which as the fractions obtained contain 
PT and FHA. 
Figure 1. SDS PAGE for PT and FHA (6-7 were 
the samples, 8 are standard FHA, 9 are stan-
dard PT) 
2. Desalting of PT and FHA 
Desalting of PT and FHA were done using pre-
viously methods and the chromatogram re-
sulted was shown in the next figure. 
Table 2. Protein recoveries in the desalting 
process
This result shown that the protein and the salt 
were not completely separated. But sample 
can be obtained by isolate the peak that were 
completely separated. After the chromato-
gram was obtained, the sample protein recov-
eries were calculated . The result was shown in 
the next table 
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CONCLUSION
Eluation pH influences the recovery percent-
age of the sample protein. The optimum re-
covery percentage resulted from the use of 
phosphate buffer  pH 7.0 with 74,23 + 3,07 % 
recoveries percentage 
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SEPARATION OF COSMETIC PRESERVATIVES
USING SILICA-BASED MONOLITHIC COLUMN
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INTRODUCTION
Cosmetic products are particularly suscep-
tible to microbial growth due to the nature of 
their ingredients. To prevent them from decay, 
preservatives such as 2-phenoxy ethanol and 
parabens have been commonly used as addi-
tives. Although the preservatives are frequent-
ly used in various cosmetic products, they are 
harmful at higher than permitted safety levels.
Phenoxyethanol (1-hydroxy-2-phenoxyeth-
anol) (Figure 1) is an organic chemical com-
pound, a glycol ether, often used in derma-
tological products such as skin creams and 
sunscreen. It is a colorless oily liquid, a bacteri-
cide, usually used in conjunction with quater-
nary ammonium compounds, and often used 
in place of sodium azide in biological buffers as 
2-phenoxyethanol which is less toxic and non-
reactive with copper and lead. It is also used 
as a fixative for perfumes, an insect repellent, 
a topical antiseptic, a solvent for cellulose ac-
etate, same dyes, inks, resins, preservatives 
pharmaceuticals, and in organic synthesis. It is 
moderately soluble in water. It is used as an 
anesthetic in the aquaculture of some fish. 
[1,2] . In Japan its usage level in cosmetic prod-
ucts is regulated. [3]
Parabens (Figure 2) are a class of chemicals 
widely used as preservatives in the cosmetic 
and pharmaceutical industries. Parabens are 
effective preservatives in many types of for-
mulas. These compounds, and their salts, are 
used primarily for their bacteriocidal and fun-
gicidal properties. Parabens can be found in 
shampoos, commercial moisturizers, shaving 
gels, personal lubricants, cosmetics, topical/
parenteral pharmaceuticals, spray tanning so-
lution and toothpaste. They are also used as 
food additives. [4]
The most common analytical technique used 
for separation and determination of preserva-
tives in cosmetics products is HPLC using RP-
18 column. The method demonstrates a good 
sensitivity, however, the peaks are not good 
resolved and a longer analysis time needed. 
Monolithic HPLC columns consist of highly 
porous silica with a bimodal pore structure, 
which gives greatly improved chromatograph-
ic performance in terms of separation perfor-
mance and column back pressure (Fig. 3) [5,6]
MATERIALS AND METHODS
Materials
Phenoxyethanol, methyl-, ethyl-, propyl-, and 
butylparaben standard were obtained from PT. 
Malidas Sterilindo, Buduran, Sidoarjo; HPLC 
Agilent LC-1100, Chromolith RP-18 (100 x 4.6) 
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MATERIALS AND METHODS
Materials
Phenoxyethanol, methyl-, ethyl-, propyl-, 
and butylparaben standard were obtained 
from PT. Malidas Sterilindo, Buduran, Sido-
arjo; HPLC Agilent LC-1100, Chromolith RP-
18 (100 x 4.6) mm stationery phase was ob-
tained from Merck (Darmstadt, Germany); 
µBondapak C18 (300 x 3.9) mm column (Wa-
ters) was also used for this study. Methanol 
(J.T Baker, USA) and acetonitrile (Lichrosolv, 
Merck, Darmstadt, Germany) of HPLC grade 
and distilled water (PT. Otsuka Indonesia) 
were used as mobile phase. Whatman 0.2 µm 
membrane filter was purchased from com-
mercial suppliers; phosphate buffer pH 3 was 
freshly prepared in our laboratory. 
Method 
Two kinds of mobile phase sytems (the mix-
ture of acetonitrile and phosphate buffer pH 
3; the mixture of methanol and water) and 
two columns (µ-Bondapak and Chromolith 
column) were used to find the optimum con-
dition for separation of preservatives in cos-
metics. Each mobile phase system with gra-
dient flow was used in each column to find 
the optimum condition for  peak separation. 
(CDER, 1994). The standard of phenoxyetha-
nol, methylparaben, ethylparaben, propyl-
paraben, and butylparaben were injected to 
the HPLC system. The wavelength was set at 
254 nm.
RESULTS AND DISCUSSION
Two different columns have been used to 
separate preservatives in cosmetics. Some 
condition of experiment were used to achieve 
a good separation of cosmetics preservatives 
contains phenoxyethanol, methylparaben, 
ethylparaben, propylparaben, and butylpara-
ben. The mixture of standard was injected to 
HPLC system.
The optimum condition for separating pre-
servatives using µBondapak C18 column was 
obtained when phosphate buffer pH 3 and 
acetonitrile were used as mobile phase with 
flow 1 mL/min and gradient system (Table 1). 
The retention time was 20 minutes (Figure 4). 
When the mixture standard of preservatives 
passed through Chromolith column, a good 
separation was obtained by using methanol 
and water as mobile phase with flow rate 3 
mL/min and a gradient system (Table 2). The 
HPLC separation time for cosmetic preserva-
tives using Chromolith Column is less than 6 
minutes (Figure 5).
CONCLUSION
From the result, it showed that Chromolith 
column with mobile phase system methanol : 
water, flow rate 3 mL/min and a gradient flow 
system gives a minimum retention time com-
pared with µBondapak column when it is used 
to separate cosmetics preservatives contain-
ing phenoxy-ethanol, methyl-, ethyl-, propyl- 
and butylparaben. The method can be used 
to determine the concentration of preservar-
tives in cosmetics.
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Figure 4. Chromatogram of preservatives separation 
using Bondapak column (1) 2-phenoxyethanol; (2) 
methyl-; (3) ethyl-; (4) propyl-; and (5) butylparaben
Figure 5. Chromatogram of preservatives separation 
using Chromolith column (1) 2-phenoxyethanol; (2) 
methyl-; (3) ethyl-; (4) propyl-; and (5) butylparaben
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PREPARATION AND CHARACTERIZATION OF TELMISARTAN-CITRIC ACID 
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ABSTRACT
Telmisartan (TMS) is an antihypertension that 
has a very low solubility in water. The aim of 
this study is to prepare and characterize co-
crystal formation between TMS and citric acid 
(CIT). TMS-CIT co-crystal was prepared by sol-
vent-drop grinding methods using methanol 
as solvent. The characterization of co-crystal 
was conducted by powder X-ray diffraction 
(PXRD), Fourier transform infrared (FTIR), and 
polarized microscope. The solubility and in vi-
tro dissolution tests were performed to know 
changed in physical properties. The PXRD 
pattern, FTIR spectra, and photomicroscope 
of co-crystal were different from its starting 
components. TMS and CIT can form co-crystal 
that can increase the solubility and dissolu-
tion rate of TMS.
Keywords: telmisartan, citric acid, co-crystal, 
solubility, dissolution.
INTRODUCTION
Telmisartan (TMS) is an angiotensin II receptor 
blocker was used to treat hypertension. TMS 
has a very low solubility in water, so its dis-
solution rate is low. Co-crystals appeared as a 
solid form that promises to change the solu-
bility, dissolution, and other physicochemical 
properties of the drug substance (McNamara 
et al., 2006). Pharmaceutical co-crystals pro-
vide an alternative to chemical modification 
of the drug substance as well as established 
salt, amorphous, solvate, and polymorphic 
drug forms that all have limitations in their 
utility (God and Rodriguez-Hornedo, 2009). 
The purpose of the study was to prepare a 
new co-crystal of TMS having better solubility 
by forming a co-crystal with citric acid.
MATERIALS AND METHODS
Materials
Telmisartan (TMS) commercial material with 
purity of >99% was obtained from Glenmark 
Pharmaceutical Limited, Mumbai, India. Citric 
acid monohydrate (CIT), methanol and other 
reagents were obtained from Merck Chemi-
cals Indonesia without any purification.
Preparation of Co-crystal TMS-CIT by Solvent-
drop Grinding
Equimolar quantities of TMSand CITwerecom-
bined in a mortar,and the material was ground 
together with the addition of three drops of 
methanol for five min. After grinding, the 
product was dried and stored at ambient tem-
perature. 
Characterization by PXRD
Experiments were performed on aPhilips 
PW1710 X-ray diffraction system, using Cu Kα 
radiation (λ = 1.54180 A°),40 kV/40 mA. Data 
collected at room temperature in the scan 
range of 2θ= 3° to 45.
Characterization by Fourier Transform Infra-
red (FT-IR)
Infrared spectras were recorded by using 
an FT-IR Affinity-1 spectrophotometer (DRS-
8000) Shimadzu, Japan. The pure TMS, CIT, 
and co-crystal sample were previously ground 
and mixed thoroughly with KBr. 
Characterization by Polarized Microscope
The physical mixture TMS-CIT (1:1) was placed 
on object glass. A drop of methanol was added 
to the physical mixture until dissolved and al-
lowed to recrystallize. Recrystallization pro-
cess was observed under a polarizing micro-
scope and compared to the recrystallization of 
its pure components. The microscopic images 
were recorded with Optilab Advance camera 
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Infrared spectroscopy can be a very powerful 
tool in detecting co-crystal formation (Schul-
theiss and Newman, 2009). In the Fig. 1b, the 
shift of the–OH group and the imine group(C 
=N) of TMS from 3063 and 1603 cm-1to 3028 
and 1646cm-1, respectively after grinding 
process indicated the formation of co-crystal 
TMS-CIT. The dissapeared of broad peak of OH 
group (3000-3300 cm-1) from water molecule 
in the citric acid monohydrate showed co-
crystal containing no water hydrate.
The TMS-CIT co-crystal formation can be ob-
served under the polarized microscope after 
addition of a few drops of methanol. Fig. 2 
shows the difference in crystal habit after a 
physical mixture of TMS-CIT recrystallized in 
methanol with TMS and CIT crystal habits. This 
indicates the formation of TMS-CIT co-crystal 
after the addition of methanol.
Solubility and in Vitro Dissolution Test
Solubility experiments showed that solubil-
ity of TMS in water  increased in the TMS-CIT 
co-crystal. The solubility of TMS from pure 
TMS and TMS-CIT co-crystal were 3.9±0.2 and 
10.5±0.1 μg/mL, respectively. The dissolution 
profiles of TMS from both pure TMS and TMS-
attached to the Olympus BX-53 polarized mi-
croscope. 
Solubility Determinations
The solubility of TMS in water from TMS-CIT 
co-crystal and pure TMS were tested at room 
temperature using an orbital shaker. Excess 
amounts of compound were added to 10 mL 
of water, mix it continuously and then filtered 
after 24 h of equilibration. The bulk solutions 
were measured spectrophotometrically.
In Vitro Dissolution Test
Dissolution test of TMS from TMS-CIT co-crys-
tal and pure TMS were carried out in pH 7.5 
phosphate buffer solution (900 ml, 37±0.5°C, 
75 rpm) for 60 min  using the USP XXIII paddle 
apparatus (ZRS-6G, Tianjin, China). At prede-
termined time intervals, 10 ml samples were 
withdrawn and spectrophotometrically as-
sayed for drug concentration at 295 nm. 
RESULTS AND DISCUSSION
Preparation of Co-crystal TMS-CIT by Solvent-
drop Grinding
Solvent-drop grinding involves the grinding of 
two materials together and a small quantity of 
solvent. This method only uses less solvent, so 
the method is more cost-effective and environ-
mentally friendly than solution method (Trask 
et al., 2004). The presence of a small amount 
of the liquid phase can improve the rate of co-
crystal formation (Shan et al., 2002).
Characterized of TMS-CIT Co-crystal formation
The co-crystal formation is mainly character-
ized by powder X-ray diffractometer (PXRD). If 
the resulting PXRD pattern of the solid prod-
uct after milling pure solid compounds (drug 
and coformer) is different from the reactants, 
it can be concluded that the new solid phase 
was formed (Shanpui et al., 2011). Fig. 1a 
shows the diffractogram of the product after 
solvent-drop grinding was different from its 
starting components. It was indicated TMS-CIT 
co-crystal formation. The TMS-CIT co-crystal 
have characterized peaks at about 6,3; 8,9; 
10,0; 11,1; 15,7; 17,5; 20,1; 22,4; dan 27,5°.
116
CIT co-crystal in pH 7.5 of phosphate buffer so-
lution were shown in Fig 3. The percentage of 
TMS dissolved after 60 min or dissolution per-
centage (DP60min) from TMS-CIT co-crystal 
was higher than from pure TMS.
CONCLUSION
The characterization by PXRD, FTIR,  and po-
larized microscope methods showed that TMS 
and CIT formed co-crystal after solvent-drop 
grinding using methanol as solvent. The solu-
bility and dissolution rate of TMS from TMS-
CIT co-crystal higher than from pureTMS.
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INTRODUCTION
Medication error is defined as “any prevent-
able event that may cause or lead to inappro-
priate medication use or patient harm while 
the medication is in the control of the health 
care professional, patient, or consumer. Such 
events may be related to professional prac-
tice, health care products, procedures, and 
systems, including prescribing; order com-
munication; product labeling, packaging, and 
nomenclature; compounding; dispensing; dis-
tribution; administration; education; monitor-
ing; and use” (US Food and Drug Administra-
tion, 2014).
Medication errors related to dispensing of 
medication at a pharmacy can occur because 
of several factors starting from pharmacists’ 
heavy workloads, disturbance or distraction 
during dispensing the medication, working 
environment for example inadequate lighting, 
similar name of medications, the provision 
of inadequate drug information and others 
(Leedock, 2011). 
Oral liquid medications are widely used either 
with or without prescription (self-medication), 
especially for pediatric and adult patients who 
have difficulty swallowing tablets or capsules. 
There is potential medication errors in admin-
istered oral liquid medications related to im-
precise dose of the drug.  The study in Minne-
sota found that a household teaspoon was the 
most frequently devices used for measuring 
liquid medication (J Madlon-Kay et al, 2000). 
According to the AAP Committee on Drugs, 
the volume of household teaspoons can range 
from 2 to 10 ml, on the other hand the volume 
of one teaspoon in liquid medication referred 
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to 5 ml. 
However, although in other countries the in-
formation about the current use of oral liquid 
medication and its devices were easily found, 
there is limited information regarding to the 
administration of oral liquid medications by 
patients and caregivers in Indonesia.
METHODS
The interview was conducted in three com-
munity pharmacies in Surabaya, Indonesia. 
This study was a convenience sample of adult 
patients and caregivers who visited the phar-
macy to purchase non-prescription oral liquid 
medication or receive liquid medication pre-
scribed by a doctor during September 2014 to 
October 2014.
The interview consisted of several parts. First, 
we collected demographic information. Sec-
ond, participants were shown the following 
liquid dosing devices: dosing spoon, printed 
dosing cup, and dropper. Furthermore, they 
were shown a household teaspoon and table-
spoon. They were asked which of the dosing 
devices they usually use for dispensing oral 
liquid medications. Third, the participants 
were asked to demonstrate how they would 
measure the oral liquid medications. The vol-
ume was later measured by graduated cylin-
der glass.  
We adapted the classification of liquid medica-
tion error rates from Gyeong Suk Ryu et al who 
classified liquid medication error into 4 groups, 
which are less than 5%, 6% to 10%, 11% to 20%, 
and more than 20%. The targeted volume was 
the volume instructed in the brochure, label or 
the medicine packaging box depends.
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RESULTS AND DISCUSSION
Participant characteristic and dose errors are 
shown in Figure 1. During the study period, 80 
participants agreed to participate. The major-
ity of the participants were caregivers (73.8%, 
n=80) and 58.8% (n=80) were female, which 
is consistent with results obtained in previous 
study (J Madlon-Kay et al, 2000 and Yin et al 
2014).  Mother has the main role in the family 
as a caregiver. Therefore, female is more likely 
administering the medication for the patient 
compare to male. Seventy one participants 
(88.7%) were younger than age 47 and 73.7% 
(n=80) participants were high school graduate 
or higher. At least 40% (n=59) of the partici-
pants whose high school degree or higher de-
gree were practicing large dose errors. 
The figure 1 reveals that more than fifty per-
cent (51.3%) of the participants have large 
dose errors in measuring oral liquid medica-
tion, both female and male participants shares 
almost equall number. Of the 29 participants 
who chose tablespoon and teaspoon as their 
common measuring devices, 20 (71.4%) expe-
rienced large dose errors. Inspite of using the 
correct calibrated measuring devices ,  40% 
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Figure 2: Type of Oral Liquid Medication Purchased
Figure 3: Age classification caregiver and their 
patient
(n=49) of the participants still experienced 
large dose errors in measuring their liquid 
medication.
More than 90% (91.3%, n=80) participants 
purchased their medicine without prescrip-
tion (self-medication). Of the 80 oral liquid 
medications purchased by participants, 30 
were not equipped with any dosing devices. 
Furthermore 60% (18) of these participants 
choose household tablespoon and teaspoon 
for measuring their medication. As illustrated 
in Figure 1, dosing spoon (53.8%, n=80) and 
tablespoon (35.0%, n=79) were the most com-
mon devices used for measuring liquid oral 
medication.  This finding is similar to previous 
studies (J Madlon-Kay et al, 2000 and Yin et al, 
2007). Data obtained in previous studies in-
dicated that regardless the recommendation 
from American Academy of Pediatrics (AAP) 
against use of unstandardized dosing instru-
ment; patient and caregiver continue to use 
household tablespoon and teaspoon for ad-
ministering their liquid oral medicine (J Mad-
lon-Kay et al, 2000)
The most frequently oral liquid medication 
purchased was product for cough, cold and flu, 
both single component and multi-components 
(66.0%, n=80) as demonstrated by Figure 2. 
According to Berardi et al, there were seven 
conditions commonly treated with nonpre-
scription drugs, such as pain, cough/flu/cold/
sore throat, allergy/sinus problem, heartburn/
indigestion, constipation/diarrhea/gas, minor 
infections, and skin problem.
As can be seen in Figure 3, there are 8 age 
groups namely 0 to 1 years (infant), 1 to 3 
years (toddler), 4 to 12 years (children), 13 
to 18 years (adolescent), 19  to 25 years (late 
adolescent), 26 to 45 years (adult), 46 to 59 
years (middle age), and 60 years old and above 
(elderly). More than 80% (n=59) patient super-
vised by caregiver were toddler and children.
It is alarming that almost 50% (28) of the 
caregivers had experienced large dose errors 
which may lead to overdosing. A systematic 
review on incidence and nature of dosing er-
rors in pediatric revealed that eleven of the 16 
studies found that dosing errors are the most 
common type of medication error (Wong et al, 
2004). 
CONCLUSION
Our study revealed that more than fifty per-
cent of the participants have large dose er-
rors in measuring oral liquid medication, both 
female and male participants shares almost 
equall number. Dosing spoon and tablespoon 
were the most frequently used dosing devices 
in administering oral liquid medication. De-
spite the correct choosing of dosing devices, 
the large dosing errors were found.    
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INTRODUCTION
The exploration to find the sources of fatty 
acids, especially essential fatty acids for hu-
mans and beneficial to health is still ongoing. 
This is due to the results of studies showing 
that unsaturated fatty acids (omega 3, omega 
6 and omega 9) could be used to prevent and 
treatment   several diseases, such as athero-
sclerosis, Alzheimer’s, arthritis and inflam-
mation (Kuhnt, et al. 2012). This paper stud-
ies the potency of canarium oil that used in 
manufacturing of structured lipid. Structured 
lipid is a triglyceride that has been modified 
by changing the composition or distribution of 
fatty acids position on the glycerol backbone 
through chemical conversions, enzymatic re-
actions and or genetic engineering. Structured 
lipids could be applied to nutritional, pharma-
ceutical, or medical applications (Osborn and 
Akoh. 2002). 
METHODS
In particular, this research have extracted and 
characterized the composition of fatty acids 
in canarium oil, followed by the synthesis of 
2-monoacylglycerols (2-MAGs) using 1,3 spe-
cific lipase against canarium oil as a substrat. 
Product of 2-MAGs will then be used for the 
synthesis of a structured lipid by incorporat-
ing medium chain fatty acid in position sn-1 
and sn-3 of  2-MAGs compound in the next 
work. Oil extraction was performed by  me-
chanical pressing with consideration that oil 
content in canarium seeds large enough and 
without using organic solvents. Analysis of 
fatty acids composition was carried out by gas 
chromatography-mass spectroscopy (GC-MS) 
and high performance liquid chromatography 
(HPLC). Enzymatic reaction for synthesis of 
2-MAG was conducted in an orbital sheaker 
waterbath and followed purification by sol-
vent extraction based on procedure by Este-
ban et al . 
The characterization of products using thin 
layer chromatography and analysis of fatty ac-
ids composition by HPLC.
RESULT AND DISCUSSIONS
The result of the hydraulic-pressure extrac-
tion obtained the yield of oil was 70 % with 
the highest fatty acid composition respec-
tivelly were oleic acid (47.0 %), palmitic acid 
(30.0%), stearic acid (15.3 %), and linoleic acid 
(7.3 %). 
A          B          C
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Figure 1.  Characterization of reaction products (MAGs, 
DAGs, TAGs and EE) by thin layer chromatography us-
ing chloroform/aceton/methanol (95/4.5/0.5) as mo-
bile phase, spots were visualized by iodine vapor. Hy-
droethanolic phase is coded by A and hexanic phase 
is coded by B. Comparison with spots using 2-oleoyl 
glycerol (C).
The characterization of 2-MAGs by thin layer 
chromatography using a standard 2-oleoylg-
lycerol (Figure 1), purification by solvent ex-
traction and followed by isolation to deter-
mine the fatty acids composition by reparative 
thin layer chromatography. After incubation 
CONCLUSION
Synthesis of 2-MAGs could be perform by 
ethanolysis reaction between canarium oil 
and dry ethanol in an orbital shaker waterbath 
incubator. Characterization of 2-MAG carried 
out by preparative thin layer chromatography 
using the standar 2-oleoylglycerol  and ob-
tained 2-MAG yield of 74% after purification 
by solvent extraction. Analysis of the fatty 
acids composition between canarium oil and 
2-MAG using high performance liquid chroma-
tography showed a similar composition.  The 
highest composition of fatty acids of 2-MAGs 
were unsaturated fatty acids, namely oleic 
acid (18:1n-9) and linoleic acid (18:2n-6) that 
Figure 2.  Fatty acids composition of 2-MAGs were analyzed by HPLC 
for 6 hours in an orbital sheaker waterbath, 
temperature 35 °C with a shaking speed of 248 
rpm to 750 mg of canarium oil and 3 grams 
of dry ethanol (1: 4 w/w) and 375 mg of the 
enzyme (10% of total substrate) was obtained 
2-MAGs yield by 74% in the phase of EtOH/
H2O (90:10 v/v). The highest composition of 
fatty acids on the 2-MAGs were unsaturated 
fatty acids, namely oleic acid (939.8 ppm) and 
linoleic acid (445.5 ppm) that analyzed by high 
performance liquid chromatography (Figure 
2), therefore it could be used for the next 
stage of the synthesis of structured lipid.
could be used for production of structured lip-
ids .
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EFFECT OF TREHALOSE ON THERMAL PROPERTIES OF PHOSPHOLIPID-
DDA AND TPGS MIXTURES
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INTRODUCTION
The freeze-dried liposome as immunological 
adjuvant/vaccine delivery systems is one of 
recent particular interest in the area. DDA is 
one of the particular interests in immunologi-
cal adjuvant materials. DDA is a quarterammo-
nium compound with long chain alkyl groups 
that contribute to its lipophilic properties. It 
also comprises dimethylammounium head-
group (positively charged) that is attached to 
the two carbon alkyl chains and contributes 
to its hydrophilic properties. Both properties 
of DDA make it suitable for such application 
in the preparation of cationic liposomes [1-3]. 
However, DDA liposomes have some draw-
backs such as physical instability, as they are 
easily aggregate in presence of small amounts 
of salt or even in pure water [7, 8]. As water 
has been considered as an ideal dispersion 
medium, then improving DDA formulations 
is still challenging. This project focuses on the 
development of potential new formulations 
of lyophilized liposomes as immunological 
adjuvant in vaccine delivery system and in-
vestigations based on their physicochemical 
characteristics. Lyoprotectant, i.e. trehalose 
and membrane stabilizer, i.e. TPGS (D-alpha 
tocopherol polyethylene glycol 1000 succi-
nate) were used in the freeze-dried liposomes 
formulations.
EXPERIMENTAL METHODS
Materials
TPGS, DDA and BSA were purchased from Sig-
ma (UK), soyphosphatidylcholines (SPC) was 
purchased from Lipoid (Germany) and tre-
halose was purchased from Ferro Pfanstiehl 
(USA).
Sample Preparation of Phospholipid-DDA-
TPGS mixture
SPC, DDA and TPGS were dissolved and mixed 
in chloroform/methanol (9:1) solvent system. 
After solvent was removed, the resulted lipid 
film was then hydrated with pre-heated (60°C) 
10 mM tris buffer (pH 7.4). Trehalose solution 
at concentration 0.02 M in this buffer were 
also used as hydration solutions. The ratio of 
DDA and SPC (1:1) was chosen for practical 
reason, regarding that these two lipids have 
same length of acyl chains.  Samples were 
stirred for 30 min (at 60°C) and then sonicated 
for 2 min (probe sonicator, Fisher Scientific, 
USA) with pulsative mode. Single lipid com-
ponents were also prepared in the same way 
with concentration 50 mg/ml. All samples 
were then freeze-dried (Advantage, VirTis, 
USA) for 36 h to obtain solid cakes.
Dry Product Characterization
Water Content. Water content in freeze dried 
cakes was measured by using thermogravi-
metric analysis (TGA) at 10°C/min to 200°C.
Differential Scanning Calorimetry (DSC). DSC 
instrument (Q-100, TA Instruments, New Cas-
tle, DE USA) was used to determine the phase 
transition temperature (Tm) of the dried sam-
ples. Tm was measured as endothermic peak 
minimum for the lipid gel-to-liquid crystal-
line phase transition during the heating scan. 
Samples were scanned from -20°C to 200°C at 
10°C/min. Annealing technique was applied 
with heating rate 10°C/min in range of 60° - 
150°C for further investigation. All samples 
were measured in three replicates using alu-
minum hermetic. An empty pan was used as 
reference. Data were analyzed using Universal 
Analysis Software. 
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RESULTS AND DISCUSSIONS 
Figure 1. DSC thermograms of freeze-dried 
DDA-SPC (1:1 molar ratio) mixtures containing 
different concentration of TPGS as indicated; 
(A) without trehalose, and (B) with 0.02 M tre-
halose.
*p<0.05, **p<0.01 as compared to the corresponding lipid mixture without trehalose. #the en-
thalpy values (∆H of Tm2) of lipid mixtures are presented in units of KJ/mol where the mol was 
calculated as total of mol fraction of every component in the mixtures.
 
Table 1. Transition temperature and the melting enthalpy of freeze-dried lipid mixture with and 
without the presence of trehalose 0.02 M (n = 3 ± represents SD).
 
A small concentration of trehalose (0.02 M) 
was applied to the lipid mixture to make 1:4 
molar ratios of sugar towards total lipid con-
centration of 0.08 M (Table 2.6.). In this par-
ticular experiment, the effect of trehalose 
was examined in the lipid mixtures with TPGS 
concentration of 0; 0.1; 0.3 and 0.5 mol %. The 
results showed that trehalose decreased the 
Tm of the lipid mixtures by approximately 10°C 
from 58° or 60°C to 49˚C, regardless of the 
concentration of TPGS (Figure 1 and Table 1).
The explanation of Tm depression by addition 
of trehalose can be attributed to the capability 
of trehalose to restrict or prevent lipid contrac-
tion during dehydration processes that would 
occur in the absence of trehalose (Ohtake, 
Schebor et al. 2005). This restriction that is 
achieved by the direct interaction of trehalose 
with phospholipids has also been reported 
in another study (Pereira, Lins et al. 2004). It 
has been proposed previously that the Tm de-
pression of lipid by the presence of trehalose 
occurs through a ‘water replacement’ theory 
(Crowe, Crowe et al. 1985).
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CONCLUSION
Trehalose as a lyoprotectant interacts well 
with the phospholipid-DDA-TPGS mixture 
through water replacement mechanism is in-
dicated by the decreased Tm of the lipid mix-
tures in the presence of 0.02 M trehalose. 
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INTRODUCTION
Fluconazole is a triazole antifungal drug used 
in the treatment and prevention of superfi-
cial and systemic fungal infections. In a bulk 
powder form, it appears as a white crystalline 
powder, and it is very slightly soluble in water 
and soluble in alcohol3.
Cyclodextrins (CDs) are cyclic oligosaccharides 
containing six (α-CD), seven (β-CD) or eight (γ-
CD) α-1,4-linked glycopyranose units, with a 
hydrophilic hydroxyl group on their outer sur-
face and a hydrophobic cavity in the center. In 
previous years cyclodextrins (CDs) have been 
recognized as an important constituents of 
pharmaceutical excipients. CDs are capable of 
forming inclusion complexes with many drugs 
by including a whole drug molecule, or only 
some non-polar part of it, inside their cavity.
The aim of this study was to improve the solu-
bility of fluconazole by the formation of fluco-
nazole- β-cyclodextrin (β-CD) inclusion com-
plex. 
MATERIALS AND METHOD
Materials fluconazole from Chemo-Switzer-
land,  ß-cyclodextrin, hydroxypropyl methyl-
cellulosa (HPMC), sodium chlorida, hydrochlo-
ric acid, sodium phosphat monobase, sodium 
hidroksida, sodium citric, citric acid, distilled 
water.
For preparation of complexes by slurry meth-
od, the fluconazole –β-CD in 1:1, 2:1, 4:1 and 
8:1 molar ratio. The β-CD were suspended in 
60% water with 0.5% hydroxypropyl methyl-
cellulose (HPMC) to obtain a homogeneous 
paste. Fluconazole was then added slowly 
while grinding. The mixtures were heated and Figure 1. Phase solubility diagram of Fluconazole-β-CD 
    
PREPARATION AND CHARACTERIZATION OF FLUKONAZOLE-β-
CYCLODEXTRIN INCLUSION COMPLEXES
Hestiary Ratih, Department of Pharmacy, University of Jenderal Achmad Yani, Cimahi, hestiary_ratih@yahoo.
co.id; , Department of Pharmacy, University of Jenderal Achmad Yani, Cimahi; Erin Karlina, Department of Phar-
macy, University of Jenderal Achmad Yani, Cimahi.
stirred in a water bath at 40o-75oC for 1 hours 
. The pastes were dried in an oven at 80⁰C. 
The dried complexes were pulverized and 
then sieved through 60 #.
RESULT AND DISCUSSION
Phase Solubility Studies
The phase solubility diagram fluconazole-β-
CD system in water can be characterized as 
AL type phase solubility curve. Results of the 
phase solubility studies are shown in Figure 1 
that presents the solubility profiles of fluco-
nazole as a function of increasing concentra-
tions of β-CD in aqueous solution. This linear 
fluconazole-β-CD correlation, with a slope of 
less than 1, suggests the formation of  a 1:1 
(mol/mol) fluconazole-β-CD inclusion com-
plex. The calculated stability constant values 
was 113,57 M-1. Fluconazole indicating that 
fluconazole -β- CD complexes (1:1 molar ra-
tio) are sufficiently stable. In fact, values of 
obtained stability constants are always within 
the range of 100 to 1000 M−1, which is be-
lieved to fluconazole an ideal value. 
Result of the inclusion complex solubility 
fluconazole-β-CD can increase the solubility 
of fluconazole in distilled water compared 
to pure fluconazole. Inclusion complex of 
fluconazole-β-CD 1: 1 has the highest solubil-
ity in distilled water compared to pure fluco-
nazole and other complex, ie 8.98 mg / mL.
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FT-IR Studies
The FT-IR spectrum of fluconazole showed 
peak at 1516,05 cm-1, corresponding to the 
–NH stretch. A decrease in the –NH stretch 
frequency of fluconazole from 1516,05 cm-1 
to 1508,33 cm-1. This shift indicates the weak-
ness of the bond energy between β- CD and 
water, so the water out of the cavity when 
fluconazole into the cavity of β-CD which was 
followed by the formation of hydrogen bond 
with fluconazole-β-CD. A broad band at 1680 
cm-1 characterizes the spectrum for β-CD, 
which is due to the glycoside linkages. The cy-
clodextrin glycoside peak is unchanged in the 
presence of fluconazole on inclusion complex 
fluconazole-β CD. Disappearance most of the 
peaks and the shift of the wave number fluco-
nazole, suggesting an interaction between flu-
conazole with β- CD, which means there in an 
inclusion complex between fluconazole- β-CD 
prepared by slurry method.
Powder X-Ray Diffraction (PXRD) Studies
Diffractogram on inclusion complex showed a 
sharp decrease in the intensity of fluconazole 
to approach the diffractogram profile β-CD. 
This suggests that the molecular flukonazole 
has entered into the structure of β-CD cavity 
so that it looks only diffractogram β-CD. 
In Vitro Dissolution Studies
Dissolution studies of fluconazole in pow-
der form, and complexes with β-CD were 
performed to evaluate drug release profile. 
Dissolution studies were performed on USP 
dissolution apparatus type II with 900 ml dis-
solution medium pH 1.2 hydrochloric acid buf-
fer, citrate buffer pH 4.5 and pH 6.8 phosphate 
buffer at 37 0C ± 0.5 0C at 50 rpm for 30 min. 
Inclusion complex capable of increase the rate 
of dissolution in hydrochloric acid buffer of 
pH 1.2, citrate buffer pH 4.5 and pH 6.8 phos-
phate buffer compared to pure fluconazole.
Figure 2. FT-IR spectrum of (a) Fluconazole, (b) β-CD, 
(c) Flukonazol-β-CD 1:1 inclusion complex
Figure 3. PXRD patterns of (a) Fluconazole (b) β-CD, (c) 
Fluconazole-β-CD 1:1 inclusion complex
Figure 5. Dissolution profiles of fluconazole – β - CD 
1:1 inclusion complex in citrate buffer pH 4.
Figure 6. Dissolution profiles of fluconazole-β-CD 1:1 
inclusion complex in pH 6.8 phosphate buffer 
Figure 4. Dissolution profiles of flukonazole-β-CD 1:1 
inclusion complex in pH 1.2 hydrochloric acid buffer
129
Conclusion
Results obtained during this study showed 
that  β-CD   is
able to improve fluconazole dissolution prop-
erties. Inclusion complex of  fluconazole β-CD 
1: 1 with an equilibrium constant value of 
113.57 M-1 provides the best solubility than 
the complex fluconazole-β-CD  2: 1, 4: 1 and 
8: 1.
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INTRODUCTION
One of the problem concerning with human 
health is the presence of free radicals in the 
human body. The most effective way to pre-
vent the deleterious effects of free radicals is 
the use of antioxidants. There is a preference 
for antioxidants coming from natural sources 
rather than from synthetic sources (Molyneux, 
2003). One of the natural sources of antioxi-
dant is turmeric (Curcuma longa L.). Virtual-
ly every higher plant is host to one or more 
endophytic fungi. These microbes may have 
established one of several kinds of biologi-
cal relationship with the plant, varying from 
symbiotic to parasitic. The microbe may mimic 
the plant and make the same secondary com-
pounds as its host that may also have phar-
maceutical applications (Strobel, 1996). The 
aim of this research was to examine the bio-
production of endophytic fungi isolate CL.SMI.
RF11 and to isolate and identify a compound 
produced by this isolate that was expected to 
have antioxidant activity.
METHODS
Material
One of endophytic fungi, CL.SMI.RF11, was 
isolated from turmeric tuber (Curcuma longa 
L.) which cultivated in  Sukabumi, West Java. 
This isolate is a collection of Natural Product 
Laboratory, Research Centre for Biotechnol-
ogy,  Indonesian Institute of Sciences (LIPI), 
Cibinong.
         
Bioproduction
The endophytic fungi isolate CL.SMI.RF11 was 
inoculated in Potato Dextrose Agar (PDA) me-
dium in Petri dish and incubated for seven days 
at room temperature (Jia-yao Li et al, 1996). 
The culture was then being transferred into 
Potato Dextrose Broth (PDB) medium and fer-
mented for 12 to 14 days while being shaken 
using the rotary shaker at room temperature. 
Extraction Procedure
The filtrate, which had higher antioxidant ac-
tivity than the biomass, was extracted using 
ethyl acetate as solvent and evaporated under 
reduced pressure using rotary evaporator. 
Antioxidant Activity Test
Series of concentration of the extract were 
made and each solution was added with one 
mL of 1,1-diphenyl-2-picrylhydrazyl (DPPH) 
solution (0.4 mM in methanol) and diluted 
until 5 mL with methanol. After being homog-
enized, the solutions were incubated for 30 
minutes at 37oC. The absorptions were mea-
sured spectrometrically at 517 nm. The ascor-
bic acid was used as standard.
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Fractionation and Purification
Fractionation procedure using column chro-
matography was carried out three times, 
and followed by preparative TLC to get pure 
substance(s).
First column chromatography: silica gel 60; gra-
dient solvent system of n-hexane-ethyl acetate 
10:1 to 4:1 followed by chloroform-methanol 
15:1 to 1:1. TLC monitoring: silica gel GF254 
plate developed in n-hexane-ethyl acetate 5:1 
and chloroform-methanol 5:1; spray reagent 
cerium sulphate solution (1% in 10% sulphuric 
acid), heated electrically until the spots were 
appeared.
Second column chromatography: silica gel 60; 
gradient solvent system of chloroform-meth-
anol 15:1 to 1:1. TLC monitoring: silica gel 
GF254, mobile phase: chloroform-methanol 
3:1, the spots were examined by  UV light 254 
nm and spray reagent DPPH solution. The spot 
which performed yellow in colour was predict-
ed containing antioxidant compound.
Third column chromatography: silica gel 60; 
n-hexane-ethyl acetate 5:1 followed by chlo-
roform-methanol 10:1 to 1:1. TLC monitoring: 
silica gel GF254, mobile phase: chloroform-
methanol 9:1, the spots were examined by UV 
light 254 nm and spray reagent DPPH solution. 
The most intensive yellow spot was predicted 
containing the most active antioxidant com-
pound and selected for further purification. 
Preparative TLC: silica gel GF254, mobile 
phase chloroform-methanol 9:1.  Each of the 
bands was extracted with solvent mixture of 
chloroform-methanol 1:1. After filtering, the 
extract(s) were evaporated until the pure sub-
stances were obtained. 
Two-dimension TLC
Two-dimension TLC was performed to  con-
firm that the substance was pure enough to be 
identified. The mobile phase for first dimen-
sion TLC was chloroform-methanol 2:1, and 
the second was chloroform-methanol 1:1. The 
isolate was examined by means of spectro-
scopic method.
RESULT AND DISCUSSION
Seven fractions eluted from the first column 
chromatography were analysed for their anti-
oxidant activities using free radical scavenger 
method, and Fraction V was found the most 
active fraction with IC50 of 10.01 ppm, com-
pared to ascorbic acid which has IC50 of 3.13 
ppm. Fraction V was further separated with 
the second column chromatography yielded 
six fractions. Examining with DPPH spray re-
agent on TLC plate indicated that Fraction V.2 
revealed the most intensive yellow colour, in-
dicating it to contain antioxidant compound(s). 
Fractination of Fraction V.2 with third column 
chromatography eluted three fractions, and 
fraction V.2.2 was the most active one, there-
fore it was further purified by preparative TLC.
Spestroscopic Analyses
 The compound obtained from preparative 
TLC was identified spectroscopically (UV-VIS 
spectrophotometry, FTIR, 1H-NMR, and 13C-
NMR).
UV-VIS Spectrophotometry spectrum of the 
isolate in the range of 190-700 nm revealed 
the maximum wavelength at 324.0 and 208.0 
nm, meaning that the compound has an 
aromatic group and saturated ketone. The 
FTIR spectrum indicated that the isolate has 
stretching vibration of C-H bonding (3059.86 
cm-1), hydroxyl group at 3611.46 cm-1, and 
carbonyl group which appears at 1727 cm-1.
The NMR spectrum of proton at δH 6.66-7.28 
revealed some protons of double bond car-
bons (δH 6.66 ppm, d, 1H; δH 6.82 ppm, dd, 
1H; δH 7.28 ppm, d, 1H). This data indicated 
that the compound has a three-substituted 
aromatic group. The 13C-NMR and its DEPT 
spectra indicated that  the compound consists 
of eight carbon atoms.  Six resonances ap-
peared  at δC 116.93, 117.76, 119.08, 122.14, 
150.01, and 155.83 ppm, showed the aro-
matic group as it is also stated by NMR-proton 
spectrum. The rest two carbon atoms reso-
nance appeared at  δC 177.06 ppm (carbonyl 
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carbon) and 30.59 ppm (methylene carbon) as 
indicated by DEPT spectrum.
CONCLUSION
Based on spectroscopic data, the compound 
that has antioxidant activity produced by bio-
production of endophytic fungi isolate CL.SMI.
RF11 was predicted as 3-hydroxy-bicyclo[4.2.0]
octa-1,3,5-trien-7-one.
Fig.2. Structure of the compound 3-hydroxy-
bicyclo  [4.2.0]octa-1,3,5-trien-7-one) isolated 
from endophytic  fungi isolate CL.SMI.RF11
Fig.2. Structure of the compound 3-hydroxy-
bicyclo  [4.2.0]octa-1,3,5-trien-7-one) isolated 
from endophytic  fungi isolate CL.SMI.RF11
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INTRODUCTION
Natural cassava starch (Cass) has poor physi-
cal properties. Through modification, it can 
be increased. Fully pregelatinized is a physical 
modification by addition of water with heat-
ing above the gelatination temperature that 
causes rupture of entire starch granules. It will 
entangle amylose that was one of the com-
ponent in starch. Co-processing method is a 
technique by combining existing excipients in 
order to obtain a new excipient with improved 
properties (Gohel, 2005). Additional excipient 
that commonly use is Acacia Gum (AG). There 
are two types of co-processing Cass with AG 
which are Partially Pregelatinized (Co-PPCass) 
and Full Pregelatinized (Co-FPCass). Accord-
ing to all of that, the aims of this study was to 
know the effect of modifications to the charac-
teristic and physical properties of Cass.
METHODS
Materials
The material used were natural cassava (Mani-
hot esculenta Crantz) and acacia gum (PT. 
Bratachem).
Methods
Preparation of cass
Cass was cutted into tiny size and then add-
ed amount distilled water to 2:1 w/v. Strain 
it with flannel cloth. After 24 hours, separate 
the supernatant from the precipitate. Then 
washed it with distilled water. After that, dried 
it at 50°C for 24 hours until it forming a slab 
of starch. Sieved it to obtain a starch powder 
(Soebagio et al, 2009).
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Prasetia, Jemmy A., C.I.S. Arisanti, N.P.P.A. Dewi, G.A.R. Astuti, N.W.N Yulianingsih, I M.A.G. Wirasuta
Department of Pharmacy, Pharmaceutical Technology, Faculty of Mathematics and Natural Science, Udayana Uni-
versity - Bali, ngurah_jemmy@yahoo.com, +628179373361.
Preparation of modified cass
1. Fully pregelatinized cass (FPCass)
 Cass suspended in distilled water   
 (1:1). The suspension was   
 then heated over water bath at 80°C  
 and stirred it for 10 minutes. The sus 
 pension was dried at 50°C for 48   
 hours. The dry starch then sieved  
 through no 20 mesh sieve (Ohwoav 
 worhua and Osinowo, 2010).
2. Co-processed cass (Co-PPCass and  
 Co-FPCass)
 Co-processed was prepared by mix 
 ing Cass and AG (92,5:7,5). The  
 required amount of Cass was dis  
 persed in distilled water to get 40% 
 w/w solid content. In the same  
 way, a number of AG was also dis
 persed in distilled water (2:3 w/v).  
 AG suspension was mixed into Cass  
 suspension with stirring for 10 min 
 utes. The CassAG suspension was  
 heated on a water-bath in different  
 temperature to obtain different  
 types of co-processing Cass. Co-  
 PPCass was obtained by heating it  
 at 55°C. Meanwhile, if the tempera 
 ture was increased into 80°C, the 
 result is Co-FPCass. Furthermore, 
 each type were dried at 60°C for 48  
 hours. The granule was powdered by  
 no 20 mesh sieve (Ohwoavworhua  
 and Osinowo, 2010).
Characteristics of starch
Organoleptics
Weigh 1 gram of Cass and then observe the 
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color, smell and taste of it. Cass has a char-
acteristic which are white color, odorless and 
tasteless.
Identification of cass
The suspension of Cass produced by weight 1 
gram of Cass and mixed it in 50 mL of distilled 
water. 1 mL of Cass solution mixed with 0,05 
mL of 0,005 M iodine.
Microscopics
Weigh 100 mg of Cass and placed on a glass 
object. Added 2 drops of distilled water and 
then observed the hilum and lamellae under 
a microscope.
Physical properties of starch
Determination of particle size
A 100 grams of Cass. Further, stratified it by 
sieving with mesh number 20, 40, 60, 80 and 
100.
Amylose content
A 100 mg starch dissolved with 1 mL of 95% 
ethanol and 9 mL of 1 N NaOH. The solution 
was heated for 10 minutes on water bath at 
100°C. After the solution was cooled, added 
100 mL of distilled water (A). Take 5 mL of A 
and put it into 100 mL volumetric flask. Then, 
added 1 mL of CH₃COOH, 2 ml of iodine solu-
tion and distilled water until 100 mL (B). Shake 
B for 20 minutes and measure the absorbance 
by UV-VIS spectrophotometry at wavelength 
620 nm (Adedokun and Itiola, 2009). Amylose 
content was calculated by the equation:
% Amylose levels = 3,06* x Absorbance x 20 
…....  Eq. (1)
     *Conversion factor of amylose
RESULTS AND DISCUSSION
According to table 1, organoleptics and iden-
tification test obtained that overall starch pro-
duce a same result. In identification test, starch 
will form a dark blue-purple color caused by 
the formation of amylose binding with iodine. 
In other side, amylopectin binding with iodine 
and produces bluish violet color. 
Tabel 1 Characteristic results of Cass and 
Cass modification
In microscopic test, hilum located in the mid-
dle point of the straight line and form a three-
pronged. Lamellae is unclear. This result can 
be seen in figure 1. From this results conclud-
ed that Cass modification does not give the 
change of the characteristics of Cass.
In figure 2 shows that Cass modification have a 
number of fines less than Cass. This is because 
of the increase in particle size of Cass modi-
fication through the process of unification of 
the starch particles are small in gelatination 
process so that the amount of fines can be re-
duced The number of small fines causes a bet-
ter flowability and compressibility (Anastasia-
des, et al, 2002; Ansel, 2005). Modified Cass 
has good flow properties better than Cass.
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Figure 3 shows about amylose content in Cass 
and Cass modification. Amylose content in 
Cass is the biggest ones and the lowest con-
tent is in Co-FPCass. The reduction of amylose 
content from Cass into Cass modification is 
because of the gelatination during the heating 
process. When starch is heated at gelatination 
temperature, the thermal energy causes the 
hydrogen bonds in the starch is become weak-
en. This facilitate the water to enter into the 
granules and cause slight dissolution. It also in-
duce the exchange of amylose molecules into 
the water (Lowenthal, 1972). Decreased lev-
els of amylose can cause a decrease ability of 
starch as a disintegration ingredient that can 
inhibit dissolution of the tablet
Figure 3 The correlation of Cass modification 
to amylose content
Conclusion
The results obtained based on this research is 
Cass modifications do not cause a changes of 
the characteristics but it leads to a change in 
particle size and amylose content in it.
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 BACKGROUND
Pharmacy services at this time has changed 
from the drug orientation paradigm to a pa-
tient orientation refers to pharmaceutical 
care. pharmaceutical care is a form of service 
and direct responsibility of the pharmacist 
profession of pharmacy work to improve the 
quality of life of patients (Kepmenkes, 2004). 
As a consequence of the change in orienta-
tion, the pharmacist is required to improve the 
knowledge, skills and behaviors to be able to 
carry out direct interaction with patients.
Diabetes mellitus (DM) is a group of chronic 
metabolic disorder due to abnormalities in 
the metabolism of carbohydrates, fats, and 
proteins are characterized by hyperglycemia 
resulting in microvascular complications, mac-
rovascular, and neuropathic for the long term 
(DiPiro, et al., 2008). International Diabetes 
Federation (IDF) in 2005 stated that in the 
world there are 200 million (5.1%) of people 
with diabetes and is thought 20 years later 
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(2025) will increase to 333 million (6.3%) peo-
ple.
DM is a long-term disease that requires long-
term treatment as well. In this case the nec-
essary education and motivation of health 
workers in health centers and support and su-
pervision taking medication from the patient’s 
family. Diabetes can lead to complications of 
acute and chronic (McPhee & Funk, 2006). Be-
cause of these complications, diabetic patients 
are also likely to use other drugs in addition to 
oral antidiabetic drugs. The use of many drugs 
at the same time is commonly known as poly-
pharmacy (Saunders, 2007).  
METHODS 
This research was a descriptive and cross-sec-
tional study were analyzed descriptively. The 
population in this study were DM patients of 
Menur, Mulyorejo, Mojo and Pucang Sewu 
Surabaya Health Center.
The sampling method of this study was non 
random sampling. Data was collected from 
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May 1st to June 30th, 2014 by interviewing 
138 patients in their homes. The variables in 
this study include the amount of the drug, 
the pharmacological group of drugs, types of 
drugs, how to use drugs, and compliance.
RESULTS AND DISCUSSION 
Table 1. Distribution of Patients by Sex
Table 1 shows that the majority of diabetic pa-
tients (68.12%) were female. Women are more 
at risk of diabetes, because women have a his-
tory of pregnancy with birth weight > 4 kg, his-
tory of diabetes during pregnancy (gestational 
diabetes), obesity, use of oral contraceptives, 
and stress levels are quite high (DiPiro, et al., 
2008) . 
The majority (48.6%) patients with DM was 
housewife. Based on interviews, mostly House-
wife just do their homework and have more 
free time at home. Lack of physical activity 
which  the one risk factor for diabetes (Perkeni 
2011). Lack of physical activity can lead to obe-
sity and is one of the factors triggering the DM. 
The effects are large changes in metabolic and 
endocrine function that can stimulate the oc-
currence of obesity (Anisa, 2008).
From the table 4, it can be seen that most pa-
tients are patients with a elementary education 
or equivalent (40.6%). People who would nor-
mally be a high level of education has a lot of 
knowledge about health. With the knowledge 
that people will have in maintaining health 
awareness (Irawan, 2010). People with low 
education levels are usually less knowledge-
able health especially so behave less healthy 
and susceptible to disease, and it will also af-
fect the patie  nt safety related to medication 
therapy. If the patient is unable to understand 
the information provided by health profession-
als, patients will be in a higher risk for medica-
tion errors (Beardsley, et al., 2012).
From the table 2, it can be seen that most pa-
tients were patients between the ages of 50-
69 years (63.5%). This is consistent with the 
statement of the American Diabetes Associa-
tion (ADA) (2014) that the age of 45 years and 
above a risk factor for diabetes. And as a re-
sult of the increasing age, a person is declining 
pancreatic beta cells and the progressive accu-
mulation of amyloid in the vicinity. Pancreatic 
beta cells are left in general is still active, but 
less and less insulin secretion and sensitivity 
of receptors is also decreased (Tjay & Rahard-
ja,2007).
Table 2. Distribution of Patients by Age
Table 3. Distribusi Patients Based Jobs
Table 4. Distribution of Patients According to 
Level of Education
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Table 6. Distribution of Patients by Type Used 
of OAD
Oral antidiabetic drugs in health centers, 
namely glibenclamide and metformin. The 
use of oral antidiabetic drugs in patients with 
diabetes is the thing to do when setting life-
style (diet, exercise, and weight loss) showed 
no improvement in blood sugar levels (Tjay 
& Rahardja, 2007). DM corresponding treat-
ment algorithm, patients with newly diag-
nosed diabetes should be given education on 
the pattern of life. If within one month there 
Table 7. Distribution of Patients According to 
Number of Drugs In Overall
From the number of drugs used in DM pa-
tients, as many as 104 of the 138 patients 
(75.36%) use more than three different drugs 
(polypharmacy). Polypharmacy may be un-
avoidable in patients with diabetes because 
it may be necessary to control blood sugar, 
medications are also needed to overcome the 
interference of blood pressure, dyslipidemia, 
and vascular complications and other disor-
Table 5. Distribution of Patients According to 
the Old suffering DM
Long suffered diabetes mellitus patients <1 
year to 5 years (72.46%) because patients are 
still relatively newly diagnosed diabetes melli-
tus, in general, very open and happy to be giv-
en the drug counseling, because the patient is 
still not well-informed about their disease and 
the treatment their suffered (Anisa, 2008). Pa-
tient became aware of their disease and their 
medicine so that patients have a great curios-
ity and want to recover so they diligently went 
to the primary health center. Meanwhile, 
long-suffering patients with diabetes mellitus 
> 5 years the percentage is small, it is because 
patients assume the disease is not harmful, or 
according to the results unsatisfactory experi-
ence during the treatment so that they no lon-
ger want to control to the clinic.
was no improvement in blood sugar levels, 
the use of oral antidiabetic drugs is required. 
First-line oral antidiabetic drugs used is met-
formin, thiazolidinediones class, and the class 
of sulfonylureas. Half of the patients in the 
study received glibenclamide and metformin 
combination therapy, ie 55.8%. Combination 
therapy is commonly prescribed for patients 
who have no improvement in blood sugar lev-
els within 3 months after the use of oral anti-
diabetic drugs. Glibenclamide and metformin 
combination therapy has a synergistic effect 
for both classes of drugs have an effect on the 
sensitivity of insulin receptors. Sulfonylureas 
(glibenclamide) will start to stimulate the se-
cretion of the pancreas that allows biguanide 
compounds (metformin) to perform effective-
ly (DiPiro, et al., 2008). 
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Table 8. Distribution based on Group of Drug 
Pharmacology 
From the table 8, it can be seen that vitamins 
and minerals (16.90%) and antihypertensive 
(13.90%) were the two groups of pharmacolog-
ical drugs prescribed highly by health centers 
in addition to oral antidiabetic (30.79%). Types 
of vitamins and minerals that were prescribed 
vitamin B1 or thiamine. The use of vitamin B1 
From the results of the study, most patients 
using glibenclamide with a frequency of 1 
time a day and metformin with a frequency 
of 3 times a day. Frequency of glibenclamide 
use is 1-2 times daily maximum 10 mg per day 
because the half-life of glibenclamide about 
3-5 hours, but the last hipoglycemic effects 
ders (Kurniawan, 2010). Polypharmacy can 
lead to negative effects of a therapeutic drug 
for example the occurrence of side effects 
and reduced patient compliance in the use of 
the medicine (Viktil et al., 2006). The results 
showed that the more the number of drugs 
used, the patient will tend to forget and con-
fused in using the medicine that will cause the 
drug therapy problem, one of which is non-
compliance in the use of drugs.
in patients with diabetes is essential, vitamin 
B1 used to treat neuropathic complications 
occur, the tingling and numbness, which is also 
known as neuralgia(Tjay&Rahardja,2007). 
Generic drugs most widely used by diabetic 
patients in East Surabaya primary health cen-
ters (97.94%). This is in line with the provi-
sions of existing legislation, the doctor on 
duty at government health care facilities are 
required to prescribe generic drugs for all 
patients appropriate medical indication (Per-
menkes, 2010).
Table 9. Distribution of Drugs by Type of Drug
Table 10. Distribusi Patients Based on Fre-
quency of Drug Use
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Table 11. Distribution of Patients Based on 
Time Drug Use
for 12-24 hours. Meanwhile, the frequency of 
metformin use is 1-3 times daily maximum of 3 
grams per day (Tjay & Rahardja, 2007).
Some patients used glibenclamide before 
meals (76.04%) and metformin after meals 
(38.74%). Glibenclamide can cause hypogly-
cemia so that the gift must be before a meal 
(15-30 minutes). Side effect of metformin is 
can cause nausea, so it must use during meals 
or after meals (Perkeni,2011). 
CONCLUSION 
1. Diabetic patients generally used more than  
one drug. 
2. Vitamins and minerals (16.90%), antihyper-
tensives drugs (13.89%) and NSAIDs (13.42%) 
were the group of pharmacological drugs that 
mostly used in addition to oral antidiabetic. 
3. Generic drugs (94%) were the type of drugs 
that were mostly used in PHC. 
4. Patients generally used glibenclamide once 
a day and metformin more than once a day. 
5. Patients used glibenclamide before meals 
(76.04%) and metformin after meals (38.74%). 
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INTRODUCTION
Human life can not be separated from the ob-
jects that come from the metal. Metals are 
toxic to humans, which can be derived from 
consuming food, beverage or air inhalation, 
contaminated dust, skin contact, eye con-
tact and parenteral. Metal that goes into the 
lungs through the respiratory events will be 
absorbed by the blood and binds to the lungs 
and then distributed to all tissues and organs6. 
The entry of the metal into the body of one 
of them can lead to the formation of a com-
pound called free radicals. Free radical formed 
cause DNA base modification, increase lipid 
peroxidation and alter calcium homeostasis 
and sulfidril. Antioxidants provide protection 
against free radical-mediated attack by the 
metal3;5. Flavonoids are antioxidants that are 
important for a high redox potential, which al-
lows the flavonoids act as reducing agents, hy-
drogen donors, singlet oxygen and eliminate7. 
Isoflavone and anthocyanine are flavonoids 
that are widely available components in soy 
and dairy products1. Consumption of soy and 
dairy product has been linked to reduced of 
various cancers and chronic inflammatory dis-
eases. Health promotion activities associated 
with soy consumption was associated with 
the presence of isoflavone content. Soy is rich 
in phytochemical compounds that are essen-
tial to human life and therefore considered to 
neutracetical functional food. In this study, the 
activity of soy isoflavones compared with the 
activity of vitamin C as an antioxidant. Vitamin 
C acts as a reducing agent for a variety of free 
radicals.
METHODS
Glycine max Detam II Variety extracted by ki-
netic maceration (Stirring Motor IKA Rw 20 N) 
with stirring speed 10rpm.
Research carried out by using 25 mice strain 
BALB/C that were randomly divided into five 
groups of five mice including negative control, 
positive control treatment, reference and pla-
cebo. All groups except positive control were 
intoxicated with lead in a dose of 25 mg/kg 
body weight for the duration of seven days. 
2.31 g/kg body weight of Glycine max detam 
II has been given to treatment and positive 
control4. Thereafter 64 mg/kg body weight 
of vitamin C has been given to the reference 
group.
Measurement of lead concentration in mice 
blood and methanol extract Glycine max De-
tam II Variety used Atomic Absorption Spec-
trophotometry (AAS), for measurement of 
malondialdehyde was used Thiobarbituric 
acid Reactive Substance (TBARS) assay.
Preparation of histology assay liver and renal 
mice by making incision (5mm), stained with 
haematoxylin-eosin (HE) and observed under 
the electron microscope2;8.
RESULT
143
Table 1. Analysis lead levels in extract  and Gly-
cine max seed Varieties Detam II
CONCLUSION
The result showed that Glycine max detam II 
varieties was significantly decrease the level of 
lead in mice’s blood, not significantly decrease 
the level of malondialdehyde in mice’s organ 
and also significantly  decrease of damage or-
gan. 
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ABSTRACT
It is proven, empirically, that Matoa leaves 
have been used as an antihypertensive medi-
cine by Pajang Surakarta people. Blood pres-
sure is the result of cardiac output and periph-
eral resistance multiplication. Cardiac output 
influenced by pulse, contractility and filling 
pressure. Filling pressure influenced by blood 
volume and venous tone while peripheral re-
sistance influenced by arterioles volume. 
Heart rate frequency influence by contractility 
and will affect cardiac output and blood pres-
sure. So, if the heart rate frequency increas-
ing, the contractility, cardiac output and blood 
pressure will automatically increasing too. 
The research used 6 groups of male  Sparque 
Dawley’s lab rats and it consists 5 lab rats for 
each group. 3 different groups had given 3 
variants dose of 50mg/kg bw, 100mg/kg bw, 
and 150mg/ kg bw. Comparison groups are 
those with atenolol 9mg/kg bw, positive con-
trol and negative control. And data analyzed 
by using one way ANOVA. 
The results showed that all groups have sig-
nificantly different treatments especially the 
one with positive control. 50mg/kg bw dose is 
the most effective way to decrease heart rate 
frequency. 
INTRODUCTION
Hypertension is one of the cardiovascular 
problems which happen to many people. It 
is commonly happen as they grow older. Hy-
pertension (6,8%) is top 3 cause of death after 
Stroke (15,4%) and Tuberculosis (7,5%). Based 
on blood pressure measurement, it shows 
about 31,7% of Hypertension happen to Indo-
nesian around 18 years old or more. 
The highest rate of Hypertension in Indonesia 
is in south Kalimantan about 39,6% of popu-
lation and west Papua province is the low-
est rate about 20,1% of population. 7,2% of 
health service Hypertension diagnosed and 
7,6% of interviews, only 0,4% of the Hyperten-
sion patients who took medications.  
So, this is why health service could only treat-
ed 24,0% out of 31,7% of Hypertension prob-
lems. It is like 76,0% of all Hypertension cases 
hasn’t been treated (Depkes, 2008).  WHO also 
explained that the percentage of Hyperten-
sion on adult (over 25 years old) men is quite 
larger than women. It is proven that 32,5% 
Hypertension happen on men and 29,3% on 
women (WHO, 2012).  
There are some problems tend to happen in 
pharmacological Hypertension treatments. 
Hypertension treatments with antihyperten-
sive medicine usually takes a lot of time to 
treat which cause some side effects. 
And then, it is impossible to precisely predict 
the individual respond of each patients to cer-
tain antihypertensive medicines and many of 
the cases need more than 2 kinds of antihyper-
tensive medicines to reach their blood pres-
sure objective (Gilman, 2006). So, that’s why 
in many Hypertension cases, a lot of patients 
got into therapy inconsistencies that cause 
them difficulties to reach their objectives. 
Therefore, this is a huge opportunity to find 
a new, save, effective and high quality anti-
hypertensive medicine. The best source to 
get a good antihypertensive medicine is from 
plants, the most natural source in every way. 
There are so many types of plant in Indonesia 
that have great effects to decrease blood pres-
sure and one of them is a Matoa plant; which 
has been used by Pajang Surakarta people in 
a while.  
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Matoa is one of the plants that has not been 
research so much. On FV. Mohammad’s re-
search in 2010, titled; A new triterpenoid sa-
ponin from the stem bark of Pometia pinnata, 
shows that he succeed to isolate new com-
pound of saponin and  triterpenoid, and that 
is: pometin, 3-O-[beta-D-glukopiranosil-(1 -> 
2)-beta-D-glukopiranosil-(1 -> 3)-beta-D-glu-
kopiranosil acid-oleanolic, and FV. Mohammad 
in 2012 succeed to isolate kaemferol 3-O- α -L-
rhamnopyranoside. 
Next research had done by Suedee A in 2013, 
he succeed to isolate epikatekin, kaempferol-
3-O-rhamnoside, quercetin-3-O-rhamnoside, 
glikolipid, 1-O-palmitoil-3-O-[. α --galacto-
pyranosyl-(1 → 6)- β -. -galactopyranosyl]-
sn-glycerol, steroid glycosides, stigmasterol-
3-O-glucoside, and  triterpenoid saponin 
pentasiklik, 3-O- α --arabinofuranosyl-. (1 → 
3) - [α --rhamnopyranosyl-(. 1 → 2)]- α -.-ara-
binopyranosyl hederagenin from Matoa leaves 
extract that has an activity as an anti HIV. 
It is said that antihypertensive effect with an 
active compound haven’t been researched be-
fore. Therefore, it is important to do a research 
to a Matoa plant as antihypertensive and find 
out how the activity mechanism to decrease 
blood pressure.
RESEARCH METHODOLOGY 
Materials and tools
Research materials that have been used are 
Matoa leaves ethanol extract, atenolol, aquad-
est, 0,5% CMC, 70% alcohol, and adrenaline. 
Then, the tools that been used are 1 ml sy-
ringe, 5ml syringe, rat lab’s oral sonde, and tail 
cuff. 
The procedures 
This research used 30 SD white male rat labs as 
sampling test and they divided into 6 groups. 
Sampling test was taking by a simple and ran-
dom sampling. The samples took randomly 
simply because population has proven homog-
enous.  Each group consist of 5 male lab rats. 
All lab rats adapted by a tail cuff test equip-
ment about 2-3 times with the same foods and 
drinks for 14 days. 
The procedures of the treatment explain as 
following: 
a. The first group has given 50 mg/kg bw dose 
of Matoa leaves extract, 100mg/kg bw dose 
of Matoa leaves extract to the second group, 
150mg/kg bw dose of Matoa leaves extract to 
the third group, 0,5% CMC to the control neg-
ative group and no treatment for the control 
positive.  b. Comparison group has given at-
enolol 9mg/kg bw.  C. All group accept group 
with control negative have given 1,2µg/kg bw 
adrenaline. d. The heart rate frequency noted 
when; 
T0 : the heart rate frequency before treatment 
T1 : the heart rate frequency after treatment 
T2 : the heart rate frequency after adrenaline 
induction   And data analyzed statistically by 
using one way ANOVA.
RESEARCHS AND FINDINGS
Athenolol is an antihypertensive medicine and 
anti-tonsillitis  which part of the beta blocker 
that worked based on heart rate decreases 
mechanism and Myocardia contractility so 
that the cardiac output will decrease. NE (nor 
epineprin) releases resistance through beta-
2 receptor resistance; renin secretion resis-
tance through beta-1 resistance receptor on 
kidney (Fatimah, 2012).  
Adrenaline is always causes blood vessel ar-
terial vasoconstriction, triggers pulse and 
cardiac contraction so the blood pressure 
increases rapidly and ends in a short term of 
time (Matsum 2008) 
Figure 1. Average heart rate frequency per-group/
per-minute
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Blood pressure happen because of cardiac 
output and the  peripheral blood vessel resis-
tance. Antihypertensive medicine is working 
through the peripheral resistance or cardiac 
output or even both. Cardiac output could de-
creasing by medicines that could clog myocar-
dial contractility or decreasing the ventricular 
pressure charging.  
The heart rate frequency related to heart con-
tractility and cardiac output. If the heart rate 
frequency decreasing, cardiac output also will 
decreasing and then finally the blood pressure 
is automatically controllable
Based on the graphic on picture 1, it is shown 
that the heart rate frequency is rising after 
adrenaline induction (T2 yellow). However, 
50 mg/kg bw dose of Matoa leaves extract in-
creasing insignificantly and equally like ateno-
lol as a comparison.
CONCLUSION
1. Matoa leaves extract proven decreasing  
    heart rate frequency. 
2. The effective dose from Matoa leaves ex       
   tract for decreasing heart rate is 50mg/kg bw. 
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INTRODUCTION
In drug development process, one of the early 
decisions that must be made is determining 
crystalline forms or polymorphs of the drug. 
Physical properties of solid polymorphs can in-
fluence the quality, safety and efficacy of drug. 
Considering that the bond can affect the physi-
cal properties at the macroscopic level, the ef-
forts to manipulate the physical properties by 
regulating the molecular re-arrangement in 
the solid state into a different crystal are things 
that can be importance in the pharmaceutical 
industry. Cocrystal has the physical properties, 
such as particle size and crystal habit that can 
influence the surface properties, suspended 
ability, dissolution rate, the behavior of pow-
der compressibility and compactibility. Me-
chanical properties are those properties of 
a material under the influence of an applied 
stress. Compressibility, tabletability and com-
pactibility are parameters to characterizing 
the mechanical properties whose are impor-
tant to produce tablet dosage form. The aim of 
this study was to reduce the compressibility of 
ramipril due to formation of cocrystal.
MATERIALS AND METHODS
Ramipril (RA) was kindly obtained from PT 
Kimia Farma, tbk, Indonesia. Vanilline (VA) and 
ethanol and other reagents were purchased 
from Merck Chemical without any purification
Hot Stages Method made to the RA and VA 
under the polarizing microscope equipped 
with an electric heater table (Hot Stage) crys-
tal growth was observed in the contact zone 
(CZ) between RA and VA crystal. RA-VA binary 
mixtures prepared by physical mixing at vari-
ous compositions based on the mole fraction. 
The physical properties of the binary system 
is characterized by DSC thermal analysis was 
EFFORT TO REDUCE COMPRESSIBILITY OF RAMIPRIL 
THROUGH CRYSTAL ENGINEERING
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then made binary system phase diagram of 
RA and VA. Formation cocrystal RA-VA con-
ducted by dissolving the molar ratio of 1: 1, 
then the samples were characterized by DSC 
and PXRD. Then cocrystal RA-VA sample test-
ed compressibility. 
The observation by polarizing microscopy, 
DSC and PXRD further processed and ana-
lyzed to identify and evaluate the RA-VA co-
crystal formation, changes in compressibility.
RESULT AND DISCUSSION
Microscopic Analysis by Hot Stage Polariza-
tion and Electron Microscope
and VA. Formation cocrystal RA-VA conduct-
ed by dissolving the molar ratio of 1: 1, then 
the samples were characterized by DSC and 
PXRD. Then cocrystal RA-VA sample tested 
compressibility. 
The observation by polarizing microscopy, 
DSC and PXRD further processed and ana-
lyzed to identify and evaluate the RA-VA co-
crystal formation, changes in compressibility.
RESULT AND DISCUSSION
Microscopic Analysis by Hot Stage Polariza-
tion and Electron Microscope
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This analysis provided a preliminary character-
ization of cocrystalline phase in binary mixture 
of RA-VA. Optical and electron microphoto was 
shown in Fig. 1 and 3. RA-VA cocrystal from 
solvent method was needle shaped habit and 
was obtained wihin two days. A sharp melting 
point at around 91.9 0C was observed for the 
RA-VA cocrystal(Fig 2). 
Figure 1 Microphoto crystal habit A) VA, B) RA 
C) CZ
The diffraction pattern of cocrystal should be 
clearly distinct from that of the superimposi-
tion of each of the compound If a true cocrystal 
has been formed beetwen two solid phases. A 
different PXRD pattern for cocrystal of RA and 
VA (Fig. 3D) from those physical mixtures con-
firms the formation of a new cocrystal phase.
Figure 3 Compressibility Curve 
Based on the above curves powder compress-
ibility RA had the highest, while the lowest VA 
powder. The higher the compressibility curve 
of a material, the more easily the material to 
be compressed.
CONCLUSION
In the contact method, observed the forma-
tion of a new crystal habit elongated needle-
shaped contact zone between ramipril (RA) 
and vanillin (VA), which has a different melting 
range from the melting point of the two com-
ponents. X-ray diffraction pattern of the com-
pound powder of the interaction of RA and 
VA showed different diffractogram of the two 
components which indicates the formation 
of cocrystal phase. The test results showed 
solubility of the sample results cocrystalliza-
tion was higher than pure and recrystallization 
results. Characterization of compressibility 
shows that a decline in the compressibility of 
the powder RA after cocrystallization process 
with the VA. The results of dissolution test 
powders and tablets of various compression 
Figure 2 Thermogram DSC A) VA, B) RA C) RA-
VA
Figure 3 Powder Diffractogram A) RA B) VA C) PM D) RA-VA 
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cocrystal RA and RA-VA showed that kokristal 
RA-VA has a lower dissolution than RA either 
on medium 0.1N HCl (pH 1.2) and phosphate 
buffer pH 6.8.
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INTRODUCTION
 Diabetes mellitus is a well-known 
metabolic disorder which is characterized by 
hyperglycemia resulting from the deficiency 
in the production of insulin by the pancreas 
or its action (Umar et al., 2010).  According to 
International Diabetes Federation, this serious 
metabolic disease has been affecting 382 mil-
lion (2013) of the population worldwide and 
this number is predicted to rise up to 592 mil-
lion by the year 2035. Type 2 diabetes mellitus 
has more prevalent compared with Type 1 dia-
betes.
 Alpha-glucosidase inhibition is one of 
the mechanisms involved in lowering blood 
glucose levels (BGLs). At present, synthethic 
alpha-glucosidase inhibitors have been made 
available as oral anti-hyperglycemic drugs, 
they have been found to cause negative he-
patic and gastrointestinal side effects (Feng et 
al., 2009). The demand in using approaches to 
treat diabetes, such as plant-based medicines, 
has increased in countries which are industri-
ally developed. Therefore, to search for new 
plant-based medicine to inhibit alpha-glucosi-
dase activity and fight diabetes mellitus, this 
research was conducted.
 Rauvolfia serpentina (L.) Benth. ex 
Kurz is a genus of the family Apocyanaceae 
(dogbane family) and occurs in nearly all habit-
able tropical and subtropical regions. This me-
dicinal plant was therapeutically important be-
cause of the presence of indole alkaloids in the 
treatment of various diseases, which is in great 
demand of modern pharmaceutical industries 
(Nair et al., 2011). For α-glucosidase inhibitory 
activity, this medicinal plant has never been in-
vestigated.
MATERIALS AND METHODS
Chemicals
 The chemical reagents used were 
analytical grade. Silica gel 60 HF254 was 
used for Vacuum Liquid Chromatography. 
Yeast α-glucosidase, p-nitrophenyl-α-D-
glucopyranoside (p-NPG) and N-deoxynojir-
imycin were purchased from Sigma (Singa-
pore).
Plant material
Sample of 3 kilos Rauvolfia serpentina leaves 
were collected from Tabang, Bulacan, Philip-
pines last October 2013. Wilfredo F. Vendivil, 
Ph.D. identified and authenticated the plant 
with Herbarium Accession Number 777-01) at 
the Botany Division of National Museum, Ma-
nila, Philippines. The leaves were air-dried at 
room temperature for 20 days and oven dried 
at 40˚C for 72 hours. The oven dried samples 
were ground using pulverized mill and were 
soaked with 80% ethanol for 3 times, 24 hours 
each time at room temperature. The ethano-
lic extracts were drained, filtered and concen-
trated in vacuo at 45˚C using a rotary evapora-
tor. Rauvolfia serpentina gave a 3.2% yield or 
97.1 g of crude extract.
Fractionation of Rauvolfia serpentina crude 
extract and subfractions
 The crude extract 97.1 g was subject-
ed to Vacuum Liquid Chromatography (VLC). 
It was mixed with Silica gel in a reasonable 
amount. The extract-Silica gel mixture was 
placed on a top of a 9 cm height Silica gel 60 
H254, 10 cm internal diameter VLC column, 
vacuum packed. Fractionation was done using 
solvents of increasing polarit and were con-
centrated in vacuo at 45˚C. The same method 
was done on the DCM and ethyl acetate sub-
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fractions. The crude extract as well as the four 
fractions were subjected to bioassay. 
In Vitro Yeast α-Glucosidase Inhibitory Activity
 The adopted method used for the 
yeast α-glucosidase enzyme inhibition assay 
was done by Lawag et al. The assay was done 
at Adamson University, Manila, Philippines.
 A concentration of 0.017 units/mL of 
the enzyme and 0.7 mM of substrate were pre-
pared and utilized for determination of the in-
hibitory activity of crude extract, fractions and 
subfractions. These were prepared in a 100 
mM sodium phosphate buffer that was pre-
pared in distilled water with the pH 6.8 which 
contains 50 mM NaCl. N-deoxynojirimycin was 
used as a positive control for the assay.
Phytochemical screening of Rauvolfia serpen-
tina
 The phytochemical screening was 
performed on the crude extract and its frac-
tions using different spray reagents: Potassium 
ferricyanide-ferric chloride was used for detec-
tion of phenols, tannins and flavonoids with a 
blue spots for positive result; Dragendorff’s re-
agent was used for detection of alkaloids with 
a brown-orange visible spots immediately on 
spraying for positive result; Vanillin-sulfuric 
acid was used for detection of higher alcohols, 
phenols, steroids and essential oils with blue-
violet spots for positive result of triterpenes 
and sterols while wide range of colors for es-
sential oils; and α-Naphthol-sulfuric acid for 
detection of sugars with a  blue spots for posi-
tive result.
RESULTS AND DISCUSSION
Table 1. α-Glucosidase inhibitory activity of 
Rauvolfia serpentina crude extract, fractions 
and subfractions
The ethanolic leaf extract of Rauvolfia ser-
pentina was found to be a potential source of 
α-glucosidase inhibitor that has half maximal 
inhibitory concentration (IC50) of 5.56±1.19 
μg/mL-1. Among the 4 fractions yielded 
from crude extract, the ethyl acetate fraction 
showed the highest enzyme inhibitory activ-
ity with IC50 of 1.06±1.04 μg/mL-1 followed 
by dichloromethane fraction with IC50 at 
1.40±1.24 μg/mL-1, methanol fraction with 
IC50 at 1.50±1.15 μg/mL-1 and hexane frac-
tion with IC50 at 4.47±1.08 μg/mL-1.
Further purification were done in dichlo-
romethane and ethyl acetate fractions. In 
dichloromethane fraction, it obtained 9 
subfractions. Among the 9 subfractions, 
hexane:dichloromethane/50:50 gave the high-
est enzyme inhibitory activity with IC50 of 
1.74±1.18 μg/mL-1. In ethyl acetate fraction, it 
obtained 5 subfractions. In 5 subfractions, eth-
yl acetate:methanol/1:1 gave the highest en-
zyme inhibitory activity with IC50 of 19.17±1.67 
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μg/mL-1 against yeast α-glucosidase enzyme.
Rauvolfia serpentina were screened for its 
phytochemical constituents. Alkaloids was 
present in ethyl acetate and methanol frac-
tion. Tannins, flavonoids and phenols were 
present in dichloromethane fraction.
CONCLUSION
The result of the assay showed that Rauvol-
fia serpentina extract (IC50=5.56±1.19 μg/
mL-1) has a better enzyme inhibitory activity 
against N-deoxynojirimycin (positive control)
(IC50=56.7±2.80 μg/mL-1).  Therefore, this 
leaves can be developed and lead to the for-
mulation of new, affordable and effective anti-
diabetic drugs as α-glucosidase inhibitors.
RECOMMENDATION
In future, specific inhibitor has to be isolated 
from the crude extract of Rauvolfia serpentina 
to characterized and therapeutically exploit-
ed. Subfractions were showed a good activ-
ity against the enzyme, further isolation and 
structure elucidation should be done to deter-
mine the compounds that are attributed to its 
α-glucosidase inhibitory activity.
ACKNOWLEDGEMENT
 The author wish to express her sin-
cere gratitude to the Center for Research 
Evaluation and Continuing Education (CRECE) 
of Adamson University, Manila, Philippines for 
financial assistance and Chemistry Laboratory 
of Adamson University for the facilities and 
equipment provided.
REFERENCES
1. Feng, J., Yang X., Wang, R., (2009).  
 Bio-assay guided isolation and iden 
 tification of α-glucosidase inhibitors  
 from the leaves of Aquilaria sinensis.  
 Phytochemistry, 242-247.
2. Lawag, I., (2014). Bio-assay Guid  
 ed Isolation and Spectral   Analysis  
 of α-Glucosidase Inhibitors from the  
 Leaves of Antidesma bunius Linn.  
 Spreng, University of Sto. Thomas.
3. Lawag, I., Aguinaldo, A., Naheed,   
 S.,Mossihuzzaman, M., (2012).   
 Α-Glucosidase inhibitory activity of  
 selected Philippine plants. Journal of  
 Ethnopharmacology, 144(1).
4. Nair, V., Panneerselvam, R., Gopi, R.,  
 (2011). Studies on methanolic extract  
 of Rauvolfia species from Southern  
 Western Ghats of India- In vitro anti 
 oxidant properties, characterization  
 of nutrients and phytochemicals. In 
 dustrial Ctops and Products, 17-25.
5.   Umar, A., Ahmed, Q., Muhammad,  
 B., Dogarai, B., Mat    Soad, S.,   
 (2010).  Anti-hyperglycemic activity  
 of the leaves of Tetracers scandens  
 Linn. Merr. (Dilleniaceae) in alloxan  
 induced diabetic rats. Journal of Eth 
 nopharmacology,140-145. 
153
INTRODUCTION
Many growth factors and their receptors play 
important roles in modulating cell division, 
proliferation and differentiation. Overexpres-
sion of growth factor receptors has been im-
plicated as an important factor in the prolif-
eration of malignancies and has also been 
identified as a marker of poor prognosis (Kuan 
et al., 2001).
Epidermal growth factor receptor variant III 
(EGFRvIII) is a mutant variant of EGFR that 
commonly overexpressed in human malignant 
cells. EGFRvIII has in frame deletion of exons 
2-7 that encodes extracellular domain, result-
ing in the formation of new Glycine residue. 
Although EGFRvIII is unable to bind EGF or 
other EGFR-binding ligands, it is constitutively 
phosphorylated and able to activate down-
stream signaling cascades, which end up with 
cell differentiation (Pedersen et al., 2001). The 
possibility of disrupting this process has led to 
the development of novel therapeutic agents 
for cancer treatment (Kuan et al., 2001).
EGFRvIII is commonly found in glioblastoma 
multiforme and has been reported also in 
breast, ovarian, prostate, lung, head and neck 
carcinomas, but did not found in normal cells 
(Huang et al., 1997; Batra et al., 1995; Sok et 
al., 2006). Lacks of 267 amino acids from ex-
tracellular domain of EGFRvIII has resulted in 
the formation of a new immunogenic epit-
ope near the amino terminus. Therefore this 
receptor might be used as an ideal molecular 
target in immunology based cancer therapy 
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(Gupta et al., 2010). In such kind of targeted 
cancer therapy, antibody fragments were 
frequently used as targeting moiety.
Fv fragment is the smallest unit of antibody 
molecule that preserves its antigen-binding 
properties. Thus, it can facilitate a targeted 
drug delivery for a treatment that requires 
high specificity. Single-chain variable frag-
ment (scFv) is an antibody fragment that 
consists of variable regions of heavy (VH) 
and light chains (VL), joined together by a 
flexible peptide linker. Thus, it can be eas-
ily expressed in Escherichia coli (Ahmad et 
al., 2012). However, an scFv molecule has 
at least two disulfide bonds in its structure 
which are required to be correctly formed in 
order to preserve its antigen-binding affin-
ity. In E. coli expression system, periplasmic 
compartment is preferably used for recom-
binant protein production that needs a cor-
rect protein folding and disulfide bond for-
mation (Kipriyanov et al., 1997). 
Periplasmic production of recombinant pro-
teins provides several advantages compared 
to cytosolic production. For example, the 
authentic N-terminal amino acid sequence 
without the Methionine extension can be 
obtained after cleavage by the signal pep-
tidase. Also, there appears to be much less 
protease activity in the periplasmic space 
than in the cytoplasm. In addition, recom-
binant protein purification is simpler due to 
fewer contaminating proteins in the peri-
plasm (Makrides, 1996; Choi et al., 2000)
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In this study, we reported the periplasmic 
expression of an anti-EGFRvIII scFv in E. coli 
BL21(DE3) periplasm. Prior to periplasmic ex-
pression, the DNA fragment encoding anti-EG-
FRvIII scFv was subcloned into pJ414 expres-
sion vector containing pelB leader sequence, 
which is derived from Erwinia carotovora (Lei 
et al., 1987). This leader sequence consists of 
22 amino acids residues, which directs the re-
combinant protein production fused with this 
leader sequence into periplasmic compart-
ment in gram-negative bacteria, such as E. coli 
(Choi and Lee, 2004).
MATERIALS AND METHODS
Plasmid containing DNA fragment of anti-EG-
FRvIII scFv  (pJ201_scFv) was obtained from 
previous research. Expression vector contain-
ing pelB leader sequence (pJ414_pelB), E. coli 
TOP10 and BL21(DE3) are available in our labo-
ratory. Primers used in this study were: scFv1-
forward primer containing NcoI site (5’-GGC-
CATGGC TCAAGTTCAATTGGTTGAGTCAGG-3’), 
scFv1-reverse primer containing XhoI site 
(5’-CGCCATGGCTCGAGT GATTAACAATGAT-
GATGGTGG-3’), and T7-promoter primer. All 
primers were purchased from IDT. 
Construction of plasmid pJ414_pelB¬_scFv
DNA fragment encoding anti-EGFRvIII scFv was 
amplified from pJ201_scFv by PCR method. 
PCR was conducted as follows: initial denatur-
ation at 95 °C for 1 m; 25 to 30 cycles of dena-
turation at 95 °C for 1 m, annealing at 60 °C for 
30 s, and extension at 72 °C for 1 m, then final 
extension at 72 °C for 5 m. PCR products were 
analyzed with 1 % agarose gel electrophoresis. 
Purified PCR product and pJ414_pelB expres-
sion vector were double digested using NcoI 
and XhoI enzymes (3 IU /1 µg product), then 
incubated at 37 °C for 18 h. Digested products 
were examined with 1% agarose gel electro-
pho-resis, subsequently isolated from an aga-
rose gel using Gel/PCR DNA Fragments Extrac-
tion Kit (Geneaid). 
Purified scFv gene and plasmid were ligated 
using T4-DNA ligase (1 IU/50 ng plasmid), then 
transformed into E. coli TOP10 using transfor-
mation and stock solution (TSS) (Chung et al., 
1989). Recombinant plasmids were isolated 
from E. coli transformants, then characterized 
by migration, restriction, and PCR analyses. 
It was subsequently sequenced to ensure no 
mutation presents within the gene sequence. 
Confirmed recombinant plasmid was then 
transformed into E. coli BL21(DE3).
Growth conditions for scFv expression
E. coli BL21(DE3) carrying pJ414_pelB_scFv 
were grown overnight in Luria Bertani medi-
um with 100 µg/mL ampicilin (LBamp) at 37°C. 
This culture was diluted 1:50 with 20 mL LB-
amp medium, grown at 37°C in 100 mL shak-
ing flask. When cultures reached OD600 = 0.8, 
IPTG was added and growth was continued at 
room temperature (20-23°C) for 18-20 h. Op-
timization of IPTG concentration was carried 
out by varying IPTG concentration from 0.1 to 
1 mM.
Isolation of soluble periplasmic proteins
Cells were harvested by centrifugation at 5000 
x g and 4°C for 15 m. Pelleted cells were resus-
pended with hypertonic solution consisting of 
20% sucrose, 30 mM Tris-Cl, and             1 mM 
EDTA pH 8. After 1 h incubation on ice with oc-
casional stirring, the spheroplasts were centri-
fuged at 11600 x g and 4 °C for 30 m, leaving 
the soluble periplasmic extract as the super-
natant and spheroplasts plus the insoluble 
periplasmic material as the pellet (Kipriyanov 
et al., 1997). Supernatant containing periplas-
mic proteins were separated, and then ana-
lyzed by 10% SDS-PAGE. 
Comparation of total proteins, soluble peri-
plasmic and cytoplasmic proteins
As much as 100 mL culture was prepared by 
method previously described, induced by op-
timized IPTG concentration. Analysis of total 
proteins was done by adding 100 µL sample 
buffer into pellet cells from 1 mL culture. The 
remaining culture was pelleted, and then solu-
ble periplasmic and cytoplasmic proteins were 
isolated. 
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Isolation of cytoplasmic proteins was per-
formed by freeze thaw method. Spheroplasts 
from periplasmic extraction were resuspended 
with lysis buffer consisting of 50 mM Tris-Cl, 3 
mM EDTA, and 1 mM PMSF. Spheroplast sus-
pension was subjected to five freeze-thaw 
cycles by freezing at -20 °C for 15 m and thaw-
ing for 15 m in room temperature. After that, 
thawed spheroplasts suspension was centri-
fuged at 11600 x g and 4 °C for 30 m, leaving 
the soluble cytoplasmic extract as the super-
natant (Johnson and Hecht, 1994; Shrestha et 
al., 2012). Total proteins, soluble cytoplasmic 
and periplasmic proteins were then analyzed 
by 10% SDS-PAGE.
RESULT AND DISCUSSION
The pJ201_scFv plasmid was used as template 
for the scFv gene amplification, resulting in 
802 bp of PCR product. The amplification prod-
uct contains poly-histidine tag at the down-
stream of scFv sequence, and also NcoI and 
XhoI restriction sites to facilitate the cloning 
step. This DNA fragment was subcloned into 
NcoI and XhoI sites of pJ414_pelB vector. The 
recombinant plasmid obtained was named 
pJ414_pelB_scFv. To confirm correct recombi-
nant plasmids, some analyses were carried out 
including migration, restriction, PCR and DNA 
sequencing.
Recombinant plasmid (4852 bp) and control 
plasmid (5452 bp) were run on agarose gel 
electrophoresis. Migration rate of recombi-
nant plasmid would be faster than the control 
plasmid due to their sizes. Figure 1A showed 
the band of recombinant plasmid compared 
to control plasmid. To determine the actual 
size of the plasmid and insert DNA, restriction 
analysis was carried out. Figure 1B showed 
restriction of recombinant plasmid using NcoI 
or XhoI, which showed a single DNA band of 
4852 bp. Double restriction analysis using both 
(NcoI and XhoI) resulting DNA bands with size 
of 802 and 4050 bp which corresponded to the 
theoretical size of insert DNA and pJ414_pelB, 
respectively. 
The PCR analysis was performed using T7-pro-
moter and scFv1-reverse primers. These prim-
ers were used to determine the full-length 
construct of the gene within the pJ414_pelB 
plasmid. Thus, the PCR product would con-
sist of T7 promoter, pelB leader sequence, 
scFv gene, and poly-histidine tag. Figure 1C 
showed a DNA band of approximately 900 bp, 
which corresponds to the theoretical size of 
desirable fragment. Based on DNA sequenc-
ing analysis (data not shown), there were no 
mutation in DNA encoding anti-EGFRvIII scFv 
gene. After all of analyses conducted, it could 
be concluded that the recombinant plasmid 
was successfully constructed.
E. coli is currently used as the host for produc-
ing antibody fragments. For disulfide-bonded 
proteins, good expression levels have been 
achieved via soluble production, secreting the 
proteins into the oxidizing environment of the 
bacterial periplasm where assembly and di-
sulfide bond formation can occur. Periplasmic 
secretion is achieved by genetically fusing the 
leader sequence onto the N-terminus of the 
antibody sequence (Popplewell et al., 2005)
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      Figure 1. (A) Migration analy-
sis of pJ414_pelB_scFv. Lane 1, comparator 
plasmid (5452 bp); lane 2, pJ414_pelB_scFv 
recombinant plasmid (4582 bp). (B) Restriction 
analysis of pJ414_pelB_scFv. Lane 1, pJ414_
pelB_scFv uncut; lane 2, digested with NcoI 
restriction enzyme; lane 3, digested with XhoI 
restriction enzyme; lane 4, digested with NcoI 
and XhoI restriction enzyme. (C) PCR analysis 
of pJ414_pelB_scFv.   Lane 1, using T7 promot-
er and reverse primers; lane 2, using forward 
and reverse primers; lane 3, negative control.
The oxidizing environment of periplasmic 
space, rich in proteins which are important 
for folding and catalyzing disulfide bond for-
mation (PDI, DsbA and DsbC) or chaperones 
such as SKp (Fernandez, 2004; Bothmann and 
Pluckthun, 2000), is most suitable for proper 
folding of scFv fragment. Antibody fragments 
expressed in the periplasmic space have been 
shown to be correctly folded with excellent 
yield. Additionally, extraction of periplasmic-
expressed proteins can easily be performed 
by a simple osmotic shock procedure (Tiwari 
et al., 2010)
The early stage in overproduction of scFv 
proteins was to optimize the optimal concen-
tration of IPTG as inducer. Figure 2 lanes 3-6 
showed total protein bands of induced E. coli 
culture using various IPTG concentrations. The 
scFv band is deduced to have approximate size 
of 28.76 kDa as it is shown on the SDS-PAGE 
analysis (Figure 2). The band size corresponds 
to the theoretical size of scFv proteins. Further-
more, total scFv proteins induced with 0.1 and 
0.25 mM IPTG has a thicker band compared 
to those from 0.5 and 1 mM IPTG. However, 
such information was not enough to be used 
as a reference to determine the optimal con-
centration of IPTG in producing scFv proteins 
in periplasmic space. Therefore, analysis was 
continued to determine the effect of various 
IPTG concentration in the periplasmic protein 
expression. 
Figure 2. SDS-PAGE analysis of total proteins 
induced with various IPTG concentration.The 
scFv band is marked with an arrow (28.76kDa). 
Lane 1, non transforman induced with  0.5 mM 
IPTG; lane 2, non induced transforman; lane 3, 
transforman induced with 0.1 mM IPTG; lane 
4, transforman induced with 0.25 mM IPTG; 
lane 5, transforman induced with 0.5 mM 
IPTG; lane 6, transforman induced with 1 mM 
IPTG.
Figure 3 gives an overview of protein profiles 
extracted from the E. coli periplasm. Analysis 
was carried out to compare periplasmic pro-
tein profiles from induced and uninduced E. 
coli cultures. Based on the electrophoregram, 
it was observed that the bands of scFv pro-
tein clearly detected in periplasmic extract of 
transformant E. coli cultures induced with 0.1 
and 0.25 mM IPTG. Considering these results, 
low concentration of IPTG was apparently op-
timum for periplasmic-proteins expression of 
this scFv.
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Figure 3. SDS-PAGE analysis of periplasmic 
proteins induced with various IPTG concen-
trations. The scFv bands are marked with ar-
rows. Lane 1, non induced transforman; lane 2, 
transforman induced with 0.1 mM IPTG; lane 
3, transforman induced with 0.25 mM IPTG; 
lane 4, transforman induced with 0.5 mM 
IPTG; lane 5, transforman induced with 1 mM 
IPTG.
To find out the protein profiles produced using 
this expression system, a comparative analysis 
of total proteins, periplasmic proteins, and cy-
toplasmic proteins was carried out. Cytoplasm 
has a much larger space than periplasm. How-
ever, Figure 4 lanes 5 and 6 showed that the 
soluble scFv protein in cytoplasmic space was 
much less than in periplasmic space. This re-
sult indicates that the majority of scFv proteins 
in the cytoplasm were in the form of inclusion 
bodies.
ScFv protein has a disulfide bond in each VH 
and VL domains, but the cytoplasmic space 
has a reductive environment (Snyder and 
Champness, 2003). Therefore, disulfide bonds 
are unlikely be formed within the cytoplasm. 
Theoretically, it could be the cause of inclusion 
bodies formation within the cytoplasm.  
All of those analyses indicates a protein band 
of 28.76 kDa  observed in protein profiles of 
periplasmic and cytoplasmic of induced cul-
ture extracts which is not present in uninduced 
culture extracts. These results suggest that the 
scFv protein has been successfully expressed 
and found in samples of total proteins, peri-
plasmic and cytoplasmic fractions. Thus, it can 
be concluded that pJ414_pelB_scFv plasmid 
has successfully express scFv protein in the 
periplasmic space using PelB leader sequence.
CONCLUSION
The pJ414_pelB_scFv plasmid has been suc-
cessfully constructed and its sequence has 
been confirmed. Protein expression analyses 
have confirmed that the scFv protein has suc-
cessfully been expressed in periplasmic space 
using pelB leader sequence and showed mo-
lecular size of approximately 28.76 kDa. 
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ABSTRACT
1,5-bis(3’-ethoxy-4’-hydroxyphenyl)-1,4-pentadiene-3-one (EHP) is a curcumin analogue which 
has been  synthesized  and  proven  to have antioxidant activities. The objectives of this research 
were to re-synthesis and  characterize EHP compound  and  to determine its LD50 value. The syn-
thesis was performed by reacting  ethyl vanillin and acetone using hydrochloric acid as a catalyst. 
The product was then characterized by thin layer chromatography, ultraviolet-visible spectropho-
tometry, FT-IR spectrophotometry, high performance liquid chromatography, gas chromatography-
mass spectrometry, densitometry and  melting point while the acute toxicity test was performed 
by determining LD50 value of the compound  with Weil C.S. method using male mice as experi-
mental animals. The result showed that the yield of EHP was  48.12%. However,  the end product 
was still founded  a rest  of ethyl vanillin mixed with  EHP. The LD50 value of the synthesized EHP 
was 6,87 g/kg body weight with the criteria of mild toxic. Therefore, it is potential as a drug sub-
stance candidate.
Key word:  characterization, EHP, LD50
INTRODUCTION
One of the curcumin analogue compounds is 
1,5-bis (3’-methoxy-4’-hydroxyphenyl)-1,4-
pentadien-3-one (abbreviated Gamavuton 
GVT-0). The chemical structure of GVT-0 was 
then modified by replacing two methoxy group 
on the aromatic ring with two ethoxy groups. 
It was obtained the 1,5-bis (3’-ethoxy-4’-hy-
droxyphenyl) -1,4-pentadien-3-on compound 
or EHP. This compound was proved to have 
an antioxidant activity more potent. (1;2). As 
anew drug substance candidate, needs to be 
determined its toxicity.
METHOD
Added aceton, ethyl vanillin (1:2) and chlo-
rid acid, stirred in flat bottom-flask on cool-
ing bath for  ± 60 minutes. Then stirred in flat 
bottom-flask in room temperature  ± 2 hours. 
Monitoring the reaction by TLC using station-
ary phase Silica Gel  GF254 and mobile phase 
Chloroform-ethyl acetate (5:1). Synthesized 
end product EHP Washed with Glacial HOAc / 
Aquadest (1:1) ; Filtered with whatman no 1; 
CHARACTERIZATION AND LD50 VALUE DETERMINATION OF
1,5-bis(3’-ethoxy-4’-hydroxyphenyl)-1,4-pentadiene-3-one (EHP)
Lestari Rahayu, tari2006@yahoo.com,  0817199415; Septian; 
Esti Mumpuni, esti¬_mumpuni@yahoo.com, 08151663201
Faculty of Pharmacy Pancasila University Jakarta
Washed  with metabisulfite / aquadest (1:1). 
Purity test by  TLC with stationary phase Silica 
Gel GF254 and  mobile phase Chloroform-
ethyl acetate (5:1) and melting point test. 
Identification and characterization by: FTIR; 
UV-Vis;GC-MS;  HPLC  and Densitometry.
The acute toxicity assay was carried out by 
determining the LD50 value of the EHP with 
Weil C.S. method using male mice as an ex-
perimental animals 
RESULT AND DISCUSSION
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Figure 5. The characterization result by HPLC
Characterization of product synthesis  was 
performed using organoleptic, the colours of 
product is yellow green, the odors is aromatic. 
It spot gave yellow flourescece at TLC plate ( 
UV 366) with average of Rf 0.65 at TLC chro-
matogram with eluent of ethyl acetat : chlo-
roform(5:1).
The melting point of product synthesized 
is 161,7-163,6 ºC and water concentration 
0.043%.The UV spectrum (MeOH 1%) of prod-
uct showed maximum absorbance at λ 390 nm 
and 267 nm. The IR spectrum (KBr) of product 
showed absorption bands at 3370 cm-1 indi-
cated the presence of OH group. Absorption 
bands at 2979 cm-1 and 2931 cm-1 indicated 
the presence of saturated C-H group. Absorp-
tion bands at 1578 cm-1 , 838 cm-1  and 654 
cm-1 indicated the presence of aromatic ring 
(C=C) and aromatic substitution (C-H). Charac-
teristic absorption band at 1676 cm-1  strongly 
correlated with C=O (carbonyl) group.Data of 
MS confirmed the existence of core EHP at 
m/z of 355.
The HPLC system results showed that the 
optimum separation was obtained with C18 
stationary phase (octadecylsilane) Grace Col-
umn VP - ODS 4.6 x 250 mm ; 4.6 µm, by us-
ing methanol – water (30:70 v / v) as mobile 
phase with ultraviolet detection at  284 nm 
and 0.5  mL/min of flow rate.
Table 7. Based on the toxicity assay.
Based on the toxicity assay it has the LD50 val-
ue of 6.87 g/kg body weight, it is belonged to 
the category of mild toxic substance, so that it 
is recommended as a safe drug substance can-
didate.
CONCLUSION
The 1,5-bis (3’-ethoxy-4-hydroxyphenyl) 
-1,4-pentadien-3-on (EHP) compound can be 
synthesized from ethyl vanillin and acetone by 
aldol condensation method using a hydrochlo-
ric acid as a catalyst. The EHP was successfully 
synthesized with yield of  48.12%
The  EHP compound was characterized  by us-
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ing thin layer chromatography, ultraviolet-visi-
ble spectrophotometry, FT-IR spectrophotom-
etry, high performance liquid chromatography, 
gas chromatography-mass spectrometry, den-
sitometry, and melting point test
The LD50 value of the synthesized product 
(EHP compound) was 6.87 g/kg body weight, 
it is belonged to the category of mild toxic 
substance, so that it is potential as a drug sub-
stance candidate. 
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DEVELOPMENT OF MELOXICAM TRANSDERMAL MATRIX TYPE PATCH 
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Lidya Ameliana, Faculty of Pharmacy, Jember University, lidyaameliana@yahoo.co.id, 0331 324736; Monica 
Iwud, Faculty of Pharmacy, Jember University, miiwudh@gmail.com, 0331 324736; Selly Rio, Faculty of Pharmacy, 
Jember University, rio.selly@yahoo.co.id, 0331-324736
INTRODUCTION
Transdermal drug delivery system is an ad-
ministration of a therapeutic agent in the 
form of patches or semisolids that deliver 
drugs through intact skin for systemic effect1. 
The advantages of transdermal drug deliv-
ery systems are to avoid of hepatic first pass 
metabolism, ability to discontinue adminis-
tration by removal of the system, to controll 
drug delivery for a longer time than the usual 
gastrointestinal transit of oral dosage form3, 
to prevent irritation of the digestive tract8, 
improves patient compliance3. Transdermal 
drug  delivery systems may prevent the drug 
from enzymatic reactions in the gastrointesti-
nal tract wall5
Meloxicam is a nonsteroidal anti-inflammato-
ry drug (NSAID) class enolate acid derivative 
oxicam6. Meloxicam inhibit the synthesis of 
cyclooxygenase-2 (COX-2) and prostaglandin2. 
Meloxicam has a partition coefficient octa-
nol / water (log P octanol / water)  3.43 and 
a molecular weight 351.4 Dalton4. The dose 
of Meloxicam is  7.5-15 mg / day7. Meloxicam 
was reported as a drug that can be applied to 
skin and mucosa because meloxicam has low-
er tissue toxicity than piroxicam, ketoprofen, 
indomethacin, diclofenac and ibuprofen6
The important component in the preparation 
of the patch is a polymer. The polymer used 
in this patch are hydrophilic and hydropho-
bic polymer. This research would be develop 
Meloxicam transdermal patch with some of 
hydrophilic and hydrophobic polymers, eth-
ylcellulose (EC) -polivinilpirolidon (PVP), hy-
droxypropylmethylcellulose (HPMC) - EC, then 
compared the physical properties and the re-
lease of Meloxicam between the formulas. 
Evaluation Test
The prepared formulation were evaluated for 
different physiochemical characteristics such 
as color, odor, consistency, weight uniformity, 
thickness, moisture content, drug content, 
and in vitro release study.
MATERIALS AND METHODS
Meloxicam was obtained as a gift sample from 
PT. Dexa Medica, HPMC, PVP K-30, Ethyl Cellu-
lose N-22, Propylene glycol, Polyethylene gly-
col, Potassium Chloride, Potasium  Phosphate 
Dibasic, Sodium Phosphate Dibasic, Sodium 
Chloride, Backing, Aquadest
Formulation of transdermal patches
Matrix type transdermal patches containing 
Meloxicam were prepared by solvent casting 
technique. HPMC or PVP K30 and EC-N22 so-
lution was prepared using ethanol as solvent. 
Polymeric solutions were mixed thoroughly 
with the help of magnetic stirrer for 15 min-
utes. Meloxicam was added to propylene gly-
col and polyethyleneglycol and stirred for 30 
minutes and then were poured into molds and 
dried at room temperature for 24 hours. The 
composition of transdermal patches is shown 
in Table 1.
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The moisture content in the formulations 
ranged from 3.528±0.024 to 7.530±0.023 %. 
The highest percentage of moisture content 
was found in F1 7.530 ± 0.023 % respectively 
which may be due to the hygroscopicity of na-
ture of PVP. The highest percentage of mois-
ture content of HPMC patchs was found in 
F4 because it was the highest concentration 
of HPMC in patch. The results of patch’s drug 
content and moisture content were listed in 
Table 3.
The In vitro drug release studies were carried 
out using cellophane membrane. The cel-
lophane was mounted on the diffusion cell 
which acted as a donor compartment. 500 ml 
of phosphate buffer saline pH 7.4 as a diffusion 
medium was taken in the dissolution chamber 
which acted as the receptor compartment to 
maintain the sink condition. The donor com-
partment was kept in contact with receptor 
compartment and receptor compartment was 
stirred with paddle during the study. Sample 
5 ml was withdrawn and replaced with 5 ml 
of PBS pH 7.4 at different time intervals. The 
samples were analyzed using UV spectropho-
tometer at 364 nm to estimate Meloxicam.
Meloxicam in PBS was scanned in the UV 
wavelength at 364 nm. Linear relationship 
was observed between the concentration and 
absorbance value. (Slope=0.0293, r=0.9933). 
This regression equation was used to calculate 
the drug content on in vitro release study of 
RESULTS AND DISCUSSION
Formulation and Evaluation of Meloxicam 
Transdermal Patch
Transdermal drug delivery system containing 
Meloxicam was prepared by using different 
polymeric ratios of HPMC, PVP and hydropho-
bic polymer of EC in combination. The meloxi-
cam patchs can be seen in Fig.1. They all yel-
low, odorless, and dry. The results of various 
physico-chemical parameters were listed in 
Tables 2  The weight of the patches varied from 
535.53 ± 0.67 to 574.53 ± 0.40 mg. The thick-
ness of the patches varied from 0.224±0.001 
to 0.229±0.001mm 
Meloxicam in methanol was scanned in the 
UV wavelength region of 200-400 nm for 
maximum absorption (λ max). The λ max was 
found to be at 364 nm. Linear relationship was 
observed between the concentration and ab-
sorbance value. (Slope=0.045, r=0.998). This 
regression equation was used to calculate the 
drug content of meloxicam patch.
The drug content of meloxicam patches were 
list in Table 3. They varied from 96.833  ± 0.673 
to 98.200 ± 0.610 %. There were in accordance 
with the requirement of that the drug content 
was range 85% - 115% and the coefficient vari-
ation is less than 6 %. 
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meloxicam patch. Flux of Meloxicam release 
study from patches can be seen in Fig.2.
Fig 2. Flux of Meloxicam release study from 
patches
The flux ranged from 364,865  to 677,851 µg/
cm2.second1/2. The highest flux was found in 
formulation F1677,851 µg/cm2.second1/2, re-
spectively which may be due to the nature of 
PVP (Fig.2).
CONCLUSION
Meloxicam patch in PVP-EC had moisture con-
tent and Meloxicam flux release higher than 
Meloxicam patch in HPMC-EC polymers. The 
highest flux and moisture content was on the 
highest PVP in Meloxicam patch formula.
Table 3. Drug Content and Moisture Content 
Properties of Meloxicam patches
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INTRODUCTION
Hepatitis C is a major healthcare problem 
worldwide. Available therapy for hepatitis C 
treatment is very expensive and probably not 
be accessible for all patients. Regarding to this 
reason, the development of safe and inexpen-
sive antiviral drugs is required. Natural prod-
ucts as a source of new drugs are potential to 
study. Some antiHCV substances from plants 
were obtained (Wahyuni, 2013; Adianti, 2014; 
Aoki, 2014).
Harpullia arborea (tulip wood tree) is a mem-
ber of Sapindaceae family commonly known as 
kayu pacat in Indonesia (Basuni, 1997). Tradi-
tionally, watery exudates from barks and fruits 
is used as leech repellant, oil extracted from 
seeds is a source of antirheumatics (Singh, 
2011). H.arborea seeds extract also shown an-
tibacterial activities against various strains of 
bacteria. H.arborea seeds contain glycosides, 
steroids, saponins and resins (Gowri, 2009). 
A norhopane triterpenoid also isolated from 
the leaves of H.arborea (Poovapatthanachart, 
2008).
This study was conducted to determine anti-
HCV activity of H.arborea extracts and isolated 
compound.
MATERIALS AND METHOD 
Plant material
Harpullia arborea was obtained from Alas 
Purwo National Park at Banyuwangi, East Java. 
Sample was authenticated by the authority of 
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Purwodadi Botanical Garden, Pasuruan, East 
Java. 
Extraction dan fractionation
H.arborea was extracted by ultrasonic assist-
ed extraction method using 80% ethanol as a 
solvent. Liquid fractionation was conducted 
using dichloromethane, ethyl acetate and 
buthanol respectively.
AntiHCV activity test
Extract was examined for antiHCV activity 
against JFH1a and J6/JFH1 in a cell culture sys-
tem using Huh7 cells at a multiplicity of infec-
tion (MOI) of 0.1. 
RESULTS DAN DISCUSSION 
Anti-Hepatitis C Virus (anti-HCV) activity 
screening of H.arborea leaves and stem ex-
tract revealed that leaves extract exhibited 
anti-HCV with IC50 value of 17.5 µg/ml and 
12.4 µg/ml against HCV JFH1a and J6/JFH1 re-
spectively, meanwhile stem extract was found 
to be not active against both HCV type. 
Fractionation of leaves extract resulted in 4 
fractions which were dichloromethane, ethyl 
acetate, buthanol and aqueous fraction. Anti-
HCV activity screening at a concentration of 30 
µg/ml revealed that buthanol fraction inhib-
ited HCV JFH1a growth by 54% in which other 
fractions only inhibited by 15-30%. Buthanol 
fraction contains yellow spot on TLC profile 
as a major compound. Further separation of 
buthanol fraction using sephadex LH-20 and 
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methanol 90% as a solvent was obtained 7 
fractions (B1-B7). Fraction B5 contain yellow 
precipitate and by recrystallization process 
obtained a yellow crystal as a glycosylated fla-
vonoid compound which identified as Kaemp-
feritrin (3,7-di-α-L-rhamnopyranosyl kaemp-
ferol). Structure determination of compound 
was done by nuclear magnetic resonance 
spectroscopy and data were compared with 
references (Ouyang Ming-An, 2003; De Sauza 
Menezes, 2007). Kaempferitrin was further 
tested against JFH1a. Anti-HCV activity test 
shown that kaempferitrin was not exhibited 
anti-HCV. It is possible to explain that anti-HCV 
activity of extract and buthanol fraction was 
produced by other compounds in the extract 
and buthanol fraction instead of kaempferi-
trin or the activity was created by synergism 
effect of many compounds. Previous studies 
were reported some activity of kaempferitrin. 
Like many flavonols, it has antimicrobial, anti-
oxidant and antiinflamatory activities. It is also 
mimics insulin in stimulating glucose uptake 
in diabetic rats, but inhibits insulin-stimulated 
glucose uptake in 3T3-L1 cells (Jorge, 2004; 
Prasad, 2009). But no report about antiviral 
activity of kaempferitrin was found. Further 
study need to be done to investigate the anti-
HCV compounds of H.arborea.
CONCLUSION
In this sudy, we concluded that H.arborea 
leaves extract and buthanol fraction were ex-
hibited anti-HCV activity against JFH1a virus, 
Figure 1. Kaempferitrin 
(3,7-di-α-L-rhamnopyranosyl kaempferol)
while the isolated compound, kaempferitrin 
was not.
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INTRODUCTION
One of the compound from Garcinia man-
gostana rind extract that has antioxidant activ-
ity is α-mangostin. Oral solution formulation 
of Garcinia mangostana rind extract has been 
done using cosolvency method. Based on 
α-mangostin solubility the best choise of cosol-
vent was PEG 400 and glycerin of 40% (Sofiah 
et al., 2013). In the oral solution there are Gar-
cinia mangostana rind extract and very com-
plex excipient. To analyse the  α-mangostin in 
oral solution, it need such a specific and sensi-
tive method. Such as high performance liquid 
chromatography (HPLC). The optimum condi-
tion for HPLC was reached using octadecylsi-
lane (C18) as stationary phase with methanol-
water (90:10) as mobile phase, flow rate of 1.0 
mL/min, and UV detector at 316 nm (Nurhi-
dayati et al., 2014). Before its application to 
assay the α-mangostin in oral solution this 
methods should be validated. In this research, 
the precision of HPLC was evaluated.
MATERIAL AND METHODS
α-Mangostin standard compound was pur-
chased from Chengdu Biopurify Phytochemi-
cals Ltd. Oral solution of mangosteen (Garcinia 
mangostana L.) fruit rind extract was prepared 
using cosolvency methods (Sofiah et al, 2013). 
This assay was conducted using Shimadzu LC-
20AD, with octadecylsilane (C18) Shim-pack 
VP-ODS 94.6 x 250 mm; 4.6 μm at the themp-
erature of 40oC.
System Suitability test
3.0 mL of oral solution was diluted until 10 mL 
with mobile phase. Shake and filter the solu-
tion. 20 µL the solution was  sonicated for 3-4 
minute and injected to HPLC with optimum 
condition and the area was measured. The 
procedure was repeated for five times.
Precision test of HPLC methods for α-mangostin 
in oral solution determination.
Calibration curve
Preparation of calibration curve was per-
formed by measuring the area of α-mangostin 
working standard solution  (1 ; 2 ; 3 ; 4 ; 5 ; 6 
and 7 ppm). 
Assay of a-mangostin content
1.0 ml of the oral solution was diluted with 
methanol-water (90:10) until 10 mL, shake 
and filter the solution. 20 μL of the solution 
was sonicated  for 3-4 minutes and injected at 
optimum condition. α-Mangostin content was 
calculated using calibration curve equation. 
The procedure was repeated for six times. 
 
RESULTS  AND DISCUSSION
Chromatogram of α- mangostin standard solu-
tion and α- mangostin in the oral solution us-
ing mobile phase of methanol-water (90:10) 
with a flow rate of 1.0 mL / minute could be 
seen in Figure 1 and 2.
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Calibration curve of α-mangostin that was 
performed using seven different consentra-
tions of α-mangostin showed that the equa-
tion of regression line was y = -14555,5124 + 
72726,5024 x with correlation coeffisient of 
0.9993 in the 
range concentration of 1.12 ppm until 6.96 
ppm. This equation was used to calculate 
α-mangostin content which was conducted six 
times to evaluate the precision of the meth-
ods. The results was showed in Table 1.
Table 1. The results of α-mangostin content determi-
nation
Determination results with six replication 
showed that the oral solution of mangosteen 
(Garcinia mangostana L.) fruit rind extract has 
α-mangostin content of 45.67 µg/mL with 
RSD of 1.30%. RSD is not allowed if more than 
2.0% (USP, 2012) or based on the analyte con-
tent  not more than 11.31% (Harmita, 2004). 
The precision of this methods fulfill both re-
quirement. It is also showed that α-mangostin 
was homogeneous dispersed in the oral solu-
tion.
CONCLUSION
The HPLC methods with octadecylsilane 
as stationary phase (C18), mobile phase of 
methanol-water (90:10) with flow rate of 1.0 
mL / minute fulfill the precision requirement.
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INTRODUCTION
Naringenin (4’, 5, 7-trihydroxy flavonone) 
is one of the naturally occurring flavonoids 
which exert a wide variety of activities such 
as anti-inflammatory, anti-mutagenic, anti-
atherogenic and anti-cancer effects [1,2,7]. 
However, the therapeutic efficacy of narin-
genin is limited due to its poor oral bioavail-
ability, which has been attributed to its poor 
aqueous solubility and extensive first-pass 
metabolism. Recently, nanochemoprevention, 
have received increased much attention for 
their ability to deliver anti-cancer drugs due 
to their small size, prolonged circulation time 
and sustained drug release profile [5]. Among 
all the recent materials used for polymeric 
nanoparticles synthesis, chitosan has gained 
considerable interest. Chitosan has promis-
ing biological implications such as nontoxic, 
biocompatible, biodegradable, bacteriostatic, 
and fungistatic [4,6]. The main aim of the pres-
ent study was to develop naringenin-loaded 
chitosan nanoparticles for chemoprevention.
MATERIAL AND METHOD
Material
Low viscous chitosan [2-amino-2-deoxy-
(1→4)-β-D glucopyranan] p.a, Pentasodium 
tripolyphosphate (TPP) p.a, and Naringenin 
≥95% p.a were obtained from Sigma, Germa-
ny. Tween-80, Ethanol, acetic acid, and double 
distilled water were purchased from Brataco 
Chemica.
Methods
Preparation of naringenin-loaded chitosan 
nanoparticles
Chitosan nanoparticles were prepared via ion-
ic gelation method developed by Calvo et al 
[3] with some modification. Chitosan solutions 
0.08% w/v was prepared by dissolving chito-
san in acetic acid (0.15% v/v). TPP solution 
(0.1% w/v) was prepared by dissolving it in 
double distilled water. For association of drug 
with chitosan nanoparticles, the pure narin-
genin powder was dissolved into 96% ethanol 
to produce 0.2% w/v naringenin solution. Af-
terward, the naringenin solution was mixed 
with chitosan solutions under magnetic stir-
ring. Then, 1,5 mL of TPP solution (0.1% w/v) 
and 1,075 mL of Tween-80 solution (0.01% 
v/v) were added dropwise into mixtures under 
magnetic stirring at 1000 rpm, and naringenin 
loaded chitosan nanoparticles were simulta-
neously obtained.
Morphology of Nanoparticles
Drops of 10 mL freshly prepared nanoparticle 
solution were placed on pioloform coated 
grids and air dried for 15 min. The redundant 
fluid was removed while the dried nanopar-
ticles remained on the grids. These grids were 
dried and examined by transmission electron 
microscope (JOEL-JEM 1400, Japan) with 
an in-column energy filter (EFTEM). Thus, 
nanoparticles were analyzed 120kV energy 
loss, depending on their density. 
Particle Size and zeta (ζ) Potential 
The resulting of cross-linked chitosan nanopar-
ticles were analyzed for mean particles size, 
particle size distributon and zeta potential by 
DelsaTM Nano Submicron Particle size. 
Fourier Transform Infrared Spectroscopy 
(FTIR) Analysis
FTIR spectra were taken in the wavelength re-
gion 4000 to 400 cm-1 at room temperature 
using potassium bromide pellets (Merck, IR 
grade) for chitosan, TPP, naringenin, and nar-
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ingenin loaded chitosan nanoparticles. The 
samples were allowed to form pellets at pres-
sure of 10.3 x 104 Pa.
Differential Scanning Calorimetry (DSC)
The termal behavior of the naringenin and 
naringenin loaded chitosan nanoparticles was 
characterized by DSC (Mettler Toledo DSC). 
The nanoparticles were heated from 30 to 
3600C at a heating rate of 100 C/min per cycle. 
Inert atmosphere was maintained by purging 
nitrogen at the flow rate of 20 cc/min.
Evaluation of Encapsulation Efficiency (EE)
EE of naringenin was determined by measur-
ing the ultraviolet (U.V) absorption of the re-
spective supernatans of naringenin loaded 
chitosan nanoparticles obtained after ultra-
centrifugation. Naringenin was measured at 
290 nm (λmax). EE of naringenin was calculat-
ed according to the following formula:
Wt is the total initial amount of naringenin 
and Wf is the amount of free naringenin in the 
supernatant after ultracentrifugation (15.000 
rpm, 80 minutes). 
RESULTS AND DISCUSSION
Naringenin-loaded chitosan nanoparticles
In this preliminary experiment, formulation 
optimization of naringenin-loaded chitosan 
nanoparticle was run by mixing chitosan solu-
tion to naringenin solution. This formula was 
stored for 3 days at room temperature to ob-
serve the formation of sediment. Nanopar-
ticles with chitosan concentration of 0.08 % 
were stable until 3 days.
Morphology of Nanoparticles
Morphology of naringenin-loaded chitosan 
nanoparticles was investigated by using a TEM. 
Result (Figure 1) generally showed that the 
shape of the nanoparticles is fairly spherical.
In nanoparticles the peaks for N-H bending vi-
bration of amine І at 1650 cm–1 shifted and 
split to 1640 cm–1 and 1603cm-1. The cross-
linked chitosan also show a P=O peak at 1157 
cm–1. These results have been attributed to 
the linkage between phosphoric and ammo-
nium ion, these indicate that the tripolyphos-
phoric groups of TPP are linked with ammo-
nium groups of chitosan.
Figure 1. TEM images of nanoparticles 
Characterization using Particle Size Analyzer 
and Zeta Sizer
The respective average diameters, measured 
by Zetasizer of naringenin-loaded chitosan 
nanoparticles were approximately 750 nm. 
Zeta potential of naringenin-loaded chitosan 
nanoparticles can greatly influence their sta-
bility in suspensions by means of electrostatic 
repulsion between the particles. The measure-
ment demonstrated respective zeta potential 
of naringenin-loaded chitosan nanoparticles 
35.72±0.64 mV. 
FT-IR Analysis
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Differential Scanning Calorimetry (DSC) Anal-
ysis
DSC spectrum of naringenin-loaded chito-
san nanoparticle does not exhibit the sharp 
peak of naringenin from that conclusion was 
drawn that in the naringenin-loaded chitosan 
nanoparticle, drug was in partial crystalline 
state in naringenin-loaded chitosan nanopar-
ticle and there is no interaction between drug 
and polymer.
Encapsulation Efficiency (EE) of Naringenin-
loaded chitosan nanoparticles
Measurement demonstated 64.45±0.028 % of 
EE. 
CONCLUSION
Chitosan  nanoparticles–TPP  conjugates  have 
the  capability  to encapsulate naringenin.
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INTRODUCTION 
 Self medication more done by individuals to 
relieve health complaints. Efforts are made by 
using drugs on their own without any guidance 
from medical. Despite the fact that there are 
many actions self medication done in the com-
munity, but not many people are aware the 
rational treatment of self medication. There-
fore, efforts to build the rational behavior in 
self medication be essential. The rational self 
medication is selecting and using appropri-
ate medications correctly include medication, 
right dose, right duration of treatment , and 
the right way of life alert side effects.  Based 
on data from the Central Bureau of Statistics 
2011, there were 70.66% of women aged 15-
49 years in Indonesia, if people feel the symp-
toms of pain then choose self medication. Re-
sults of research on self-medication profiles 
of consumers pharmacies in Surabaya in 2012 
reported the incidence of self-medication of 
pain, rheumatism and toothache by 24% (liza, 
2012). The results of the study in Chile on the 
pattern of self-medication pharmacy clients in 
mind that most clients use the drug without 
proper knowledge about the benefits of drug 
use, how to use drugs and duration of treat-
ment (Katherin, 2008) 
Self medication action  describe the behavior 
in the community  formed through the pro-
cess and interaction between individuals and 
their environment. Drugs widely used in the 
community self medication is piroxicam are 
include drugs known as anti-inflammatory 
non-steroidal that may be submitted by the 
pharmacist directly to the clients. The drug is 
indicated to treat symptoms of rheumatoid ar-
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thritis , osteoarthritis, acute gout, menstrual 
pain, migraines and headaches . The main 
side effects are more felt by clients with the 
use of piroxicam  oral  are  the gastrointestinal 
tract as nausea ,vomiting ,diarrhea ,stomach 
bleeding and dyspepsia . Despite the fact that 
there are many acts of self medication in the 
community, but not many people who know 
the correct treatment of self-medication. 
Therefore, in this study wanted to know the 
relationship between the level of knowledge 
and behavior of the client in self medication 
piroxicam drug in the sub-district community 
Sukun, Malang City. The hypothesis of this 
study is a significant relationship between the 
level of knowledge and behavior of the client 
in self medication Piroxicam.
METHOD 
This study was an observational analytic study 
with a questionnaire instrument. According 
to the time is the cross-sectional study, con-
ducted in June 2013. The sample size of 100 
people, sampling is done with accidental sam-
pling method that is to the clients who buy 
drugs for his own use of piroxicam tablets. 
Sampling is done in several  pharmacy dis-
trict Sukun of Malang city. Clients were given 
a questionnaire on knowledge and behavior 
of the client in self medication piroxicam. The 
data were analyzed by the method of Spear-
man crosstab and correlation using SPSS.
RESULTS 
Demographic characteristics 
In this study obtained data from 100 respon-
dents who are clients of several pharmacies 
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in the district Sukun of Malang City. From the 
data collected to analyze the characteristics of 
the respondents included: age, gender, edu-
cation and employment. The survey results 
revealed, the highest percentage age distribu-
tion of respondents was 43-53 years by 33%. 
Picture of the distribution of respondents by 
sex unknown female respondents 62%. The 
highest education level is high school known 
by 38%. The results can be seen in Table 1
Against the behavioral questionnaires per-
form calculations using values of T scores, fur-
ther categorized by the criteria of positive and 
negative behaviors, the results can be seen in 
Table 3. From Table 3 note that clients who do 
self medication piroxicam 47% showed posi-
tive behavior and 53% showed negative be-
havior.
Table 3. Categories of client behavior self-
medication piroxicam
From Table 4 it can be seen that a client with 
a good level of knowledge, all of the respon-
dents (37%) positive behavior, while clients 
Remark : 
Positives: scores -T ≥ average T group 
Negatives: scores -T≤ average T group 
DATA ANALYSIS 
Crosstabs analysis 
Furthermore, from the data level of knowledge 
and behavior analysis with crosstabs method 
to describe the percentage of each group of 
levels of knowledge on behavior. Crosstabs 
analysis results can be seen in Table 4. 
Table 4. Level of Knowledge and Behavior 
Crosstab clients in self medication Piroxicam
The data from the client questionnaire cal-
culating the level of knowledge score of the 
correct amount, further categorized by the 
following criteria: good, quite good, less good, 
not good. The survey results revealed that the 
highest level of client knowledge on the cri-
teria good enough (53%). It shows that most 
clients who do self medication piroxicam, have 
a good enough knowledge about the use of 
piroxicam, how to wear and why the use of 
piroxicam. The results can be seen in Table 2.
Table 2. Category Level of Knowledge
Remarks: 
Good: The value of 76-100% 
quite good: the value of 56-75% 
Less good: the value of 55-40% 
Not good: the value of <40%
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DISCUSSION 
Based on the analysis of crosstabs known 
clients with the level of knowledge of good, 
behave entirely positive, otherwise the client 
with the level of knowledge of less well be-
haved entirely negative. client with a pretty 
good level of knowledge, 10% were positive 
behavior, while 37% of the negative behav-
ior. This indicates that the level of sufficient 
knowledge of self medication  piroxicam can 
not guarantee that the client’s positive behav-
ior. To achieve positive behavior of the client, 
then it should be a good level of knowledge. 
From the Spearman correlation analysis it is 
known that a significant relationship between 
the level of knowledge and behavior of the cli-
ent in self medication piroxicam.
CONCLUSION 
1. The level of knowledge of clients who  
 do  self medication piroxicam 37% had  
 a good level of knowledge, 53% had a  
 fairly good level of knowledge, 10% had  
 less good of  knowledge and no clients  
 with the level of knowledge is not good 
2. The behavior of client self medication  
 piroxicam 47% positive behavior, and   
 53% negative behavior.
3. There is a significant correlation be  
 tween the level of knowledge   
 and behavior of the client in self medi 
 cation piroxicam at some phar  
 macies Sukun district in Malang   
 city with a count value of rs (0.08)> rs  
 tables (df = 98, α = 0.05) (0.199) 
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with a level of knowledge is quite good for 
53%, only 10% of positive behavior while 43% 
of negative behavior. While clients with the 
level of knowledge is not good (10%) , behave 
entirely negative and no clients with a level of 
knowledge is not good. While clients with the 
level of knowledge about behaving entirely 
negative or no positive client behavior. And no 
clients with a level of knowledge is not good.
Spearman Correlation Test 
To prove a significant relationship between 
the level of knowledge and behavior of cli-
ents who do self medication piroxicam with 
the Spearman correlation test. The test results 
show the value of rs count is 0.08  > rs table 
0.199 (df = 98, α = 0.05) and the significance 
value 0.000 < 0.050, these results indicate that 
Ho rejected and H1 accepted, which means 
there is a significant relationship between the 
level of knowledge and client behavior in self 
medication piroxicam. The results can be seen 
in Table 5.
Table 5. Analysis of Results of Spearman Re-
lationship between Knowledge and Behavior 
Clients in a self-medication piroxicam
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INTRODUCTION
Increasing in chronic kidney disease in USA 
was mainly caused nephrolithiasis. The prev-
alence in men was 10,6% and women 7,1% 
(Ferraro et al., 2013). The use of energy drinks 
has been widely used in the community and 
been a part of their lifestyle. Changes in life-
style such as lack of drinking water and highly 
consumed energy drinks often lead to chronic 
kidney disease (Shoham et al., 2008). Some 
cases in hospitals showed an association be-
tween renal dysfunction and the use of energy 
drinks previously. A main content of energy 
drinks, caffeine was correlated with diuret-
ics and the electrolyte balance. Caffeine also 
stimulates glomerural filtration and inhibition 
of sodium reabsorbtion. Caffeine also increas-
es the excretion of water and ions (Carrillo, 
2000). This study was aimed to determine the 
effect of chronic uses of energy drink on renal 
function based on the parameters of hematol-
ogy, urinalysis and renal histopathology. 
MATERIAL METHOD
Animal and other materials
Animal that used in this research were male, 
wistar rat and about 150-200 g of weight in 
the starting time of experiment. Animal were 
housed in animal cage which had constant 
temperature set at 23 ±0.5 C. Light was set 
so the time of dark and bright for each 12 h. 
Animals were acclimatized for at least 7 days 
before used. 
Three (3) major brands of energy drinks in 
Indonesia were used, two in solution dosage 
form and one in effervescent powder dosage 
form. Other materials that used in this re-
search were propofol, diethyl-ether, paraffin, 
phosphate buffer, formalin buffer, aquadest, 
NaCl 0.9%, dan hematoksilin-eosin.
Dose and Administration
All of energy drinks were administered per-
orally twice a day for 30 days using animal 
sonde. The dose of energy drinks was cal-
culated based on caffeine concentration of 
each energy drink. Each dose of energy drinks 
equivalent to 12.5 mg/kg caffeine. Volume of 
administration of each energy drink was 6.75 
ml/kg of rat. Water was administered as a con-
trol. The powder dosage form of energy drink 
was dissolved in water before administration.
Urinalysis and Hematological Analysis
Twenty-four hours after last administration of 
energy drink 
or water, 24h urine sampling was done by col-
lect animal urine using standard metabolic 
cage for rat.
 Albumin and creatinine level in urine were 
analyzed using standard enzymatic analysis for 
albumin and creatinine. 
For hematological analysis, from each animal 
2 ml of blood was collected via cardiac punc-
ture method. The hematological analysis for 
serum creatinine, blood urea nitrogen and 
electrolyte were evaluated using standard he-
matological analyzer. 
Histopathological Analysis
Animal was amnesties using intravenous 20 
mg/kg propofol and sacrificed. Left kidney was 
collected and fixed with 10% formalin buffer 
for at least 7 days. After dehydrated by alco-
hol sample was put in toluene for dealcohol-
ization. Embed the kidney in paraffin for 4 h 
and sliced with the thickness of 5 µm. Sliced 
sample next putted on object glass for Hema-
toxylin-eosin staining.
Statistical Analysis
All statistical analysis that used in this research 
was performed using Graphpad® Prism 6.0. 
The difference between control and energy 
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drink groups in urinalysis and hematological 
analysis were analyzed using one-way ANOVA 
followed with Dunnet post-hoc analysis.
RESULTS
Effects of energy drink on urinalysis and hema-
tological analysis can be seen at figure 1 and 2, 
respectively. 
administration of energy drink or water. Left: 
Albumin; Middle: creatinine; Right: Ratio of 
Albumin/creatinine. Post hoct analysis of one-
way anova showed significant difference be-
tween control vs. ED1, ED2 (p<0,01) dan con-
trol vs. ED3 (p<0,001).
Figure 2. Profile of hematological analysis pa-
rameter on control (NK) and energy drink groups 
(NED1, NED2 and NED3) after 30 days admin-
istration of energy drink or water. Above-left: 
BUN; Above-right: creatinine serum; Lower-left: 
natrium serum; Lower-middle : kalium serum, 
Lower-right: chloride serum,  Post hoct analysis 
of one-way anova showed significance different 
vs control group **p<0,01; ***p<0,001.
The histopathological analysis data of kidney me-
dulla of treated animal can be seen at figure 3.
Figure 3. Representative histopathological anal-
ysis of the kidney medulla of rats which were 
30 days treated half dose of with water (A) or 
energy drinks 1, 2 and 3 (B, C and D). Sliced 
sample were stained with haematoxylin-eosin, 
400x magnification, showed thickening of me-
dulla wall (line arrow) and dilatation of medulla 
lumen (dashed arrow).
DISCUSSION
Chronic administration of energy drinks for 
30 days significantly change the urinalysis 
parameters especially on creatinine urine 
but not albumin urine, furthermore the ra-
tio of albumin/creatinine also significantly 
increased on energy drinks administration 
groups. Decrease on 24 h creatinine urine 
concentration indicates decreased in the fil-
tration rate of kidney glomerulus. While un-
changed on albumin excretion in urine indi-
cates that the level of kidney abnormality still 
on mild to midle stage of kidney diseases (Joy 
et al., 2008). 
Hematological analysis data of kidney func-
tion indicates positive correlation with urinal-
ysis data. None of serum electrolyte (Natrium, 
Kalium an Chloride) level were changed after 
chronic treatment with energy drinks. Even 
blood urea nitrogen (BUN) did not change, 30 
days chronic administration of energy drinks 
significantly increased the level of creatinine 
serum (Saldana et al., 2007).
To investigate the abnormality in the kidney 
tissue, histopathological examination by hae-
178
matoxylin-eosin stained kidney sample were 
obtained. Half dose of energy drinks did not 
induces any abnormality in the glomerulus of 
kidney cortex (data not shown). In contrast, 
abnormalities were shown in medulla area of 
the kidney. Thickening of medulla wall and va-
sodilatation of medulla lumen at least in part 
contribute to the energy drinks-induced ab-
normalities on kidney function.
 
CONCLUSION
All urinalysis, hematological analysis and his-
topathological data proved that chronic ad-
ministration of energy drink for 30 days could 
induce negative effect for the kidney. 
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INTRODUCTION
Nanosuspension consists of two components: 
active pharmaceutical ingredient (API) and 
surface modifier or widely known as surfac-
tant/stabilizer. In the nanosuspension system, 
the role of surface modifier is important to 
prevent nanoparticles from aggregation and 
agglomeration. Up to this date, the selection 
of surface modifier for the formulation of 
nanosuspension is most likely based on the 
experience of the formulators. Additionally, 
this process is  time consuming,  less effective 
and only limited information available in the 
literature on how to perform the screening of 
surface modifier. To overcome this problem, 
this work was performed to study the influ-
ence of physico-chemical properties of API on 
the stabilization system of nanosusoension 
and to provide a  general  guidance to select 
proper surface modifier in order to produce 
stable nanosuspensions.
MATERIALS
Amphotericin B (AmB) (Alpharma, Copenha-
gen, Denmark), curcumin (CUR) (Phytoche-
mindo Reksa, Bogor, Indonesia), hesperetin 
(HES) (Exquim, S.A., Barcelona, Spain), ibupro-
fen (IBU) (BASF, Ludwigshafen Germany), res-
veratrol (RES) (E.Denk Feinchemie, Germany), 
rutoside trihydrate  (RUT)  (Exquim,S.A., Bar-
celona, Spain).
As surfactant and stabilizers the following 
excipients have been used: sodium dodecyl 
sulphate (SDS), sodium docusate, sodium cho-
late, Tween 80 (Sigma Aldrich, Steinheim, 
Germany), dehyquart A-CA (Cognis, Düssel-
dorf, Germany), poloxamer 188 (Molekula, 
Dorset, UK), tocopheryl polyethylene glycol 
succinate (TPGS) (Eastman, Anglesey, UK), 
polyvinyl alcohol (PVA) molecular weight 
80.000 (Serva Feinbiochemical , Heidelberg, 
Germany), hydroxypropyl methylcellulose E5 
(HPMC E5)  (Colorcon Ltd, Kent, UK).
METHODS
0.5g API was dispersed into vial containing 
9.5g of surfactant/stabilizer solution and 5 mL 
of milling beads. Three concentrations of sur-
face modifier were applied : 5x lower than its 
CMC value (low), at its CMC value (mid) and 5x 
higher than its CMC value (high). This mixture 
was then being stirred up to 72h and samples 
withdrawn every 24h, 48h and 72h. The nano-
suspension formed was then characterized by 
photon correlation spectroscopy (PCS, Zeta-
sizer Nano ZS (Malvern Instruments, UK)), la-
ser diffractometry (LD, Mastersizer 2000 (Mal-
vern Instruments, UK)), and light microscopy 
(Leitz Orthoplan, 
Germany)
RESULTS AND DISCUSSION
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Figure 1. Percent success of each API during 
milling, from 24h to 72h based on : (a) z-aver-
age; (b) D50% value; (c) D90% value.
Based on the API applied, hesperetin was the 
API with highest millability to be nanosized 
whilst rutoside trihydrate was found to have 
the lowest millability as observed with its low 
percent of success to be nanosized. No corre-
lations were found between the millability of 
the APIs with their physico-chemical proper-
ties such as molecular weight, log P value that 
represents lipophilicity, pKa and also melting 
point. 
One important consideration for the surface 
modifier is the applied concentration. Screen-
ing results have shown that for anionic surfac-
tant, concentrations higher than the CMC are 
beneficial to produce nanosuspensions with 
particle size <250nm. 
Based on the screening result, the capa-
bility of anionic surfactants to produce 
stable nanosuspensions with particle size 
<250 nm can be ranked as follows: sodium 
cholate>SDS>sodium docusate. Furthermore, 
higher CMC value of anionic surfactant leads 
to better stabilization. 
CONCLUSIONS
No general trend was found with regard to the 
physico-chemical properties of APIs and their 
millability. The API can be classified into com-
pounds with good, medium or bad millability. 
Moreover, particle size obtained and particle 
size stability of the nanosuspensions depend 
on the stabilization principle and concentra-
tion of the surface modifiers. There are some 
surface modifiers that can be used to produce 
stable nanosuspensions independent from 
the API applied.  These surface modifiers can 
be considered as “general surface modifiers”
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INTRODUCTION
Based on various studies, it is well known that 
coffee has positive effect on human health as 
it consumed regularly as beverage1. Coffee ex-
hibited various pharmacological effects, such 
as reducing risk of diabetes, parkinson’s dis-
eases, and increasing cognition and mood2. 
The polyphenolic compounds found in coffee 
are known responsible for their health effects, 
and their aromatic properties of coffee3.
Chromatographic (HPLC)4,5 and spectropho-
tometric (UV-Vis)6 method were used widely 
for polyphenol determination in coffee. Nev-
ertheless, chromatographic and spectrometric 
methods suffer from tedious length procedure 
and the use of expensive and complicated in-
strumentation. Therefore, the development of 
alternative methods for polyphenol determi-
nation which simplify the analysis is needed. 
One alternative method is using chemical sen-
sor or biosensor for polyphenol determina-
tion, as these technologies are applicable for 
this field. This research was aimed to develop 
simple sensor for determination of total poly-
phenol content in coffee by immobilization of 
sodium meta periodate (NaIO4) and 3-meth-
yl-2-benzothiazolinone hydrazone (MBTH) 
reagents onto filter paper. NaIO4 can oxidize 
the ortho-diphenols (in polyphenol’s chemical 
structure) into their related ortho-diquinones, 
mimicking the natural polyphenol oxidase 
enzyme7. MBTH is chromogenic reagent for 
ortho-diquinones detection which in turn, 
resulting red color on the surface of the poly-
phenol sensor8. 
DEVELOPMENT OF SIMPLE POLYPHENOL SENSOR BASED ON SODIUM 
META PERIODATE AND 3-Methyl-2-Benzothiazolinone Hydrazone FOR 
COFFEE SAMPLES
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EXPERIMENTAL DETAILS
Reagents 
All reagents were used as purchased without 
further purification. NaIO4 were obtained 
from BDH-Merck (UK). MBTH were obtained 
from Fluka (UK). Chlorogenic Acid (CA) were 
obtained from Aldrich (UK). For immobiliza-
tion, a phosphate buffer solution (PBS) with 
pH 7.0 was prepared by adjusting amounts of 
NaCl, KCl, Na2HPO4 and KH2PO4 buffer sys-
tems; in all cases, the mixture were 0.2 M in 
each constituent. Whatman filter paper (CAT 
No.1095.093) for sensor host were obtained 
from Merck (UK).  
Reagent Immobilization
Fresh solution containing 8 mM NaIO4 dan 48 
mM MBTH at equal volume was prepared for 
sensor reagent. The reagent was pipetted (4 
l) and dipped onto 0.5 x 0.5 cm2 filter paper, 
and dried for 30 minutes at ambient tempera-
ture to make colorimetric sensor membrane. 
Afterward, the sensor membrane was placed 
gently onto plastic film to construct polyphe-
nol sensor as it given in Fig. 1.
Figure 1. Sensor design and its application on 
samples. 
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Color Change Measurement
Since, the proposed sensor was intended to be 
used in visual mode, so that the color chang-
es during polyphenol detecti on can be easily 
viewed by the naked eye. For quanti fi cati on 
of color measurements of the sensor, a simple 
method using a fl atbed scanner (CanoScan 
Lide110, Canon, Japan) was used. The color 
change of the sensor from colorless to red was 
used as the measurable response of the sen-
sor toward polyphenol, aft er the sensor (as a 
dip sti ck test) was dipped into a sample solu-
ti on for 5 seconds (Fig. 1). The color change 
of the sensor was quanti fi ed using ImageJ pro-
gram9,10, as previously scanned to determine 
the mean RGB value of the sensor color.
Opti mizati on of Sensor
Since CA is known as major compound found 
in coff ee as polyphenols, thus it can be used to 
represent polyphenol profi le in coff ee. Hence, 
CA (25-250 g/mL) was used for opti mizati on 
of the proposed sensor, and calibrati on curves 
were made for polyphenol determinati on. 
Here, polyphenol contents were expressed as 
mg/L chlorogenic acid equivalent (CAE).
Preparati on of Coff ee Samples
Coff ee (Robusta and Arabica) samples were 
purchased from PT. Perkebunan Nusantara 
X, Jember-East Java, Indonesia. Coff ee bev-
erages were made by brewing dried powder 
of coff ee bean with boiling water at 1% w/v. 
The coff ee suspension were decanted and fi l-
tered through fi lter paper to obtain sample 
soluti ons. Aft erward, sample soluti ons were 
cooled at ambient temperature for polyphe-
nol analysis. 
RESULTS AND DISCUSSION
Analyti cal Properti es of the Sensor
The proposed sensors were used for the visual 
determinati on of total polyphenol content. 
The calibrati on curves are presented in Figure 
2. Here, the sensor has a linear response in the 
range of 25-250 g/mL CAE (i.e., the intensity 
of red color increases) with a correlati on co-
effi  cient (r) of 0.999. The limit of detecti on of 
the sensor was 11,067g/mL CAE, while limit 
of quanti tati on was found in the 36,888 g/
mL CAE.
Response Time 
The response ti me of the sensor was found as 
a ti me needed to change the color aft er the 
sensor reacted with polyphenol soluti on. A 
soluti on of 150 g/mL CA was used to deter-
mine response ti me. The response ti me was 
found to be 15 minutes, in which aft er this 
ti me, the sensor response was constant (Fig-
ure 3).
Reproducibiity 
In order to determine the reproducibility, the 
sensor response was tested toward 1% of cof-
fee soluti on samples as given in Figure 4. The 
sensor response shows good reproducibility 
for both of Robusta (R.S.D. = 0.53%) and Ara-
bica (R.S.D. = 0.87%) coff ees. This reproduc-
ibility is higher compared to other reported 
polyphenol biosensors8.
Figure 2. Calibrati on curve of CA for total poly-
phenol quanti fi cati on.
Figure 3. Response ti me of NaIO4/MBTH sensor toward CA.
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Determination of Polyphenol Content in Cof-
fee Samples
The proposed sensor was used to determine 
polyphenol content in coffee beverages. The 
standard Folin-Ciocalteu method was used to 
validate total polyphenol content obtained by 
the developed sensor. No significant different 
results (p = 0.05) were found compared with 
the Folin-Ciocalteu method as it can be seen 
at Figure 5. Thus, the proposed sensor can be 
used as an alternative tool for determination 
of total polyhenol content in coffee beverage 
samples.
CONCLUSION
The proposed chemical sensor based on 
NaIO4/MBTH reagents offers simplicity, rapid 
and cost effective in determination of total 
polyphenol content in coffee samples. Thus, 
the proposed sensor can be used as alterna-
tive method for polyphenol determination in 
coffee beverage samples. 
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INTRODUCTION
Levofloxacin is the active L-isomer of ofloxa-
cin, a fourth-generation fluoroquinolone de-
rivative (Figure 1). The presence of unwanted 
or in certain cases unknown chemicals, even 
in small amounts, may influence not only the 
therapeutic efficacy but also the safety of the 
pharmaceutical products [04]. As per the re-
quirements of various regulatory authorities 
[01,02,03], the impurity profile study of drug 
substances especially for impurity C ((S) -Eth-
yl9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-
1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-
benzoxacine-6-carboxylate) has to be carried 
out using a suitable analytical method in the 
final product. 
The research studied that the optimum chro-
matographic separation for levofloxacin and 
degradation products takes place when an 
aqueous solution containing 0.025 M phos-
phate buffer pH 6.0±0.05 and acetonitrile 
(88:12 v/v) are used as the mobile phase at a 
flow rate of 1.5 mL min−1, and PDA detection 
at 294 nm [05].
MATERIALS AND METHOD
Materials
Levofloxacin Hemihydrate ex. DR. REDDY’S/
INDIA Batch No.ABBH001535, Volox Eye Drop 
Placebo pH 6.4, Volox Eye Drop Recovery 
(70%, 100%, 130%) (PT. Interbat Sidoarjo), 
Acetonitrile gradient grade for Liquid Chro-
matography, KH2PO4, TEA, HCl, NaOH, H2O2, 
H3PO4, C2H5OH analytical grade (Merck), 
highly pure HPLC grade Milli-Q water (Milli-
pore).
Instrument
UHPLC Nexera L20154908961 Shimadzu, 
UFLC Shimadzu LC-20AD Prominence, Column 
Phenomenex Luna 5u C18(2) 100A 150 mm x 
4.6 mm, Milli-Q water purification with Mil-
lipak-40 filter 0.22 μm, Analytical scales Met-
tler Toledo XP205, pH meter Mettler Toledo 
Seven Multi.
Chromatographic conditions:
The mobile phase consisted of a mixture of 
0.025 M phosphate buffer pH 6.0±0.05 and 
acetonitrile (88:12), delivered at a constant 
flow rate of 1.5 mL/min, PDA detection at 294 
nm, and the injection volume was 10 μL. Col-
umn temperature was fixed at 35°C. All mo-
bile phases were filtered through a 0.22 μm 
Millipore filter.
Sample Preparations:
Standard solution:
Accurately weighed 50.0 mg levofloxacin 
hemihydrate is transferred to 25.0 mL volu-
metric flask, added 15 mL of mobile phase & 
sonicated to dissolve, diluted up to volume 
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with mobile phase. Pipetted 1.0 mL of solu-
tion, put in a 10.0 mL volumetric flask, diluted 
with mobile phase up to the mark, shake ho-
mogeneous. Obtained levofloxacin 200 ppm 
standard solution.
Impurity C solution [06]:
Accurately weighed 50.0 mg levofloxacin hemi-
hydrate is transferred to 50.0 mL volumetric 
flask, added 40 mL of ethanol & sonicated to 
dissolve, diluted up to volume with ethanol. 
Added 1.0 mL of concentrated hydrochloric 
acid, shake homogeneous. Then the solution 
was heated in a water bath at 60°C for 3 hours.
RESULT AND DISCUSSIONS
Analytical Method development:
As results of these studies, using Phenomenex 
Luna 5u C18(2) 100A 150 mm x 4.6 mm column 
and a mobile phase consisted of a mixture of 
buffer phosphate pH 6.0±0.05  and acetonitrile 
(88:12 v/v) at a flow rate of 1.5 mL min−1, and 
PDA detection at 294 nm was found appropri-
ate to obtain an adequate separation of all the 
related impurities and degradation products of 
the levofloxacin. 
Method validation study:
Selectivity:
The observation was made from the chro-
matogram of interference of diluent, placebo 
and impurities that no peak was found at the 
retention time of levofloxacin peak (Figure 2). 
Resolution between levofloxacin and impu-
rity C was found more than 2.0. The peak pu-
rity angle was less than peak purity threshold, 
which indicated that the concern peak is spec-
trally homogeneous.
Linearity:
The standard solution of levofloxacin hemihy-
drate at levels 140, 170, 200, 230, 260 ppm 
was injected. Parameter values obtained lin-
earity of levofloxacin that r=0.9994. From 
these data it can be concluded that there is 
a linear relationship between the concentra-
tion of levofloxacin in the area over a range of 
concentrations (Figure 3).
 
Accuracy:
The % recovery for three sets of accuracy 
sample preparation at each accuracy level 
was found within the acceptance criteria with 
acceptable limit (98%-102%).
Stressed Study:
The standard solutions are prepared to get 
the degradation at least in one condition and 
subjected to various stress condition as men-
tioned below (Table 1).
Table 1. Stress study conditions
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Intermediate Precision:
Intermediate precision was evaluated by car-
rying out six independent assays at standard 
solution of levofloxacin on different tools by 
different analysts. Samples were analyzed by 
6 times replication (Table 2).
Intermediate Precision:
Intermediate precision was evaluated by car-
rying out six independent assays at standard 
solution of levofloxacin on different tools by 
different analysts. Samples were analyzed by 
6 times replication (Table 2).
Robustness:
The determination was observed with small 
but deliberate changes in the parameters (col-
umn temperature (+5oC) and flow rate (+2)). 
Resolution between levofloxacin and impurity 
C, theoretical plates, tailing, %RSD were ob-
served and found good with all the different 
altered conditions.
CONCLUSION
An HPLC method was proposed for the deter-
mination of levofloxacin in ophthalmic prepa-
rations and validated for selectivity, linearity, 
accuracy, stress study, intermediate precision 
and robustness.
Table 2. Data of Intermediate Precision 
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INTRODUCTION
Eperisone (EPE)  is chemically 4’-ethyl-3-meth-
yl-3-piperidinopropiophenone (Figure 1), is 
antispasmodic drug (Paresh, et al., 2012). It is 
used in the treatment of different pathologi-
cal conditions like acute and chronic muscle 
spasm, electroconvulsive therapy, neuro-
logical conditions, orthopedic manipulation, 
myelopathy, encephalomyelitis, spondylosis, 
spondylarthrosis, cervical and lumbar syn-
drome, arthrosis of the large joints obliterat-
ing arthrosclerosis of the extremity vessels, 
diabetical angthromboangitis obliterans and 
Reynaud’s syndrome (Maske and Nagras, 
2013).  Literature survey revealed that EPE is 
estimated by HPLC (Din, et al., 2004) and AUC 
method of UV spectrophotometry (Maske and 
Nagras, 2013) in single component formula-
tion. In this presentation we report  a simple 
and rapid assay for the quantitation of EPE us-
ing UV spectrophotometry method.
MATERIAL AND REAGENT
Working standard of pharmaceutical grade 
Eperisone Hydrochloride from PT Eisai Indo-
nesia, (Wuhan Grand Pharmaceutical Group 
Co., Ltd.), methanol, commercial tablets con-
tain EPE.
EXPERIMENTAL
Preparation of Standard Solutions and Phar-
maceutical Samples
Stock standard solution was always freshly 
prepared by dissolving 25 mg of Eperisone Hy-
Figure 1 Chemical stuctures of eperisone
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drochloride in 100 ml methanol (stock stan-
dard solution I) and 30 mg of Eperisone Hy-
drochloride in 50 ml methanol (stock standard 
solution II). Working standard solutions were 
prepared by dilution of stock solution with 
methanol to get solutions in concentration 
range of 1-18 µg/ml. For sample preparation, 
twenty tablets  was weighed; average weight 
was determined and finely powdered. An ac-
curately weighed quantity of tablet powder 
equivalent to 10 mg of Eperisone Hydrochlo-
ride was transfered to 100 ml volumetric flask 
and dissolved by sonication with methanol, 
volume was made up to mark. The solution 
was then filtered through filter membrane 
0.45 µm. A 1.0 ml of the filtrate was further 
diluted with methanol in a 10 mlvolumetric 
flask up to mark (10  µg/ml) on label claim 
basis. 
Determination of λ max
A 10 μg/ml solution of Eperisone Hydrochlo-
ride was prepared and scanned in UV range 
of 200-400 nm and spectrum was obtained. 
The spectrum of Eperisone Hydrochloride as 
shown in figure 2.
Method Validation
The developed method was validated with 
the following parameters.
Specificity
The Specificity of this method was determined 
by analyzing standard and sample. Specificity 
was showed by scanning at 200nm – 400 nm 
and analyzed the spectrum of standard and 
sample.  
Linearity
The evaluation of the calibration curve’s lin
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earity was done based on the absorbance of 
the standard solutions that were prepared in 
methanol at the concentrations 1-18 µg/ml. 
The calibration curve was plotted as concen-
tration versus absorbance.
Limit of Detection and Quantification
Limit of detection (LOD) and Limit of Quanti-
fication (LOQ) were determined by preparing 
the standard solutions in methanol at the con-
centrations 1-18 µg/ml.
Precision
The precision of this method was performed 
by repeatability and intermediate precision 
studies. Repeatability studies was performed 
by analyzing one concentration of the drug for 
six times on the same day. The intermediate 
precision was checked by repeating studies on 
three different days.
Accuracy
The accuracy of this method was evaluated 
through recovery experiments by adding three 
different amounts of Eperisone Hydrochloride 
standards i.e. 30, 45 and 60% of the concen-
tration samples. Each concentration were rep-
licated (n=3)
Analysis of Marketed formulations
The Samples that is contain of Eperisone Hy-
drochloride  (brand A and brand B) were pre-
pared as sample preparation method. Each of 
samples were replicated (n=3). The analysis 
was done in the same way as described earlier.
RESULTS AND DISCUSSION
A validated, simple and accurate UV-Spectro-
photometric methods has been developed for 
determination of Eperisone Hydrochloride in 
tablet dosage forms. Eperisone hydrochloride 
showed maximum absorbance at 255.5 nm. 
From UV-spectrophotometric, showed that 
the absorbance of analyte in sample were 
same as standard (figure 2). 
The LOD and LOQ were found to be 0.485 µg/
ml and 1.373 µg/ml. The values of relative 
standard deviation (RSD) were found to be 
1.13%; 0.16% and 0.74% in the different day.
The three measurement were perfomed with-
in one laboratory by same analyst in different 
days. The accuracy of the proposed method 
were 100.94% ± 0.81. 
Analysis of Marketed formulations
The proposed method has been applied to the 
determination of  Eperisone Hydrocloride  in 
commercial tablet formulations and the recov-
ery of label claim were  98.84% ± 0.32 µg/ml 
for brand A and 99.74% ± 0.47 µg/ml for brand 
B. The result of the analysis of marketed for-
mulations indicate that the concentrations of 
Eperisone hydrochloride in tablet is within the 
requirements (USP) 95-105% .
CONCLUSION
A new UV-spectrophotometry method has 
been developed for the quantification of 
Eperisone hydrochloride in tablet dosage 
forms. The method was found to be simple, 
rapid, specific, precise and accurate for esti-
Figure 3 calibration curve of Eperisone in methanol
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mation and can be employed for the routine 
quality control analysis Eperisone hydrochlo-
ride in tablet.
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INTRODUCTION 
Osteoporosis is a disease characterized by de-
crease in BMD (Bone Mineral Density) and de-
generation of bone microarchitecture, there-
by increasing the risk of fracture (Noor et al, 
2011). 
Osteoporosis influences the health of more 
than 200 million people around the world in 
recent years (Jia et al, 2012). Prevalence of 
osteoporosis in women is higher than men. 
This is due to women 50 years of ages, women 
going through menopause (Rao et al, 2008). 
Menopause is the permanent cessation of 
menstruation due to the ovaries fail to pro-
duce estrogen (Goodman et al, 2011). the 
decrease in production can increase bone 
resorption process thus increasing the occur-
rence of osteoporosis (O’connell et al, 2008).
In a previous study, powder of leave’s gedi red 
bulbs (Abelmoschus manihot (L.) Medik) have 
shown that  the ability to prevent bone loss 
in rats that had their ovaries removed. Gedi ‘s 
leaf consumption can increase the BMC (Bone 
Mineral Content) on the femur as a whole in 
these mice, because it increases the BMC at 
the femur metaphysis and diaphysis (Puel et 
al, 2005).
Based on the above research, it is necessary to 
study to determine the activity of 96% ethanol 
extract of the leaves of red gedi (Abelmoschus 
manihot (L.) Medikin increasing trabecular 
bone density of the femur. In this study, the 
activity of the extract to be tested using ani-
mal research subjects mice female who has 
osteoporosis.
MATERIALS AND METHODS
PLANT MATERIAL 
Leaves of red gedi (Abelmoschus manihot (L.) 
Medik) were used in this study was obtained 
from the area Buha village, Mapanget, Ma-
nado, North Sulawesi, the 90-day-old taked on 
January 20, 2014.
CHEMICALS
Dexamethasone, Ethanol 96% technical, Alen-
dronate, CMC Nat, Dyes HE (Hematoxylin eo-
sin)
TOOLS
Mice cages, maseras tool set, Rotary Evapora-
tor Buchi R-200, Laminar air flow cabinet, Tool 
- glassware, animal scales, Sonde, Mortar and 
Stamper, Microscope Boeco, computer and 
software Nikon Image, Means treadmill for 
mice
ANIMAL TRIAL
Animals used in this study were adult female 
mice aged 70-80 days with a healthy body 
condition on visual observations, has a weight 
between 20-30 gramsIn this study required 36 
mices, all the mice with dexamethasone in-
duced osteoporosis were divided into 6 groups 
with each group containing 6 mices.
RESEARCH DESIGN
1. Preparation of materials
Leaves were elected cleaned under running 
water until clean and then drained. After it 
leaves aerated in open to dry. After becoming 
simplicia dried, then ground to obtain a fine 
powder.
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2. Extraction of materials
Gedi red’s leaves powder 356 grams of macer-
ated with ethanol using 96% as much as 9 L. 
Furthermore allowed to stand for 24 hours and 
stirring regularly. Then filtered with a Buchner 
funnel connected to a vacuum pump to obtain 
the filtrate. The filtrate obtained was concen-
trated using a rotary evaporator at 50 ° C until 
a viscous extract.
3. Test antiosteoporosis activity
Determination of the activity test antioateopo-
rosis 96% ethanol extract of the leaves of red 
gedi (Abelmoschus manihot (L.) Medik) in in-
creasing bone density performed using female 
mices study subjects. Mices were induced with 
dexamethasone for 4 weeks, then continued 
with the different treatment regarding to the 
division of the group. Effect of increased bone 
density in this study was determined by mea-
suring the thickness of the trabecular bone of 
the femur in microscopy and by computer. The 
thickness of the trabecular bone is comparison 
of trabecular bone area to total area of pre-
parat. 
• positive control group
After induced osteoporosis, alendronate was 
given the suspension as much as 0.4 ml / 20 g 
mice / day orally for 4 weeks.
• The negative control
After induced osteoporosis, given the 0.5% Na 
CMC suspension as much as 0.4 ml / 20 g mice 
/ day orally for 4 weeks.
• Group 1 test
After induced osteoporosis, given the suspen-
sion of 96% ethanol extract of leaves of red 
gedi (Abelmoschus manihot (L) .Medik) at a 
dose of 24.89 mg / 20 g of as much as 0.4 ml / 
20 g mice / day orally for 4 weeks.
• Test Group 2
After induced osteoporosis, given the suspen-
sion of 96% ethanol extract of the leaves of 
red gedi (Abelmoschus manihot (L) .Medik) at 
a dose of 24.89 mg / 20 g of as much as 0.4 
ml / 20 g mice / day orally along with physical 
exercise 3 times a week for 4 weeks.
Physical exercise in mice conducted in this 
study is an exercise run by means of a tread-
mill. Physical exercise performed starting 
from a low initial velocity which is 10m / min 
with a duration of 5 minutes and then will be 
increased according to the ability of mice.
• Group 3 test
After the suspension-induced osteoporosis 
given 96% ethanol extract of the leaves gedi 
(Abelmoschus manihot (L.) Medic) at a dose 
of 49.78 mg / 20 g of as much as 0.4 ml / 20 g 
mouse / day orally for 4 weeks.
Group exercise
After physical exercise induced osteoporosis 
done for 4 weeks, the walking exercise using 
a treadmill means. Physical exercise is started 
from the speed of 10m / min with a duration 
of 5 minutes, kemudan increased gradually 
according to the ability of mice.
RESULTS
The occurrence of osteoporosis with a de-
crease in bone density as a result of dexa-
methasone induction is characterized by the 
formation of a bump on the vertebrae that 
is shown in Figure 1. After administration of 
dexamethasone daily for 4 weeks, all female 
mice visually osteoporosis.
96% leaf Red Gedi in increasing bone density 
obtained from the average value histomor-
fometri trabecular bone density of the femur. 
In the negative control group, ie, in a state of 
widespread osteoporosis bone trabekularnya 
lowest when compared with the group given 
ethanol extract after experiencing
The observation of the ethanol extract activ-
ity test
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INTRODUCTION
Newly, we found many cosmetics combined of 
sunscreen substance and lightening agent in 
their ingridients. 
Kojic acid is a skin lightening agent which has 
very small molecular size, so easily absorbed 
up through the basal membrane. Because of 
its small molecule, kojic acid hardly absorbed 
through the lipid membrane of its target sites, 
the melanocytes (Manosroi et al, 2005) and 
can penetrate into the systemic (Nakayama et 
al., 2005). It is likely absorbed through voids 
between cells on the skin. Kojic acid is pro-
duced mainly by microbial fermentation us-
ing aspergillus and penicillium spp. In in vivo 
test, cream containing kojic acid compounds 
have been reported as effective in prevent-
ing pigmentation changes in human skin due 
to exposure to UVA and UVB. This inhibition 
has been shown to be due to chelation of 
Cu, a prosthetic group in tyrosinase (Barel et 
all, 2001). Cream contained 1 % of kojic acid 
showed steady but slow whitening effect. 14C-
labeled kojic acid cream was observed to be 
quickly absorbed from the skin to the liver , 
intestines, and kidneys in mice.
When the absorption was thus quick, the 
depigmentation agent did not stay at the 
epidermis where it had its target organ, me-
lanocytes, for a long enough time to inhibit 
melanogenesis. Therefore, kojic acid was 
mixed with β-cyclodextrin to slow the absorp-
tion into the dermis (Elsner and Maibach, 
2005). Losses due to kojic acid to the systemic 
is not able to work effectively inhibits melanin 
formation took place in the basal membrane 
of skin that results are not optimal lightening 
effect. Addition of β-cyclodextrin reported 
can decrease penetration of kojic acid (Na-
kayama et al., 2005).
Cyclodextrins are cyclic oligosaccha-rides with 
a hydrophilic outer surface and a somewhat 
hydrophobic central cavity. Cyclodextrins are 
able to form inclusion complexes with many 
drugs by taking up the drug molecule, or a li-
pophilic moiety of the molecule, into the cav-
ity (Loftsson and O’Fee, 2003).
MW: 142.1
MP: 153-154oC
pKa: 7.90-8.
Log P (octanol-
water): -0,64 
    Fig 1. Properties of Kojic Acid
          5-hidroksi-2-hidroksimetil-4-pyron
     Fig 2. β-cyclodextrin (Sweetman, 2007)
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Sunscreen agents, such as: oxybenzone and 
octyl dimethyl PABA, are commonly present 
in whitening products to compensate for the 
photosensitivity effect caused by the whiten-
ing agent. This combination is more efficient 
but may have a profound effect on the efficacy 
of the sunscreen agent. 
Therefore, this study was aimed to investigate 
the SPF value of sunscreen product contained 
oxybenzone and octyl dimetyl PABA (3:7) with 
the addition of kojic acid 1% b/b as whitening 
agent and their complex with β-cyclodextrin 
in 1:1 molar equivalent. In this research, we 
also studied the effect of b-Cyclodextrin (BCD) 
on penetration of Kojic Acid, as lightening sub-
stance In Vanishing Cream Base Formulation 
(on Sunscreen Product Contained Oxyben-
zone), by determination of tyrosinase activity 
inhibition.
MATERIAL AND METHODE
Material
Oxybenzone, Octyldimethyl PABA and Kojic 
Acid were from Surya Dermato, β-cyclodextrin 
p.a (Sigma Aldrich), Stearic Acid, cetyl alco-
hol, span 80, tween 80), Methyl paraben Pro-
pyl paraben, sorbitol 70%, Isopropanol p.a., 
(Brataco Chemicals). All of the active ingre-
dients used here were in a pharmaceutical 
grade except for the chemical reagent isopro-
panol and β- cyclodextrin which were in pro 
analytical grade. While material for inhibition 
of tyrosinase activity test is the Mushroom 
tyrosinase, L-Tyrosine, NaH2PO4. 2H2O (p.a) 
and Na2HPO4 (p.a). 
The SPF assay were carried out by using a 
Double Beam Spectrophotometer UV- Vis Per-
kin Elmer Lambda EZ 201, Ultrasonic Branson 
3510, Hettich zentrifugen EBA 20, Mettler 
Toledo AL 204 analytical balance. Digital pH 
meter Schott CG 842 and spreading capacity 
measurer are also used for the organoleptic 
analysis.
Methode
The sunscreen product contained oxybenzone 
and octyl dimetyl PABA (3:7) with the addition 
of kojic acid 1% w/w as whitening agent and 
their complex with β-cyclodextrin in 1:1 mo-
lar equivalent.  Vanishing cream as base was 
made with inversion technique.
The characteristics of the finished product 
evaluated were emulsion type, pH, spreading-
ability, and organoleptic such as colors, odors.
Table 1. Formula composition
Determination of SPF value
The SPF value was determined by Petro cor-
relation for in vitro method. 2 mg/cm2 or 2 
µL/ cm2 sunscreen agent for in vivo test was 
equivalent with 10 ppm sunscreen agent dis-
solved in isopropanol.  An UV spectrum of this 
solution was then measured at 290-400 nm 
by using Double Beam UV-Vis Spectrophoto-
meter Perkin Elmer Lambda EZ 201 at an in-
terval of 2 nm which has absorbance for 0.05 
or more. According to Petro, the absorbance 
was then converted into the absorbance for 
10 ppm solution concentration for each wave-
length. Then it was proceed in this following 
equation:
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Determination of tyrosinase activity inhibi-
tion: 
A. Preparation of a solution of the re-
action components. The solution should be 
prepared for the implementation of this study 
was 0.1 M phosphate buffer pH 6.5, solution 
of tyrosinase (5370 units / mg solid in 0.1 M 
phosphate buffer pH 6.5 to 100.0 ml volume), 
a solution of 5.52 mM L-tyrosine, and 30% 
TCA. 
B. Preparation of test sample solution. 
The cream (around 3 grams) was put in the 
diffusion cell then covers with the Millipore 
membrane which was impregnated with iso-
propyl-myristate as modified lipid membrane. 
Then the preparation of cream in diffusion cell 
was put into the penetration chamber contain 
500 ml of phosphate buffer pH 6.5 ± 0.05 at 
37 ± 0.5ºC as diffusion medium, and then the 
paddle was stirred 100 rpm. The sample solu-
tion around 3 ml was collected at 6 hours after 
it penetrated. 
Determination of the dopakrom  maximum 
wavelength. L-tyrosine solution of 5.52 mM 
has taken a number of prepared and then 
added 0.5 ml 3 ml of buffer solution pH 6.5 
± 0.05. Then  the mixture add with 1.0 ml of 
tyrosinase and oxygenated for 5 minutes. The 
mixture was incubated for 15 minutes at 26 ± 
0.5 ºC then added 0.5 ml of 30% TCA. The so-
lution is then inserted into cuvet and placed 
on the sample position in the spectropho-
tometer. Used as a blank solution 0.1 M phos-
phate buffer pH 6.5. Then do the reading of 
absorbance values from a wavelength of 400 
nm to 500 nm, and the selected wavelength 
that gives the greatest absorption. 
Inhibition Tyrosinase Activity Determination
L-tyrosine solution 5.52 mM added with 0.5 
ml 3 ml of sample solution. Then the mixture 
added with 1.0 ml of tyrosinase and oxygenat-
ed for 5 minutes. The mixture was incubated 
for 15 minutes at  26 ± 0.5 ºC. Then add 0.5 ml 
of TCA 30% and observed the absorbance at 
dopacrom maximum wavelength.  Inhibition 
tyrosinase activity is the percent inhibition 
values obtained from the later absorbance 
value calculated by the equation: 
   A x 100 
    % Inhibition = 100 –                                                  
                                                    B
A = Absorbance at the maximum with the skin 
lightening 
B = Absorbance at maximum λ without the 
skin lightening
RESULT AND DISCUSSION
All the formulas had either pH in skins pH 
range or simillar spreadability.
The SPF value increased in formula 3. The 
complex formation of the sunscreen agent 
with BCD was suspected to be responsible for 
this phenomenon. It might becaused of com-
plex formation of the sunscreen agent with 
β- cyclodextrin increased sunscreen agent 
solubity.  
Based on one way ANOVA test, known that 
the addition of BCD decreased inhibition per-
cent compared to the control constraints. 
Nevertheless the addition of sunscreen does 
not affect the inhibition percent of tyrosinase 
activity. Addition of BCD on combination kojic 
acid-sunscreen preparations showed the 
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same phenomena such as decreased its inhi-
bition percent of tyrosinase activity. Decreas-
ing of inhibition percent of tyrosinase activity 
after addition of BCD  or combination BCD-
sunscreen was might be caused by decreas-
ing of kojic acid penetration.  It was probably 
caused by some of the things that the release 
process of kojic acid from base and in the pro-
cess of penetration through the membrane. 
Before reach basal membrane where the kojic 
acid site of action, kojic acid molecule should 
released from base further more penetrate 
through the skin. Increasing viscosity will de-
crease the molecules mobility of active ingre-
dient that caused barriers against the release 
of kojic acid. 
CONCLUSION
1. The complex formation of the sun-
screen agent with BCD decreased the SPF val-
ue of sunscreen product.
2. BCD decrease penetration kojic acid 
based on inhibition of tyrosinase enzyme ac-
tivity in invitro.  
3. The existence of BCD and combina-
tion sunscreen oxybenzone and octyl dimethyl 
PABA     (3:7)%  w/w decrease penetration kojic 
acid based on inhibition of tyrosinase enzyme 
activity in invitro.
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INTRODUCTION
Probiotics is live microorganisms which, when 
administered in adequate amounts, confer a 
health benefit on the host. Probiotics are live 
microbes that can be formulated into many 
different types of products, including foods, 
drugs, and dietary supplements. Species of 
Lactobacillus and  Bifidobacterium are most 
commonly used as probiotics. The treatment 
of diarrhea can be done by using probiotics. 
The use of probiotics has been developed and 
is essential for maintaining the balance of mi-
croflora in the digestive tract (WGO, 2008). 
In addition to the use of probiotics, diarrhea 
treatment can be done with the use of medici-
nal plants. Based on research, the medicinal 
plants is Psidium guajava L. leaves. Psidium 
guajava L. leaves contain tannins, essential oils, 
flavonoids, carotenoids, sertaresin, also avicu-
larin and guaijaverin. Quercetin  is  thought  to 
contribute to the anti diarrhea effect of guava, 
it is  able  to  relax  intestinal  smooth  muscle 
and inhibit  bowel  contractions.  (Joseph et.al, 
2010). 
Antibacterial effect of combination of Lacto-
bacilli probiotic milk and guava leaf ethanolic 
extract is not yet investigated. The purpose of 
this study is to determine the antimicrobial ac-
tivity of combination of Lactobacilli probiotic 
milk and guava leaf ethanolic extract. Lacto-
bacillus acidophilus, Lactobacillus casei, and 
Lactobacillus plantarum were used for making 
probiotic milk, while Eschericia coli, Salmo-
nella typhimurium, and Vibrio cholerae were 
used as pathogenic microbes. Based on the 
content of compounds in guava leaf ethanolic 
ANTIMICROBIAL ACTIVITY OF LACTOBACILLI PROBIOTIC MILK AND 
GUAVA LEAF ETHANOLIC EXTRACT (Psidium guajava) COMBINATION 
AGAINST BACTERIAL CAUSE OF DIARRHEA
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extract and probiotic microbes from milk, it is 
expected that the antibacterial power combi-
nation probiotic milk and guava leaf extract in 
ethanol increases, so will obtain a better anti-
bacterial activity than antibacterial potency of 
each component.
MATERIALS AND METHODS 
Samples used : simplicia guava leaves, skim 
milk, microbial growth media: media Nutrient 
Agar (NA), MRS (de Man ROGOSA and Sharpe) 
broth and MRS agar, isolates of lactic acid bac-
teria (Lactobacillus acidophillus, Lactobacillus 
casei, Lactobacillus plantarum) and bacterial 
isolates pathogens (Escherichia coli, Salmo-
nella typhimurium, Vibrio cholerae).
Source of samples : Isolates of lactic acid bac-
teria and pathogenic bacteria derived from 
pure isolates were obtained from the Institute 
of Tropical Disease, Airlangga University, Sura-
baya. Simplicia guava leaves originating from 
Materia Medika.
Preparation Media : Nutrient agar as much 
as 18.0 grams dissolved in 1 liter of distilled 
water and stirred until homogeneous. The so-
lution is heated by heating slowly to the boil 
for a minute or two. That has a homogenous 
solution was poured into a container and ster-
ilized at 121 ° C for 15 minutes. MRS broth 
as much as 52.0 grams dissolved in 1 liter of 
distilled water and stirred until homogeneous 
and MRS agar as much as 56.0 grams of me-
dium MRS agar dissolved in 1 liter of distilled 
water and stirred until homogeneous. 
Preparation of Guava Leaf Extract : Prepara
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tion of extracts made by maceration, extrac-
tion bulbs using 40 grams of simplicia guava 
leaves in 400 ml of 70% ethanol at room tem-
perature for 24 hours. Results maceration 
filtered and concentrated by rotary vacuum 
evaporator at a temperature less than 50°C to 
evaporate the solvent depleted. Furthermore, 
extracts prepared in a concentration of 20% by 
weighing 20 grams of the extract, dissolved in 
100 ml of distilled water. 
Probiotic Milk Preparation : 200 ml of skim 
milk 15% (w / v) heated by means of reconsti-
tuting skim milk 15 grams in 100 ml of distilled 
water at a temperature of 80-85° C for 15 min, 
cooled to a temperature of 45 ° C and then 
added 20ml starter probiotics, were incubated 
at 37 ° C for 24 hours.
Test Antibacterial Activity Guava Leaf Ethano-
lic Extract and Probiotic Milk : Ethanol extract 
of guava leaves 20% in water mixed with a 
probiotic milk in the ratio 1: 9, 2: 8, 3: 7, 4: 
6, 5: 5, 6: 4, 7: 3, 8: 2, and 9: 1. Test antibac-
terial power of probiotic milk and guava leaf 
extract performed using Nutrient Agar media 
was planted pathogenic bacteria test is then 
perforated, the available hole shed 100 mL 
probiotic milk has been added guava leaf ex-
tract with various comparisons. Samples were 
incubated for 24 hours at 37°C, then observed 
and measured the resulting inhibition zone di-
ameter in millimeters. Tests performed on the 
activity of pathogenic bacteria to replicate as 
much as three times.
RESULTS AND DISCUSSION
Activity against pathogenic bacteria in milk 
containing the probiotic Lactobacillus occurs 
through multiple mechanisms function, is pro-
tective function by its ability to inhibit patho-
gens in the gastrointestinal tract. The forma-
tion of the colonization of probiotics in the 
digestive tract. The growth of probiotics will 
also produce a variety of anti-bacterial compo-
nents (organic acids, hydrogen peroxide, and 
bacteriocins were able to suppress the growth 
of pathogens); the function of the immune 
system, with an increase in the body’s im-
mune system (Collado et al, 2009). While the 
guava leaf extract, there are four antibacte-
rial compounds discovered from the results of 
the isolation and effective against pathogens 
that two flavonoid glycosides, morin-3-O-α-
L-lyxopyranoside and morin-3-O-alpha-L ara-
bopyranoside, and two flavonoids, quercetin 
and guaijavarin (Arima and Danno, 2002). 
The use of a combination of Lactobacillus 
acidophillus, Lactobacillus casei and Lacto-
bacillus plantarum based on that each type 
of probiotic bacteria bacteriocins have dif-
ferent kinds of compounds. In Lactobacillus 
acidophillus known to produce bacteriocins 
named lactacin B and acidocin A (Barefoot 
and Kleinhamer, 1984; Kanatani et al., 1995), 
Lactobacillus casei produce bacteriocins ber-
namacaseicin (Olasupo et al., 1995), whereas 
bacteriocins plantaricin is produced by Lac-
tobacillus plantarum (Son et al., 2009). The 
presence of bacteriocins produced more than 
one type of bacteria that can help protect the 
producer from the effects of antimicrobial 
compounds produced guava leaf extract and 
inhibition of pathogenic bacteria stronger.
Antibacterial activity test was carried out by 
combining the ethanol extract of guava leaf 
in water and 20% probiotic milk with varying 
ratios (1: 9.2: 8, 3: 7, 4: 6, 5: 5, 6: 4, 7: 3, 8: 2, 
9: 1). Tests performed on the activity of patho-
genic bacteria with the replication of three 
times. Activity test was also performed on a 
single probiotic milk, a single guava leaf etha-
nolic extract, positive control and a negative 
control. Positive control used was antibiotic 
Ciprofloxacin and negative control used was 
milk skim. From the results of the antibacterial 
activity of a combination of Lactobacilli pro-
biotic milk and guava leaf ethanolic extracts 
against diarrhea-causing bacteria, inhibition 
zone diameter data obtained. Combination 
dosage that produces the greatest inhibition 
of bacterial third test is the ratio of 9: 1 as 
shown in Table 1, and in combination with a 
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ratio of  9: 1 was chosen as a component in the 
formulation of probiotic preparations. Inhibi-
tion zone on a combination of probiotic milk 
plus ethanol guava leaf extract at a concentra-
tion of 20% has inhibitory effect on bacterial 
pathogens test. In combination preparations, 
the ratio of 9: 1 has the largest clear zone 
between the ratio of the combination of the 
other preparations. In the test preparation 
combined inhibition against Escherichia coli, 
Salmonella typhimurium, and Vibrio cholerae 
inhibition zone values obtained by an average 
of 14.10 mm, 15.50 mm and 15.17 mm.
Table 8. Diameter of Inhibition Zone of Guava Leaf Eth-
anolic Extract and Probiotic Milk bacteria test against 
Escherichia coli, Salmonella typhimurium, Vibrio chol-
erae
CONCLUSION
The antibacterial activity combination of Lac-
tobacilli probiotic milk and guava leaf ethanolic 
extract against Escherichia coli, Salmonella ty-
phimurium and Vibrio cholerae has the largest 
inhibition zone ratio of 9: 1. Average inhibitory 
combination preparations Lactobacilli probiot-
ic milk and guava leaf ethanolic extract against 
Escherichia coli, Salmonella typhimurium and 
Vibrio cholerae are 14.10 mm, 15.50 mm and 
15.17 mm.
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THE INFLUENCES OF PARTICLE SIZE AND SHAPE ON ZETA POTENTIAL OF 
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INTRODUCTION
Coenzyme Q10 (CoQ10) nanosuspension, 
which is colloidal dispersion of nanosized 
CoQ10 particle stabilized by surfactants, was 
produced to enhance its solubility by cold 
high-pressure homogenization technique in 
this study. A decrease in size of CoQ10 is not 
only enhancing its solubility, but also its stabil-
ity [1]. Zeta potential or surface charge, which 
directly measures the electrophoretic mobil-
ity of dispersed particles, can predict a long 
term stability of nanosuspension. According 
to Henry’s equation, zeta potential increases 
with increasing the electrophoretic mobil-
ity that is a proportion of the drift velocity of 
dispersed particles and the applied electric 
field strength [2]. Therefore, the particle size 
and shape of dispersed particles attribute to 
get the drift velocity resulting in the differ-
ences of the obtained zeta potential. To prove 
the above equation, this present investigation 
aimed at studying the influence of particle size 
and shape on zeta potential of CoQ10 nano-
suspension.
MATERIALS AND METHODS
Materials
CoQ10 was obtained from Cognis (Germany). 
Polyoxyethylene (20) sorbitan monooleate 
(Tween® 80) was purchased from Uniqema 
Ltd. (Belgium). Milli-Q water was produced by 
a Milli-Q Plus system, Millipore (Germany).
Methods
Production of CoQ10 nanosuspension
5% CoQ10 was dissolved in 1% Tween® 80 
solution at an ambient temperature. A pre-
homogenization was homogenized 2 cycles at 
each pressure of 200, 500 and 1000 bar by us-
ing a Micron Lab 40 high pressure homogeniz-
er (APV Gaulin GmbH, Germany). Then it was 
homogenized by applying a pressure of 1500 
bar for up to 20 cycles at 4°C.
Characterization of CoQ10 nanosuspension
The particle size, polydispersity index and 
zeta potential of CoQ10 nanosuspension were 
characterized by using a Malvern Zetasizer ZS 
(Malvern Instruments, UK). In order to detect 
the larger particles, Laser diffraction (LD) were 
performed with a measuring range of particle 
up to 2000 μm by static light scattering (SLS) 
by using a Mastersizer 2000 (Malvern Instru-
ment, UK) [3]. In addition, the morphology of 
CoQ10 nanosuspension was analyzed by us-
ing light microscope (Leitz, Wetzlar, Germany) 
equipped with a CMEX-1 digital camera (Eu-
romex microscopes, Arnhem, Netherlands) 
connected to Image Focus software version 
1.3.1.4. (Euromex microscope, Arnhem, Neth-
erlands). The magnification of the analyzed 
material was possible with the equipment by 
100x10-fold.
RESULTS AND DISCUSSION
A decrease in particle size of CoQ10 nanosus-
pension from 914 to 258 nm with a uniform 
particle size distribution (PI < 0.4) was achieved 
by cold high-pressure homogenization at 1500 
bar and 20 cycles, and a significant difference 
between an electrostatic potential surface 
or zeta potential of pre-homogenization and 
CoQ10 nanosuspension is shown in Table 1. 
More negative charge of CoQ10 nanosuspen-
sion was found with increasing the number of 
homogenization cycle for up to 20 cycles. This 
assumed that decreasing particle size leads to 
increasing the drift velocity resulted in more 
negative zeta potential. Owing to a zeta poten-
tial more negative than 30 mV, CoQ10 nano-
suspension will have a good physical stability 
for long-term storage. 
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Table 9. Size, polydispersity index and zeta potential 
of CoQ10 nanosuspension by a Malvern Zetasizer ZS.
In addition, light microscopy was used to get 
more valuable information about the particle 
size and shape of CoQ10 nanosuspension. Fig-
ure 2 shows a big morphological difference 
between a pre-homogenization of CoQ10 
and CoQ10 nanosuspension at 1500 homog-
enization bar and 20 cycles. The big crystals 
with non-spherical and some small spherical 
CoQ10 particles are shown in a pre- homog-
enization image on the left, and the mixture of 
smaller non-spherical and spherical particles 
the limitation of particle size measurement 
from Zetasizer ZS (0.6 nm – 6.0 µm); the larger 
particles than 6 µm were detected in CoQ10 
nanosuspension by laser diffraction as shown 
in Figure 1. These particles might effect to a 
size distribution of CoQ10 nanosuspension.
Figure 1. Size distribution of CoQ10 nanosus-
pension by laser diffraction.
are pronounced in CoQ10 nanosuspension 
image on the right. These results can be ex-
plained how the differences of zeta potential 
of CoQ10 nanosuspension were obtained. 
According to Henry’s equation, more nega-
tive zeta potential causes by increasing elec-
trophoretic mobility and the smaller particles 
with more spherical shape of dispersed parti-
cles attribute to a higher electrophoretic mo-
bility. Therefore, more negative zeta potential 
of CoQ10 nanosuspension was obtained by 
decreasing particle size with more spherical 
shape of CoQ10.
CONCLUSION
CoQ10 nanosuspension was successfully pro-
duced by cold high-pressure homogenization 
technique. It was proven that more negative 
zeta potential was obtained with increas-
ing the number of homogenization cycles, 
and the smaller particles with more uniform 
spherical shape influenced on zeta potential 
of CoQ10 nanosuspension according to Hen-
ry’s equation. 
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Figure 1. Scheme of synthesis reaction of com-
pound DBDM
INTRODUCTION
Some urea derivatives have been used as anti-
cancer drug, such as hydroxyurea (HU) which 
act by inhibiting the enzyme ribonucleotide 
reductase/RR (1). Benzoylureas (BU) has been 
reported as potential antitumor agents (2). 
The research has been continued to improve 
their antitumor activity by attaching two aro-
matic ring and methyl groups on both N atom 
of urea. The objectives were to synthesize 
N,N’-dibenzoyl-N,N’-dimethylurea(DBDM), in-
vestigate its antitumor activity against human 
breast cancer lines, and  explore in silico mo-
lecular interaction between tested compound 
and target molecule, RR (pdb id. 3HNC) (3). 
 
MATERIALS AND METHODS
Materials 
All reagents were purchased from standard 
commercial suppliers. The N,N’-dibenzoyl-
N,N’-dimethyl urea (DBDM) was synthesized 
by reacting benzoyl chloride with  N,N’-di-
methylurea using tetrahydrofuran (THF) as 
solvent in the presence of  pyridine (Figure 1). 
Melting point was measured by a Fischer-
Johns melting point apparatus without correc-
tion. TLC was carried out on aluminium plates 
coated with silica gel using UV lamp 254 nm 
to spot detection. The molecular structure of 
compound was confirmed by IR, 1H-NMR, 13C-
SYNTHESIS, MOLECULAR DOCKING, AND ANTITUMOR ACTIVITY OF 
N,N’-Dibenzoyl-N,N’-Dimethylurea AGAINST HUMAN BREAST CANCER 
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NMR, and Mass spectroscopy. IR spectrum 
was recorded on Jasco FT-IR 5300, 1H-NMR 
and 13C-NMR spectra were taken at JEOL ECS-
400 spectrometer using internal standard Me-
4Si. Mass spectrum was measured by Agilent 
6890N spectrometer using EI methods. 
Synthesis procedure
To N,N’-dimethylurea in THF and a few drops 
of pyridine, an equimolar of benzoyl chloride 
was added at ice bath while stirring. Then the 
temperature was raised and the mixture was 
refluxed for 24 hours at room temperature. 
The THF was evaporated and the solid was 
washed with water and saturated sodium bi-
carbonate respectively.The resulting solid was 
recrystalised from hot ethanol-water (1:1). 
Antitumor Activity
In vitro antitumor activity was tested against 
MCF-7 cancer cell lines and expressed in IC50 
(4). Cancer cell lines at a density of 5x103 
cells/well in 96-well plates were exposed to 
the test compounds in DMSO. After 48 hours 
incubated in a 5% CO2 incubator at 370C, cell 
survival was determined using the MTT re-
agent where the absorbances were observed 
at 595 nm on ELISA-reader. The survival ratio 
of living cells were exppressed in percentages 
with respect to untreated cells. Hydroxyurea 
(HU) was used as the reference drug.  The 
IC50 value of tested compounds were shown 
in Table 1.
Molecular Docking
The structure of human RR (pdb. 3HNC, at 
2.5o resolution) was obtained from the Pro
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tein Data Bank (www.pdb.org). 3D structure of 
compounds were built using CS ChemBioDraw 
Ultra 11.0 (Cambridge Soft) and their geom-
etry were optimized by the MMFF94 method 
and then saved as Sybyl Mol2 format. Mole-
gro Virtual Docker ver 5.0 (CLC Bio) was the 
docking program used. The tested compounds 
were placed into binding site of 3HNC (cav-
ity-3) by aligning to the reference ligand, TTP 
(5).  The binding affinity between ligand and 
enzyme was evaluated using MolDock Score, 
which is the total of ligand-protein interaction 
energies including hydrogen bonds. The high-
est-scoring pose (lowest energy) represent the 
best-found binding mode of ligand-protein.
The docking procedure was validated by red-
ocking TTP into cavity-3. Docking score of test 
compounds were listed in Table 1.
RESULTS AND DISCUSSION
Synthesis product
N,N’-dibenzoyl-N,N’-dimethylurea (DBDM) 
can be synthesized from N,N’-dimethylurea in 
one step. The compounds is white solid and 
water insoluble substances. The structure of 
the synthesized compounds were confirmed 
by IR, 1H-NMR,13C-NMR, and MS spectros-
copy as follows: 
N,N’-carbonylbis(N-methylbenzamide)=N,N’-
dibenzoyl-N,N’-dimethylurea: Yield 50% 
as white crystal, m.p. 143 0C. UV (ethanol, 
max, nm): 234.0. 1H-NMR (CDCl3, 400 
MHz,  ppm): 7.5 (=CH benzene, 2H, m); 7.4 
(=CH benzene,8H,m); 3.0 ppm (CH3,6H,m). 
13C- NMR (CDCl3, 400 MHz,  ppm): 171.18 
(Ar-(C=O)-N); 158.94 (N-(C=O)-N); 135.21 (ar 
=C-C=); 132.26 (ar =C-C=);  128.21 (ar =C-C=); 
127.81 (ar =C-C=); 34.3 (CH3). IR (KBr, max, 
cm-1): 3059 (Csp2–H), 2977 (Csp3–H), 1713, 
1676 (–C=O amide), 1600 (C=C). MS m/z EI : 
296(M+). 
The N,N’-dibenzoyl-N,N’-dimethylureas were 
produced from acylation of N,N’-dimethylurea 
by benzoyl chloride. The structural change of 
N,N’-dimethylurea to N,N’-dibenzoyl-N,N’-
dimethylureas was characterized by the con-
version of –NH– moeity of dimethylurea to 
–N–C=O(Ar). As there are two symmetric –
NH–, the new compounds bear two symmet-
ric benzoyl moeities, each attached on their N 
atom. It could be observed in 1H-NMR spec-
trum which didn’t showed proton peak at –NH 
region, supported by IR spectrum without N-H 
bands.
In table 1 the new compound, DBDM, shows 
IC50 lower than BU and anticancer drug, HU, 
indicating that DBDM is more active than BU 
and HU. Its highest docking score among BU 
and HU which indicating high ligand-protein 
binding affinity support its higher antitumor 
activity. Molecular interaction between tested 
Table 1. IC50 of tested compounds against MCF-7 cell 
lines and their docking score to RR binding site
Figure 2. 3D-view of three molecules (yellow dashed-
line) in secondary structure of ribonucleotida re-
ductase (2A), in its binding site (2B). 2D-view show 
H-bond (blue dashed-line) and hydrophobic interac-
tion (red dashed-line) of DBDM (2C) and BU (2D) with 
amino acid residue Serin 269. There was no H-bond 
interaction for HU.
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Figure 3.3D-view show H-bond interaction (blue 
dashed-line) of DBDM with Serin 269 (3A) and mol-
ecule in electrostatic surrounding of  cavity-3, 3HNC 
binding site (3B).
compounds with amino acids in the RR binding 
site are displayed in Figure 2 and Figure 3. 
From Figure 2 and 3 it could be explained that 
the aromatic ring and methyl groups on both N 
atom urea contributed to stronger binding of 
DBDM to the protein enzyme as DBDM could 
formed two H-bonds whereas BU only formed 
one H-bond.
CONCLUSION 
This study concluded that N,N’-dibenzoyl-
N,N’-dimethyl urea which has been synthe-
sized from reaction of N,N’-dimethylurea and 
benzoyl chloride showed antitumor activity 
against human breast cancer cell line (MCF-7) 
three-fold higher than hydroxyurea. The anti-
tumor activity was enhanced by methyl and 
aromatic rings attached to both N atom which 
could strenghten the binding affinity of com-
pound to target molecule, 3HNC. 
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INTRODUCTION
Epidermal growth factor receptor variant III 
(EGFRvIII) is the most common variant of the 
EGF- receptor (EGFR). This mutant variant 
of EGFR is expressed in some cancer such as 
glioblastoma multiforme (GBM) (50-60%) [5], 
breast cancer (67,8%) [6], non-small cell lung 
cancer (30-76,39%) [11], and head and neck 
squamous cell carcinoma (42%) [13]. How-
ever, this mutant is not observed in normal 
tissue. Expression of EFGRvIII in cells leads to 
unregulated growth and cells proliferation. 
This variant receptor was formed due to in-
frame deletion of exons -2 through exon-7 of 
the native EGFR. This causes a deletion of a 
large portion of the extracellular domain and 
the generation of a novel glycine at the fusion 
junction between exon-1 and exon-8. EGFRvIII 
becomes a spesific target for cancer therapy 
because of the juxtaposition of exon-1 and 
-8 plus the novel glycine that creates a highly 
immunogenic tumor specific antigen at its N-
terminal domain [4].
Single chain variable fragment (scFv) antibody 
is an engineered antibody fragment that con-
tains a complete antigen-binding site of an 
antibody. This antibody fragment should have 
the same monomeric binding affinity as the 
parental monoclonal antibody [14]. Yeast sur-
face display system is engineering techniques 
that express any heterologous protein on the 
surfaces of yeast’s cell wall [9]. This system 
becomes an increasingly popular tool for pro-
tein engineering and offers many applications, 
such as  application for selection and screen-
ing of antibody library [12]. Most of proteins 
that have been engineered by yeast display 
are monomeric proteins or single chain oligo-
mers [2, 8].
In the present study, cell surface expression of 
a fusion protein of an anti-EGFRvIII scFv and 
TagRFP in Pichia pastoris was attempted using 
glycosylphosphatidylinositol (GPI)-anchored 
α agglutinin protein (AGα), derived from Sac-
charomyces cerevisiae. This α- agglutinin func-
tions as a covalently anchoring system of the 
displayed molecules to the cell wall by fusing 
it to a cell wall bound protein [1]. The methy-
lotropic yeast P. pastoris has advantages as a 
recombinant protein expression system, such 
as high-level 
Expression and post-translation modifications 
processing. Unlike S. cerevicae, hyper-glyco-
sylation was not observed in P. pastoris during 
post-translation likes modification [10]. The 
aim of this research is to express and display 
an anti-EGFRvIII scFv using α-agglutinin as the 
ligand and TagRFP as a reporter protein on cell 
surface of P. pastoris.
MATERIAL AND METHODS 
Strain and Media
Escherichia coli TOP10F’ was used as the host 
for transformation of recombinant plasmids. 
Cells were cultivated at 37°C in Low Salt Luria-
Bertani (LSLB) medium with 25 µg/mL zeocin 
when necessary. P. pastoris SMD1168H was 
used as the host for protein expression.          P. 
pastoris was grown in yeast peptone dextrose 
(YPD) medium or buffered minimal glycerol 
yeast (BMGY) medium. Heterologous protein 
expression was induced in buffered minimal 
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methanol yeast (BMMY) medium that had the 
same BMGY formulation except that 0.5% (v/v) 
methanol was substituted with glycerol. 
Construction of Plasmids and Transformation
The anti EGFRvIII-scFv coding region (scFv) 
was amplified from the pJ201-scFv plasmid 
(DNA 2.0) by PCR method. Primers used were 
as follows: VH101-SalI forward (5’-CGTC-
GACCAAGTTCAATTGGTTGAGTCA G-3’) and 
VL101-SalI reverse (5’-CGGTCGACTCT AGAATC-
GATAGAACCAC-3’). Two SalI sites were added 
at two terminals of scFv fragment during 
Introduction of the Recombinant Plasmid into 
P.pastoris 
Both plasmids, pJ912-AGα and pJ912-
AGα::scFv, were linearized (0,5 μg each) by 
SacI and introduced into the     P. pastoris 
SMD1168H by electroporation method (Gene 
Pulser Xcell Electroporation System, Bio-Rad) 
[7]. The Pichia transformants were spread on 
YPDS agar plates containing 100 µg/mL zeocin. 
To obtain high stability and multi-copies gene 
integration clones, the Pichia clones that grew 
on zeocin selection plates were recultured in 
fresh YPD-zeocin agar plates with multilevel 
concentration of zeocin (0-1000 µg/mL). To 
confirm the integration of scFv gene in the 
Figure 1. A. PCR colony analysis of E. coli TOP10F ‘ transformant. Positive clone of E. coli transformant for scFv 
genes were indicated by a 750 bp DNA band. Lane M = 1 kb DNA marker. Lane 1: positive control (pJ201-scFv). 
Lane 2: negative control (pJ912-Agα). Lane 3-8: positive clone containing scFv gene. B. Restriction analysis of 
a recombinant plasmid with SalI. The recombinant plasmid realeases the insert scFv genes (750 bp) after SalI 
restriction. Lane M: 1kb DNA marker. Lane 1: negative plasmid (pJ912-Agα). Lane 2: recombinant plasmid (pJ912-
Agα-scFv).
amplification. The amplified product was di-
gested by SalI  and inserted into the cassette 
vector pJ912-AGα at the SalI site. The scFv 
gene in the recombinant vector was ana-
lyzed by colony-PCR using primers: VH101-
SalI forward and VL101-SalI reverse. Gene 
orientation was analysis using primers: AOX1 
forward (5’-GACTGGTTCCAATTGAC AAGC-3’) 
and VH101 reverse (5’-AGACGACACTGTTA 
CCAGCGT-3’). The vector was also and ana-
lyzed by restriction digest using SalI.  The final 
conctruct of recombinant scFv plasmids was 
named as pJ912-AGα-scFv.
A
yeast genome, transformant clones were am-
plified by colony PCR using the VH101 forward 
and VL101 reverse primers. 
Expression Analysis of the Fusion Protein
Some colonies of recombinant P. pastoris 
were cultured in YPD containing zeocin (100 
µg/mL) and incubated at room temperature 
(30°C) for 48 hours. Next, the cultures were 
transferred into a fresh BMGY medium and 
incubated at (30°C) for 24 hours. The cells cul-
ture BMGY were harvested by centrifugation 
and supernatant was removed. BMMY was 
added to the cell pellet at an OD600 = 1. Next, 
methanol was added into the culture to give 
0.5% (v/v) 
208
every 12 h of culture for 72 h to induce pro-
tein expression. Fluorescence microscopy was 
employed to observe directly the expression 
of active reporter protein (TagRFP) that should 
be displayed on the cell surface of P. pastoris. 
The induced cultures of P. pastoris were spot-
ted on microscope slides. Fluorescence was 
detected with Leica DM1000 fluorescence 
microscope using N2.1 filter cube (exitation at 
515-560 nm, emission > 590 nm).
RESULT AND DISCUSSION
Vector Construction for Yeast Surface Display
The antiEGFRvIII-scFv gene was fused in-frame 
with α factor signal peptide at 5’ –end and 
TaqRFP::AGα gene at 3’ –end under control 
of inducible AOX1 promotor. The open read-
ing frame (ORF) of antiEGFRvIII-scFv gene 
was fused C-terminally to the ORF of TaqRFP 
gene. Taq RFP is a red fluorescence protein 
that would facilitate observation of the tar-
get protein expression from the host cells. To 
display antiEGFRvIII-scFv and Taq RFP protein 
on the cell surface of P.pastoris, the 3’-half of 
the AGα1 gene of            S. cerevisiae was 
fused N-terminally to the TaqRFP gene. This 
costruct was cloned into SalI site in pJ912-
AGα. To screen E. coli transformant having re-
combinant plasmids with scFv insert, colony-
PCR method was carried out. Figure 1 shows 
screening of E.coli transformant having the 
recombinant plasmids. Positive clones hav-
ing scFv gene showed a DNA band at 750 bp. 
These positive clones were futher analyzed 
for the gene orientation. Nearly all of those 
clone showed a correct orientation (data not 
showed). Furthermore, several plasmids with 
correct construction was verified by DNA se-
quencing (data not shown). 
Screening P.pastoris Transformant
Vectors with and without scFv gene were 
transformed into P. pastoris SMD1168H as 
described above giving the novel strain of 
P.pastoris pJ912-AGα and P. pastoris pJ912-
AGα-scFv. Genomic DNA analysis showed that 
the scFv gene had been integrated into the 
chromosomal DNA of P. pastoris pJ912-AGα-
scFv (Fig. 2). 
Selection of transformants on zeocin medium 
needs to be done to have genetically stable 
transformants and potentially to have multico-
py gene integrant. The level of antibiotic resis-
tance will reflect the number of the recombi-
nant gene dosage that has been incorporated 
into the yeast genome. P. pastoris expression 
vector carry Sh ble gene which encodes a pro-
tein conferring resistance towards zeocin. An 
increased number of inserted sequence (plas-
mids) can indeed enhance expression of  the 
heterologous protein. In this study, selection 
on varying antibiotic concentrations was ap-
plied with zeocin concentration of 0, 100, 200, 
500 and 1000 µg/mL. All of transformants of 
P. pastoris pJ912-AGα and P. pastoris pJ912-
AGα-scFv could grow on zeocin medium up to 
1000 µg/mL whereas non transformant strain 
of P. pastoris SMD1168H could not grow on 
zeocin medium.
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Figure 2. PCR colony analysis of P. pastoris transformant and non transformant clones. P. pastoris 
pJ912-AGα-scFv positive clones showed by a DNA band at 750 bp. Lane M= 1 kb DNA marker. Lane 
1: positive control (pJ912-AGα-scFv). Lane 2: negative control (P. pastoris SMD1168H non trans-
formant). Lane 3-6: P. pastoris pJ912-AGα-scFv positive clones containing scFv gene. Lane 7-9: P. 
pastoris pJ912-AGα transformant clones without scFv gene.
Figure 2. PCR colony analysis of P. pastoris transfor-
mant and non transformant clones. P. pastoris pJ912-
AGα-scFv positive clones showed by a DNA band at 
750 bp. Lane M= 1 kb DNA marker. Lane 1: positive 
control (pJ912-AGα-scFv). Lane 2: negative control 
(P. pastoris SMD1168H non transformant). Lane 3-6: 
P. pastoris pJ912-AGα-scFv positive clones containing 
scFv gene. Lane 7-9: P. pastoris pJ912-AGα transfor-
mant clones without scFv gene.
Expression of Fusion Protein on Surface of Pi-
chia pastoris 
To verify the expression efficiency of fusion 
protein  on the cell surface, pJ912-AGα plas-
mid was designed in fusion with TagRFP that is 
used as a reporter protein. The successful dis-
play of Tag RFP on the cell surface of P. pasto-
ris was confirmed by fluorescence microscopy. 
After induction of gene expression using meth-
anol, both P. pastoris transformants (P. pasto-
ris pJ912-AGα and P. pastoris pJ912-AGα-scFv) 
have been observed to successfully expressed 
TagRFP under fluorescence microscope obser-
vation. On the other hand, non-transformant 
strain of P. pastoris SMD1168H showed no flu-
orescence at all (Fig. 4). These results strongly 
suggest that the recombinant fusion anti-EG-
FRvIII scFv protein including TagRFP had been 
successfully expressed on the cell surface of P. 
pastoris. Fusion with a fluorescence protein 
has been a popular choice for recombinant 
protein expression since the expressed re-
combinant protein is easly observed by visual 
means using a microscope fluorescent. Pro-
tein fusion with a fluorescence protein could 
also be applied to study other than protein ex-
pression, such as protein localization, protein 
translocation, interaction between proteins 
or degradation of the fusion protein in the 
cell. Fluorescent protein monomers such as 
TagRFP is generally able to function properly 
even after fusion with other proteins [3]. A 
GPI anchor attachment domain located in the 
3’-half region of α-agglutinin functioned to 
binds and localizes this fusion protein into the 
cell wall structure. Binding of the GPI-anchor 
domain was facilitated by covalent binding to 
the carbohydrate moieties of the yeast cell 
wall structure, resulting a very stable protein 
attachment on the cell surface. The reporter 
system on the cell surface developed in this 
work will have a much more powerful ability 
to detect molecular events inside or outside 
living cells than the system in which the re-
porters were expressed inside the cells. This 
yeast display system is very useful for the de-
velopment an antibody screening method, in 
which a cDNA library of any antibody could be 
expressed on the surface of yeast cell and the 
gene of this antibody could be retrieved back 
from the yeast genome. 
CONCLUSION
The recombinant vector pJ912-AGα-scFv has 
been constructed and successfully trans-
formed into P.pastoris SMD1168H. This re-
combinant vector was stably integrated into 
the genome of P. pastoris SMD1168H through 
homologous recombination. Stable trans-
formed yeast has been obtained through se-
lection on zeocin medium. Observation using 
fluorescence microscopy has demonstrated 
that the transformant cells successfully emit
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ted red fluorescence light derived from func-
tionally expressed TagRFP, which is actually 
part of the fusion molecules. It suggests that 
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INTRODUCTION
Granulocyte Colony-Stimulating Factor (G-
CSF) is a protein that stimulates the formation 
and maturation white blood cells, especially 
neutrophils (Leischke, 1994). The protein con-
sists of 174 or 177 amino acid with molecular 
weight of 19.6 kDa. G-CSF also has an O-glyco-
sylation site to protect the protein from coag-
ulation without affecting binding to its recep-
tor. G-CSF is important for the formation and 
maturation of neutrophils and is widely used 
by patients with neutropenia. Therefore, this 
protein G-CSF had been used for more than 2 
decades as therapeutic produced by recombi-
nant way (Lieschke, 1994).
G-CSF is encoded by csf3 gene located on chro-
mosome no. 17 loci q21 - q22 (Nagata et al., 
1986; Hill et al., 1993). Lasnik (2001) and Bah-
rami  (2007), have been successfully subclone 
csf3 gene into pPIC9 and expressed in Pichia 
pastoris GS-115. However, they used c-DNA-
derived csf3 gene to produce recombinant G-
CSF.  In this study, we reported subcloning of 
csf3syn synthetic gene in pGAPZα expression 
vector and transformation of the recombinant 
vector into P. pastoris.  The gene had been syn-
thesized previously by a PCR-based method 
and cloned in a cloning vector pTZ57R/T (Fuad 
et.al, 2009).  The csf3syn gene has been codon 
optimized for efficient expression in P. pasto-
ris. 
MATERIALS AND METHODS
Construction of pGAPZα-CSF3ye-I (Type I Re-
combinant Vector)
Synthetic gene csf3syn had been cloned pre-
viously in the cloning vector pTZ57R/T.  The 
gene was separated from the vector by diges-
tion with enzyme XhoI.  Expression plasmid 
pGAPZα [Invitrogen] was digested with en-
zyme XhoI. Furthermore, the gene was ligated 
with pGAPZα using T4 DNA ligase [Fermentas]. 
The recombinant vector was transformed into 
E.coli XL1-Blue. Transformation was carried 
out using Transform Aid™ Bacterial Transfor-
mation Kit [Fermentas]. Transformants were 
grown in Low Salt Luria Bertani agar medium 
(LS--LB) containing zeocin 25 µg/ml [Invitro-
gen] and pH 7.5. LS--LB agar medium consists 
of 1% trypton, 0,5% yeast extract, 0,5% NaCl, 
and 1,7% agar. Transformants were verified 
using PCR, plasmid restriction, and DNA se-
quencing. Positive clones were PCR-verified 
using pGAP forward and AOX1 reverse prim-
ers and recombinant vectors were purified 
prior to DNA sequencing analysis.  Figure 1 
(A) shows the construct of pGAPZα-CSFye-I 
(named as type I recombinant vector).
Construction of pGAPZα-CSF3ye-II (Type II 
Recombinant Vector)
pGAPZα-CSF3ye-II (named as Type II recom-
binant vector) was obtained by digesting type 
I recombinant vector with SalI restriction en-
zyme [Fermentas].  In this process DNA frag-
ment located between 2 site of SalI on type I 
recombinant vector were removed so that the 
3’-end of csf3syn gene was directly fused with 
6xHis Tag.  Furthermore, the recombinant vec-
tor was religated using T4 DNA ligase [Fermen-
tas] and transformed into E. Coli XL1-Blue.  
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Transformants were verified by plasmid re-
striction method.  First, transformant plasmids 
were digested with XhoI that cut the plasmid 
once and makes linear vector from the correct 
vectors.  Second, transformant plasmids were 
digested with EcoRI that do not from the cor-
rect recombinant vector. Figure 1 (B) shows 
the construc of type II recombinant vector 
(pGAPZα-CSF3ye-II).
Transformation  of Type II  Recombinant vector 
(pGAPZα-CSF3ye-II)  into Pichia pastoris
PGAPZα-CSF3ye-II vector was digested BspHI, 
so the plasmid become linier.  Linear plasmid 
would facilitate integration of the vector into P. 
pastoris genome. The            P. pastoris compe-
tent cell was prepared according to the meth-
od of invitrogen (2008:17).  Transformation of 
recombinant vector into P. pastoris was carried 
out using electroporation method (Invitrogen 
2008:18).  Transformants were grown in YPDS 
agar plates (yeast extract, peptone,  dextrose, 
agar, sorbitol) containing zeocin (100 µg/ml) 
[Invitrogen].  The  plates was incubated at 30° 
C for 2-3 days until colonies formed. Transfor-
mants colonies that grew on YPD agar plates 
(yeast extract, peptone, dextrose) containing 
zeocin  at 200 µg/ml and 1000 µg/ml.
RESULT AND DISCUSSION
Construction of Type I Recombinant vector 
(pGAPZα-CSF3ye-I)
Figure 1.  Construct of pGAPZα-CSF3ye-I (type I) vector 
(A) and pGAPZα-CSF3ye-II (type II) vector (B).
The csf3syn  gene used in this research  was 
PCR amplified from pTZ57R_CSF3ye_PR3_005 
clone.  The gene was ligated with pGAPZα li-
nier using T4 DNA ligase. Insert DNA and plas-
mid used in ligation reaction were 1 : 2.  The 
ligation reaction was transformed into E.coli 
XL1-Blue. A number of 30 transformant colo-
nies were obtained LS--LB agar medium con-
taining zeocin 25 µg/ml.
Verification of  the target gene in recom-
binant vectors was carried out using PCR 
method. Transformants  were grown in LS--LB 
liquid medium containing zeocin (25 µg/ml) 
for plasmid isolation. The clones were PCR-
amplified with AF_1 forward and PR3_CSFye 
reverse primers. Positive clones showed PCR 
product (around 567 bp).  Figure 2 shows PCR 
results of several clones that were amplified 
gene specific primers.  A number of 10 posi-
tive clones were obtained out of 15 clones. 
The positive recombinant vectors show a DNA 
band because they have the target gene (cs-
f3syn) that are recognized by AF_1 forward 
and PR3_CSF3ye reverse primers.  Both prim-
ers are specific to csf3syn gene. 
Gene orientation in recombinant vectors 
were also verified using PCR method. Proper 
orientation was achieved when the 5’-end of 
csf3syn gene fused with α-factor secretion 
signal and the 3’-end fused with restriction 
sites. Positive clones that were previously ob-
tained were amplified with AF_1 forward and 
AOX1 reverse primers. AF_1 forward attached 
to the 5’-end of csf3syn gene and AOX1 re-
verse primer attached to the termination 
sequence (AOX1-TT) as part of pGAPZα back-
bone. Inserted gene with correct orientation 
would produce a 825 bp of DNA fragment us-
ing those pair of primers.  Figure 3 shows 4 
positive clones out of 8 that were succesfully 
obtained.
Verification of recombinant vectors were also 
carried out by plasmid digestion method. 
Clones that have been verified with PCR 
214
method were digested with XhoI. This en-
zyme was used because the XhoI restriction 
site were found in both the 5’-end and the 
3’-end of csf3syn gene.  Those clones showed 
that the gene (csf3syn) of 567 bp was cleaved 
out after digestion.  Figure 4 shows 4 positive 
clones out of 4 gave a DNA band after diges-
tion with XhoI. 
Three positive vectors have been choosed 
and sequenced. DNA sequencing analysis con-
firmed that the sequence of csf3syn gene in re-
combinant vectors was similiar with sequence 
of csf3syn gene that has been constructed pre-
viously (Fuad et al., 2009). It also showeds that 
the 5’-end of csf3syn gene has been correctly 
fused with α-factor signal (Figure 5A), whereas 
the 3’-end of the gene contain SalI site and 
stop codon (Figure 5B). The gene sequence 
was not fused with 6xHis Tag in this pGAPZα-
CSF3ye-I vector. This recombinant vector was 
used for the construction of pGAPZα-CSF3ye-II 
(type II) vector.
method were digested with XhoI. This en-
zyme was used because the XhoI restriction 
site were found in both the 5’-end and the 
3’-end of csf3syn gene.  Those clones showed 
that the gene (csf3syn) of 567 bp was cleaved 
out after digestion.  Figure 4 shows 4 positive 
clones out of 4 gave a DNA band after diges-
tion with XhoI. 
Three positive vectors have been choosed 
and sequenced. DNA sequencing analysis con-
firmed that the sequence of csf3syn gene in re-
combinant vectors was similiar with sequence 
of csf3syn gene that has been constructed pre-
viously (Fuad et al., 2009). It also showeds that 
the 5’-end of csf3syn gene has been correctly 
fused with α-factor signal (Figure 5A), whereas 
the 3’-end of the gene contain SalI site and 
stop codon (Figure 5B). The gene sequence 
was not fused with 6xHis Tag in this pGAPZα-
CSF3ye-I vector. This recombinant vector was 
used for the construction of pGAPZα-CSF3ye-II 
(type II) vector.
Figure 5.  Sequence analysis of pGAPZα-
CSF3ye-I (type I) vector at the 5’-end (A) and 
the 3’-end (B)
Construction of Type I Recombinant vector 
(pGAPZα-CSF3ye-I) 
pGAPZα-CSF3ye-II recombinant vector is a 
vector in which the 3’-end of csf3syn gene was 
fused with 6xHis Tag. This type II recombinant 
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Figure 6.  Verification of type II recombinant 
vectors by restriction analysis.  The recom-
binant vectors  were digested with XhoI (A). 
The recombinant vectors were digested with 
EcoRI (B)
vector was made by digesting previously con-
struct type I recombinant vector with SalI.  The 
plasmid that have been digested and purified 
was religated using T4 DNA ligase and then 
transformed into  E. coli XL1-Blue. Transforma-
tion into E.coli produce a number of 190 colo-
nies that were grown in LS--LB agar medium 
containing zeocin (25 µg/ml).
pGAPZα-CSF3ye-II recombinant construct 
were verified by restriction analysis.  Plasmid 
restriction was perfomed in 2 different reac-
tions, the first reaction using XhoI and the sec-
ond reaction using EcoRI. Positive construct of 
type II recombinant vector would produce  a 
single DNA band 3,530 bp (Figure  6 A) after 
digestion with XhoI and no restriction occured 
with EcoRI (Figure 6B). Figure 6A shows  9 posi-
tive vectors out of 10 were obtained. The type 
II recombinant vector has one XhoI site left in 
the plasmid backbone.  Therefore, restriction 
with XhoI will produce a linear plasmid.
Type II recombinant vector was derived from 
type I vector constructed after plasmid restric-
tion with SalI.  This process led to removal 
of some restriction site including EcoRI. The 
correct type II plasmids are not affected by 
restriction with EcoRI.  Therefore, the type II 
recombinant vector would show as indigested 
plasmid pattern when digested with EcoRI (Fig-
ure 6B). The result shows 9 positive clones out 
of 10 were obtained.  Figure 6B (Lane 2) shows 
pGAPZα plasmid that was digested with EcoRI. 
Plasmid pGAPZα has one unique EcoRI restric-
tion site (Invitrogen, 2008).
Two positive recombinant vector were choose 
and sequenced. The result of DNA sequencing 
analysis showed that sequence of csf3syn gen 
was correct and no mutation was observed. 
The sequencing analysis showed that the 5’-
end of csf3syn has been fused in-frame with 
α-factor signal (Figure 7A) and the 3’-end of cs-
f3syn gene also fused in-frame with 6xHis Tag 
(Figure 7B)
Transformation of Type II Recombinant Vec-
tor (pGAPZα-CSF3ye-II) into P. pastoris
Type II recombinant vector  (pGAPZα-CSF3ye-
II) was transformed into P. pastoris in order to 
express recombinant G-SCF an eukaryot ex-
pression system.               P. pastoris was used 
in this research for its ability to produce com-
plex protein and high yield protein.  Yeast sys-
tem is also known to enable post-translational 
modification process, such as protein folding, 
glycosylation and disulphide bond formation 
(Glick & Pasternak, 2003).
The recombinant plasmid pGAPZα-CSF3ye-II 
was digested with BspHI to form linear plas-
mid before transformation. The BspHI was 
Figure 7. Sequence analysis of pGAPZα-
CSF3ye-II (type II) vector at the 5’-end (A) and 
the 3’-end (B).
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used in this purpose since it cut once within 
the promotor region of pGAP in the recombi-
nant vector, so the vector become linear  (In-
vitrogen, 2008). Linearisation of the plasmid 
aims to facilitate the integration of recombi-
nant vector into P. pastoris  genome.  Accord-
ing to Glick & Pasternak (2003),  plasmid can 
be integrated into the host genome, if those 
plasmids have any sequence that comple-
mented with the host genome. The recombi-
nant pGAPZα-CSF3ye-II plasmid was designed 
to be integrated into GAP promoter sequence 
of the P.pastoris genome.  The GAP promoter is 
a promoter that drive glyceraldehyde-3-phos-
phate-dehydrogenase (GAP) gene (Gellisen, 
2005).  
Plasmid was transformed into P. pastoris using 
electroporation method (Invitrogen, 2008). 
The method is used because it doesn’t destroy 
the host cell or limit the cell damage.  Electro-
poration technique uses an electric shock to 
open the pores of the cell membrane.  Elec-
tric shock caused the gap in membrane cell 
which permit the DNA can go through to the 
cell membrane and the gap in the cell mem-
brane will be closed again (Wong, 1997). Fig-
ure 8A shows competent cells as control that 
grew well on the YPDS agar medium after elec-
troporation. This result indicates that cell has 
a good quality after elctric shock. Figure 8B 
shows transformant colonies that grew well 
on YPDS medium containing zeocin (100 µg/
ml).  Transformation efficiency obtained was 
4.9 x 103 cfu/µg plasmid DNA.  This transfor-
mation efficiency is fair enough if compared 
to the protocol given by invitrogen, which 
mentioned that tranformation efficiency could 
reach 103 to 104 cfu/µg plasmid DNA using 
this plasmid system.
Transformant colonies were grown on YPD agar 
plates containing higher zeocin concentration 
(200 µg/ml and 1,000 µg/ml).  This was carried 
out to assay the stability of transformant colo-
nies well as to screen colonies having multiple 
gene integration. It was observed that 85.5% 
of transformant colonies grew well on YPD 
agar medium containing 200 µg/ml zeocin (Ta-
ble 1).  It means that 85.5% of those colonies 
were stable transformnts. When the screening 
was continued using medium containing 1,000 
µg/ml zeocin, it showed that 96% of the trans-
formant colonies that grew well on YPD agar 
medium containing 1,000 µg/ml zeocin (Table 
1).  This result indicates that transformant col-
onies have high stability against antibiotic zeo-
cin and allegedly had multicopy gene.  Recom-
binant clones that have been obtained would 
be used as prodecer strain for expression of 
csf3syn gene in P. pastoris. 
Table 1.  Stability assay of P. pastoris  transfor-
mant colonies on medium containing higher 
zeocin concentration
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CONCLUSION
The csf3syn gene was successfully subcloned 
into pGAPZα and produce two versions of re-
combinant vector, pGAPZα-CSF3ye-I (no fusion 
with 6xHis Tag) and pGAPZα-CSF3ye-II (fusion 
with 6xHis Tag). The pGAPZα-CSFye-II has been 
successfully transformed into P. pastoris with 
transformation efficiency of 4.9x103 cfu/µg 
plasmid DNA.
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INTRODUCTION
The pericarp of the mangosteen fruit (Garcinia 
mangostana L.) containing xanthon which has 
many benefits, one of them as an antioxidant 
(Subroto 2008). Based on previous studies 
showed that 5% viscous extract of pericarp 
of mangosteen (Garcinia mangostana L.) as a 
potent antioxidant (Trifena 2012). Viscous ex-
tract of pericarp of mangosteen formulated in 
a cream-type oil in water (O / W). To stabilize 
the cream-type O / W required the addition of 
an emulsifier, more easily by using a combina-
tion of hydrophilic surfactant and lipophilic 
surfactant (Lachman et al., 1994).
In this study, the viscous extract of pericarp 
mangosteen made into a cream dosage form 
by using a combination of Tween 80 and Span 
80 as emulsifier with different concentrations 
in each formula. This study aims to determine 
the concentration of combination between 
Tween 80 and Span 80 as an emulsifier in a 
cream formula of  the viscous extract of peri-
carp mangosteen which fulfill physical stabil-
ity.
MATERIALS AND METHOD
Materials 
Dry extract of pericarp mangosteen (PT. Boro-
budur Semarang), H2SO4p (pa), FeCl3, etha-
nol 70%, cetyl alcohol (Cognis), paraffin oil, 
white petroleum (Merkur), methyl paraben, 
propyl paraben (Gujarat), butyl hydroxy tolu-
ene (BHT) (SPP Chemical), Tween 80 (Kao Co.), 
Span 80, propylene glykol (Dow Chemical Co.) 
and aquadest.
Preparation and Evaluation of the Viscous Ex-
tract of Pericarp Mangosteen
The powder dry extract of pericarp mango-
steen macerated using 70% ethanol. Then 
maserat thickened by using a rotary evapora-
tor at a temperature of 60°C to obtain a vis-
cous extract. Characteristic evaluation to vis-
cous extract of pericarp mangosteen (VEPM) 
include organoleptic test, loss on drying, vis-
cosity and flavonoid.
Preparation of Cream
Preparation of oil phase : cetyl alcohol, white 
petroleum, paraffin oil, span 80, propyl para-
ben, and BHT melted at water bath until the 
temperature reaches above 70º- 72ºC. Then 
the manufacturing of water phase : methyl 
paraben, Tween 80, and propylene glycol di-
luted with distilled water and heated until the 
temperature reaches 70ºC - 72ºC. Further-
more phase of water mixed with the oil phase 
at a temperature of 70ºC - 72ºC then homoge-
nized using a mixer until the homegen creamy 
base obtained with  40ºC temperature. To 
the base is added viscous extract of pericarp 
mangosteen, then homogenized again to form 
a homogenous cream dosage form. Evaluate 
the cream of viscous extract of pericarp man-
gosteen.
Table 10. Cream Formulas of Viscous Extract of Peri-
carp Mangosteen.
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Evaluation the Cream of Viscous Extract of 
Pericarp Mangosteen 
Evaluation cream consists of organoleptic test, 
homogeneity, pH, viscosity, flow properties, 
emulsion type, and test phase separation with 
freeze-thaw and centrifugation method. Data 
analysis of the results of the pH and viscosity 
measurements using 2-way ANOVA to see any 
difference of each formula. 
RESULTS AND DISCUSSION
Evaluation of the Viscous Extract of Pericarp 
Mangosteen
Characteristic of viscous extract of pericarp 
mangosteen were has dark brown color, loss 
on drying at 30.84%, viscosity at 9500 cps us-
ing spindle numbered 6 at 20 rpm and positive 
contain flavonoids. 
Evaluation the Cream of Viscous Extract of 
Pericarp Mangosteen 
Organoleptic and homogeneity test of the 
cream indicates that the storage of the cream 
for 6 weeks did not change the color, consis-
tency, odor and remain homogeneous.
Results of pH measurements for 6 weeks 
showed that there were difference between 
the fifth creamy formula, but the difference 
was not significant by 2-way ANOVA statisti-
cal analysis that obtained sig 0.164 > α of 0.05, 
so it can be said that the fifth formula cream 
were stable. Values of pH were obtained from 
the fifth formula is within the normal pH of the 
skin is 4,5 to 6,5.
Test the cream-type performed by coloring 
method using methylene blue solution. Meth-
ylene blue is water soluble so that when meth-
ylene blue solution mixed in the cream with 
the type of O / W, it directly mixed with water 
and spread evenly on the cream. From the test 
results of the five formulas, the resulting type 
of cream is a cream-type O / W, because af-
ter adding methylene blue then blue color is 
uniformly dispersed in the cream. There were 
no change of the type of cream during storage 
time and an increase in the concentration of 
combination between Tween 80 and Span 80 
(1: 1) does not affect the type of cream.
Viscosity measurements for 6 weeks per-
formed using Brookfield viscometer-type 
RVDVE with spindle number 6 at a speed of 
10 rpm. Based on Figure 2 shows that there 
is an increasing viscosity on the fifth formulas 
with increasing storage time. Viscosity value is 
different in each formula. The higher of con-
centration of combination between Tween 80 
and Span 80 (1: 1) used in the formula pro-
duces a more viscous cream and the higher 
of the viscosity value. The higher viscosity 
will decrease the rate of precipitation due to 
the climate of the movement of particles of a 
material tends to be difficult so that the ten-
dency to join the dispersed phase becomes 
smaller and more stable emulsion. Stokes law 
shows that the rate of separation formation 
is inversely proportional to viscosity, generally 
increase the viscosity will minimize the occur-
rence of creaming or separation so as to im-
prove the stability of the cream (Kim, 2004).
Two-way ANOVA test results on viscosity data 
based on concentration (formula) and storage 
time showed the value of sig 0.000 < α 0.05, 
which indicates that the value of the viscos-
ity on the fifth formulas and at storage time 
has significant differences. Tukey test results 
against concentration (formula) that there 
are significant differences in the viscosity of 
each formula, and the results of Tukey’s test 
against the storage time is significantly differ-
ent in each week of storage means storage 
time affects the viscosity value.
Figure 1.  The Results of pH Measurement
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Figure 2.  The Results of Viscosity Measurement
Rheology curve created using data between 
torque (dyne/cm2) and sliding speed (rpm) 
(Triantafillopoulus 1988), it can be concluded 
that the five-cream formula has thixotropic 
plastic flow properties. Determination of 
the nature of plastic flow because the curve 
does not start from the point (0,0) but cut the 
shearing stress axis, or be cut off if the straight 
part of the curve is extrapolated to the axis 
at a certain point, known as the yield value. 
The existence of a yield value due to the con-
tact between adjacent particles that must be 
broken down first so that preparations flows 
(Martin et al., 1993).
The five creams also have thixotropic flow 
properties due to the curve looks curves down 
to the left of the curve up, it shows the cream 
has a lower viscosity at all shear rates on the 
curve down. This is due to the breakdown 
structure is not formed again immediately if 
the stress is removed or reduced (Martin et 
al., 1993). Flow properties of the fifth formula 
from week 0 to sixth week were unchanged. 
Test phase separation with freeze-thaw meth-
od performed a total of 6 cycles (Lachman et 
al., 1994). Testing is done by storage at two 
different temperatures is 4°C and 45°C re-
spectively for 48 hours. The results of these 
tests showed that there is a separation of For-
mula 1 at the time of cycle 4, and Formula 2 
separation occurs during cycle 5. Separation 
that occurs is indicated by the formation of 
two layers of cream. This occurs due to tem-
perature changes can alter the density of the 
particles. The larger the particle density differ-
ence between the two phases, the easier it is 
to join together the dispersed phase so that 
the larger the oil balls are formed and decreas-
ing the viscosity of the external phase, so that 
the greater the rate of creaming (Martin et al., 
1993). Meanwhile, Formula 3, Formula 4 and 
Formula 5 did not occur phase separation so 
that the cream can be said to be stable at cold 
and hot temperatures during storage. Separa-
tion that occurs can be influenced by the con-
centration of emulsifier. If a high enough con-
centration of emulsifier, emulsifier will form a 
rigid layer between the phases, which act as a 
barrier to the merger of the emulsion droplets 
(Lachman et al., 1994). 
Test phase separation by centrifugation meth-
od, performed at a speed of 3750 rpm for 5 
hours (Lachman et al., 1994). Based on Table 2 
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shows the fifth formula cream had separation 
but the high separation in each formula were 
different forms. The higher the concentration 
of combination between Tween 80 and Span 
80 (1: 1) were used resulting in lower sedimen-
tation. This happens because the higher con-
centration of emulsifier were used, the ability 
to form a film coating will be greater so as to 
minimize the occurrence of phase separation. 
CONCLUSION
Increasing the concentration of combination 
between Tween 80 and Span 80 (1: 1) can 
increase the viscosity of the cream so as to 
minimize the occurrence of phase separation, 
thereby improving physical stabillity cream of 
viscous extract of pericarp mangosteen (Gar-
cinia mangostana L.). Formula cream of vis-
cous extract of pericarp mangosteen that fulfill 
the physical stability is a cream formula with a 
concentration of combination between Tween 
80 and Span 80 (1: 1) by 10% of the concentra-
tion range 2-10%.
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INTRODUCTION
Chitosan, a cationic polysaccharide has many 
advantages as carrier for drug delivery system 
such as biocompatible, biodegradable and 
non toxic.Chitosan has amino group that could 
be crosslinked with polianion such as tripoly-
phosphate so that the active ingredient will 
be entrapped  (Agnihotri, 2004, Sinha, 2004). 
Diterpene lactone fraction of sambiloto (An-
drographis paniculata) has antimalarial activ-
ity but it has low solubility in water. Entrapped 
diterpene lactone into chitosan matrix could 
improve the bioavailability of the active sub-
stance.   
The  aim of this  research is to  investigate the 
effect of process parameter of chitosan carrier 
preparation : stirring rate (500 rpm and 1000 
rpm) during ionic gelation and nozzle diam-
eter (0.5 mm and 1.0 mm) of spray dryer on 
physical characteristics of diterpene lactone 
fraction-chitosan particles. Evaluation of mor-
phology, thermal analysis and drug entrap-
ment were conducted.
EXPERIMENTAL METHODS
Material and Methods
Material
Diterpene lactone fraction of sambiloto was 
obtained from Department of Pharmacognosy 
and Phytochemistry, Faculty of Pharmacy, Air-
langga University, chitosan  with deacetylation 
degree 85% was purchased from Biotech Su-
rindo, Natrium tripolyphosphate, pro analysis 
grade from Nacalay Tesque. All other reagents 
used in this experiment were pro analysis 
grade.  
Preparation of chitosan particles
Chitosan wasdissolved chitosan inof 0,15% 
acetic acid to make 0,1% chitosan solution. 
Preparation of diterpen lactone - chitosan 
particles was done by mixing chitosan solu-
tion and diterpene lactone fraction solution 
and then 0,1%tripolyphosphatesolution was 
added while stirring with two stirring speed.. 
The mixture was continuously stirred with 
magnetic stirrer for 2 hours.Subsequentlythe 
mixture wasdriedwithLabplantSD-Basic Spray 
Dryerat 100°C, flow rate 5 ml/min, pressure 2 
bar with two different nozzle diameter.The ra-
tio of drug-chitosan-TPP was 4:10:8. 
Evaluation ofnanoparticlesmorphology
The particles was evaluated by Scanning Elec-
tron Microscopy (SEM) FEI Inspect S50. Par-
ticles were dried and coated with gold pal-
ladium and then observed for its  shape and 
surface morphology.
Thermal analysis
Thermal analysis for diterpen lactone fraction 
of sambiloto, chitosan and nanoparticles was 
performed with Differential Thermal Analyz-
er (DTA) Metler Toledo FP 85. Samples were 
scanned from 50to 250°C at a rate of 10°C/
min. 
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Sem photograph of particles diterpene lactone 
- chitosan (figure 1) showed that the particles 
have  spherical shape  and smooth surface 
with wide range particle size.
From DTAthermogram (Figure 2) it was indi-
cated that endothermic peak of diterpene 
lactone appears at 222 °C and chitosan glass 
transition appears at 146.6 °C. Endothermic 
peak of diterpene lactone fraction was no lon-
ger exist in chitosan particulate system since it 
had been entrapped in chitosan matrix. 
Entrapment efficiency (EE)
5 mg sample was dissolved in10mlof ethanol-
thenfiltered. Solution wasanalyzedbyHPLCAgi-
lent1100with mobile phaseof methanol: phos-
phoricacidpH3=50: 50at wavelength of228nm. 
The assayswere performed in triplicate. The 
entrapment efficiency (EE) of diterpenelac-
tone in chitosan nanoparticles was calculated 
by this equation :
EE = (actual drug/theoritically drug) x 100%
FTIR analysis was performed to confirm the 
crosslink interaction of chitosan and tripoly-
phosphate. Absorption band at 1643 cm-1 at-
tributed to amide bond of chitosan.New band 
at 1555 cm-1 indicated hydrogen bond and 
1643 cm-1 band confirmed linkage between 
P3O5-5 of tripolyphosphate and NH3+ of chi-
tosan (Figure 3).  
From drug entrapment efficiency, it was 
known that as  stirring speed increased from 
500 rpm to 1000 rpm,  the entrapment of 
drug become lower decrease from  about 24-
26% to 21% (Table 2). From statistical analysis 
of one way Anova with α 0.05,  it was known 
that drug entrapment efficiency of particles 
prepared with different stirring rate was  sig-
nificantly difference since nozzle diameter 
didn’t affect  the entrapment efficiency.
RESULTS
Figure 1 SEM micrographs of particles of diterpene 
lactone-chitosan prepared with different condition 
(mag 10.000x)
Figure 3. FTIR spectra of diterpene lactone (A), tripoly-
phosphate (B), chitosan (C), diterpen lactone-chitosan 
particles (D)
Table 2. Drug content  and Entrapment Efficiency (EE) 
of diterpen lactone- chitosan particles  (n=3)
Figure 2. DTA thermogram of  diterpene lactone (A), chitosan 
(B) and diterpene lactone-chitosan particles (C)
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CONCLUSION
The result showed that diterpen lactone – 
chitosan particles prepared by ionic gelation-
spray drying  withcomposition and condition 
in this study has spherical shape with wide 
range size from 400 nm to 4000 nm. Highest 
drug entrapment efficiency was  obtained 
from particles prepared with 500 rpm stirring 
rate and  1,0 mm nozzle diameter. 
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INTRODUCTION
The use of pesticides can leave residues that 
may cause pollution of the environment and 
human health problems1. It is necessary to 
supervise the use of pesticides through the 
fulfillment of the MRL (Maximum Residue Lim-
its). And so as to ensure food safety by limit-
ing the levels of pesticide residues, including 
organophosphate and organochlorine, in food 
commodities.
Organophosphate is a toxic compound that 
affect the nervous system in a way disrupt 
enzyme that regulates acetylcholine, a neu-
rotransmitter that is necessary for our nerves 
can work normally. In general, organophos-
phate pesticides are not persistent both in the 
environment and in living organisms, including 
plants. Consequently, to obtains the necessary 
level of effective pesticides, farmers spraying 
with increasing frequency. Organochlorine 
compounds are non-volatile, insoluble in wa-
ter, except for lindane, easily soluble in organic 
solvents, persistent in the environment, while 
in plant tissues undergo biotransformation 
into metabolites that can be toxic.
Samples of food, such as vegetables and fruit, 
has a very complex matrices that requires 
optimal, accurate, economical, and efficient 
extraction procedure for routine analysis. 
Various extraction procedures organochlorine 
and organophosphates pesticides have been 
published in scientific articles and to achieves 
the level of very small concentration of the 
residue, chromatographic methods such as 
High Performance Liquid Chromatography 
(HPLC) or gas-chromatography (GC) is used. 
Several studies using GC/MS with different 
sample preparation techniques have been de-
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veloped for the analysis of pesticides in food. 
Lehotay4 analyzed 22 samples of pesticides in 
apples, green beans and carrots by GC/MS-
MS, sample preparation is done using solvent 
extraction with acetonitrile without clean-up 
process, and using GC/MS with supercriti-
cal extraction (Supercritical Fluid extraction/
SFE)5, Saqib Hussain11 examined the pesti-
cide residues on fruits mango with GC-ECD 
method (Electron Capture Detector) using 
cyclohexane and ethyl acetate to solvent ex-
traction and gel permeation chromatography 
(Gel Permeation Chromatography/GPC) for 
the clean-up stage, to eliminate the effect of 
the sample matrix Consuelo1 added analyte 
protectant in the analysis of pesticides in soil, 
juice, and honey using GC/MS.
Pesticide analysis methods easily and quickly 
introduced by Steven J Lehotay6,7,8, known 
by the method of “QuEChERS” (Quick, Easy, 
Cheap, Effective, Rugged, and Safe). The study 
was conducted to analyze 229 pesticides 
with samples of lettuce and citrus fruit. This 
method includes the step of solvent extrac-
tion with acetonitrile, liquid-liquid partition 
using MgSO4 and NaCl, and clean up using a 
dispersive phase Solid Phase Extraction (SPE 
dispersive), whereas the analysis was con-
ducted using GC/MS and LC/MS. This method 
was later refined to analyze pesticides that 
can not be detected in the previous method 
by adding acetate buffer for extraction pH 4-5. 
Other studies are still using GC/MS and LC/MS 
analysis of deltamethrin in plants by extract-
ing acetone, petroleum ether, and dichloro-
methane and clean-up using GPC2; analysis of 
446 pesticides in fruit and vegetable samples 
with three-cartridge SPE ex
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traction using acetonitrile-toluene solvent10 
and Yukiko13 using supercritical extraction. 
GC method used for the analysis of pesticide 
multiresidues has been done by Yanli12 with 
FPD detector and Nuria9 using ECD detector. 
The QuEChERS method has been adopted as 
the AOAC method in 2007. 
In Indonesia, there was indication of an in-
crease in the use of pesticides based on pes-
ticide product registration data from 1557 
products in 2006 to 2628 products in 2010. 
However, it is only few testing laboratories that 
have capability to perform pesticide residue 
analysis with adequate analytical methods. In 
this study, the validation of analytical method 
to determine the residue of pesticides on fruit 
and vegetable using GC-MS and QuEChERS 
kit is conducted to provide valid and ready to 
use analytical methods. Pesticides used in this 
study are organochlorine and organophos-
phates pesticides. GC is the chosen analytical 
method in thi study because it can achieve 
high sensitivity and also equipped with a 
highly selective detectors such as MS (Mass 
Spectrometry). Besides, GC does not require 
expensive HPLC solvent system.
METHODS
Materials
Fruits and vegetables are used as samples 
(cabbage, carrots, tomatoes, apples and green 
grapes), Organochlorine p.a (Sigma-Aldrich); 
Organophosphates (Sigma-Aldrich), acetoni-
trile pa (Merck); ethyl acetate p.a (Mallinck-
rodt), acetone pa (Merck); anhydrous Na2SO4 
pa (Riedel-de Haen); NaCl pa (Merck), general 
purpose Agilent QueChERS AOAC kit.
Instrument 
Agilent 6789 GC with Agilent Technologies 
5973 inert Mass Selective Detector, Agilent 
capillary column HP-5 413 320 x 30.0 x 0.25 
lm, QuEChERS AOAC kit (Agilent Bond Elut 
Buffered extraction kit and Bond Elut disper-
sive SPE kit for general vegetables and fruits), 
micro scales (Mettler Toledo Balance micro-
gram AB204-S), micropipette (Thermo Scien-
tific FJ76476).
Sample Preparation
Fruits and vegetables are cut into pieces and 
then washed and drained for 15 minutes and 
blend until homogen.The sample then stored 
in the freezer for subsequent analysis. The 
samples are removed from the freezer and al-
lowed to room temperature and then weighed 
again and ready to be used for analysis.
Extraction method 
Extraction method used in this research is in 
accordance with the manual of Agilent QuECh-
ERS AOAC kits, according the following chart.
Gas Chromatography conditions
Oven temperature: 180°C maintained 2 min-
utes increased 190°C (1°C/min), up 204°C 
(2°C/min), increased to 206°C (1°C/min) and 
then rose again to 290°C (2°C/min) was main-
tained for 2 minutes.
Validation Methods
Validation of test methods based on USP with 
parameters : specification/selectivity, linear-
ity, range, limit detection, limit quantitation, 
accuracy, and precision.
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Sample Preparation
Fruits and vegetables are cut into pieces and 
then washed and drained for 15 minutes and 
blend until homogen.The sample then stored 
in the freezer for subsequent analysis. The 
samples are removed from the freezer and al-
lowed to room temperature and then weighed 
again and ready to be used for analysis.
Extraction method 
Extraction method used in this research is in 
accordance with the manual of Agilent QuECh-
ERS AOAC kits, according the following chart.
Linearity, Limit Detection and Limit Quantita-
tion
The linear calibration curve of each pesticide 
was 0.7 – 7 ppm, 6 concentrations according 
to AOAC procedures. The result shows that 
the regression equation of each pesticide has 
correlation coefficient R2 > 0.99, giving a good 
Gas Chromatography conditions
Oven temperature: 180°C maintained 2 min-
utes increased 190°C (1°C/min), up 204°C 
(2°C/min), increased to 206°C (1°C/min) and 
then rose again to 290°C (2°C/min) was main-
tained for 2 minutes.
Validation Methods
Validation of test methods based on USP with 
parameters : specification/selectivity, linear-
ity, range, limit detection, limit quantitation, 
accuracy, and precision.
linearity on the contentration range. 
LOD-LOQ determination is done by measur-
ing the slope of the standard deviation of the 
response calibration curve consisting of five 
low concentrations in the area LOD-LOQ. Data 
obtained regression equation in the concen-
tration range 0.7-1.5 ppm. The data is shown 
in Table 1.
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Accuracy and Precission
Accuracy and precision test are performed to 
measure the accuracy and repeatability of the 
analytical method. Accuracy is expressed in 
per cent recovery, using spiking of organochlo-
rine and organophosphate standard mixture 
into the vegetables and fruits matrix, ie 0.02 
mg/10 g samples for each analyte and 6 repli-
cations is performed (ICH, 2005). 
Table 11. Linearity of each pesticide 
Table 2. Accuracy and Precission of each pesticide
Precission is expressed in coefficient vario-
ation (CV). Some pesticides are haviing rela-
tively larger CV than the other due to the peak 
of the analyte compounds produced relatively 
smaller compared to others, so that the result-
ing error is also greater. Based on the value 
of the CV of all pesticides, then this method 
meets the acceptance criteria for precission, ie 
CV≤20% for biological analysis (AOAC, 2002).
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CONCLUSION
Based on the validation parameter values ob-
tained in this study, it can be concluded that 
the gas chromatographic method for the anal-
ysis of organochlorine and organophosphate 
pesticide residues in fruit and vegetable sam-
ples with QuEChERS extraction method has 
met the requirements. 
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INTRODUCTION
Paracetamol, a para-aminophenol derivative, 
is usually given per oral as antipyretic and 
analgesic for the treatment of fever1. Pedi-
atric patients may have difficulty in ingesting 
conventional tablets because of their under-
developed muscular and nervous systems2. 
The concept of Orally Disintegrating Tablets 
(ODT) emerged with an objective to improve 
patient’s compliance. ODTs disintegrates and 
dissolves in the mouth in less than 1 minute 
without the need of water3. Various technolo-
gies used in the manufacture of ODT include 
freeze drying, moulding, direct compression, 
spray drying, sublimation, and mass extrusion. 
In the freeze drying method, drying is carried 
out at low temperature under conditions in-
volving removal of water by sublimation. Here, 
the drug is physically entrapped in a water sol-
uble matrix, which is then freeze dried to give 
a product that is highly porous and amorf3. 
Freeze drying has some disadvantages such 
as the product obtained has  poor mechani-
cal stability  and fragile4. Gelatin can inhibit 
the  recrystallization process of amorphous 
paracetamol by cross-linking  and hydrogen 
bonding between paracetamol and polymer. 
This interaction may increase the mechani-
cal strength of ODT and keep the amorphous 
structure5. This study aims to determine the 
characterization of paracetamol ODT using 
gelatin as binder  (1% and 2%)6, polyplasdone 
XL-10 as disintegrant (10%)7, and mannitol as 
filler which prepared by freeze drying method. 
Paracetamol ODT, physical mixture, and single 
compound of the material were characterized 
using Powder X-ray Diffractometry (PXRD), Dif-
ferential Thermal Analyzer (DTA), and Scan-
ning Electron Microscope (SEM).
MATERIALS AND METHODS
Materials
Paracetamol (Hengshui Jiheng Pharmacy®), 
Mannitol (Cargill® Cpharm Mannidex 16700), 
Gelatin (Megasetia®), and Polyplasdone XL-10 
(ISP Technologies, Inc.).
Methods
Formulation
There were 3 formulation of paracetamol ODT 
used in this study, each formula contained 120 
mg paracetamol/tablet (Table 1).
*The content of gelatin and polyplasdone XL-
10 calculated from the total weight of the ODT
Table 12. Formulation of Paracetamol ODT
Preparation of Paracetamol ODT
Mix paracetamol, mannitol and Polyplasdone 
XL-10 carefully by geometric dillution. Gelatin 
solution was added to powder mixture until 
a good suspension obtained. The suspension 
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were then filled into blister by syringe. The 
blisters were  placed  in a deep freezer ( -80oC) 
for  24 hours and then freeze dried (-4oC, 20 
Pa)  for 24 hours. Tablets obtained were stored 
at room temperature in a  close container. 
Characterization of Paracetamol ODT
PXRD (Philips X’pert, Netherland): radiation 
source Cu-Kα filter Ni and scintillation coun-
ter detector. The condition of instrument was 
about 40kV, 30 mA, and the divergence-scatter 
slits 0,5o. Scattering intensity used  to fixed-
time step scanning around 5o-40o. 
DTA (Melter Toledo FP 85 TA Cell, US): the ex-
periment were conducted with temperature 
50-250oC and heat flow 10oC/minute. 
SEM (Jeol-JSM-6360LA, Japan) was performed 
on the surface and cross section of the tablet 
with 200x magnification.
RESULTS AND DISCUSSION
Figure 1 showed that single compound of 
paracetamol showed  characteristic crystal-
line  intensity peaks at 12,1o and 13,7o. These 
peaks showed the alteration of crystallization 
intensity between paracetamol single com-
pound with paracetamol ODT. The diffracto-
gram showed that F2 has the lowest intensity. 
However, the decreasing of paracetamol in-
tensity of F2 and F3 was not very significant 
because of the differences in the amount of 
gelatin was very small.
Figure 2 showed  the melting point of 
paracetamol ODTs in each formulation com-
pared to pure paracetamol. The melting 
point of paracetamol, mannitol, F1, F2, F3 
were 171,8oC; 169,6oC; 163,6oC; 162,9oC; 
161,2oC. The decreasing  in melting point of 
F1, F2, F3 were due to the eutectic formation 
of paracetamol and other excipients Formula 
F3 (with 2% gelatin) showed the lowest melt-
ing point.  DTA study showed that paracetamol 
enthalpy could not be determined because 
of the overlapping of endothermic peaks oc-
cured between paracetamol and other excipi-
ents.
Figure 3 showed  the SEM  photomicro-
graph of  the paracetamol ODTs. F3 (gelatin 
2%) showed  the most subtle particles.  This 
is due to the rigid nature of the gelatin. The 
characterization using SEM showed that 
paracetamol ODT prepared by freeze drying 
method was porous.
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CONCLUSION
PXRD study demonstrated that there was sig-
nificant decrease of  paracetamol’s intensity in 
the freeze dryed ODTs compared to the single 
compound of paracetamol, but there was no 
significant decrease between F2 (gelatin 1% 
) and F3 (gelatin 2%). DTA study showed that 
paracetamol enthalpy cannot be determined 
because of the overlapping of endothermic 
peaks occured between paracetamol and 
other excipients. The SEM photomicrograph 
showed that paracetamol ODTs prepared by 
freeze drying method were porous.  
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INTRODUCTION
Mangosteen (Garcinia mangostana L.) is a 
tropical fruit where utilization of mangosteen 
rind mostly for tanning leather, anti-rust and 
textile dyes. Research showed that mango-
steen rind contains many compounds that are 
beneficial to health such as anthocyanins, tan-
nins, polyphenols, epicatechin, and xanthone. 
More than 50 xanthone have been isolated 
from the rind including α-, β-, γ-mangostin in 
which α-mangostin is the largest component 
and is regarded as a marker for product quality 
control (1). Jung HA, et al showed α-mangostin 
has antioxidant potency with IC50 of 1,0 ppm 
using the Mouse Mammary Organ Culture As-
say (MMOC) (2). 
Mangosteen rind extract were marketed in 
capsule dosage form meanwhile it is known 
that mangostin solubility in water is very low 
(1:>10.000). Enhancement of α-mangostin 
solubility and in vitro antioxidant effect has 
been studied by Fatimah who formulate oral 
solution mangosteen rind extract by using co-
solvency technique. The formula include PEG 
400, glycerol, sorbitol and 70% demineralized 
water as cosolvent. The results showed that 
cosolvent solution meet the requirements for 
organoleptic, pH, specific gravity and clarity 
and has antioxidant activity (3). 
Thus, to determine in vivo antioxidant ef-
fect of cosolvent mangosteen rind solution 
a comparation study agaist mangosteen rind 
extracts suspension was conducted. There are 
two types of extracts:  the same extracts of 
cosolvent solution (hereinafter referred to as 
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extract) and marketed extracts from capsule 
dosage form (hereinafter referred extract®). 
Levels of α-mangostin in cosolvent solution 
and extracts is equated, 33.1 mg/kg.
MATERIALS AND METHOD
Materials
Mangosteen rind extract solution with 8,94% 
α-mangostin; mangosteen rind extract cap-
sule with 15,32% α-mangostin; vitamin C; 
chloroform-ethanol (3:5) solution; 0,01 M 
epinephrine; 70% and 90% alcohol; 0,0518 M 
carbonate buffer; ethylene diamine tetra ac-
etate (EDTA); distilled water; 0,9% NaCl; 70% 
sorbitol; PEG 400; glycerol; aqua demineral-
ization; 0,01 N HCl; MDA standards (SIGMA); 
carbon tetrachloride (CCl4); olive oil; 20% tri-
chloroacetic acid (TCA); 0,067% tiobarbiturat 
acid (TBA) (Merck).
Method
Cosolvent Solution and Extracts Suspen-
sion Preparation. Determination of mango-
steen rind was performed at “Herbarium 
Bogoriense”, Indonesian Institute of Sciences 
- Cibinong. 1 kg of mangosteen rind powder 
was extracted by maceration using 70% etha-
nol (1:4) for 3x24 hours with stirring. The fil-
trate is evaporated at 400C and 120 mBar, and 
evaporated on a water bath to obtain a viscous 
extract. Solution is made from the extract by 
cosolvency techniques. Extract and extract® 
suspension were suspended into CMC.
Animals. Twenty five of Sprague-Dawley strain 
rats were adapted to the laboratory environ-
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ment for a week and divided into 5 groups: 
group I (negative control) were given cosol-
vent, group II (positive control) were given vi-
tamin C, group III (cosolvent solution), group 
IV (extract suspension), group V (extract® sus-
pension). Treatments were given for 14 days. 
CCl4 (dose of 1 mL/kg bw) were induced on 
day 14, two hours after the last administration 
of preparation. Blood was collected on day 16.
Measurement of MDA concentration. 200μL 
of EDTA plasma was added 1.0 mL of 20% 
TCA and 2 mL of 0,067% TBA. Mixed on a wa-
ter bath for 10 minutes. Ambient solution is 
centrifuged at 3000 rpm for 10 minutes. Pink 
filtrate absorbance was measured by UV-Vis 
spectrophotometer at 532 nm wavelength. 
MDA levels were calculated by using MDA 
standard curve (4).
RESULT AND DISCUSSION
The average of MDA concentration on day 16 
is ranged from 0,3 to 1,0 nmol/mL. Table 1 
showed that there were significant differenc-
es between group I with group II, III, IV and V 
(p<0,05) where the highest MDA levels found 
in group I. High levels of MDA was due to ad-
ministration of CCl4 which generated trichlo-
romethyl radicals. This radicals can bind cova-
lently to proteins and unsaturated lipids cause 
lipid peroxide while animal in group I has no 
protection.
Generally, a product of lipid peroxidation is 
determined by measuring the levels of MDA. 
Highest MDA products in group I related to 
lowest antioxidant status (5). Lower level 
of MDA in group II, III, IV and V mean the 
treatments was able to inhibit the forma-
tion of MDA. There was no significant differ-
ence (p>0,05) between groups II and group III 
showed that cosolvent solution has the same 
capacity as positive control to inhibit MDA for-
mation.
Administration of vitamin C as positive control 
impacted to the lowest MDA level compare to 
all groups. As known that vitamin C is an an-
tioxidant which has electron donating groups 
that can inhibit lipid peroxidation process and 
stop a formation of new free radical. The same 
result performed by Ismiyati who found the 
administration of vitamin C can eliminate free 
radicals as indicated by the decrease in MDA 
levels (6).
MDA levels in groups III, IV and V are lower 
compare to group I, meaning cosolvent solu-
tion and extractss have the ability to prevent 
lipid peroxidation and MDA formation. The re-
sults in line with Arsana, et al. which showed 
that mangosteen rind extract can inhibit the 
formation of MDA in rats given maximum 
physical activity (5).
Potential inhibition of MDA formation against 
negative control in group II by 70% and group III 
by 60%, the ability of inhibition in both groups 
did not differ significantly (p>0,05). Group IV 
Notes:
I: Negative control; II: Positive control; III: Cosolvent solution; 
IV: Extract suspension; V: ekstrak® suspension
Figure 1. Average MDA concentration after treatment
Note: different sign on the same column showed sig-
nificant differences (p<0,05)
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is able to inhibit the formation of MDA by 40% 
and group V by 50%, both lower than cosol-
vent solution. Difference ability to inhibit MDA 
formation between treatments occur due 
to the differences in the dosage form. Cosol-
vent solution was able to decrease MDA levels 
higher than extracts suspension, because the 
solubility of α-mangostin has been enhanced 
with cosolvency method. The results of this 
study indicate that the dosage form cosolvent 
solution has a higher antioxidant capacity than 
the extracts suspension dosage form. These 
results are supported by previous research by 
Fatima who showed solubility of α-mangostin 
enhancement with cosolvency techniques ob-
tained IC50 value 2,4809 ppm (very active) by 
using 1,1-.Difenil-2-picrylhydrazyl (DPPH) (3).
CONCLUSION
The results showed that cosolvent solution 
has higher antioxidant capasity to inhibit MDA 
level compare to extracts suspension. Poten-
tial inhibition of MDA formation of cosolvent 
solution is 60% while extracts suspension are 
40% and 50%.
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INTRODUCTION
A number of developing countries all around 
the world are still dependently using tradi-
tional herbal medicines in curing numerous ill-
nesses since it is the only affordable sources of 
healthcare with fewer side effects (Odhav et 
al., 2010). Traditionally, diabetes is one of the 
common diseases that are used to be treated 
with herbal medicines. Diabetes is a chronic 
metabolic disorder of carbohydrates, fats and 
proteins that can affect a large number of 
populations in the world (Patel et al., 2012). 
It is generally attributed to the in unhealthy 
lifestyle and aging that is characterized by a 
high blood glucose level due to some abnor-
malities in pancreas that results to low insulin 
level (Patel et al., 2012 and Lawag et al., 2012).
According to Odhav et al., 2010, it is about 173 
million of people suffer from diabetes world-
wide and about 5% of those diabetic patients 
died. If this would not be prevented, the ex-
pected mortality would increase by 50% in the 
next 10 years. In the Philippines, over a mil-
lion of Filipinos have been suffering from such 
chronic disease (Patel et al., 2012 and Lawag 
et al., 2012).
A number of different ways of treating such 
disease were established by many research-
ers. The α-glucosidase enzyme inhibition 
would be one of the responsible for the de-
crease of blood glucose level that is needed 
to breakdown the sugars which resulted to 
decrease in glucose levels (Odhav et al., 2010 
and Lawag et al., 2012). These enzymes inhibi-
tors only delays and prevents the absorption 
SCREENING OF SELECTED PHILIPPINE ROOT CROPS FOR α-Glucosidase 
INHIBITION
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of ingested carbohydrates that controls the 
elevated blood glucose level therefore treats 
diabetes and prevents other complications 
brought by the disease (Lawag et al., 2012).
Plants are always been good provider of dif-
ferent medicine for different illness. Numer-
ous of plants and its parts such as leaves, 
fruits, bark and roots have been investigated 
and reported to possessed anti-diabetic prop-
erty that lowers blood glucose activity with-
out side effects (Odhav et al., 2010). 
Similar with the numerous edible plant spe-
cies, root crops can also be identified for having 
a compound which can inhibit α-glucosidase 
enzyme (Kumari et al., 2012). Root crops are 
one of the most important staple foods and a 
substitute food worldwide. It is grown all over 
the world and usually has low commercial val-
ue for direct consumption (Champagne et al., 
2011 and Wickramasinghe et al., 2009). Root 
crops are widely used as food and as major 
ingredients for the production of beverages, 
pasta, alcohol drink, and natural colorants (Xu 
et al., 2010). There are several root crops have 
been reported to treat various diseases such 
as diabetes. In this study, the selected Phil-
ippine root crops used (Fig.1) are Dioscorea 
alata L. and Dioscorea sp. (Dioscoreaceae), 
Manihot esculenta Crantz (Euphobiaceae), 
Maranta arundinacea L. (Marantaceae), Xan-
thosoma sagittifolium (L.) Schott (Araceae) 
and Stenomeris dioscoreifolia Planch (Diosco-
reaceae). These root crops are widely used 
as folk medicine in treating diverse diseases 
and can be identified for having a compound 
which can inhibit α-glucosidase enzymes (Ku-
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mari et al., 2012). In order to investigate the 
anti-diabetic property of selected Philippine 
root crops, the crude extract was screened for 
METHODS
The root crops were washed, peeled, sepa-
rated the peel from the flesh, oven-dried at 
40°C, pulverized using laboratory mill and 
extracted using 90% ethanol. Crude extracts 
were obtained by using rotary evaporator un-
der reduced pressure at 40-50°C. These crude 
extracts were screened for phytochemical 
constituents such as alkaloids, phenolic com-
pounds, essential oils, triterpenes, steroids, 
sugars, and flavonoids using 20% H2SO4 in eth-
anol, vanillin-sulfuric acid, α-naphtol-sulfuric 
acid, potassium ferricyanide-ferric chloride 
and Dragendorff’s reagent as spray reagents. 
The α-glucosidase enzyme inhibitory activity 
was screened using yeast α-glucosidase en-
zyme and analyzed using enzyme-linked im-
munosorbent assay (ELISA). 
RESULTS AND DISCUSSION
Except for the Stenomeris dioscoreifolia 
Planch peel, with the highest inhibition ac-
tivity, Dioscorea sp. peel, Stenomeris diosco-
reifolia Planch flesh, Dioscorea alata L. peel 
and Dioscorea alata L. flesh with IC50 value 
of 55.10±1.48 µg/mL, 109.72±1.58 µg/mL, 
166.32±3.34 µg/mL, 346.49±1.35µg/mL and 
651.79±1.39 µg/mL respectively; all other 
crude extracts shows no inhibition or has 
an IC50 values that is greater than 1000 µg/
mL. The qualitative phytochemical analysis of 
ethanolic crude extract showed the presence 
α-glucosidase enzyme inhibitory activity and 
for phytochemical constituents.
of alkaloids, flavanoids, triterpenes, phenols, 
tannins, steroids, sugars, and essential oils.
Table 13: IC50 values of selected Philippine 
root crops
Diabetes is one of the chronic diseases world-
wide that is necessary to have immediate 
action for its prevention. A lot of herbal me-
dicinal plants have been proven to be effec-
tive on preventing diabetes. The significance 
of this study was its contribution to the new 
information about the root crops which has 
α-glucosidase enzyme inhibitory activity that 
may help in controlling the blood glucose lev-
el. It also provides a new α-glucosidase inhibi-
tor which is necessary in preventing diabetes. 
The effects of starchy foods, such as root crops 
which are rich in carbohydrates, on blood glu-
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cose and insulin level may differ extensively 
because of the difference in carbohydrate, fat, 
protein and dietary fiber content that may be 
ingested (Bornet et al., 1989).  
CONCLUSION
The crude extract of Stenomeris dioscoreifolia 
Planch peel and flesh, Dioscorea sp. Peel and 
Dioscorea alata L. peel and flesh showed a 
significant enzyme inhibitory activity. This in-
dicated that the root crops can be identified 
as α-glucosidase enzyme inhibitor which may 
help in controlling the blood glucose level that 
may prevent diabetes. 
This study contributes to the aim of the other 
researchers to give additional knowledge by 
providing adequate information about the 
capabilities of the selected root crops. More-
over, it could also be a reference of the medi-
cal practitioners specially the pharmacist and 
pharmacological laboratories in formulating a 
new drug that may help in preventing diabe-
tes. 
This is the first screening of the anti-diabetic 
property of the selected Philippine root crops, 
this study also gives awareness to the diabetic 
patients specially the local people that eating 
root crops as part of their diet may help pre-
vent diabetes and may reduce the number of 
mortality of diabetic patients. Since this is the 
first screening of the anti-diabetic property of 
the selected Philippine root crops and further 
study must be done to determine the com-
pound that is responsible for the α-glucosidase 
enzyme activity.
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INTRODUCTION
Exposure of UV radiation on earth is a serious 
threat for human skin because of its ability to 
increase the risk of photo oxidative damage 
which can lead to skin aging by the presence 
of free radical. Therefore, added of exogenous 
antioxidant may needed to prevent the dam-
age caused by free radical. There was a study 
who claimed that cinnamon contains several 
compounds such as phenol, flavonoid, and 
tannin that have antioxidant activity and an 
emulgel formulation of cinnamon extract was 
also already developed. However, the emulgel 
formulation of cinnamon extract showed a 
decreasing antioxidant activity. This research 
aimed to make a niosome formula of cinna-
mon extract to increase its stability
MATERIALS AND INSTRUMENT
Materials 
Cinammon bark, ethanol, sorbitan monostear-
ic, cholesterol,  water de ion, ascorbic acid, 
DPPH (2,2-difenil-1-pikrilhidrazil), Virgin co-
conut oil  (VCO), glycerin, Sodium lauryl sulfic, 
cetostearyl alcohol, polyvinyl pirolidone (PVP).
Instrument
Reflux apparatus, rotary evaporator  , UV lamp 
(Desaga Starded Gruppe), vortex,  spectrofo-
tometer UV-Vis (Beckman coulter DU 720), par-
ticle size analyzer (Beckman Coulter®DelsaTM 
Nano C Particle Analyzer), probe sonicator 
(Ivymen Homogenaizer), vacuum desicator.
Simplisia preparation 
Cinammon bark collected from Lembang , East 
Java, in January 2014. Plant determination 
was done in Herbarium Bandungense, SITH 
ITB. Cinammon bark cut  and dried in oven at 
40oC for 4 days, after that its grinding  until a 
fix range of particle size 
EXPERIMENT METHODE
Extraction and extracts characterization 
Crude drug of cinnamon bark was extracted 
by reflux method using solvent ethanol 96%, 
monitoring was done using thin layer chroma-
tography with toluene-ethyl acetate (93:7) as 
mobile phase and then determinate the  spot 
appearance 
Phyto chemistry  screening  
Identification chemistry group in extracts in-
cludes : alkaloid, flavonoid, saponin, , steroid 
/terpenoid, tannin and quinon. Completed 
with another  test included: determined wa-
ter content of simplisia  , concentration of ex-
tracts that its soluble in water and soluble in 
ethanol and also  extracts densities  
Antioxidant activity test of extracts with DPPH 
as scavenging agent  
Absorption determination  of extracts 
Cinammon bark after incubation the extracts 
methanol solution 1 : 1 (volume) with DPPH 
methanol solution for 30 minutes.The change 
of absorbance determined with spectrofo-
tometri method, at maximum wave length 
517 nm . As standard solution used 50 μg/ml 
ascorbic acid  solution in methanol  to com-
pare the antioxidant activities.  
Niosome preparation of ethanol extracts 
cinammon bark 
Niosome was prepared using thin layer hydra-
tion method with various weight of cinnamon 
extract loaded and various molar ratio of sur-
factant and cholesterol. Sorbitan monostearic, 
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cholesterol and  extracts  dissolved in choro-
form  and then the solvent evaporated used 
rotary evaporator until its formed dry lipid 
thin layer in the evaporator vessel.   After that 
lipid thin layer hydrated with water de ion,  its 
formed  vesicles with random particle sizes.   
Reduced particle size of niosome 
Reduced the vesicle size with probe sonicator 
for 5 minute in cool box, with 60 %  amplitudo 
and pulse mode 5 seconds  ran and 5 seconds 
stop. These method to obtain vesicles with av-
erage size less than 300 nm  
Evaluation and characterization of extracts cin-
namon bark niosome 
Determined the particle size and  polydisper-
sion index of niosome  vesicle, activities anti-
oxidant and scavenging activity of niosome, 
emulgel  and emulgel niosome formulation of 
extracts ethanol cinammon bark, performance 
evaluation of the dosage form, and acceler-
ated stability test.   
EXPERIMENT RESULTS
Table 1 Phytochemistry  Screening  
Table 2 Characterization of Cinnamon Bark 
simplisia 
.Table 3. Final Formula of emulgel and emulgel 
niosome of extracts ethanol cinnamon bark 
CONCLUSION 
IC50 of extracts ethanol cinnamon bark was 
0,299 ppm and IC50 of ascorbic acid was  0,280 
ppm. From these result IC50 extracts ethanol 
of cinnamon bark compared with ascorbic acid 
most equal. Composition of niosome consist 
of  200 µmol surfactant and 20 µmol choles-
terol and 10 mg extracts ethanol of cinnamon 
Amount of extracts about  29,27%  calculated 
from simplisia weight  and density of 1% ex-
tract ethanol of cinnamon bark 0,8189 g/mL.
Determined scavenging activity of DPPH as 
free radical, gave value of  Ic50  extracts  etha-
nol cinnamon bark provide DPPH scavenging 
activity, compared with ascorbic acid as a 
standard solution 50 ppm was 0.299 μg/ml 
and Ic50 value of ascorbic acid was 0.280 μg/
ml .
Statistically, scavenging activity DPPH emulgel 
niosome of extracts ethanol cinnamon bark, 
there was no significant change of the scav-
enging activity DPPH (p<0,05). In the other 
side decreased scavenging activity DPPH of 
extracts ethanol cinnamon bark significantly 
changed (p<0,05). 
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bark have a good stability and could optimal 
entrapment.  Based from characterization and 
stability test of the niosome,  there was no dif-
ferentiation of particle size  166,63±1,72 nm, 
polidispersity  index  0,296±0,02 and activity 
antioxidant 80,44±1,58%. Formulation final 
emulgel exhibited good physical stability and 
for extracts and extracts niosome 
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INTRODUCTION
Sustained release dosage form , in the last 
two decades, have made significant progress 
in term of clinical efficacy and patient compli-
ance (Merkus, 1986). Sustained release prepa-
ration is a pharmaceutical preparation which 
releases the drug substance in the long term. 
The duration of this release is intended to 
minimize the release rate so that it can func-
tion as a decisive step to achieve the desired 
therapeutic effect like.
Various synthetic as well as natural polymer 
have been investigated and developed in sus-
tained drug delvery  application. 
Non ionic cellulose ether, and most frequently 
hydroxypropyl methyl cellulose ( HPMC) have 
been widely studied for their applications in 
oral slow drug released  system , Sustained Re-
leased (SR) system. mong the polymers which 
can be used as an active ingredient elepasan 
controller, HPMC K100M has been widely 
studied. As a hydrophilic matrix, HPMC K100M 
has advantages such as: can release the ac-
tive ingredient to 100%, thereby reducing the 
trapped material.
sses HPMC K100M is a high viscosity so that it 
can significantly slow down the release. To fix 
these adverse characteristics, HPMC K100M 
is often combined with other matrriks having 
high solubility so as to increase the release of 
the active ingredient. B Polymers of this kind 
is referred to as channeling agent. Materials 
that can be used as a channeling agent include 
lactose and PVP K30. 
The influence of commonly used chaneling 
agent, lactose and PVP K30, on drug release 
from HPMC K100M 
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(  Hydroxypropylmethylcellulose K100M ) has 
been investigated.
HPMC K100M  matrix tablet of theophylline 
using lactose and PVP K30M as a chanelling 
agent were prepared by wet granulation.
A model formulation contained 60% w/w 
drug (theophylline) , 30% w/w HPMC K100M 
, 0,5% w/w Magnesium Stearate, 4%, 6% and 
8% PVP K30 and 10%, 15% and 20% Latcose.
METHODS
Table 1 A model HPMC and Chanelling Agent 
formulation Used in This Study
Tablets containing 200 mg drug, were  com-
pressed using a  Graseby Specac hydraulic 
press equipped with an 10,0 mm flat faced 
punch and die set. The compression force and 
compession time were  0,5 ton,  30 seconds 
respectively ( FP1, FP2 and FP3 ) and 0,5 ton. 
5 seconds (F, FL1, FL2 and FL3)
In vitro release studies of theopylline
Drug release was determined by using dis-
solution tester USP XII. The dissolution tester 
were performed using 900 ml distiled water at 
370C ± 0,50C and rpm was set at 50. Samples 
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of 5 ml were withdrawn from the dissolution 
medium at 5’, 10’.20’ 30’, 60’, 120’, 180’, 240’, 
300’, 360’.420’ and 480’.  That amount was 
replaced with fresh medium to maintain the 
volume constant.
The absorbance of the sample, were measured 
at 272 nm using a Schimadzu UV-1201 UV/Vis 
doubled beam spectrophotometer (Shimadzu 
, Japan )
RESULT AND DISCUSSION 
Kinetic modelling of drug release
Afer completing in  vitro dissolution of all 
batches for eight hours, the data was treated 
with zero order  , Higuchi  and First order 
1. Mt= M0 +k0.t
2. Ln Mt = ln M0 + k1.t
3. Mt = M0 – kHt1/2
Table 2 : Release rate constant and R-squared 
values for different release kinetics 
From the kinetic of drug release studying, the 
result showed that all of the formulation fol-
lowed Higuchi’s model. 
The experimental was undertaken to observe 
the influence of chanelling agent ( lactose and 
PVP K30) on theopylline release from HPMC 
K100M.
Drug release of tablet containing chanelling 
agent (lactose and PVP K30) and tablet with-
out chanelling agent ( F ) were evaluated . The 
result shows that chanelling agent increase 
theophylline release, that is attributed mainly 
to the excipients solubility.
Table 3 : The criteria of theophylline release 
(states in USP XXIV) and Theophylline Release 
Table 3 : The criteria of theophylline release 
(states in USP XXIV) and Theophylline Release 
All of the formulation didn’t meet to the cri-
teria of theophlline release from sustained re-
lease dosage form that stated in USP XXIV
CONCLUSION :
1.Theophlline release affected by chanelling 
agent in this formulation. Lactose and PVP K30 
increase drug release
2.All Formulation did not meet o the criteria 
of theophlline release from sustaned release 
dosage form that stated in USP XXIV
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EFFORTS TO PRODUCE 1-(BENZOYLOXY)UREA
AS ANTICANCER DRUG CANDIDATE
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Backgrounds 
Hydroxyurea is an antineoplastic compound 
which has activity to inhibit ribonucleotide re-
ductase  enzyme. The function of the enzyme 
is to inhibit DNA biosynthesis by converting 
ribonucleotides to deoxyribonucleotides. This 
activity is called cytotoxic or antineoplastic, 
which has special effects  on S phase. (Salim, 
2004). 
Hydroxyurea is also useful in treatment of sick-
le cell anemia because it eases the paint of the 
patients, which has been attribute to its ability 
to generate nitric oxide, a potent vasodilator. 
Nitric oxide may also contribute to the antitu-
mor effect of hydroxyuirea, since it is known 
to inhibit ribonucleotide reductase probably 
because it contains an unpaired.electron and 
therefore it is able to quench the thyrosine 
radical. (Avendano. 2008)
There are facts which show that with the sub-
stitution on the lead compound has the conse-
quence which will change the lipophilic, elec-
tronic and steric effects (Korolkovas, 1988). 
To design new drugs, the physicochemical 
properties of the drugs molecules should be 
predicted before they are synthesized and pu-
rified. 
Molecular modeling and virtual screening 
have become an established method to lead 
discovery to enhance efficiency in activity op-
timization of lead compound. In silico test or 
molecular modeing is term for experiment or 
test that been done with computer simula-
tion. (Istyastoro, 2007). Molecular interation 
energy between receptor and ligan is obser-
vised with Rerank Score. In silico test is done 
through docking the molecules of drug com-
pound candidate with the chosen receptor. 
Docking is a mean to harmonize ligan which is 
small molecule into receptor which is big pro-
tein molecule, with regard their nature to one 
another (Jensen, 2007).
Ribonucleotide reductase was established as 
the principal target of anticancer compounds 
as hydroxyurea and its derivative 1-(benzoy-
loxy)urea. These compound formed a complex 
with crystal structure of  yeast ribonucleotide 
reductase I (2EUD). 
Synthesis of 1-(benzoyl-oxy)urea was per-
formed by reacting hydroxyurea with benzoyl 
chloride. The reaction mechanism is inclusion 
of the nucleophilic hydroxyl group of hydroxy-
urea to the carbonyl group of benzoyl chloride 
(Clayden et al., 2001; Zinner et al., 1969.
The objectives of this research are to synthe-
sis the compound and determine  anticancer 
activity. 
Methods 
The docking scores of hydroxyurea and 
1-(benzoyloxy)urea which formed a complex 
with crystal structure of  yeast ribonucleotide 
reductase I (2EUD) calculated by Molegro pro-
gram. 
 Synthesis of 1-(benzoyl-oxy)urea was per-
formed by reacting hydroxyurea with benzoyl 
chloride. The reaction mechanism is inclusion 
of the nucleophilic hydroxyl group of hydroxy-
urea to the carbonyl group of benzoyl chloride 
The TLC and melting point test were indicated 
the purity of the compound. Structure identifi-
cation was done based on FT-IR, and H/C-NMR 
spectrometry.
Results
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Discussions
Hydrogen bonding involved in interaction of 
1-(benzoyl- oxy)urea with 2EUD are: Cys 428, 
Cys 218, Ser 217, Asn 426 and Leu 427. While 
hydroxyurea only interacted with Cys 428, 
and Cys 218.
The final Rerank Score (RS), which is the score 
of the last stage.  Rerank score of the com-
pounds with 2EUD by molegro showed that 
1-(benzoyloxy)urea (-79.9432) has lower en-
ergy values than hydroxyurea (-43.3565) It 
means that the compounds are reasonable to 
be synthesized. 
TLC results of only one spot and sharp melting 
point indicates that the pure powder. Accord-
ing to the FT-IR, 1HNMR, 13CNMR and MS 
spectra, 1-(benzoyloxy)urea was successfully 
synthesized.
The result of anticancer activity test with 
HeLA cell showed tha 1-(benzoyloxy)urea 
(IC50 76,38 µg/ml) more active than hydroxy-
urea (IC50  430.21 µg/ml). 
Conclusions
1. From the results of the in silico   
 test can be predicted    
 that    1-(benzoyloxy)ureahas   
 anticancer activity better than hy  
 droxyurea. It means that the   
 compounds is reasonable to be syn 
 thesized.
2. From the results of the identification  
 of the structure showed that 1-(ben 
 zoyloxy)urea has been successfully  
 synthesized.
3. As anticancer drug candidate, 1-(ben 
 zoyloxy)urea was more active than  
 hydroxylurea.
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INTRODUCTION
Rapamycin is an inexpensive but effective li-
pophilic macrolide antibiotic with anti-fungal, 
immunosuppressive, and anticancer charac-
teristics. Rapamycin was formulated as an 
anti-rejection drug for kidney transplant, i.e. 
Rapamune©, and an anti-restenosis agent in 
drug-eluting coronary stents, e.g. Johnson and 
Johnson’s Cypher© stent. In addition, recent 
studies reported that rapamycin can induce 
significant regression of colonic adenomas in 
CPC;Apc mice and could improve therapy of 
colorectal cancer. Rapamycin has poor water 
solubility (2.6 μg/mL at 25oC), and is difficult to 
formulate as an injectable solution without us-
ing a co-solvent. In addition, rapamycin is very 
unstable in PBS and HEPES buffer. Micelles are 
attractive drug delivery systems for hydropho-
bic drugs because of their solubilizing ability 
that can increase drug loading, extend drug 
release, and lengthen plasma half-life. Many 
of micellar platform are biocompatible and 
biodegradable. They also have been studied 
extensively for drug delivery.  Deoxycholic acid 
and derivatives have been used to modify chi-
tosan as nanocarriers for cancer treatment. In 
this study, hydrophobic lithocholic acid (LCA) 
was conjugated with hydrophilic polyethylene 
glycol (PEG) to prepare micelles for packag-
ing rapamycin, a model lipophilic drug. This 
micelle was expected to increase rapamycin 
solubility, has good in vitro stability and long 
circulation half-life from a PEG sheath. 
METHODS
Synthesis of micelle platform
PEG amine (3 kDa) was dissolved in ethanol 
and NaOH was added. LCA was dissolved in 
ethanol. EDC was added to LCA solution, fol-
lowing by adding NHS. PEG amine solution was 
DEVELOPMENT OF PEGYLATED RAPAMYCIN LITHOCHOLIC ACID MI-
CELLE FOR CANCER THERAPY
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added to LCA after 10 min for activation. The 
reaction was allowed to stir overnight at RT. 
The solvent was partially removed under N2 
and the product was precipitated in cold di-
ethyl ether, centrifuged, and vacuum dried. 
Micelle preparation
Micelles were prepared by dissolving pegylat-
ed LCA in PBS. Conjugates were sonicated. 
Rapamycin stock solution was added to poly-
mer solution. The solution was sonicated. The 
organic solvent was removed by purging with 
N2. The micelle solution was centrifuged to 
remove insoluble material.
Figure 1. FTIR spectrum of LCA-PEG and par-
ent compounds. Inset shows chemical struc-
ture of LCA (blue)-PEG (red) conjugate. 
micelle solution was centrifuged to remove 
insoluble material. 
Micelle characterization
Dynamic Light Scattering (DLS)
Hydrodynamic diameters and surface charges 
of micelles were determined on a Mavern 
nanosizer. 
Transmission Electron Microscopy (TEM)
Samples were prepared onto copper grids 
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with 1% uranyl acetate (negative staining). 
TEM images were obtained on a Philips CM-
100 TEM.
Critical micelle concentration (CMC)
CMCs were determined by following changes 
in the fluorescence emission spectra of pyrene 
in the presence of different concentrations of 
micelles. Pyrene was dissolved in acetone and 
aliquots of stock solution were added to tubes 
Mobile phase was methanol and 0.1% glacial 
acetic acid in water (85:15) at a flow rate of 1 
mL/min. 
Release study
Micelle solutions were prepared at 6.7 mM. 
Rapamycin was encapsulated ~9% (w/w) in 
micelles, and 6 mL of each solution was trans-
ferred into 12 kDa MWCO dialysis bag.  Dialysis 
bags were placed in PBS (37oC). At fixed time 
points, aliquots were taken and drug concen-
trations were measured by HPLC. 
RESULTS AND DISCUSSION
Synthesis of LCA-PEG had high yield 
(91.6±3.7%). The change in structure of re-
sulting product was monitored using FTIR. 
LCA-PEG showed a combination of LCA and 
PEG characteristics (3200-3600 cm-1) and 
had similar C-H stretching (2800-3000 cm-1) 
compared to parent compounds (Fig. 1). On 
dynamic light scattering, the mean hydrody-
to provide final pyrene concentrations of 6 
μM. Acetone was evaporated and replaced 
with micelles prepared in serial dilution. Solu-
tions were incubated at 55oC overnight. Exci-
tation and emission wavelengths were set at 
335, 371 and 383 nm, respectively.
Entrapment efficiency (EE)
The amount of rapamycin was determined by 
HPLC with C18 column. Detection was set at 
wavelength of 276 nm.  
namic diameters of plain and rapamycin LCA-
PEG micelles were 183.2±19.3, 234.6±4.5 
nm, respectively, with slight negative surface 
charges. The micelle has polydispersity index 
(PDI) of ~0.1. This parameter provides an esti-
mate of the size distribution, and shows that 
the micelles were relatively monodispersed. 
Micellar size observed on TEM was similar 
with that determined on DLS. The TEM ob-
servation revealed that the spherical micelles 
were formed by self-assembly of pegylated 
lithocholic acid, Fig. 2A. Fluorescence probe 
studies with pyrene on micelles revealed low 
critical micelle concentration (CMC), 17 μM, 
Fig. 2B. CMC is the concentration at which mi-
celles form spontaneously. Micelles that have 
low CMCs are good candidates for solubiliza-
tion of hydrophobic substances in water. The 
entrapment efficiency (%EE) of rapamycin 
LCA-PEG micelle was 24.9±1.1 or 9% (w/w). 
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With pegylated LCA micelle, rapamycin solubil-
ity was improved (~86 fold). Rapamycin LCA-
PEG micelles showed sustained release of ra-
pamycin with a half-life of 9.5 hours.
CONCLUSION
The lack of suitable rapamycin formulations 
had hampered its progression into clinic. We 
have reported a formulation of rapamycin that 
does not require organic co-solvent or harsh 
surfactants to solubilize rapamycin. The sus-
tained release and high rapamycin loading of 
this micelle may offer significant benefits in 
cancer treatment, and the nanoscale dimen-
sion may improve tumor delivery through the 
EPR effect. This approach may be generalized 
further to formulation of other large, lipophilic 
chemotherapy or imaging agents.
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INTRODUCTION
Japanese encephalitis virus (JEV) causes hu-
man encephalitis in several of Asian countries 
including Japan, South Korea, Taiwan and Thai-
land. There are estimated 35,000-50,000 an-
nual cases and approximately 20%-30% of pa-
tients die (1). There is no effective treatment 
for encephalitis from JEV and the therapy only 
consists of palliative care and management of 
complication. Hence, vaccination presents the 
most efficient and cost-effective disease con-
trol tool to prevent JE encephalitis in humans. 
However, JE vaccine is administered only via 
subcutaneous (S.C.) or intramuscular (I.M.) 
routes, which may have a high risk of infec-
tion with blood-borne pathogens. Oral vacci-
nations are safe and a convenient alternative. 
It offers several advantages over parenteral 
immunization. Due to the needle-free, non-
invasive nature, oral administrated vaccines 
may reduce the risk of infection, and may 
also be more cost-effective because they en-
able large scale immunization without trained 
medical personnel. They also can increase vac-
cinee compliance. Particulate delivery systems 
are known to protect the associated antigen 
from degradation when in contact with the 
gastrointestinal (GI) fluids and to enhance 
absorption of antigens in the GI tract (2). To 
design these systems, chitosan was chosen as 
particulate carrier because it is biodegradable, 
biocompatible and safe for use in humans (3).
In the pharmaceutical field, chitosan is used 
as excipient and drug carrier. Moreover, chito-
san is able to reversibly open the tight junc-
tions and possesses mucoadhesive properties 
which enhance the absorption across mucosal 
epithelium as well as it is able to prolong the 
residence time of delivery systems at the ab-
sorption sites (4). Also, it has been reported 
that the molecular weight (MW) of chitosan 
influences the potency and duration of im-
mune responses (5). Therefore, the aim of this 
study was to evaluate the feasibility of using 
chitosan particles for oral vaccination against 
JEV.
MATERIALS AND METHODS
Materials
Three types of chitosan having low (Chi-L), 
medium (Chi-M) and high (Chi-H) molecular 
weight (MW) were used. Chi-L (MW = 160 
kDa, degree of deacetylation (DD) = 96%) 
and Chi-H (MW = 500 kDa, DD = 96%) were 
obtained from Aqua Premier (Chonburi, Thai-
land). Chi-M (MW = 270 kDa, DD = 93%) was 
received from Primex (Haugesund, Norway). 
Mouse brain-derived formalin inactivated JEV 
(Beijing-1 strain, lot JVJ51001) was a kind gift 
from the Thai Government Pharmaceutical 
Organization (GPO) (Bangkok, Thailand).
Preparation of JEV-loaded chitosan particles 
JEV-loaded chitosan particles were prepared 
by ionic gelation with tripolyphosphate (TPP) 
as reported by Boontha et al. 2010 (6). For 
characterization of particles, size and surface 
charges of particles were determined by using 
a photon correlation spectroscopy (PCS) (Zeta-
Plus, Brookhaven Instrument, UK). Loading ef-
ficiency (LE) was determined by using Micro 
bicinchoninic acid (Micro BCA) assay. Particles 
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morphology were determined with a scanning 
electron microscope (SEM) (LEO 1455VP, LEO 
Electron Microscopy Ltd, UK).
Immunization protocol
Five groups of 8 Swiss albino mice were immu-
nized orally or subcutaneously (s.c.) on days 0, 
7 and 30 with various formulations (Table 1). 
Blood samples were collected on days 37. JEV 
neutralizing antibody in mouse sera was mea-
sured using a virus plaque reduction neutral-
ization test (PRNT) with a 50% plaque reduc-
tion endpoint (PRNT50).
Table 14. Immunized formulations. 
The protective immunization titers of JEV-
neutralizing antibodies were determined 
from all groups of mice as shown in Fig. 2. 
Immunization of JEV via s.c. route (Group 5) 
induced the highest level of JEV-neutralizing 
antibodies (GMT = 3366) when compared 
with immunization potential of free JEV and 
JEV-loaded chitosan particles via the oral 
route. JEV encapsulated in all types of chito-
san particles could induce the JEV-neutralizing 
antibodies levels higher than the minimal re-
quested level (>1:10) by the WHO following 
oral immunization. Using the different types 
of chitosan, Chi-M particles could induce the 
highest JEV neutralizing antibodies GMT lev-
el of 119 whereas Chi-L and Chi-H particles 
could generate the JEV antibodies GMT level 
of 46 and 40, respectively. However, the JEV 
neutralizing antibodies initiated by particles 
prepared using three types of chitosan were 
not significantly different. This may be due 
to the fact that the JEV-loaded chitosan par-
ticles have similar characteristics in terms of 
size, charge and loading contents, resulting 
in the similar results of the potential of car-
riers for provoking immune responses to JEV 
following oral administration. Also, compari-
son between mice administered with Free JEV 
(inducing JEV-neutralizing antibodies GMT of 
120) and JEV encapsulated in chitosan par-
ticles through the oral route, resulted in no 
significant differences. 
CONCLUSION
The results of this work demonstrate that chi-
tosan particles as adjuvant have the feasibility 
for oral JEV immunization and the MW of chi-
tosan appeared to have no effect on the abil-
ity to elicite protective neutralizing antibodies 
to JEV in Swiss albino mice after oral immuni-
zation. Interestingly, although the differences 
were not statistically significant, free JEV (i.e. 
JEV in SWFI) seemed to be better in the initia-
tion of immune responses to JEV compared 
with particles-encapsulated JEV. 
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INTRODUCTION
Synthesis of drugs  interest in the development 
of the pharmaceutical industry.  Modifying of 
the structures can  change to its biological 
activity. Hydrazide derivatives are often used 
because they have biological activities and di-
verse clinical applications such as anticancer, 
antimicrobial and anti-tuberculosis. Awathi 
et al (2007) have conducted research synthe-
sis hydrazide derivative 2-hydroxybenzylidene 
and ((1H-indole-3-ilmetlen) hydrazide) using 
microwave irradiation, a mixture of ester and 
hydrazine hydrate (mole ratio 1:1), the results 
obtained about 85 -90%. In another study con-
ducted Jain et al, 2007,  the synthesis of  2-hy-
droxybenzohydrazide using microwave irradia-
tion within 120 seconds, the synthesis results 
obtained 90%. In this research synthesis ben-
zohydrazide, 2-hydroxybenzohydrazide and 
4-hydroxybenzohydrazide. Synthesis is done 
by using the conventional method , without 
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the toxic solvents and more environmentally 
friendly methods. Reduced use of toxic sol-
vents and energy savings in accordance with 
campaign green chemistry.
Based on the background above, the prob-
lems are formulated in this study : whether 
can be synthesized benzohydrazide, 2-hy-
droxybenzohydrazide and 4-hydroxybenzo-
hydrazide compounds? Is there any effect of 
the hydroxy group at the ortho and para po-
sitions on the methylbenzoate of synthesized 
benzohydrazide derivatives? The benefits of 
research can yield new knowledge about the 
reaction method to synthesize of benzohy-
drazide, 2-hydroxybenzohydrazide and 4-hy-
droxybenzohydrazide compounds. The reac-
tion is described as Figure 1.
MATERIALS  AND METHODS
 Materials
All chemicals  were used in this study with a 
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degree of purity p.a unless otherwise stated. 
The chemical were methylben-zoate,  methyl-
salicylate, methyl-4-hydroxybenzoate, hydra-
zine hydrate,  ethanol 95%, chloroform, ethyl 
acetate, acetone, hexane, KBr, silica gel 60 
GF254.
Instruments
Glasswares commonly used in the chemi-
cal synthesis laboratories ; Sanyo microwave 
EM-S 800 Watt, UV-Vis Spectrophotometer 
HEWLETT PACKARD 8452A; IR Spectrophoto-
meter M 500 Buck Scientific; FT- NMR spec-
trometer JEOL ECS -400.
Figure 1. Reaction of  benzohydrazide deriva-
tives formation from methylbenzoate  and hy-
drazine hydrate
Table 2. Identification of  UV-Vis , Infrared, and 
1H-NMR  spectra  of  2-hydroxybenzohydra-
zide 
Table 1.  Identification of  UV-Vis , Infrared, and 
1H-NMR  spectra  of  benzohydrazide 
Methods
Synthesis of  benzohydrazide and hydroxyben-
zo-hydrazide derivatives (Qinrong et al , 2011)
Methylbenzoate/derivatives (10 mmol) and 
hydrazine hydrate (20 mmol)  were mixtured 
enter in the reaction flask (25 ml). A mixture 
was stirred until homogeneous. The mixed 
solution was refluxed on a water bath for 2 h 
with stirring (perfection reaction was moni-
tored by thin layer chromatography). The 
mixture was cooled to room temperature and 
then added to 20-30 ml of aquadest, washed 
with ethanol, filtered. Crystals were  recrystal-
lized with  ethanol 95%.  The purity tests  use 
melting point and thin layer chromatography 
using three different eluent. Identification of 
compounds  were performed using UV-VIS, FT-
IR and 1H-NMR spectroscopies.
C
O
O
CH3 H2N-NH2+
C
N
H
O
NH2 CH3OH+
methylbenzoate
hydrazine
benzohydrazide derivatives
R2 R2R1 R1
               a. R1=H  ; R2=H
               b. R1=H   ;R2=OH
               c. R1=OH; R2=H
RESULTS AND DISCUSSION
 Synthesis benzohydrazide derivatives 
were done with nucleophilic substitution re-
action. Benzohydrazide is obtained as a white 
needles crystalline. Synthesized percentage is 
61%. Purity test results with thin-layer chro-
matography shows a stain, with  melting point 
109-111 oC. Identification benzohydrazide 
with UV-Vis, FT-IR, and 1H-NMR spectrosco-
pies can be seen in Table 1. 2-Hydroxyben-
zohydrazide is white needles crystalline. Syn-
thesized percentage is 75%. Purity test results 
with thin-layer chromatography shows a stain, 
m.p 140-141 oC . Identification results of 2-hy-
droxybenzohydrazide with UV - Vis, Infrared, 
and 1H - NMR  spectroscopies can be seen in 
Table 2. 
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Table 3. Identification of  UV-Vis, Infrared,  and 
1H-NMR  spectra  of  4-hydroxybenzohydra-
zide
4-Hydroxybenzohydrazide is white needles 
crystalline. Synthesized percentage is 79%. 
Purity test results with thin-layer chromatog-
raphy shows one stain, m.p 264-265 oC. Iden-
tification results of 4-hydroxybenzohydrazide 
with UV-Vis, Infrared,  and 1H-NMR  spectros-
copies can be seen in Table 3.
Shintesized of 2-hydroxybenzohydrazide and 
4-hydroxybenzohydrazide compounds are 
obtained respectively  75% and 79% greater 
than benzohydrazide  (61%). The presence of 
hydroxy groups in positions ortho and para at 
methylsalicylate and methylparaben cause to 
the carbonyl C increase the reactivity. Hydroxy 
groups act as negative inductive (-I) that can 
increase the electron density on the aromatic 
rings (from methylsalycilate and  methylpara-
ben), so it becomes more electronegative. As 
a result, the carbonyl C atom becomes more 
electropositive. Thus C carbonyl of methyl-
2-hydroxybenzoate (methylsalicylate) and 
methyl-4-hydroxybenzoate (methylparaben) 
are more easily attacked by nucleophiles (hy-
drazine). So that the hydroxy group at ortho 
and para positions can increase the yield of 
hydroxybenzohydrazide derivatives.
CONCLUSION
 The compounds of benzohydrazide, 2-hy-
droxybenzohydrazide and 4-hydroxybenzo-
hydrazide can be synthesized by react meth-
ylbenzoate derivatives and hydrazine hydrat 
. The yield percentage were obtained 61% 
(benzohydrazide ), 75% (2-hydroxybenzohy-
drazide) and 79% (4-hydroxybenzohydrazide). 
Hydroxy group at orto and para positions on 
methylbenzoate can increase yield percent-
age 2-hydroxybenzohydrazide and 4-hydroxy-
benzohydrazide.
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INTRODUCTION
Propolis or bee glue is a resin collected by hon-
ey bees from the sap flow sources such plants 
or sapling which is mixed with saliva and vari-
ous enzymes that exist in honey bees(1). Prop-
olis has antioxidant activity, contains a variety 
of compounds such as polyphenols (flavonoids 
aglycones, phenolic acids, alcohols and ke-
tones), sesquiterpenes, coumarins, steroids, 
sour variety of trees. The chemical composi-
tion of propolis varies depend on the origin of 
the material collected by honeybees, different 
trees will produce different compositions. The 
most important is the composition of propolis 
flavonoids and phenolic acids (2). Test antioxi-
dant activity using 1,1-diphenyl-2-picrylhydra-
zyl (DPPH) as a source of free radicals. DPPH 
in this test is reduced by antioxidants which 
releases hydrogen to form the reduced DPPH-
H (3). The color changed from violet to yellow 
and followed by a decrease in the absorption 
wavelength of 517 nm, with a decrease in ab-
sorption, then the catcher radical antioxidant 
activity can be determined. (4) The antioxidant 
activity of propolis is affected by its chemical 
composition. In this study assessed the antioxi-
dant activity of honey bee propolis originating 
from the three  different types of kapok, ram-
butan and longan trees(4).
MATERIALS  AND METHODS  
MATERIALS.Pure propolis is derived from the 
kapok, longan and rambutan trees. Equipment 
used in this investigation were extraction unit, 
evaporation unit and one set of ascorbic acid 
(vitamin C) unit, DPPH radical scavenging activi-
ties were evaluated by using spectrophotom-
etry.
ANTIOXIDANT ACTIVITY TEST OF BEE PROPOLIS EXTRACT  
(Apis mellifera L.) 
USING DPPH (1,1-diphenyl-2-picrilhidrazyl) FREE RADICALS 
SCAVENGING ACTIVITY
Titiek Martati, Faculty Pharmacy Univ.of Pancasila, Srengseng Sawah Jagakarsa, South Jakarta, titiek_martati@
yahoo.com, (021) 7864727: Shahyawidya, FFUP, Srengseng Sawah Jagakarsa, South Jakarta, 6281315377950
METHODS. Isolation of propolis. Pure propolis 
from 3 trees was isolated by extraction. Ap-
proximately 10 g of propolis was maserated 
with 500 ml of ethanol for 6 hour  at 40o C al-
lowed to stand 24 h and partition with ethyl 
acetate:water (1:1) 3 times 100 ml. Solvent was 
then evaporated using vacuum rotary evapora-
tor to obtain dry extract. The weight and yield 
of the dried extract were then calculated.(5)  
Analysis of free radical scavenging activity  Phy-
tochemical screening showed that ethanol and 
ethyl acetate extracts were contained flavo-
noids. The antioxidant activity was analyzed by 
1,1-diphenyl-2-picrylhydrazyl (DPPH) 0.4 mM. 
IC50 (Inhibition Concentration) is the concen-
tration of antioxidants (ppm) capable of inhibit-
ing 50% of the activity of free radicals. The data 
were analyzed using the regression equation. 
IC50 obtained from the equation y = a + bx 
where y = 50 and showed IC50 values of x. 
Data analysis. The data obtained were analyzed 
by two ways ANOVA (p<0.05), followed by the 
Least Significant Difference Test (LSD).
RESULTS AND DISCUSSION 
Yield of ethanol extract showed 89.93%,79.96%, 
81.83% and ethyl acetate extract 98.31%, 
75.41%, 66.55% and all extracts positive for fla-
vonoids.  IC50  of the ethanol extract of propo-
lis kapok tree is 10.04 ppm and ethyl acetate 
fraction of propolis kapok tree is 7.79 ppm. 
IC50 of the ethanol extract of propolis rambu-
tan tree is 11.02 ppm and ethyl acetate fraction 
of propolis rambutan tree is 9.07 ppm. IC50 
value of ethanol extract of propolis longan tree 
is 9.31 ppm and the ethyl acetate fraction of 
propolis longan tree is 6.35 ppm.
The highest antioxidant activity of ethyl ac-
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etate fraction of propolis longan tree because it 
has the smallest IC50 among all the samples of 
propolis, it caused by  vitamin C  and quercetin 
contained as antioxidants. Beside longan leaves 
also contain flavonoids which are antioxidants. 
Longan and rambutan fruit both contain vita-
min C  84 mg, 58 mg each in 100 g samples. 
The antioxidant activity of propolis extracts 
kapok tree is higher than the propolis extract 
rambutan tree, this is due to the presence of 
the polyphenol contained in kapok tree. Sugar 
or carbohydrates contained in the longan and 
rambutan tree act as  antioxidants. 
Statistical analysis (α = 0.05) showed significant 
differences in the respective extracts of propolis 
and propolis samples of each treatment. Two-
ways analysis of variance (ANOVA) was tested 
and showed significant differences result due to 
Fcount > Ftable is 956.82 > 3.98 for samples and 
3364.91 > 4.84 for treatment at α = 0.05. The 
LSD showed significant differences as indicated 
by the difference in the values.
CONCLUSION
1. Each sample of  propolis extract has antioxi-
dant activity due to the IC50  of less than 200 
ppm.
2. The best antioxidant is ethyl acetate fraction 
of propolis longan tree because it has the small-
est IC50 value among all the samples and treat-
ments (6.35 ppm). 
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INTRODUCTION
Hypertension is a major risk factor for death 
from cardiovascular disorders that result in 
20-50 % of all deaths . Control of hyperten-
sion is done with the goal of primary preven-
tion and prevent complications . Hypertensive 
therapy can be done with pharmacological and 
non-pharmacological therapies . Treatment of 
hypertension in general require considerable 
time and thus the cost is quite expensive This 
encouraged many people are turning pick herbs 
CAPSULE FORMULATION and  EVALUATION COMBINATION OF AQUE-
OUS EXTRACT  OF Phaleria’s (Phaleria macrocarpa (Scheff Boerf)) 
FRUITS and LEAVES as ANTIHIPERTENSIVE AGENT
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gram Studi Farmasi, Fakultas Farmasi UNJANI;  Julia Ratnawati, Program Studi Farmasi, Fakultas Farmasi UNJANI ; 
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ABSTRACT
Some plants have traditionally been used as an antihypertensive , one of which is the fruit and 
leaves of Phaleria’s (Phaleria macrocarpa (Scheff Boerf)).  Aqueous ekstrak  of phaleria’s ( Phaleria 
macrocarpa ( Scheff Boerf ) ) has been studied and shown to have efficacy as an antihypertensive 
. Based on research conducted by Wahyuningsih S, a combination of 25 % aqueous extract of the 
fruit of the phaleria’s  ( 155 mg / kg body weight ) and 75 % aqueous extracts of leaves phaleria’s 
( 75 mg / Kg body weight ) is the best combination for antihypertensive dose  to be able to use for 
human  it was designed for pharmaceutical capsules of the extract combinations , dose aqueous 
extract of fruits and leaves of phaleria’s is 1064 mg divided into 2 capsules size 0 with aerosil filler 
. Evaluations were conducted on combination  leaf and fruit  aqueous extract phaleria’s capsules is 
disintegration time , weight uniformity , moisture content , aflatoxin contamination , and microbial 
contamination . Evaluation results capsule fruit and leaf extracts aqueous phaleria’s is destroyed 
time 7 minutes 23 seconds , uniformity of weight 552 ± 14 mg , 4 % moisture content , aflatoxin 
contamination is negative, total plate count of 0 CFU / g , mold and yeast numbers 0 Colony Form-
ing Units ( CFU ) / g , E. coli bacteria contamination 0 CFU / g , contamination of Salmonella sp 0 
CFU / g , and the contamination of Pseudomonas aeruginosa 0 CFU / g . Evaluation results capsule 
combination of  fruit and leaves extracts aqueous phaleria’s indicates that the aqueous extract 
fruit capsules and leaves of phaleria’s with a dose of 552 mg / capsule meets the requirements 
BPOM No. 12 of 2014 on Quality Requirements for Traditional Medicines .
Keyword : Aqueous extract of fruits and leaves of Phaleria’s , antihypertensives, traditional medi-
cines,  capsules.
as alternative medicine(1). One plant that is 
often used by the public is the fruit Phaleria ‘s 
(Phaleria macrocarpa (Scheff Boerf)). Commu-
nity Phaleria ‘s used to treat diabetes mellitus , 
cancer , gout , heart , liver , high blood pressure 
, rheumatism , kidney and others . This plant is 
native to Indonesian and the flora is very easily 
cultivated and very promising in terms of the 
economy so as to be readily accessible to the 
public . For that need to be made herbal medi-
cine preparations . The preparation of herbal 
medicine is a form  in capsule , because it is 
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easier to form capsules in the formulation and 
can mask the taste of the plant extracts .
METHOD
Preparation of aqueous extract of leaves and 
fruit of Phaleriacarried by hot extraction which 
is done by boiling for 30 minutes repeated 3 
times, the liquid extract is then concentrated 
then dried at 900C to obtain dry extract.
After each dose was calculated from the aque-
ous extracts of fruit and leaves to be formulated 
into a hard shell capsule.
Evaluations were conducted on combination of 
leaves and fruit aqueous extract capsules is dis-
integration time, weight uniformity , moisture 
content , aflatoxin contamination, and microbial 
contamination.
RESULTS AND DISCUSSIONS
Formulation of aqueous extract of fruits and 
leaves Phaleria ‘s is a capsule dosage form . The 
preparation has been selected capsule that is 
easy and economical construction . In addition, 
the formulations into capsule form is intended 
to reduce taste and odor typical of the extract.
Determination of aqueous content of the fruit 
and leaf extracts Phaleria ‘s each capsule is 
based on test results of the antihypertensive 
effect of aqueous extracts of fruit and leaves 
Phaleria ‘s on male Wistar rats . (Wahyuningsih, 
2013) Capsule formulations aqueous extract of 
fruits and leaves Phaleria ‘s can be seen in Fig-
ure 1.
Results of testing the disintegration time cap-
sule aqueous extract of fruits and leaves Phal-
eria ‘s is 7 minutes 23 seconds so it can be said 
that the aqueous extract capsules fruit and 
leaf aqueous Phaleria ‘s meet the requirement 
that destroyed waktur requirements capsule is 
≤ 30 minutes.
Results of testing uniformity of weight capsule 
aqueous extract of fruits and leaves Phaleria 
‘s was 552 ± 14 mg , so it can be said that the 
capsule aqueous extract of fruits and leaves 
Phaleria ‘s meet the requirement that 20 cap-
sules of no more than 2 capsules , each of 
which weighs it deviates from the bulk density 
average -rata greater than 10 % and not the 
weight of its contents kapsulpun that deviate 
from the average bulk density of greater than 
25 %.
 
Picture 1. Capsule fruit and leaf aqueous ex-
tract Phaleria ‘s
Results of organoleptic examination showed 
preparations in powder form , distinctive smell 
, taste typical extract and brown.
Result of KLT from combination of Aqueous 
extract fruit and leaves phaleria’sshown in pic-
ture 2.
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Results of testing the disintegration time cap-
sule aqueous extract of fruits and leaves Phal-
eria ‘s is 7 minutes 23 seconds so it can be said 
that the aqueous extract capsules fruit and 
leaf aqueous Phaleria ‘s meet the requirement 
that destroyed waktur requirements capsule is 
≤ 30 minutes.
Results of testing uniformity of weight capsule 
aqueous extract of fruits and leaves Phaleria 
‘s was 552 ± 14 mg , so it can be said that the 
capsule aqueous extract of fruits and leaves 
Phaleria ‘s meet the requirement that 20 cap-
sules of no more than 2 capsules , each of 
which weighs it deviates from the bulk density 
average -rata greater than 10 % and not the 
weight of its contents kapsulpun that deviate 
from the average bulk density of greater than 
25 %.
According to the requirements, the maximum 
moisture content is 10 %, while the result of 
the determination of the aqueous content of 
the fruit aqueous extract capsules and leaves 
Phaleria ‘s is 4 % so that it can be said that the 
aqueous extract fruit capsules and leaves Phal-
eria ‘s meet the requirements.
TLC results capsule fruit and leaf aqueous 
extract Phaleria ‘s showed that capsules con-
taining aqueous extract of fruits and leaves 
Phaleria ‘s not contaminated with aflatoxin . 
Examination of aflatoxin contamination needs 
to be done especially when storage is not done 
properly extract . Aflatoxins are produced by 
Aspergillus flavus that may grow can cause liv-
er damage and carcinogenic , especially if used 
continuously ( Kepmenkes , 1994).
The test results of bacterial contamination 
of the aqueous extract fruit capsules and 
leaves Phaleria ‘s is negative, this shown that 
the aqueous extract fruit capsules and leaves 
Phaleria ‘s meet the requirements.
The results of contamination testing molds 
and yeast extract capsules fruit and leaf aque-
ous Phaleria ‘s is negative, this shown that the 
leaf aqueous extract capsules phaleria’s meet 
the requirements.
The test results of microbial contamination (E. 
coli, Salmonella sp,  and Pseudomonas aeru-
ginosa) aqueous extract capsules Phaleria ‘s 
fruit and leaves are negative, so  it mean that 
the aqueous extract combination of  fruit and 
leaves Phaleria ‘s capsules meet the require-
ments.
CONCLUSION
The results of the evaluation of the combi-
nation of aqueous extract fruit capsules and 
leaves Phaleria ‘s grading 552 mg extract per 
capsule , has met the requirements BPOM No. 
12 of 2014 on Quality Requirements for Tradi-
tional Medicines.
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Abstract
Gliclazide is an active substance which has a solubility practically insoluble in water and into BCS class II, low solu-
bility and high permeability.  In order to increase the solubility of gliclazide performed various methods of increas-
ing the solubility , one of which used the method of solid dispersion . Study begun by physical mixing glikazid and 
PVP K - 90 solid dispersions then glikazid with PVP K - 90 with a ratio of one ( 1 : 1 , 2 : 1 , 3 : 1 , 4 : 1 ) using the 
solvent methylene chloride . The results showed the highest solubility in solid dispersion glikazid and PVP K - 90 as 
compared with the pure and mixed physical glikazid glikazid with PVP K - 90 in four media ( water , pH 6.8 ; pH 4.5, 
and pH 1.2 ) . Dissolution rate of gliclazide solid dispersion PVP K - 90 is higher than the pure and mixed physical 
glikazid glikazid with PVP K - 90 . There were changes in the physical form of glikazid seen from the results of X-ray 
powder diffraction showed a change in the physical form of gliclazide crystalline form into a form more amorphous 
Keywords : gliclazide , PVP K - 90 , solid dispersion , dissolution rate
INTRODUCTION
Gliclazide are derivatives toluilsulfonilurea sec-
ond generation hypoglycemic drugs sulfonyl-
urea group used to treat diabetes mellitus type 
2. Long working six times more powerful with 
longer work more than 12 hours (t1 / 2 was 
approximately 10 hours).(1) Class of first -gen-
eration sulfonylureas include (asetohekasmida 
, klorpropamida , tolazamide and tolbutamide) 
, while in group II generation sulfonylureas 
include (glibenclamide , glipizida , gliclazide , 
glimepirida and Gliquidone) . Gliclazide includ-
ing active compounds belonging to the group 
II of the classification system biofarmasetika or 
Biopharmaceutical Classification System (BCS), 
which means that gliclazide has a low solubil-
ity in water but has a high permeability . Low 
solubility in water associated with a low disso-
lution rate , thus limiting absorption and result 
in low bioavailability(1).
Several experiments have been conducted to 
overcome formulation problems of drug solu-
bility class II such as the use of surfactants , 
cyclodextrins , nanoparticles , solid dispersions 
, micronization , and use of lipid components 
focused on improving drug bioavailability poor 
solubility in water(2). Table I. Solubility test results in four media namely 
phosphate buffer pH 6.8 ; hydrochloride buffer pH 
1.2; acetate buffer pH 4.5 and water
METHOD
Making Solid dispersions by solvent method 
using methylene chloride solvent . Gliclazide 
and PVP K - 90 were weighed separately and 
carefully in accordance with the ratio of each 
( 1 : 1 , 2 : 1 , 3 : 1 , 4 : 1 ) . PVP K - 90 was dis-
solved in methylene chloride until dissolved , 
then add gliclazide and shaken with a magnet-
ic stirrer. The solution was put in a drying cabi-
net until the solvent evaporates , and then put 
in a desiccator . After a solid mass is obtained 
, the mass of crushed and then sieved with a 
sieve mesh 60. Once it was ready to do fur-
ther testing.
RESULTS AND DISCUSSIONS
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Explanation
Picture 1. The results of the dissolution rate of glicla-
zide solid dispersions -PVP K90, pure glicazide and phi-
sycal mixture of glicazide and PVP K-90.
CONCLUSION
Results of this study of manufacture and char-
acterization of solid dispersions of gliclazide 
- PVP K90 showed that the manufacturing of 
solid dispersions with PVP K90 polymer can 
increase the solubility and dissolution rate of 
gliclazide . Deformed glikazid seen from the 
results of X-ray powder diffraction showed a 
change in the physical form of gliclazide crys-
talline form into a form more amorphous.
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INTRODUCTION
Inflammation is a protective mechanism of the 
local microcirculation to tissue injuries caused 
by physical trauma, stimulation by hazardous 
chemicals, heat, antigen-antibody reaction 
and the effect of microbial.[2]  It is known 
to be involved in the inflammatory reactions 
such as release of histamine, bradykinin, pros-
taglandins, fluid cell migration, extravasations, 
tissue break down and repair which are aimed 
at host defense and usually activated in most 
disease conditions. Para methoxy cinnamic 
acid (PMCA) known has topical anti-inflam-
matory effect but only 0.64 compare with 
Na-diclophenac.[4] Its cause PMCA is a poorly 
soluble drug substance (BCS II), the solubility 
in acetate buffer pH 4.2 ± 0.2 was 70.04 ± 0.66 
mg/liter.[3]  So in this study to increase the 
solubility PMCA loaded in nanoemulsion using 
soybean oil. And then the anti-inflammatory 
activity of PMCA in nanoemulsion was mea-
sured by the release rate, penetration rate 
through rat skin using Franz diffusion cell and 
histological test on mice’s ear skin.
MATERIAL AND METHODS 
Research Material:
Para methoxy cinnamic Acid (Sigma Aldrich), 
soybean oil (PT Kurniajaya),  Tween 80 (Sigma 
Aldrich), Span 80 (Sigma Aldrich), ethanol 96 
% (Merck), acetic acid (Merck), sodium ac-
etate (Merck), NaCl (Merck), NaH2PO4 (Mer-
ck), Na2HPO4 (Merck), croton oil (Sigma) and 
aquademineralisata (PT Brataco)
Animals 
Male Wistar rats (150 - 230 gm) and mince (20 
- 30 gm) were taken from PUSVETMA Suraba-
ANTI-INFLAMMATORY ACTIVITY OF PARA METHOXY CINNAMIC ACID 
(PMCA) IN NANOEMULSION USING SOYBEAN OIL
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ya. The animals were housed under standard 
conditions of temperature (25±2)⁰C, 12/12 
hours light/dark cycles and fed with standard 
pellets. All animal experiments were conduct-
ed with the permission from Animal Care and 
Use Committee (ACUC) of Veterinary Faculty, 
Airlangga University, Indonesia. (Reference 
number; 378-KE).
Research Method
Nanoemulsion formula containing PMCA
PMCA in nanoemulsion produced base on the 
formula presented in Table 1.
Table 1. PMCA Nanoemulsion Formula
Nanoemulsion formula used in this study is 
the result of a previous study by Erawati et.al, 
using a combination of surfactant Tween 80 
and Span 80 with a ratio of 9:1 (having HLB 
14), the ratio of surfactant and co surfactant 
6:1, the ratio of oil phase (soybean oil) and 
water phase (acetate buffer solution pH 4.2 ± 
0.2) is 27.5:1. [3]
Solubility test
PMCA solubility test; on the nanoemulsion 
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using soybean oil (as oil phase) added with 
500 mg PMCA, then it was sonicaited for 10 
minutes and shaking with 150 rpm for 60 min-
utes. And then, the amount of PMCA dissolve 
in nanoemulsion was determined using spec-
trophotometer. After that the nanoemulsion 
PMCA characterized include; density, viscosity, 
pH, droplet morphology, droplet size and poly-
dispersity index.
Release test
Membrane Preparation; the membrane used 
in the test release of PMCA in nanoemulsion 
system is a cellophane membrane. Membrane 
cut to size, then immersed in aqua-demin-
eralization for ± 12 hours. A moment before 
use, the membrane is drained until no water is 
dripping, and then mounted on the surface of 
the receptor compartment of Franz diffusion 
cell.
Measurement the amount of the PMCA re-
lease from the nanoemulsion; receptor com-
partment of Franz diffusion cell filled with 
phosphate buffer pH 6.0 ± 0.2 up to full. Then, 
2 ml of nanoemulsion PMCA inserted into the 
donor compartment. Experimental tempera-
ture is set and maintained at a temperature of 
32 ± 2°C. Magnetic stirrer rotated at a speed 
of 100 rpm. Samples of 1 ml were taken with-
in a certain time interval, i.e. at 0, 5, 10, 15, 
30, 45 minutes, and then 1, 1.5, 2, 3, 4, 6, 8, 
10, 12, 24 hours. Immediately after sampling 
medium was replaced with phosphate buffer 
pH 6.0 ± 0.2 with a volume of samples taken. 
Subsequently, samples were taken observed 
with spectrophotometer. PMCA concentration 
in the sample was calculated using the regres-
sion equation of standard curve. Determina-
tion of PMCA cumulative amount released per 
unit membrane area (mg/cm2) was calculated 
from the concentration obtained each time 
(μg/ml) which had been corrected with the 
Wurster’s equation. Furthermore, multiplied 
by the number of medium and divided by the 
membrane surface area. The results obtained 
by the cumulative number of PMCA released 
per unit time. The release profile of PMCA, is 
done by making a relations curve between the 
cumulative number of PMCA released (mg/
cm2) versus time (minutes). The release rate 
of (Flux release) PMCA was obtained from the 
slope of the regression equation in the steady 
state.
Penetration test
Membrane Preparation; skin male Wistar rats 
that had been shaved used as the membrane 
in the penetration test of PMCA in nanoemul-
sion system. 
Measurement the amount of PMCA penetrate 
through rat skin; receptor compartment of 
Franz diffusion cell filled with phosphate buf-
fer pH 7.0 ± 0.2 up to full. Then, 2 ml of nano-
emulsion PMCA inserted into the donor com-
partment. Samples of 1 ml were taken within a 
certain time interval as in release test.
RESULT AND DISCUSSION 
The PMCA solubility in nanoemulsion 3.07 ± 
0.19 g/liter (presented in Table 2) increased 
than its solubility in acetate buffer pH 4.2  
0.2 is 70.04 ± 0.66 mg/liter. The characterics of 
nanoemulsion containing PMCA presented in 
Table 3; the density value was 1.0263 ± 0.0002 
is almost equal to the density of water; the 
viscosity was 5.58 ± 0.05cP; the pH value was 
4.47 ± 0.006 it was`in the range of human skin 
pH, so it will not cause irritation; the droplet 
size was 57.3 ± 7.6 nm and the polydispersity 
index was 0.548 ± 0.044 it was indicate a mod-
erate particle size distribution.[1] The drop-
let morphology of empty nanoemulsion and 
nanoemulsion containing PMCA in saturated 
solubility by TEM.type JEM-1400 was resented 
in Figure 1.
Table 2. The solubility of PMCA in nanoemul-
sion and in acetate buffer pH 4.2  0.2
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Table 3. The characteristics of nanoemulsion 
containing PMCA
The release profile and the release rate of PMCA in acetate buffer pH 4.2  0.2 and in nanoemul-
sion were presented in figure 2 and figure 3. After investigate for 24 hours (1440 minutes) the 
result shows that the release rate of PMCA in nanoemulsion (0.4024± 0.0339 μg/cm2/minute) 
increased compare with it in acetate buffer pH 4.2  0.2 is 0.0239 ± 0.0003 μg/cm2/minute. 
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Also the penetration rate of PMCA in nano-
emulsion was increased too (0.1513  0.0314 
μg/cm2/minute) compare with the penetra-
tion rate of PMCA in acetate buffer pH 4.2  
0.2 (0.0341 0.0003 μg/cm2/minute) as pre-
sented in figure 4 and 5. The increased of pen-
etration rate of PMCA in nanoemulsion caused 
by 1) the solubility of PMCA in nanoemulsion 
increased (more than 43x compare with the 
solubility of PMCA in acetate buffer pH 4.2  
0.2) and 2) the surfactant and co surfactant 
in nanoemulsion formula can function as en-
hancers.
From figure 6 and table 4, known that 
the anti-inflammatory effect of PMCA in 
nanoemulsion (F I*) higher than the anti-
inflammatory effect of PMCA in acetate 
buffer pH 4.2  0.2 (control). The result 
of statistical test using ANOVA-one way 
(P = 95%), known there are no signifi-
cant different between the ears mice skin 
thickness after treated with PMCA in na-
noemulsion (F I*) with health skin (K-) 
but thinner than inflammation skin (K+) 
also with the ears mice skin after treated 
with PMCA in acetate buffer pH 4.2  
0.2 (control).
Figure 6. The histology profile of ears mice 
skin, health skin (K-), inflammation skin (K+), 
after treated with PMCA in acetic buffer pH 4.2 
 0.2 (control), and in nanoemulsion (F I*)
CONCLUSION
The nanoemulsion with soybean oil as drug 
delivery system can increase the anti-inflam-
matory activity of PMCA.
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INTRODUCTION
Vesicular system, both liposomes and nio-
somes are uni- or multi lamellar spheroidal 
structures composed of amphiphilic molecules 
assembled into bilayers. They are considered 
primitive cell models, cell-like bioreactors and 
matrices for bio encapsulation. In the recent 
years, nonionic surfactant vesicles known as 
niosomes received great attention as an alter-
native potential drug delivery system to con-
ventional liposomes. Moreover, compared to 
phos-pholipid vesicles, niosomes offer higher 
chemical and physical stability (Vora et al., 
1998) with lower cost and greater availability 
of surfactant classes (Manconi et al., 2006). 
Niosomes have been reported to enhance 
the residence time of drugs in the stratum 
corneum and epidermis, while reducing the 
systemic absorption  of the drug and improve 
penetration of the trapped substances across 
the skin. In addition, these systems have been 
reported to decrease side effects and to give a 
considerable drug release (Schreier and Bou-
wstra, 1994). They are thought to improve 
the horny layer properties both by reducing 
trans epidermal water loss and by increasing 
smoothness via replenishing lost skin lipids 
(Junginger et al., 1991). Moreover, it has been 
reported in several studies that compared to 
conventional dosage forms, vesicular formula-
tions exhibited an enhanced cutaneous drug 
bioavailability (Manconi et al., 2006; Mura et 
al., 2007).
Non-ionic surfactant in niosome system can af-
fect the conformation alstructure of skin lipid 
bilayer to facilitate penetration  of the drug 
(Shahiwala, 2002). In addition, the niosome 
system can  be a depo of drug on hydrophobic 
layer (Tangri&Khurana, 2011) so that the ser-
vice life ofthe drug becomes longer. 
This research was to compare the penetration 
of diclofenac sodium in span 20 and span 60 
niosomal system with molar ratio of diclof-
enac sodium– span – cholesterol was 1:6:6.
MATERIALS AND METHODS
Diclofenac sodium (Yung Zip Chemical Ind-Tai-
wan), Span 20 and span 60  (Sigma), choles-
terol (Sigma), HPMC 4000 (Shin-Etsu Chemical 
Co. Ltd),  chloroform (Biesterfeld Siemsgluss 
International GmBH),  on pharmaceuticals 
grade. Sodium Cloride, Na2HPO4.2H2O and 
KH2PO4 (E.Merck) on  analytical grade
Identification and standardization of drug 
and other excipients were carried out as the 
official procedures mentioned in respective 
monographs.
Preparation of Niosomes 
Niosomes containing diclofenac sodium were 
prepared by Reverse Phase Evaporation Tech-
nique using non ionic surfactant (span 20 and 
span 60) with a molar ratio of diclofenac so-
dium : span : cholesterol 1 : 6 : 6. Cholesterol 
and surfactant were dissolved in chloroform, 
add this mixture with a solution of diclofenac 
sodium in free carbon dioxide aqua and then 
sonicated them on 4 – 5 oC for 16 minutes. 
Pour into this mixture a solution of buffer 
phosphate saline with pH 7.4and then sonicat-
ed again on 4-5oC for 12 minutes. Evaporation 
proccess to remove chloroform at temperatur 
40oC and pressure ± 200 mmHg. The evalua-
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tion of niosome included organoleptics (odor, 
color and consistency), morphology and size 
of vesicle, entrapment efficiency, and in-vitro 
drug penetration across abdominal skin from 
male Wistar rat.
RESULT AND DISCUSSION
Organoleptics of Niosome
Entrapment efficiency of Span 20 and Span 60
Span 60 (C=16) has a longer chain alkyl than 
span 20 (C=12), consequently the molecule 
of Span 60 is bigger and more hydrophobic. 
Whereas span 20 with HLB 8,6 (Rowe, 2009) 
is more hydrophilic. Diclofenac sodium has a
partition coefficient value 13,4 (O’Neil, 2001), 
consequently, diclofenac sodium more hydro-
phobic. Because of this reason, span 60 more 
ability to trapped a diclofenac sodium than 
span 20, consequently the amount of diclof-
enac sodium which is trapped more than span 
20, and the amount of diclofenac sodium 
whish is trapped is 
bigger. In Niosom span 60, the entrapment 
efficiency value is 65%, whereas in niosome 
span 20 has an entrapment efficiency value 
43%.
Table 1. Organoleptic Evaluation Niosome 
Span 20 and Span 60
The organoleptic of diclofenac niosome span 
20 and span 60 was similary, but consistency of 
niosome span 60 is higher than niosome span 
20.
Morphology of Niosome Span 20 and Span 60
Morphology of  diclofenac sodium span 20 and 
span 60  were evaluated with Scanning Elec-
tron Microscopy (SEM) with a magnification of 
2500 times.This result showed on figure 1 and 
2.
The size of niosome diclofenac sodium span 
60 (1.3 -14.00 µm)   higher than niosom diclof-
enac sodium span 20 (0.1-3,75μm).
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Table 4. pH value of niosome span 20 and span 
60
The statistical test showed that  different pH 
value of  niosome span 20 and niosome span 
60 is not significant, so
influence pH on ionized / unionized drug in 
this research which may affect the penetration 
does not exist.
Penetration Test of Diclofenac Sodium
Penetration profile of diclofenac sodium span 
20 and span 60 showed in figure 3 and 4. 
Figure 3 Penetration profile of diclofenac so-
dium  span 20 niosome system and control
Table 8. Membrane Permeability for Diclof-
enac Sodium Niosome Span 60
Penetration test on this research used disolu-
tion medium solutio buffer phosphat salin pH 
7,40,05 at temperature 37 oC with with the 
speed 100 rpm as long as 6 hours  In penetra-
tion test, it was used penetration flux  and 
permeability of membrane to diclofenac so-
dium as a penetration parameter. Each nio-
some (niosome span 20 and niosome span 
60 are performed three times replication and 
they were compared with a control where it 
the same formula but wasn’t made a niosome 
system. The result of penetration test of diclof-
enac sodium span 20 was obtained flux 1,3062 
 0,0929 µg/cm2/minute and control 1,1010 
 0,1553µg/cm2/minute. Diclofenac sodium 
span 60 was obtained flux 0,8627 ± 0,1094 
µg/cm2/minute and control 0,5003 ± 0,0076 
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µg/cm2/minute.
Based on statistically analysis, It can be con-
cluded that no significant differences of flux 
and membrane permeability between diclof-
enac sodium niosom span 20 and control was 
found, whereas there were significant differ-
ences on the diclofenac sodium niosom span 
60. Flux of diclofenac sodium niosom span 20 
was higher than diclofenac sodium span 60, 
this may be due to low entrapment efficiency 
of diclofenac sodium span 20 caused very few 
diclofenac sodium was unentrapped.
CONCLUSION
It can be conclude that unentrapped diclof-
enac sodium had been penetrated within 6 
hours study, therefore it is recommended to 
have longer study period and also suggested 
to separate niosom and its medium.
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INTRODUCTION
Lime (Citrus aurantifolia) is a plant that is ef-
ficacious and commonly used by the people. 
It is used for juice, dessert, pickle, medicinal 
purpose and cosmetic.  In the field of beauty 
lime is used to whiten the skin, obesity and 
cellulite and has an astringent and toning ac-
tion to clear oily skin and acne 1,2. 
The content of lime is very much, such as car-
bohidrate, sugar, protein, minerals (Ca, Fe, Mg, 
P, K, Na, Zn), vitamins (ascorbic acid, thiamin, 
riboflavin, niacin,vitamin B6, folate, vitamin 
B12, vitamin A, vitamin E)3 and volatile oil 
that most important flavoring oils, lemon es-
sential oil are complex mixtures of chemical 
compounds like limonene, γ-terpinene, citral, 
linalool and β-caryophyllene 4. The organic 
acid component of acid lime juice is primarily 
composed of citric acid 5. Ascorbic acid and 
citric acid have antioxidant activity and  one of 
the activities of antioxidant is to prevent pre-
mature aging 6,    so the lime can be used as 
a sunscreen.
This study was to determine of physical and 
chemical characteristics of the juice of lime 
gel formulation with dosage levels of 10%, 20% 
and 30% in the CMC-Na base.
MATERIAL AND METHODS
The research material used is lime (Citrus au-
rantifolia) was obtained from Malang and was 
identified by Materia Medica Technical Service 
Unit. 
PREPARATION GEL JUICE OF LIME
The composition of the gel lime juice with dos-
age levels of 10%, 20% and 30% seen in Table 1. 
Table 15. The composition of the gel formula-
tion of lime juice.
Method of preparation gel juice of lime as fol-
lows: Making gel of juicy lime begins by dis-
persing CMC-Na in aqua CO2-free to make a 
gelling base. Juice of lime mixed into the gell-
ing base, then nipagin dissolved in propylene 
glycol, which is then appended to the gelling 
base that contained the juice of lime slowly 
and mixed until homogeneous. Last added 
aqua distilled until the desired weight and 
stirred until homogeneous.
EVALUATION PREPARATION
Characterization of the gel formulation of 
lime juice
Characterization of the gel formulation of lime 
juice includes organoleptic,viscosity and pH.
Organoleptic examination
 Organoleptic examination of the gel formula-
tion of lime juice includes texture, color, and 
odor
. 
Measurement of the viscosity
Measurement of the viscosity of the gel of 
lime juice using a cup and bob Viscometer 
(Visco Rion tester vT-04F).
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Measurement of pH gel of lime juice
Measurement of pH gel of lime juice done  by 
20 + Basic pH meter.
Determination of the release of citric acid 
from lime  juice gel formulation
Diffusion cells, which had been prepared, put 
into the glass beaker at  test release tools con-
tained  CO2-free distilled water. The experi-
ments were performed at room temperature 
(270C ± 0,50C). Paddle rotated every 10 min-
utes, 10.0 ml of footage taken at minute 0, 
60, 120, 180, 240 and 300, subsequently it’s 
absorption observed with UV-Vis spectropho-
tometer at a wavelength of 512 NM. To ac-
count for the dilution of 10.0 ml of the release 
medium, the measured levels corrected with 
Wurster equation.
Determination of acceptability of lime juice gel 
preparation.
The test is performed using a 10 woman aged 
19-24 years old with no distinguishable types 
of skin. Respondents using gel juice of lime on 
the forearm and then asked his opinion about 
the ease of smeared, sensation while in use 
and easy to clean.
RESULTS AND DISCUSSION From the results of 
the observation appears that the organoleptic 
of lime juice at a dosage level of 10%, 20% and 
30% has a dense and creamy texture, but it 
possesses a different color and odor, the lime 
juice gel at a dosage of 10% is clear and odor-
less, the dosage of 20% is slightly yellowed 
and a bit smelly, whereas dosage of 30% is 
yellow with lemon smell sharper. Its suggest 
that elevated dosage of lime juice will increase 
the intensity of the color gel preparation and 
sharpen the lemon smell. For the viscosity of 
lime juice gel preparations at a dosage of 10 
%, 20% are similar, and at dosage of 30% the 
viscosity of gel of lime juice is increasing (Table 
2).
Table 2. Characteristic of lime juice gels at dos-
age of 10% (F1), 20% (F II) and 30% (F III) of 
lime juice.
Figure 1: Histogram of AUC of citric acid re-
lease  from the lime juice gel preparation at 
dosage of 10% (F I), 20% (F II) and 30% (F III) 
of lime juice.
Measurement of pH on the lime juice gel at a 
dosage of 10% and 20% are  similar, where use 
the gel of lime juice at a dosage of 30% is high-
er  than the other  formula (Anova, α=0.05). 
This is caused by  the pH of lime juice is 2.33, 
so that the addition of lime juice will lower the 
pH of the gel preparation (Table 2).
Based on the data obtained from the release 
of citric acid from lime juice gel preparation, 
calculated the area under the curve (AUC) to 
determine the release rate of citric acid  from 
the gel of lime juice (Citrus aurantifolia). The re-
sult of AUC calculation can be seen in Figure 1.
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 It is showed that the AUC of the three formulas 
are not significantly different (Anova, α=0.05). 
It can be concluded that elevated concentra-
tion of lime juice on the formula of this gel for-
mulation does not increase the value of AUC 
on a test release of citric acid from lime juice 
gel preparation. These may be caused by the 
interaction between active ingredient with 
material  and viscosity of preparation.
From the results of the test acceptability of gel 
lime juice preparation is known that the for-
mula contained 30% of lime juice has a high 
percentage of ease smeared (softness) and 
cold sensation. For ease of cleared, gel  con-
tent  of 20% of lime juice has a higher percent-
age, this is due to its has lower viscosity than 
gels lime juice content of 30%, so that the for-
mula of gel contained of 30% lime juice  is the 
most acceptable (Table 3).
Table 3. The results of acceptability test of 
lime juice gel content of lime fruit at dosage of 
10% (F1), 20% (F II) and 30% (F III).
CONCLUTION
The results obtained in this study showed that 
the differences in the levels of the juice of lime 
(10%, 20% and 30%) on lime juice gel formula 
with CMC-Na base produces a characteristic 
and acceptability are different, but the results 
of the test release of citric acid from lemon 
juice gel is similar. Base in characteristic physi-
cal (organoleptic, pH and viscosity), accept-
ability and effectiveness of the  lime juice gel 
formulations, the formula that content of 20% 
of lime juice is the best. 
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ABSTRACT
The aim of this study are to prove the influence 
of hepatoprotective time infusion of Bidens 
pilosa L. herb in acute and the most effective 
protection time of the Alanine Aminotrans-
ferase (ALT) and Aspartate Aminotransferase 
(AST) serum in rats that induced by carbon tet-
rachloride.
This study is a pure experimental with ran-
domized complete direct sampling design. A 
total of 30 female Wistar rats, age 2-3 months, 
weighing ± 150-250 g were divided into seven 
groups by five rats each. Rats in group I were 
orally administered 2 mL/kgBB olive oil, group 
II were intraperitoneal administered 2 mL/
kgBB carbon tetrachloride 50% as hepatotox-
in, group III were orally administered 2 mg/
kgBB infusion of Bidens pilosa L. for 6 hours, 
group IV administered 1 mg/kgBB infusion of 
Bidens pilosa L. and was injected with 2 mL/
kgBB carbon tetrachloride 50% after 1 hours, 
group V administered 1 mg/kgBB infusion of 
Bidens pilosa L. and was injected with 2 mL/
kgBB carbon tetrachloride 50% after 4 hours, 
group VI administered 1 mg/kgBB infusion of 
Bidens pilosa L. and was injected with 2 mL/
kgBB carbon tetrachloride 50% after 6 hours. 
Data of ALT-AST activity were analyzed by One 
Way ANOVA and continued to Post Hoc Schef-
fe test.  
This study showed that infusion of Bidens pi-
losa L. herb in acute influence Alanine Amino-
transferase (ALT) serum and Aspartate Amino-
transferase (AST) serum in rats that induced 
by carbon tetrachloride. The most effective 
protection time to give influence of Alanine 
Aminotransferase (ALT) serum and Aspartate 
Aminotransferase (AST) serum in rats that in-
duced by carbon tetrachloride is 4 hours with 
% hepatoprotective ALT serum was 107.83 % 
and the % hepatoprotective AST serum was 
102.34 %.
  
Key words : Bidens pilosa L., herb, infusion, 
acute, ALT, AST, carbon tetrachloride
INTRODUCTION
Liver is an important organ which regulating 
homeostasis in the body. It is involved in the 
detoxification and excretion of various endog-
enous and exogenous substances. It protects 
against the harmful effects of drugs and chem-
icals and thus frequently exposed to variety 
of toxicants resulting in liver diseases1. The 
major functions of the liver are carbohydrate, 
pretein and fat metabolism, detoxification, se-
cretion of bile and storage of vitamin. Thus, to 
maintain a healthy liver is a crucial factor for 
overall health and well being. But it’s continu-
ously and variedly exposed to environmental 
toxins, and drug abuse along with alcohol and 
prescribed & over-the-counter drug which 
can eventually lead to various liver ailment 
like hepatitis, cirrhosis, and alcoholic liver 
disease2,3. Liver diseases, a leading cause of 
death in many countries, is a major concern 
throughout the world. The different medical, 
surgical, and therapeutic methods available 
at present for the treatment of liver diseases 
are inadequate with generally poor results4. 
Therefore, it is essential to search for newer 
drugs for the treatment of liver diseases.
Liver injury due to chemicals (or) infections 
agents may lead to progressive liver fibrosis 
and ultimately cirrhosis and liver failure4. 
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However, no effective treatment that delays 
disease progression and complications has yet 
been found. Several recent studies suggest 
that traditional herbs and micronutrients such 
as carotenoids and selenium may be useful for 
this purpose5,6.
Carbon tetrachloride CCl4 is widely used for 
experimental induction of liver damage7. The 
principle cause of carbon tetrachloride (CCl4) 
is induced hepatic damage in lipid peroxida-
tion and decreased activities of antioxidant 
enzymes and generation of free radicals8,9. 
Various medicinal plants have been used to 
treat for various diseases in all over the world. 
Nowadays, Indian medicinal plants are belong-
ing to about 40 families were investigated as 
liver hepatoprotective drugs10.
Figure 1. Bidens pilosa L.
The Bidens pilosa L. has various chemical 
constituents like polyacetylenes, polyacety-
lenic glycosides, aurons, auron glycosides, p-
coumeric acid derivatives, caffeoylquinic acid 
derivatives, pheophytins, diterpenes, tannins, 
phytosterols, ascorbic acid, carotene, essen-
tial oils, saponins, steroids and flavonoids and 
many others were recognized in this plant13. 
MATERIAL AND METHODS
Procurement and Authentification of the Plant 
The herbs of Bidens pilosa L. were collected 
from local area of village Jenengan, Maguwo-
harjo, Depok, Sleman, Yogyakarta and it was 
authenticated by Yohanes Dwiatmaka, M.Si., 
at Laboratory of Pharmacognosy and Phyto-
chemistry, Faculty of Pharmacy Sanata Dhar-
ma. The herb was deposited at Department of 
Pharmacognosy and Phytochemistry, Faculty 
of Pharmacy Sanata Dharma.
Preparation of An Infusion of Bidens pilosa L.
The infusion was prepared with the dry pow-
dered herbs 10,0 g in 100 mL of aqudest at 
teperature 90 0C for 15 minutes so obtained 
the concentrate of infusion 10%.     
Animals
Female Wistar albino rats (120-200 g) used 
in studies, was procured from Laboratory of 
Imonology, Faculty of Pharmacy Sanata Dhar-
ma, Yogyakarta. The animals were fed with 
standard pellet diet (AD-2 pellet) and reverse 
osmosis (RO) water. All the animals were ac-
climatized for a week before use. Before and 
during the experiment, the rats were kept in 
a standard environmental conditions (temp. 
25-28 0C and 12h light / dark cycle). The ex-
perimental protocols were approved by Medi-
cal and Health Research Ethics Committee 
(MHREC) after scrutinization. Animals were 
received the drug by oral administration. The 
laboratory conditions duly undertaken by reg-
istered veterinary practitioner.
Chemicals
All the chemicals and solvents were of ana-
lytical grade. Standard kits for SGOT and SGPT 
were obtained from PT. Kimia Farma, Indone-
sia.
Treatment schedule
Animals were divided into six groups of five 
animals each in all the sets of experiments. 
CCl4 mixed with olive oil (1:1) was used as 
hepatotoxic agent. The drugs were adminis-
tered in 1, 4, and 6 hours after CCl4 admin-
istration. 
Group I was olive oil control by giving as much 
as 2 mL/kgBW intraperitoneally; Group II was 
carbon tetrachloride hepatotoxin control 
dose 2 mL/kgBW intraperitoneally; Group III 
was control treatment given 2 g/kgBW infu
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sion of Bidens pilosa L. herb orally; Group IV 
was treatment group for infusion of Bidens pi-
losa L. dose 1 g/kgBW and was injected with 2 
mL/kgBW carbon tetrachloride after 1 hours; 
Group V was treatment group for infusion of 
Bidens pilosa L. dose 1 g/kgBW and was in-
jected with 2 mL/kgBW carbon tetrachloride 
after 4 hours; Group VI was treatment group 
for infusion of Bidens pilosa L. dose 1 g/kgBW 
and was injected with 2 mL/kgBW carbon tet-
rachloride after 6 hours.  
Assessment of hepatoprotective activity  
After 24 hour of  CCl4 administration, all 
groups had blood drawn at the orbital sinus 
region. Blood samples were allowed to clot 
for 10 min at room temperature. Serum was 
separated by centrifugation at 8000 rpm at 30 
0C for 15 min and utilized for the estimation 
of various biochemical parameters including 
SGOT and SGPT13. After collection of blood 
samples, the animals were sacrified under 
deep ether anesthesia.
The hepatoprotective activity, expressed as 
percentage hepatoprotection (H), was calcu-
lated using the following equation,
H = [1-(T-V)/(C-V)] x 100
Where, T = mean value of treatment group, C 
= mean value of CCl4 control group, and V = 
mean value of olive oil control group14. 
Statistical analysis
The results of the biochemical estimations are 
reported as mean ± S.E. Statistical analysis was 
done by one-way analysis of variance (ANOVA) 
followed by Scheffe test by using 16th version 
of SPSS software. P values < 0.05 were consid-
ered as significant. 
RESULTS AND DISCUSSION
The effect of exposure time of Bidens pilosa 
L. infusion on carbon tetrachloride induced 
hepatotoxicity in rats is presented in table no 
1. The levels of SGOT and SGPT were markedly 
elevated. In hepatotoxin control group as com-
pared to the olive oil control, indicating hepa-
tocellular damage. The activities of biomarker 
enzymes for liver such as SGOT and SGPT were 
elevated on administration of CCl4 to 409.6 ± 
7.79 and 149.2 ± 1.39 U/L respectively in com-
parison to olive oil control values of 101.8 ± 
2.08 and 57.2 ± 3.07 U/L respectively. Treat-
ment of the rats with infusion of Bidens pilosa 
L., a standarized infusion of Bidens pilosa L. at 
dose levels 1 g/kgBW, prevented CCl4-induced 
elevation of SGOT and SGPT. The effect of ex-
posure time of Bidens pilosa L. infusion on 
carbon tetrachloride induced hepatotoxicity 
in rats prevented the CCl4 induced hepato-
toxicity as they decreased the levels of SGOT 
(106.4 ± 1.81; 94.6 ± 1.50; 234 ± 3.67 U/L) and 
SGPT (71.4 ± 3.14; 50 ± 3.08; 69 ± 3.00 U/L). 
% hepatoprotective SGPT and SGOT group IV 
are 84.57 and 98.51 %; group V are 107.83 and 
102.34 %; group VI are 87.17 and 57.05%. 
Table 16. The effect of exposure time of Bidens 
pilosa L. infusion on carbon tetrachloride in-
duced hepatotoxicity in rats
Keys: Values are Mean ± S.E. (n = 5 animal per 
group); SGOT –Serum Glutamic Oxaloacetic 
Acid Transaminase; SGPT- Serum Glutamic Py-
ruvic Transaminase; 
P denotes statistical not significance P*>0.05 
vs CCl4; significance P**<0.05 vs CCl4.
In the group III CCl4 induced animals were 
showed the level of marker enzymes signifi-
cantly elevated (P<0.05) when compared to 
the group II (control) oilve oil. But there was 
a sig
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Figure 2. Mechanism biotransformation and 
oxidation of carbon tetrachloride17
Figure 4. Chemical Structures of Quercetin12
This study was under taken to demonstrate the 
protective ability and the effect of exposure 
time of Bidens pilosa L. infusion on carbon tet-
rachloride induced hepatotoxicity in rats. The 
best exposure time of Bidens pilosa L. infusion 
is in 4th hours after administered carbon tetra-
chloride, % hepatoprotective SGPT and SGOT 
are 107.83 and 102.34 %. The damage of the 
liver caused by CCl4 was evident by the altera-
tion in serum marker enzymes concentration 
nificant decrease of the enzyme level (P<0.05) 
in the infusion of Bidens pilosa L. herb, treated 
animals (group IV-VI). Carbon tetrachloride is 
reported to produce free radicals, which affect 
the cellular permeability of hepatocytes lead-
ing to elevated levels of serum biochemical pa-
rameters like ALT and AST.
 
CCl4 is the one of the most commonly used 
hepatotoxins in experimental studies of liver 
diseases15. The hepatotoxic effects of CCl4 
are largely due to its active metabolite, tri-
chloro methyl (CCl3) radical16 that disrupts 
the structure and function of lipid and protein 
macromolecules in the membrane of the cell 
organelles. The elevated levels of serum bio-
marker enzymes are indicative of cellular leak-
age and loss of functional integrity of the cell 
membrane due to toxicity produced by CCl4. 
Significant rise in serum enzymatic concentra-
tion viz. SGOT and SGPT could be taken as an 
index of liver damage.
beside the clinical signs and histopathology. 
The use of infusion of Bidens pilosa L. protects 
the liver from damage by CCl4 as evident by 
biochemical markers of liver damage. The 
mechanism of the hepatoprotective action 
of the plant is uncertain but may be related 
to the ability of the plant to inhibit lipid per-
oxidation in the liver. The CCl4 induced hepa-
totoxicity produced in rats leading to hepatic 
injury triggers the generation of toxic radicals 
which can be masked by using a correct an-
tioxidant in adequate amount. The presence 
of flavonoids and polyphenols in Bidens pi-
losa L. explain its role in hepatoprotection by 
inhibiting the free radicals mediated damage 
claimed that flavonoids and polyphenols were 
antioxidant agent and may interfere with free 
radicals formation stated that hepatoprotec-
tive activities of certain flavonoids are known. 
The hemorrhage caused by CCl4 in the liver 
was minimized by use infusion of Bidens pi-
losa L. as flaovonids are known to be vasculo 
protector. On the basis of results obtained it 
can be concluded that the infusion of Bidens 
pilosa L. seems to possess hepatoprotective 
activity in Wistar albino rats.   
Quercetin is one of the flavonids of Bidens 
pilosa L. herb, is a well established hepato-
protective drug capable of decreasing the 
elevated levels of liver enzymes in various 
drug induced hepatotoxicity through multiple 
actions. The antioxidant property and cell-re-
generating functions as a result of increased 
protein synthesis are considered as the most 
important18.
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CONCLUSION
In the present study, administration of infusion 
of Bidens pilosa L. containing quercetin (flavo-
noids group) significantly protected against 
CCl4 induced hepatotoxicity in rats. The best 
exposure time of Bidens pilosa L. infusion dose 
1 g/kgBW in 4th hours after administered car-
bon tetrachloride, % hepatoprotective SGPT 
and SGOT are 107.83 and 102.34 %. Further 
studies are needed to evaluate the potential 
usefulness of this infusion in clinical condi-
tions associated with liver damage.
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INTRODUCTION
Cancer is still remains to be the most feared 
diseases in the modern world. In most of 
developed countries, cancer is the second 
biggest cause of death after cardiovascular 
disease. Judged from its development, the 
number of cancer cases in developing coun-
tries is less compared than in the developed 
countries, but mortality cases is greater [1] . 
Based on research conducted by Basic Medi-
cal Research, cancer ranks sixth in the various 
largest disease cause of death in Indonesia [2], 
which also one of developing countries. Based 
on the facts that rapid development of cancer 
and the failures of cancer therapy goal, the 
development of anticancer agent is needed to 
treat cancer, with the aim of obtaining drugs 
with higher cytotoxic activity, lower toxicity 
and more selective in the receptor binding. 
One example of an anticancer agent is urea.
Various kinds of research have been conduct-
ed to confirm that urea derivatives also have 
anticancer cytotoxic activity, for example, thi-
enopyridine urea working as anticancer agent 
by inhibiting KDR kinase [3], phenylurea and 
its derivative were developed as anticancer 
agent [4], hydroxyurea as an anticancer agent 
which has been used clinically as well. Howev-
er, this urea derivative anticancer compounds 
need to be developed to improve its potency 
and lower its toxicity. To increase its activity, 
in our previous research we tried to develop 
a new urea derivative anticancer agent. Our 
previous research has confirmed that in silico 
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study of N-(phenylcarbamoyl)isobutiramide 
gives higher anticancer activity than hydroxy-
urea by using 2YWP receptor. In silico study 
approach has became the earliest way to de-
velop a new urea derivative anticancer agent. 
The results of in silico study is a proof that N-
(phenylcarbamoyl)isobutiramide deserves to 
be synthesized. N-(phenylcarbamoyl)isobuti-
ramide obtained from the synthesis of starting 
material phenylurea with isobutiril chloride 
through acylation reaction. With the aim to de-
termine the potency of N-(phenylcarbamoyl)-
isobutiramide as an anticancer agent, we con-
ducted a research to assay cytotoxic activity of 
N-(phenylcarbamoyl)isobutiramide by  MTT 
assay method.
MATERIALS AND METHODS
Material
Our previous studies have managed to syn-
thesize N-(fenilkarbamoil)isobutiramida from 
starting materials fenilurea and isobutiril chlo-
ride through acylation reaction. Synthesized 
compound was identified qualitatively to de-
termine its purity by determining the melting 
range and thin layer chromatography. And the 
structure was confirmed by IR and 1H-NMR.
Cytotoxicactivity assay of N-(phenylcarbamoyl)-
isobutiramide againts HeLa cell lines In vitro an-
titumor activity against MCF- 7 cancer cell lines 
was assayed by MTT method and expressed in 
IC50, concentration of the compounds induc-
ing a 50% inhibition of cell growth of treated 
cells compared to the growth 
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of control cells. Hydroxyurea (HU) was used as 
reference drug. RPMI was used as growing me-
dium. Cancer cell lines were seeded at a densi-
ty of 104 cells/well in 96-well microplates. Af-
ter 24 hours, exponentially growing cells were 
exposed to the test compounds in DMSO at 
final concentration ranging from 62,5 to 4000 
mg /mL. After 24 hours incubated in a 5 % 
CO2 incubator at 370C, cell survival was deter-
mined by the addition of MTT solution (100 µL 
of 10 % MTT solution in RPMI medium). Once 
formazan was formed, 100μL 10 % SDS in 0.1 
N HCl was added and plates were incubated in 
the dark at 370C overnight. The absorbance 
was observed at 595 nm on ELISA-reader and 
survival ratio of living cells were exppressed in 
percentages with respect to untreated cells. 
Each experiment was performed at least three 
times. IC50 value was determined by using log 
probit analysis [5].
RESULT AND DISCUSSION
Our previous study managed to synthesize N-
(phenylcarbamoyl)isobutiramide from starting 
materials phenylurea and isobutiril chloride. 
Synthesized compound was identified quali-
tatively to determine its purity by determining 
the melting range and thin layer chromatog-
raphy. And the structure was confirmed by IR 
and 1H-NMR. Table 1 and 2 shows confirma-
tion result by using IR and 1H-NMR
Table 1 Confirmation result by using IR spec-
trophotometry
With the aim to obtain new anticancer 
agents, we examined anticancer activity of 
N-(phenylcarbamoyl)isobutiramide that we 
already have synthesized before. In vitro anti-
cancer activity assay conducted against cervi-
cal cancer cells (HeLa cells). The results of the 
absorbance of the test compound treatment 
can be seen in Table 3 and Table 4.
After we got absorbance value, we subse-
quently converting this absorbance value 
into survival ratio. This survival ratio needed 
in probit analysis to calculate IC50 value of 
tested compound.
Table.5  IC50 value of in vitro cytotoxic activity 
assay of tested compounds againts HeLa cell 
lines
Table 5 indicated that N-(phenylcarbamoyl)
isobutiramide gives lower IC50 values than 
those in hydroxyurea. So the activity of N-
(phenylcarbamoyl)isobutiramide is higher 
than those in hydroxyurea. Lower IC50 values 
prove that the ability of N-(phenylcarbamoyl)
 (*) consentration expressed in µg/mL
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isobutiramide to inhibit the growth of cancer 
cells is larger than those in hydroxyurea.
Table.6  Comparison beetwen in vitro cytotox-
ic activity against HeLa cell lines and in silico 
study with 2YWP receptor of tested com-
pounds.
Table 6 Indicated that both of in silico and in 
vitro study proves that N-(fenilkarbamoil)iso-
butiramida gives higher activity than those in 
hydroxyurea. 
Lower rerank score value indicated that N-
(phenylcarbamoyl)isobutiramide gives lower 
affinity bond with receptor 2YWP than those 
in hydroxyurea, thus N-(phenylcarbamoyl)iso-
butiramide more stable in the drug-receptor 
binding. In silico study predicted correctly that 
N-(phenylcarbamoyl)isobutiramide has high-
er activity than hydroxyurea. So that in silico 
study can be used as an initial approach to de-
velop new anticancer agent.
CONCLUSSION
This research concluded that N-
(phenylcarbamoyl)-isobutiramide gives 
higher anticancer activity than hydroxyurea. 
N-(phenylcarbamoyl)isobutiramide gives 
IC50 values lower than those in hydroxyurea. 
Lower IC50 values indicated that the ability of 
N-(phenylcarbamoyl)-isobutiramide to inhibit 
the growth of cancer cells is higher than those 
in hydroxyurea. This research also concluded 
that in silico study can be used as an initial ap-
proach to develop new anticancer agent. With 
in silico approach, we can reduce trial and er-
ror as well as time and costs consumed in the 
developing of new anticancer agents.
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ABSTRACT
To have correct information of biological analysis, pure recombinant protein is required. Con-
sequently a suitable and efficient techniques for protein purification was needed. In this study, 
simple two step chromatographic purification process was developed with relatively high yield 
and purity of rhEPO using bluesepharose affinity chromatography combined with Q-sepharose 
ion exchange chromatography. A single protein zone with molecular mass of 47 kDa was appeared 
in SDS-PAGE analysis of the purified rhEPO. Final result showed that rhEPO protein exhibited at 
more than 90% purity.
Key words: bluesepharose, erythropoietin, purification, ion exchange.
 
INTRODUCTION
       Erythropoietin (EPO) is a glycoprotein hor-
mone that controls red blood cell formation. 
Lacking of EPO in the body can cause anemia 
due to low process of erythropoiesis. rhEPO 
has been used for clinical treatment of patients 
with anemia caused by cancer, HIV infection, 
kidney failure, and bone marrow transplanta-
tion (Park et al. 2000). Therapy with recombi-
nant EPO decreases the need for blood trans-
fusion, thus reducing the risk of coming down 
with illness such as viral hepatitis or HIV AIDS 
[1]. 
Methods of EPO purification have been devel-
oped (Ben-Ghanem et al.,1994). Surabattula et 
al. (2011) described an improved purification 
of EPO from mammalian cell cultures. In this 
study, a two step chromatographic purification 
process that combines blue sepharose affin-
ity chromatography with Q-sepharose ion ex-
change chromatography was examined.
MATERIALS AND METHODS 
Cell Culture 
CHO-K1 cells were cultured in Dulbecco’s 
Modified Eagle’s medium (DMEM) (Gibco) 
supplemented with 10% Fetal Bovine Serum 
(FBS) (Gibco) and 1% Penicillin-Streptomycin 
(Gibco).  
Clarification and Diafiltration
Supernatant was filtered through 0.45 μm 
membrane using a sterile syringe filter (Corn-
ing) to remove the remaining cells and debris. 
After the clarification, filtrate was concentrat-
ed by TFF (tangential flow filtration) system 
using a 10 kDa cut-off membrane (Millipore) 
to about 10 fold volume reductions. 
Affinity Chromatography and Buffer Ex-
change
Glass column 10 mm internal diameter and 
100 mm length) was packed with 1 ml of Blue 
sepharose 6 fast flow matrix (Amersham). 
Column was equilibrated with 3 column vol-
umes of 20 mM phosphate buffer pH 8. Col-
umn was washed 10 column volumes with 20 
mM phosphate buffer pH 8 after loading with 
concentrated supernatant. The protein was 
eluted with 20 mM phosphate buffer + 1.5 M 
NaCl, peak containing the active fractions was 
pooled and buffer exchanged against 20mM 
Tris pH 8 by Amicon 10 kDa cut off membrane 
(Millipore). 
Ion-Exchange Chromatography
 Prepack column Sartobind IEX 15 (Sartorius) 
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mounted on AKTA system (AKTA purifier 10, GE 
Healtcare). Column was equilibrated with buf-
fer A containing 20 mM Tris (pH-8.0). After de-
salted blue sepharose elute was loaded on to 
the column. Column was washed with Buffer 
A. EPO protein was then eluted with gradient 
using buffer B containing 20 mM Tris, 1M NaCl 
(pH-8.0). Result of purification was detected 
by UV detector with wavelength 280 nm.  Frac-
tion containing EPO was sterilized by passing 
through a 0.22 μm pore size filter (Corning). 
SDS-PAGE Analysis
SDS/PAGE and Western blot analysis were per-
formed to detect each fraction of protein af-
ter purification.  Following SDS/PAGE, protein 
inside the gel was transferred into Hybond 
nitrocellulose membrane (GE Healthcare) by 
using electroblotting. Immunodetection was 
achieved by using anti-hEPO antibody (Calbio-
chem) as primary antibody and anti-rabbit IgG 
peroxidase conjugate (Biorad) as secondary 
antibody. 
Result and Discussions
The cell culture supernatant was filtered 
through 0.45μm membrane filter and then 
directly loaded onto Blue sepharose column 
(1ml). To eliminate non-specific adsorption 
caused by weak interactions, the column was 
washed properly with 20 mM Phosphate buf-
fer. The band of interest band was seen in elu-
tion 1-3 which corresponds to EPO molecular 
weight on SDS-PAGE (Fig: 1). No EPO band 
was seen in flow through fraction or wash-
ing fraction, this result showed that the pu-
rification process was performed properly. In 
mammalian cell growth medium contains lots 
of albumin which is one of the contaminants 
that must be removed. Affinity purification is 
a helpful tool for cleaning up and removing al-
bumin contamination from samples. One puri-
fication method which can be used to remove 
these contaminants is blue sepharose affinity 
chromatography. In This method, The dye of 
blue sepharose (Cibacron Blue) is capable of 
removing over 90% of albumin in the sample 
(Travis et al, 1976). In This result (Fig 1), blue 
sepharose can substantially remove albumin 
in the sample
However, some contaminant protein bands 
with high and low molecular weights were still 
present. The next stage is purification by ion-
exchange chromatography in order to obtain a 
more pure rhEPO protein.
Purification used ionic exchange 
Figure 2. Graphic of  ion exchange data from 
AKTA System.
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Figure 2 shows two peaks which contained 
in the flow-through and elution fractions. 
The separation is expected to occur between 
the target protein and other impurities. For 
conformation, fractions were analyzed using 
Western blot protein and Commasie brilliant 
blue analyses.
Figure 3.  Western blotting and Commasie Bril-
iant analysis. Lane 1: Marker Protein, Lane 2: 
fraction A2, Lane 3: fraction A3, Lane 4: frac-
tion A7 , Lane 5: fraction B10, Lane 6: fraction 
B11, Lane 7: fraction B12, Lane 8: fraction C1.
EPO band was seen in fraction B11, B12 and 
C1, (Fig. 3). These bands correspond with the 
peak in the graph. This data showed that com-
bination of two chromatography methods was 
able to purify the rhEPO from impurities that 
are present in the media. Signifies the purifica-
tion process is well. 
CONCLUSIONS
Simple two step chromatographic purifica-
tion process was developed with relatively 
high yield and purity of EPO using bluesepha-
rose affinity chromatography combined with 
Q-sepharose ion exchange chromatography. 
Densitometric scanning of gels demonstrated 
that the final purity of the protein is more than 
90%. 
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INTRODUCTION
The compounds with low solubility drugs can 
be a problem in the development of drugs for 
the pharmaceutical industry. Group of drugs 
that are included in the Biopharmaceutical 
Classification System (BCS) class II drugs can 
be a challenge for the preparations of pharma-
ceutical development because of low solubility 
drugs as well as the rate of dissolution. In this 
case to increase the solubility of drugs besides 
salts, pharmaceutical cocrystals opened a new 
dimension to search for solid forms such as 
solubility, dissolution rate, stability, and shelf 
life of active pharmaceutical ingredients (APIs) 
without affecting their inherent pharmacologi-
cal properties1.
Pharmaceutical co crystals are materials or 
crystalline materials consisting of at least two 
different components (multicomponent crys-
tals or mixed crystals)2-3. Co crystal could be 
prepared by several methods, such as solvent 
evaporation, slurry, melt, and grinding. Co 
crystals formed between ketoconazole (KTZ) 
as an active pharmaceutical and succinic acid 
(SA) as a co crystal former (co-former)4 was in-
creased dissolution rate of pure ketoconazole 
in equimolar ratio (1:1)1. Physical character-
ization of co crystal was performed by physical 
mixture of binary system with molar ratio us-
ing different thermal analyzer (DTA) data from 
KTZ and SA. Besides that, physicochemical 
characterizations of cocrystal were performed 
by using PXRD and infrared spectroscopy (IR).
Active solid materials in the manufacture of 
pharmaceutical preparation suffered in vari-
ous thermic or machanical proccessed such 
as grinding, milling, granulations (wet and 
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dry granulations), tabletasi, and storage at 
various temperature, so the materials can 
occure transformation polymorph or hidrat/
solvat5. Kinetic study of cocrystal KTZ-SA pre-
pared with slurry method at various solvent 
concentrations a follows 2%, 3%, 4%, 5% and 
6% (w/w). Therefore, the aim of the present 
study was determined the kinetics of co crys-
tals KTZ-SA prepared with slurry method by 
using Powder X-ray Diffraction (PXRD) data 
such as the research of co crystalline phase 
transformation of binary mixture of trime-
thoprim (TMP) and sulfamethoxazol (SMZ) by 
slurry technique5. 
MATERIALS AND METHODS
Materials
Ketoconazole was purchased from Zhejiang 
East-Asia Pharmaceutical Co., Ltd, China, 
bacth no. DC-0101H-1209001. Succinic acid 
was purchased from Merck KGaA, Germany, 
bacth no. K43601782. Destilled water and 
ethanol p.a.
Methods
Preparation of Phase Diagram of Binary Sys-
tem
KTZ and SA were sifted and weighed to obtain 
particle size in similar range. The obtained 
physical mixtures were obtained by simply 
mixed KTZ with SA at different molar ratios as 
follows: (10:0), (9:1), (8:2), (7:3), (6:4), (5:5), 
(4:6), (3:7), (2:8), (1:9) and (0:10) respectively. 
The mixtures were gently mixed in mortar 
for 5 minutes. The melting point of physical 
mixtures of KTZ-SA was determined by DTA. 
Endothermic peak was plotted against molar 
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fraction of mixture to obtain the phase dia-
gram of KTZ-SA.
Preparation of KTZ-SA Physical Mixture
KTZ and SA equimolar carefully weighed; 
0.5314 grams and 0.1181 grams respectively. 
Both powders were mixed homogenously in a 
mortar.
Preparation of Cocrystal Using Solvent Evapo-
ration Method
KTZ and SA equimolar carefully weighed; 
0.5314 grams and 0.1181 grams respectively. 
Each compound was dissolved in ethanol sep-
arately. KTZ was dissolved in approximately 30 
mL of ethanol to form a clear solution. SA was 
dissolved in approximately 8 mL of ethanol to 
form a clear solution. The two solutions were 
mixed and stirred for a few minutes. The sol-
vent evaporated at room temperature for 48 
hours. Co crystal solids stored in a desiccators 
under vacuum6.
Preparation of Cocrystal Using Slurry Method
KTZ and SA equimolar carefully weighed; 
0.5314 grams and 0.1181 grams respectively. 
Both powder were mixed homogeneously 
with various solvent concentration added in 
mortar. Slurry method used water distilled as a 
solvent. Various solvent concentration added 
to the mixture mixed slurry samples formed 
as follows: 2%, 3%, 4%, 5% and 6% (w/w), it 
means waters added to the mixture mixed 
slurry samples formed as follows: 2 mL, 3 mL, 
4 mL, 5 mL and 6 mL. The mixtures were gen-
tly mixed in mortar for 10 minutes. Co crystal 
formed was dried at room temperature for 48 
hours. Co crystal solids stored in a desiccators 
under vacuum.
Physicochemical Characterization Co crystals
Differential Thermal Analyzer (DTA) was used 
to analyze the thermal properties. The DTA 
(Metller Toledo FP 85, Switzerland) was cali-
brated with indium before analysis. Certain 
amount of samples i.e. 5-7 mg samples were 
placed in a sealed aluminum pan. The analysis 
was performed in a temperature range of 50-
300oC with heating rate of 10oC per minute.
Characterization By Powder X-Ray Diffraction 
Method
Powder X-Ray Diffraction (Philips X’Pert Dif-
fractometer) analysis performed at room 
temperature. Condition of measurement 
was set as follows: Cu metal target, Kα filter, 
voltage of 40 kV, 40 mA. Performed analysis 
on the range of 2θ (theta) of 5-40o. Sample 
placed on the sample holder and lattes to pre-
vent particle orientation during preparation.
Characterization Using Fourier Transform In-
frared Spectroscopy (FTIR)
Approximately 1% (w/w) dispersion of sample 
powder in potassium bromide (KBr) was pre-
pared by mixing the sample powder with KBr. 
The infrared spectrum was obtained using 
infrared spectrophotometer (Spectrum One, 
Perkin Elmer) in wave length range 400-4000 
cm-1.
PXRD Calibration Curve
Prepared calibration curve of co crystal with 
mixed physical mixture KTZ-SA equimolar 
and co crystal KTZ-SA equimolar at various 
percentage comparation as follows: (0/100), 
(10/90), (30/70), (50/50), (70/30), (90/10) and 
(100/0). A value percentage of zero percent 
is a KTZ-SA physical mixture of binary system 
and a hundred percent is KTZ-SA co crystalline 
phase. Both of mixed powders characterized 
with PXRD, choose the unique interference 
peaks or different peaks among co crystal, 
physical mixture and pure each component 
material, and than choose a unique peak with 
the highest maximum intensity made calibra-
tion curve of co crystal and calculated kinetics 
of co crystal. The calibration curve of co crys-
tal plotted the value of maximum intensity 
(intensity-background) against percentage of 
co crystal in binary mixture. We get a value of 
linier regression equation (y= ax ± b), a value 
of x showed co crystal percentages. 
Kinetics Study of Co crystal Prepared with 
Slurry Method Using PXRD 
The results of characterization prepared with 
slurry method used PXRD at each various sol-
vent concentration were calculated maximum 
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intensity respectively to linier regression equa-
tion from calibration curve of co crystal. 
RESULT AND DISCUSSION
Phase Diagram of Binary System
The phase diagram of KTZ-SA mixture was made 
using different molar ratio (i.e. (10:0), (9:1), 
(8:2), (7:3), (6:4), (5:5), (4:6), (3:7), (2:8), (1:9) 
and (0:10)) respectively presented in figure 2 
and the result of DTA thermogram respectively 
presented in figure 1. KTZ melted at 152.4oC 
and SA melted at 192.3oC. The result showed 
two eutectics (E1 and E2), it means that the 
type of phase diagram of binary mixture is a 
congruently melted point of molecular com-
pound (co crystal). First eutectic (E1) at molar 
ratio (3:7) has a melting point temperature of 
143,9oC ΔH = 68.7 J/g and second eutectic (E2) 
at molar ratio (9:1) has a melting point tem-
perature of 147,9oC ΔH = 56.0 J/g. KTZ melted 
at 152.4oC was decreased until minimum melt-
ing point temperature of E1 when it was added 
in SA into the mixture and melting point of E1 
increased because SA added in the mixture 
until maximum melting point temperature of 
164.7oC ΔH = 20.0 J/g, it was called congru-
ently melting  point of molecular compound7. 
Increasing the number of fraction mol of SA 
will further cause a decrease in melting point 
of binary mixture at minimum temperature of 
SA, it was called second eutectic (E2)
DTA Analysis
DTA analysis was performed to characterize 
thermal behavior of KTZ-SA co crystal phase 
in relation to intact component and KTZ-SA 
physical mixture of binary system presented 
in figure 3. KTZ and SA showed a single en-
dothermic peak at 152.4oC ΔH = 63.3 J/g and 
192.3oC ΔH = 199.0 J/g respectively. KTZ-SA 
physical mixture showed two endothermic 
peaks at 143.5oC ΔH = 26.2 J/g and 164.7oC 
ΔH = 20.0 J/g . KTZ-SA co crystal showed only 
a single endothermic peak at 165oC indicated 
co crystalline phase formed between KTZ and 
SA5. It was occurred fusion of eutectic mixture 
in KTZ-SA physical mixture due to KTZ-SA co 
crystal phase5. 
Figure 1: DTA thermogram  KTZ (A), SA (K), KTZ-SA 
physical mixture (9:1) (B), (8:2) (C), (7:3) (D), (6:4) (E), 
(5:5) (F), (4:6) (G), (3:7) (H), (2:8) (I), (1:9) (J).
Figure 2: Phase diagram of binary system KTZ-SA with 
various compared of fraction mol.
Figure 3: DTA Thermograms of KTZ (A), SA (B), KTZ-SA 
physical mixture (1:1) (C), KTZ-SA cocrystal (1:1) (D). 
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PXRD Analysis
PXRD analysis used to characterize a new crys-
talline phase formed in solid state and showed 
superposition of two materials, it means that 
there is an interaction between two materi-
als, such as interactions between KTZ and SA 
in this case, the interactions may produce 
new diffraction peaks as compared the con-
stituent materials6. In this case, PXRD analysis 
performed at the angle of 2θ = 5-50o. PXRD 
difractograms of KTZ, SA, KTZ-SA physical mix-
ture (1:1) and KTZ-SA co crystal (1:1) solvent 
evaporation were showed at figure 4. 
Based on these data, PXRD diffractogram of 
KTZ was showed at the angle of 2θ = 5.3o, 
7.1o, 9.4o, 10.4o, 11.9o, 14.3o, 15.9o, 16.4o 
and 17.4o. PXRD diffractogram of SA was 
showed at the angle of 2θ = 15.8o, 16.0o, 
18.0o, 18.8o and 19.9o. KTZ-SA physical mix-
ture (1:1) diffractogram was specific angle of 
2θ = 5.4o, 6.7o, 7.2o, 7.8o, 9.4o, 10.5o, 12.0o, 
13.5o, and 14.6o. KTZ-SA co crystal (1:1) (sol-
vent evaporation) diffractogram was specific 
angle of 2θ = 6.6o; 7.8o and 13.3o whereas no 
peaks were found in KTZ-SA physical mixture 
diffractograms,
FTIR Spectroscopy Analysis
FTIR spectroscopy analysis used to study the 
chemical and physical structure changed in 
the molecular structure of substance6. Infra-
red spectra of KTZ, SA, KTZ-SA physical mix-
ture (1:1) and KTZ-SA cocrystal (1:1) solvent 
Figure 4: PXRD diffractograms of KTZ (A), SA(B), KTZ-SA 
physical mixture (1:1) (C) and KTZ-SA co crystal (1:1) 
(solvent evaporation) (D).
evaporation were showed at C=O, O-H and N-H 
stretch bend (figure 5). KTZ has a C-H alkana 
stretch bends at 2883 cm-1, C-H amine stretch 
bends at 1290, 1244, 1224, and 1201 cm-1, 
C-N stretch bends at 1546 and 1512 cm-1, C=O 
stretch at 1755 and 1647 cm-1, C=C aromatic 
stretch bends at 1647, 1546 and 1512 cm-1, 
C-Cl stretch bends at 815 cm-1, O-H stretch 
at 3448, 3176, 3118 and 2883 cm-1  and 
N-H stretch at 3448 cm-1. SA has a peak O-H 
stretch at bends 2931 cm-1, C-H alkana stretch 
at 2931 cm-1, C=O stretch at 1691 cm-1, C-C 
stretch at 1203, 1074 and 916   cm-1. The in-
teractions of KTZ-SA were showed at 1755 and 
1647 cm-1 referred peaks of C=O stretch from 
KTZ and at 1691 cm-1 referred peak of C=O 
stretch from SA shifted peaks 1710 and 1691 
cm-1 referred peaks of C=O stretch from KTZ-
SA physical mixture of binary system and shift-
ed peaks at 1787 and 1714 cm-1 referred C=O 
stretch from KTZ-SA co crystalline phase. Sec-
ond, the interactions of KTZ-SA were showed 
peaks at 3448, 3176, 3118 and 2883 cm-1 re-
ferred peaks of O-H stretch from KTZ and at 
2931 cm-1 referred peaks of O-H stretch from 
SA shifted at 3431 and 2885 cm-1 for KTZ-SA 
physical mixture of binary system and shifted 
at 3421, 3271 and 2893 cm-1 for KTZ-SA co 
crystalline phase. The last, interactions of KTZ-
SA were showed at 3442 cm-1 referred peak 
of N-H stretch, and there was no peak in SA, 
the peak of N-H stretch was appeared at 3431 
cm-1 for KTZ-SA physical mixture of binary sys-
tem and appeared at 3421 for KTZ-SA co crys-
talline phase8.   
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Figure 5: Infrared spectra  of KTZ (A), SA (B), 
KTZ-SA cocrystal (1:1) (solvent evaporation) (C) 
and KTZ-SA physical mixture (1:1) (D).         
PXRD Calibration Curve
Based on the data from PXRD diffractogram, 
KTZ-SA cocrystal (1:1) (solvent evaporation) 
diffractogram was specific angle of 2θ = 6.6o; 
7.8o and 13.3o whereas no peaks were found 
in KTZ-SA physical mixture diffractograms, Se-
lected a unique interference peak from three 
specific peaks from the angle of 2θ = 6.6o; 7.8o 
and 13.3o which have highest maximum inten-
sity. The angle of 2θ = 6.6o; 7.8o and 13.3o 
have maximum intensity at 213, 620 and 151 
respectively. The angle of 2θ = 7.8o was se-
lected for a unique peak for making calibration 
curve and reference calculated kinetic study 
cocrystal KTZ-SA prepared with slurry method 
used PXRD data. 
Calibration curve of cocrystal prepared with 
mixed physical mixture KTZ-SA equimolar and 
cocrystal KTZ-SA equimolar at various per-
centage compare as follows: (0/100), (10/90), 
(30/70), (50/50), (70/30), (90/10) and (100/0). 
Zero percent as KTZ-SA physical mixture of bi-
nary system and a hundred percent as KTZ-SA 
co crystalline phase. The results of PXRD dif-
fractogram at various percentage compare 
were showed at figure 6. After that, calculated 
maximum intensity (intensity - background) for 
each percent of cocrystal and than prepared 
the calibration curve with plotted percent of 
cocrystal against maximum intensity of char-
acteristic interference peak showed at figure 7 
and table 1. WinPLOTR (version march 2007) 
software was used to determine the maximum 
intensity (intensity - background) in PXRD dif-
fractogram.
Figure 6: PXRD diffractograms  of KTZ-SA mixed 
physical mixture of binary system and KTZ-SA 
co crystalline phase at various percentage of 
(0/100) (A), (10/90) (B), (30/70) (C), (50/50) 
(D), (70/30) (E), (90/10) (F) and (100/0) (G). 
Figure 7: Calibration curve of percentage co-
crystal in binary mixture against maximum 
intensity based on PXRD analysis data at the 
angle of (2θ = 7.8o). 
Kinetics Study of Cocrystal Prepared with Slur-
ry Method Using PXRD
Kinetics study of cocrystal prepared with 
slurry method using PXRD data from each 
various solvent concentration (i.e. 2%, 3%, 
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4%, 5% and 6% (w/w)) calculated with linier 
regression equation of maximum intensity cal-
ibration curve of percentage cocrystal, so we 
will get cocrystal percentage. PXRD diffracto-
gram of slurry method was showed at figure 
8. A good linier curve of percentage of solvent 
concentration prepared with slurry method 
obtained by plotting various solvent concen-
tration against maximum intensity (figure 9 
and table 2) and so do the curve of percent-
age cocrystal prepared with slurry method by 
plotting various solvent concentration against 
percentage of cocrystal (figure 10 and table 3). 
WinPLOTR (version march 2007) software was 
used to determine the maximum intensity (in-
tensity - background) in PXRD diffractogram.
Based on these data (figure 10 and table 3), the 
kinetics of cocrystals were determined based 
on PXRD analysis data. Cocrystal formed occur 
between contact of solvent activated with the 
molecular compounds of the energy added in 
the mixture during grinding both components 
(KTZ and SA) in mortar. So, increasing percent-
age solvent concentration was made contact 
activated with both molecular compounds in-
creased so percentage cocrystal was produced 
faster.  So that the number of cocrystal form 
were increased. 
Figure 8: PXRD diffractograms of KTZ-SA slurry 
method with various solvent concentrations of 
2% (A), 3% (B), 4% (C), 5% (D) and 6% (E).
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CONCLUSION
The kinetics study of cocrystals KTZ-SA pre-
pared with slurry method were determined 
based on PXRD analysis data.
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INTRODUCTION
Single chain antibody fragment (scFv) is part 
of an antibody molecule comprising the vari-
able light chain (VL) and variable heavy chain 
(VH), connected by a peptide linker. The scFv is 
much smaller in size (30 kDa) compared to the 
intact antibody molecule (eg. IgG 150 kDa). Be-
cause of its small size, scFv molecules can pen-
etrate tissues and tumor cells easily (Sun et al. 
2003). ScFv showed rapid pharmacokinetics, 
high specificity to target molecules and low 
immunogenicity in animal models. In addition, 
autoradiography studies showed that scFv can 
penetrate more extensive and homogeneous 
in tumor cells than intact antibody molecules 
or other greater antibody fragments (eg. Fab’, 
Fab’2). This characteristic is important for ra-
dioimmunotherapy (Kuan et al. 2000, Ahmad 
et al. 2012).
EGFR (epidermal growth factor receptor) has 
been extensively studied in relation to can-
cer in the last few decades since this recep-
tor protein was often found overexpressed on 
the surface of various cancer cells. It was sug-
gested that this molecule plays a major role in 
the development of cancer cells. Therefore, 
this protein becomes a potential target mol-
ecule in cancer therapy (Mammoth & Rochlitz 
2006). However, native EGFR is also present 
in normal tissue. Thus, targeting EGFR could 
cause serious side effects, immune damage, 
and be tolerant of this treatment. Studies have 
shown that EGFR mutates on cancer cells and 
many different EGFR mutant variants found 
in various types of cancer (Kuan et al., 2001, 
Frederick et al. 2000).
EGFR variant III (EGFRvIII) is the most com-
mon mutant variant found in a number of 
solid tumors, including glioblastoma multi-
forme (GBM), breast, brain and cervical can-
cers. EGFRvIII is not present in normal tissues. 
This mutant receptor has deletion of exon-2 
through exon-7 from native EGFR gene. A gly-
cine residue is formed at the junction of fusion 
between exon-1 and exon-8. This fusion cre-
ates a new specific antigen. This mutant vari-
ant is known as EGFRvIII (Gupta et al. 2010).
An alternative strategy for development of 
targeted drug delivery is using basic immuno-
toxin. Immunotoxin is an a toxin molecule that 
is fused or conjugated to an antibody or anti-
body fragment (eg. scFv) . Researches on im-
munotoxin-based immunotherapy have been 
more developed. One example is an ‘imunoR-
Nase’ (IR) that uses ribonuclease (RNase) as 
the active compound (toxin) (Lorenzo et al. 
2004). One type of RNase that is used in this 
study is a human pancreatic RNase (HP-RNase 
or HPR). This RNase is not toxic outside the 
cell, however it becomes toxic when it enters 
the target cells.  It may find a way to enter the 
cell through binding to surface epitopes that 
are recognized by the antibody moietie (Rybak 
& Newton 1999).
Pichia pastoris was chosen as the host for the 
chimeric protein production. It is a metylo-
tropic yeast that are able to grow at high cell 
densities in a simple media. The yeast has oth-
er advantages as the host such as high level 
protein production and secretion, and geneti-
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cally stable transformant. Peterson (2006) has 
reported that scFv can be expressed in P. pas-
toris into correct structure. This yeast-based 
expression system provides a right protein 
folding of scFv molecules. It also offers a vi-
ruse-free as well as endotoxin-free expression 
system that can be applied not only for drugs 
production, but also for other biotechnological 
applications (Joosten et al. 2003).
The aim of this research is to construct an 
immunotoxin conjugate comprising an anti-
EFGRvIII scFv fused with HPR variant mutant, 
and expressed the chimeric protein in yeast P. 
pastoris.
MATERIALS AND METHODS
Microorganisms used were Escherichia coli 
TOP10F’, E. coli DH5α and Pichia pastoris 
SMD1168H (Invitrogen). E. coli TOP10F’ and 
DH5α were used for cloning purpose. Plasmids 
used were pPICZαA (Invitrogen), pJ201-scFv 
(DNA 2.0), and pJ912-HPR (DNA2.0). All DNA 
primers used in this study were purchased 
from 1st Base. The anti-EGFRvIII scFv and 
HPRmut genes were ordered and made syn-
thetically by DNA 2.0, cloned in pJ201-scFv and 
pJ912-HPR, respectively.
Construction of scFv::HPRmut fusion protein
Sub-cloning of scFv gene into pPICZαA vector. 
The scFv gene encoding anti-EGFRvIII was 
made synthetically at DNA2.0 based on previ-
ously published sequence (Weber et al., 2009) 
and cloned in pJ201-scFv. The scFv gene was 
PCR-amplified by PCR method and was cloned 
into the pPICZα vector at XhoI site right after 
α-factor secretion signal, resulted in the re-
combinant plasmid pPICZα-scFv. The plasmid 
sequence was verified and the correct one was 
used for the next sub-cloning. The HPRmut 
gene was then subcloned into pPICZα-scFv 
and fused at 3’-end of the scFv. The HPRmut 
gene (Leland et al., 2001) was PCR-amplified 
from pJ912-HPR in two steps. First, the gene 
was amplified using internal primers pair, then 
the gene was re-amplified using another pair 
of primers containing a short spacer (G4S) and 
XbaI sites. Both gene and plasmid were cut 
with XbaI, isolated and purified. The gene was 
ligated and transformed into E. coli TOP10F’ 
according to Ausubel (2002). E. coli transfor-
mants were selected on LS-LB agar medium 
(1% peptone, 0.05% NaCl, 0.5% yeast extract, 
1.7% agar) containing zeocin (25 g/ml) and 
analyzed by colony PCR. Positive clones were 
further analyzed to determine gene orienta-
tion by PCR and sequence verified. 
Expression of scFv::HPRmut fusion protein in 
P. pastoris
Transformation and selection of transformed 
cells. 
The selected pPICZa-scFv-HPR recombinant 
plasmid was linearized with SacI. Transforma-
tion of the plasmid into             P. pastoris 
was carried out by electroporation according 
to the protocol suggested by Invitrogen and 
Biorad. Transformed colonies were grown and 
selected on YPDS zeocin medium (1% yeast 
extract, 2% peptone, 2% dextrose, 1 M sor-
bitol, 1.7% agar) containing 100 µg/ml zeocin 
(Invitrogen). Selection of yeast transformants 
was carried out according to the procedure 
given by Invitrogen. All of transformant colo-
nies that grew on the selection medium were 
transferred into a new fresh YPD zeocin me-
dium containing 100 µg/ml zeocin. The plates 
were incubated at 30°C for 2 to 4 days. Sta-
ble transformants that grew on this medium 
were further transferred into YPD zeocin agar 
medium containing higher concentrations of 
zeocin (200, 500, and 1000 µg/ml) to acquire 
recombinant clones having multicopy gene in-
tegration.
Protein expression from transformed P. pas-
toris
A number of 10 individual transformant colo-
nies were cultured to evaluate recombinant 
protein expression according to protocols of 
Pichia expression kit (Invitrogen). Cultures 
were incubated at 30°C and 250 rpm for 3 
days and methanol was added at 0.5% (v/v) 
into the culture every 24 hours.  Cultures 
were harvested by centrifugation (10.000 
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rpm, 15 min, 4°C). Cell biomass was stored at 
-20°C and the cell-free culture medium (super-
natant) was stored at 4°C for further protein 
analysis. Recombinant protein (extracellular 
product) was analyzed using SDS-PAGE meth-
od. Proteins were precipitated from cell-free 
supernatant samples by TCA (trichloro acetic 
acid) solution (Sanchez, 2001). Protein purifi-
cation using Pure Proteome Nickel magnetic 
beads (Merck) was performed for isolation 
and purification of the recombinant protein. 
Detection was carried out using Coomasie 
Blue (Biorad).
RESULT AND DISCUSSION
Construction of fusion protein scFv::HPR
Recombinant plasmid containing anti-EGFRvIII 
scFv gene (pPICZαA-scFv) has been previously 
constructed. The scFv gene was inserted at 
XhoI site next after mating secretion signal 
factor-α (MF-α) for secretion of recombinant 
proteins. The pPICZα-scFv plasmid used in 
the construction of the fusion antibodies had 
been previously sequence-verified. This fusion 
scFv::HPR protein has a relatively small size 
which is expected to be effective in targeting 
tumor cells. The pPICZα-scFv clone no. 41 has 
been confirmed both in size and gene orien-
tation, as well as its sequence. This plasmid 
clone was further used in the next HPRmut 
subcloning. 
The HPRmut gene was successfully inserted 
into pPICZα- scFv at XbaI site. Selection of 
transformed colonies by PCR was performed 
from 100 E. coli colonies using HPR-F and HPR-
R primers to detect the inserted HPRmut gene 
in the plasmid (Figure 1). Positive clones were 
indicated by the presence of a 400 bp DNA 
band. This PCR-colony analysis showed that 90 
colonies out of 100 were positive clones. 
Figure 1. Electropherogram of colony PCR re-
sult for selection of pPICZ-scFv-HPR recom-
binant plasmids in E. coli. 1: DNA marker; 2: 
negative control; 3-13: clones of E. coli trans-
formants. Positive clones were indicated by 
the presence of 400 bp DNA band.
Further analysis was carried out to determine 
the gene orientation by PCR using HPR-F and 
AOX1-R primers. Clones containing gene in-
sert in the correct orientation produces a DNA 
band around 650 bp. It was found that 42 
clones out of 90 had allegedly correct HPRmut 
gene insertion (Figure 2A). Restriction analysis 
using XbaI resulted 8 positive clones in which 
the insert gene were completely restricted and 
released from the plasmid backbone (Figure 
2B). Furthermore, three of the eight clones 
were analyzed for their nucleotide sequences. 
One clone with a correct nucleotide sequence 
has been obtained, which is the pPICZ-scFv-
HPR clone no. 44. Riccio et al. (2012), reported 
the same technique for constructing fusion of 
RNase and antibody fragment of anti-ErbB2 
receptor, named as ERB-HP-RNase-DDADD. 
The construct was subcloned into pET22b+ 
vector and expressed in E. coli BL21(DE3). Im-
munoRNase molecule is reported to demon-
strate biological activities of both the antibody 
domain and the RNase domain.
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Figure 2 Electropherogram of colony PCR (A) 
and the plasmid digestion results (B) for the 
selection of recombinant plasmids contain-
ing the scFv:: HPR gene fusion. (A) Colony PCR 
analysis to confirm gene orientation using 
HPR-F and AOX-R primers. M: DNA marker; 
1: negative control; 2-12: Positive clones of 
E. coli transformants. (B). Restriction analysis 
of recombinant plasmids using XbaI. 1: nega-
tive control; 2: DNA marker; 3-9: recombinant 
plasmids. Positive clones were indicated by a 
400 bp DNA band.
HPRmut gene has been successfully fused at 
the 3’-end of scFv gene in pPICZα-scFv. The 5’-
end of scFv was fused to the secretion signal 
sequence factor-. A peptide linker (L) was 
placed between the scFv and HPR, providing 
sufficient free space and minimize steric hin-
drance between the two domains. The scFv 
was preferred to be placed at the N-terminal 
rather than C-terminal of the HPR to provide 
better accessibility to the target antigen. The 
relative position of scFv and HPR is similar 
to the research conducted by Lorenzo et al. 
(2004), in which the anti-ErbB2 scFv was fused 
with HPR. Riccio et al. (2012) has also reported 
the construction of protein chimera compris-
ing a fusion protein of an anti-ErbB2 scFv Er-
bicin and HPR.
The recombinant plasmid pPICZα-scFv-HPR 
was linearized with SacI before it was trans-
formed into P. pastoris. Transformation of this 
plasmid into the yeast has resulted in a small 
number of yeast transformants. We did have 
27 independent clones only of P. pastoris 
transformants with a transformation efficiency 
of 0.54 x 102 cfu/ug DNA. This transformation 
efficiency rate is very low if compared to the 
level of efficiency that could be attained as 
high as 103 to 104 cfu/ug DNA as it is men-
tioned in some references (Invitrogen, 2010). 
Many factors may affect transformation pro-
cess that lead to low level of transformation 
efficiency, such as low amount of DNA, DNA 
impurities, excess volume of DNA, poor inte-
gration process, imperfect competent cells 
preparation (too low or too high cell concen-
tration), unoptimal electroporation process 
(Hornstein 2012). In this experiment, the 
amount of DNA used for transformation was 
500 ng, much smaller than the recommend-
ed amount, which was 1 to 5 g (Invitrogen, 
2010).
Genetic stability analysis was performed by 
growing the transformant colonies from the 
selection medium into to a new fresh media 
containing zeocin (100 ug/ml). It was found 
that all of transformant colonies could grow 
very well on this new medium, indicating that 
all of those transformed colonies were geneti-
cally stable.
Yeast transformants having potentially multi-
copy gene integration could be screened us-
ing medium with higher zeocin concentration. 
Yeast transformants were grown and screened 
on YPDAzeo medium containing 100, 200, 500, 
and 1000 μg/ml of zeocin (Figure 3). Number 
of integrated plasmid of each transformed 
clones might be different one to another. 
Higher copy-number of integrated plasmid has 
a linear correlation to the resistency toward 
higher zeocin concentrations. All transformed 
colonies grew well on media control and media 
with zeocin 100 µg/ml. In zeocin concentration 
of 200 and 500 µg/ml several colonies began 
to look stunted, leaving approximately 93% of 
the clones that grew well. At zeocin concentra-
tion of 1000 µg/ml, there was about 70% of 
transformed clones that grew well. Norden et 
al. (2011) suggested that resistency variation 
against antibiotic (zeocin) could be used to 
determine the gene copy number integrated 
into the genome,  Assuming that Sh ble gene 
(zeocin resistance gene) has the same ratio as 
the target gene, one copy of  Sh ble gene is 
the minimum requirement to be able to grow 
at zeocin concentrations of 100 µg/ml, 4 cop-
ies of gene to grow at 500 µg/ml and 9 copies 
of gene to grow at 1000 µg/ml. Clones with as 
many as 17 copies of the Sh ble gene are able 
to grow on zeocin concentration of up to 2000 
µg/ml (Norden et al., 2011). 
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Figure 3 Genetic stability test and selection 
of multiple gene integration of yeast transfor-
mant colonies on YPDAzeo medium, with dif-
ferent zeocin concentrations: 0 µg/ml (A), 100 
µg/ml (B), 200 µg/ml (C), 500 µg/ml (D), and 
1000 µg/ml (E).
The pPICZα plasmid containing scFv::HPR fu-
sion gene has been successfully integrated into 
the genome of P. pastoris. Analysis of the ge-
nomic DNA of yeast transformants were per-
formed by PCR using two primer pairs (HPR-F 
/ HPR-R and F-VH101 / VH10-R) to confirm the 
integration of each genes (HPRmut and scFv) 
within the P. pastoris genome. PCR results 
from 10 colonies of P. pastoris transformants 
showed that all clones gave a 400 bp (Figure 
4A) and 750 bp DNA bands (Figure 4B), cor-
respond to the size of HPRmut and scFv genes 
respectively. This result suggests that all yeast 
transformants contain both HPRmut and scFv 
genes in their genome. 
Figure 4 Electropherogram of colony PCR to 
confirm the insertion of scFv::HPR fusion gene 
in the genome of P. pastoris transformants. 
(A) Colony PCR using HPR-F and HPR-R prim-
ers. Positive clones having HPRmut gene give 
a 400 bp DNA band. M = DNA marker; 1= posi-
tive control; 2-10= clones of P. pastoris trans-
formants. (B). Colony PCR using VH101-F and 
VL101-R primers. Positive clones having scFv 
gene give 750 bp DNA band. M= DNA marker; 
1= positive control; 2-11= P. pastoris transfor-
mants.
This recombinant scFv::HPR fusion protein 
contains  his-tag marker (6xHis) at its C-ter-
minal to facilitate production, purification, 
and detection of the desired protein. Secreted 
protein produced by P. pastoris transformant 
was analyzed on SDS-PAGE analysis as shown 
in Figure 5A. There are few bands of extracel-
lular protein observed from the sample prepa-
ration. To confirm the target protein band, 
the protein sample was purified through an 
affinity-based protein isolation. This recombi-
nant fusion protein has been successfully iso-
lated and purified using Pure Proteome Nickel 
magnetic beads (Merck) as shown in Figure 
5B. From these results, it was suggested that 
the recombinant fusion scFv::HPR protein has 
a molecular size of around 50 kDa (Figure 5B).
Figure 5 SDS-PAGE analysis.of extracellularly 
expressed P. pastoris-derived scFv::HPR fu-
sion protein from several yeast transformant 
clones. (A) Concentrated recombinant fusion 
protein. (B) Purified fusion scFv-HPR protein 
(mark by arrow). C= protein sample of un-
transformed clone; M= protein marker; 1, 2, 
3= protein samples of transformed yeast clone 
no.3, 4, 5 respectively.
CONCLUSION
Gene fusion of anti-EGFRvIII scFv::HPR has 
been successfully constructed and trans-
formed into P. pastoris SMD1168H with a 
transformation efficiency of 54 cfu/μg DNA. 
Approximately 93% of P. pastoris transfor-
mants were able to grow up to 500 μg/ml zeo-
cin (~4 gene copies) and 70% up to 1000 μg/
ml zeocin (~9 gene copies). The recombinant 
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fusion protein has been successfully expressed 
and secreted from P. pastoris as showed by 
SDS-PAGE analysis, showing a molecular size 
of around 50 kDa..
REFERENCES
1. Ahmad ZA, Yeap SK, Ali AM, et   
 al. (2012). Review Article:  
 scFv Antibodi: Principles and Clinical 
 Application. Clin & Devel   
 opImmunol Volume 2012,    
 doi:10.1155/2012/980250.
2. Ausubel FM, Brent R, Kingston RE, et   
 al. (editors). (2002). Short Protocol in  
 Molecular Biology. 5th Edition. John   
 Wiley & Sons Inc.
3. Frederick L, Wang XY, Eley G, James   
 CD. (2000). Diversity and Frequency   
 of Epidermal Growth Factor Receptor  
 Mutations in Human Glioblastomas.   
 Cancer Res 60, p1383–1387.
4. Gupta P, Han S-Y, Madruga MH, Mitra  
 SS, Nitta GLiRT, Wong AJ. (2010). De  
 velopment of an EGFRvIII specific re  
 combinant Antibodi. BMC Biotechnol  
 2010 10:72.
5. Invitrogen. 2010. EasySelect™ Pichia 
 Expression Kit; For Expression of   
 Recombinant Proteins Using pPICZ
 and pPICZα in Pichia pastoris. Cat. no.  
 K1740-01. MAN0000042. Carlsbad, CA.
6. Joosten V, Lokman C, vd Hondel CAM  
 JJ, Punt PJ. 2003. The Production of   
 Antibody Fragments and Antibody Fu  
 sion Proteins by Yeasts and Filamen  
 tous Fungi. BioMed Central Ltd. 
7. Kuan CT, Wikstrand CJ, Archer G, et   
 al. (2000). Increased Binding Affin  
 ity Enhances Targeting of Glioma Xeno 
 grafts by EGFRVIII-Specific scFv. Int J   
 Cancer: 88, 962–969.
8. Kuan C-T, Wikstrand CJ, Bigner DD.   
 (2001). EGF Mutan Receptor vIII as a   
 Molecular Target In Cancer Therapy.   
 Endocr Relat Cancer 8: 83–96. 
9. Leland PA, Staniszewski KE, Kim B-M,  
 Raines RT. (2001). Endowing Human   
 Pancreatic Ribonuclease with Toxicity
 for Cancer Cells. J Biol Chem Vol. 276,
 No. 46, Issue of November 16, Pp.   
 43095–43102.
10. Lorenzo CD, Arciello A, Cozzolino R, 
 Palmer DB, Laccetti P, Piccoli R, D’Alessio  
 G. (2004). A Fully Human Antitumor Im 
 munoRNase Selective for ErbB-2-Posi 
 tive Carcinomas. Cancer Res 64, 4870– 
 4874.
11. Mamot C, Rochlitz C. (2006). Target  
 ing the epidermal growth factor re  
 ceptor (EGFR) – a new therapeutic   
 option in oncology?. Swiss Med Wkly  
 136: 4 – 12.
12. Nordén K, Agemark M, Danielson 
 JÅH, Alexandersson E, Kjellbom P,   
 Johanson U. (2011). Increasing gene   
 dosage greatly enhances recombi  
 nant expression of aquaporins in Pi  
 chia pastoris. BMC Biotechnol, 11:47.
13. Peterson E, Owens SM, Henry RL. 
 (2006). Monoclonal Antibodi Form   
 and Function: Manufacturing the 
 Right Antibodies for Treating Drug   
 Abuse. The AAPS Journal 2006; 8 (2)   
 Article 43.
14. Riccio G, D’Avino C, Raines RT, De 
 Lorenzo C. (2012). A novel fully hu  
 man antitumor ImmunoRNase resis  
 tant to the RNase inhibitor. Protein   
 Engineering, Design & Selection 
 26(3): 243–248. DOI 10.1093/pro  
 tein/gzs101.
15. Rybak SM,  Newton DL. (1999). Im  
 mune Enzymes, in Antibody Fusion   
 Proteins (Chamow, S. M. and Ashke  
 nazi, A., eds.). Wiley, New York, pp.   
 53–110. 13.
16. Sanchez L. (2001). TCA protein pre  
 cipitation protocol. www.its.caltech.  
 edu. Downloaded on 1 May, 2012.
17. Sun C, Wirsching P, Janda KD. (2003).  
 Enabling scFvs as Multi-Drug Carri  
 ers: A Dendritic Approach. Bioorg &   
 Med Chem,11 : 1761–1768.
18. Weber R, Feng X, Foord O, et al.   
 (2009). Antibodies directed to dele  
 tion mutants of epidermal growth fac 
 tor receptor and     
 uses thereof. US Patent Application   
 Publication No. US2009/0240038 A1.
 
303
ALTERED PHARMACOKINETIC OF LEVOFLOXACIN 
BY COADMINISTRATION OF ATTAPULGITE
Zamrotul Izzah, Department of Clinical Pharmacy Faculty of Pharmacy Airlangga University, Jl. Dharmawangsa 
Dalam Surabaya – Indonesia, zamrotulizzah@ff.unair.ac.id, phone +62 31 5033710 ext. 119; Toetik Aryani, Depart-
ment of Clinical Pharmacy Faculty of Pharmacy Airlangga University, Jl. Dharmawangsa Dalam Surabaya – Indo-
nesia; Amalia Illiyyin, Undergraduate Student Faculty of Pharmacy Airlangga University, Jl. Dharmawangsa Dalam 
Surabaya – Indonesia; Budi Suprapti, Department of Clinical Pharmacy Faculty of Pharmacy Airlangga University, 
Jl. Dharmawangsa Dalam Surabaya – Indonesia
INTRODUCTION
Levofloxacin is a third-generation of fluoroqui-
nolone which exhibits broad-spectrum in vitro 
bactericidal activities against gram-positive 
and gram-negative aerobes (Mc Evoy, 2002). 
It shows elevated activity against Staphylococ-
cus aureus, S. epidermidis, and Streptococcus 
spp. Besides that, levofloxacin has lower inci-
dence of resistance, higher concentration in 
bone, and longer half-life, so it can be admin-
istered once daily. The most common side ef-
fects of levofloxacin are nausea, vomiting, and 
heartburn (Lee et al., 1997). 
Attapulgite, a hydrated magnesium aluminum 
silicate, has aluminum cations which can bind 
to the carboxylic acid and ketone groups at 
positions 3 and 4 on levofloxacin thus forming 
nonabsorbable chelate complexes. Adsorp-
tion nature of attapulgite may also inhibit the 
absorption of levofloxacin after oral adminis-
tration. As a result, this drug-drug interaction 
may reduce levofloxacin bioavailability. 
However, impact of this interaction on the 
pharmacokinetic of levofloxacin was unknown. 
The purpose of this sudy was to determine the 
effect of coadministration of attapulgite on 
the pharmacokinetics of a single orally-admin-
istered levofloxacin. (This study was presented 
at the 1st International Conference on Phar-
maceutics and Pharmaceutical Sciences, Sura-
baya, Indonesia, 14-15 November 2014)
METHODS
Subjects and study design
The study was ethically approved by the Ani-
mal Care and Use Committee of Airlangga 
University. Six New Zealand white rabbits (3-6 
months and 2.0-3.0 kg) received each of the 
following oral treatments in a randomized, 
two-way crossover sequence, separated by a 
7-day washout period: (i) levofloxacin (23 mg/
kgBW) alone; (ii) levofloxacin (23 mg/kgBW) 
given simultaneously with attapulgite (28 mg/
kgBW). The rabbits were fasted overnight prior 
to treatments and given free access to water. 
Blood samples (1.0 mL) were collected from 
the marginal ear vein by direct venipuncture 
just prior to levofloxacin administration up to 
240 min postdose (Fernandez et al., 1999). 
Samples were collected into sterile vacuum 
tubes and centrifuged within 30 min of collec-
tion. Plasma was stored in a sterile microtube 
at -20°C until analyzed. 
Drug assay
The plasma concentrations of levofloxacin 
were determined by a validated high-perfor-
mance liquid chromatography assay and a 
modification of the method reported by USP 
(USP/NF, 2009). Briefly, 200.0 µL of spiked 
standards (levofloxacin 5.0 μg/mL) was added 
to 200.0 µL of plasma, and the mixture was 
vortexed for 60 s. Next, 200.0 µL of acetoni-
trile and 100.0 µL of H3PO4 0.02 M (pH 3.0, 
adjusted with triethanolamine) were added to 
the mixture and then centrifuged at 4,000 rpm 
for 20 minutes. The supernatant was filtered 
by a 0.2 µL filter membrane and then 10.0 µL 
of solution was injected into the HPLC system. 
The chromatographic system was composed 
of a HPLC-DAD Agilent 1100 series, diode ar-
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ray detector, and Licrospher ODS @ 100 RP-
18 column. The detector wavelength was set 
to 280 nm. Mixtures of acetonitrile : H3PO4 
0,02 M (pH 3, adjusted with triethanolamine) 
(16:84, v/v) were used as the mobile phase at 
a flow rate of 1.5 mL/min. The retention time 
was 6.9 min. The calibration curve of levofloxa-
cin was linier within range 0.50 to 13.0 µg/mL 
(r = 0.9997). Detection limit was 0.025 µg/mL 
and quantification limit was 0.084μg/mL. The 
within-day (n = 6) and day-to-day (n = 6) coef-
ficient of variation was 1.93 ± 0.06 %. Recovery 
(%) was assessed from replicate analysis (n = 6) 
and shown 87.17 ± 2.34%.
RESULTS
The concentration-versus-time profiles of a 
single orally-administered levofloxacin and co-
administered with attapulgite in rabbits are 
shown in Figure 1. The pharmacokinetic pa-
rameters of levofloxacin are described in Table 
1. As shown in Table 1, no significant difference 
in the time to reach maximum plasma concen-
tration was observed (p>0.05). Tmax was 120 
min either in control or with attapulgite. 
In contrast, levofloxacin concentrations in 
plasma were decreased when levofloxacin was 
used concurrently with attapulgite. Concomi-
tant administration of attapulgite significantly 
decreased the peak plasma concentration 
and oral bioavailability (AUC0-240 min) of le-
vofloxacin by around 55% and 60% (p<0.001) 
Table 1. Pharmacokinetic parameters of a single orally-administered levofloxacin and co-adminis-
tered with attapulgite in rabbitsa
a. Data are mean values (± standard deviations as appropriate) for six subjects
b. Significantly different (p < 0.001) from control
c. No significant difference (p > 0.05) from control
Pharmacokinetics and statistical analysis
The maximum concentration (Cmax) and the 
time of maximum concentration (Tmax) of le-
vofloxacin in plasma were obtained directly 
from the plasma concentration-time curve 
for each subject. The area under the plasma 
concentration-time curve from 0 to 240 min 
(AUC0-240) was calculated by using the linear 
trapezoidal rule method. 
Differences in the mean AUC0-240min and 
the maximum levofloxacin concentrations 
among the treatment groups were analyzed 
for significance by a two-way ANOVA (analysis 
of variance) with an alpha value of 0.05.
respectively. Cmax of levofloxacin decreased 
(7.99 ± 0.80 and 3.60 ± 0.56 µg/mL for control 
and with attapulgite, respectively), and AUC0-
240min of levofloxacin reduced (1407.06 ± 
155.01 and 544.25 ± 55.59 µg.min/mL for 
control and with attapulgite, respectively).
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Figure 1. Mean plasma levofloxacin concen-
tration-versus-time profiles for levofloxacin 23 
mg/kgBW alone and levofloxacin 23 mg/kgBW 
with attapulgite 28 mg/kgBW 
(Values are means ± standard errors)
DISCUSSION
The absorption process plays an important role 
in achieving maximum concentrations and bio-
availability of drugs in the systemic circulation. 
If there is an interaction during this phase, it 
will reduce the amount of drug that enters the 
body. Furthermore, reduced bioavailability of 
drug has an impact on decreasing the effec-
tiveness of therapy (Garrelts et al, 1990; Stock-
ley, 2008). The present study demonstrated 
that the bioavailability of levofloxacin was 
markedly reduced by concomitant ingestion of 
attapulgite. Attapulgite is not absorbed in the 
gastrointestinal tract and its adsorption nature 
may also inhibit the absorption of levofloxacin 
after oral administration. 
Furthermore, the most plausible explanation 
for levofloxacin-attapulgite interaction is the 
formation of levofloxacin-aluminium chelates 
during the absorption phase (Lautenbach et al, 
2002). Attapulgite has aluminium ions which 
are available to form chelation complexes with 
levofloxacin, resulting in impaired absorption 
of levofloxacin. Chelation probably occurs be-
tween the cation and the 4-keto and 3-carbox-
yl groups of levofloxacin (Figure 2).
Some investigators have evaluated the effect 
of staggered dosing of fluoroquinolones and 
sucralfate on the extent of drug-drug inter-
action (Garrelts et al, 1990; Stockley, 2008). 
Sucralfate which also has aluminum cations 
appeared to reduce the bioavailability of cip-
rofloxacin by 88% (with 1 g of sucralfate ad-
ministered four times on the day before the 
study and the fifth dose given with ciprofloxa-
cin). However, when a 1 g dose of sucralfate 
was given 6 and 2 h before ciprofloxacin, only 
a 30% decrease in the bioavailability of cipro-
floxacin was observed (Garrelts et al, 1990). 
Clearly, not only the time interval between 
administrations of these interacting drugs, but 
also the sequence in which they are given, is 
important when trying to prevent this poten-
tial interaction. 
Levofloxacin should not be used together with 
attapulgite. Since levofloxacin is administered 
once daily, drug-drug interaction is easier to 
manage. The interaction, however, should be 
minimal if the interval separating the intake 
of both agents is lengthened. The maximum 
concentration of levofloxacin in plasma was 
achieved in 2 h, so it is reasonable to assume 
that levofloxacin should be given 2 h before 
attapulgite. The absorption process was com-
pleted before levofloxacin came into contact 
with released aluminum ions when levofloxa-
cin given 2 h before attapulgite.
This present study does not investigate the 
impact of drug-drug interaction on decreasing 
the effectiveness of therapy. Nonetheless, fur-
ther studies on assessing the clinical outcomes 
from the concomitant use of attapulgite and 
levofloxacin are needed to address this issue. 
CONCLUSION
The oral bioavailability of levofloxacin was 
markedly reduced when coadministered with 
attapulgite. Therefore, it may not be advisable 
to concomitantly administer levofloxacin with 
attapulgite. The altered pharmacokinetic of le-
vofloxacin might decrease its clinical efficacy 
and promote antimicrobial resistance.
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